

A Decade of Excellence

THE 10TH ANNUAL

Bio *Investor Forum*

Company Profiles

13therapeutics.....	3	Flexion Therapeutics, Inc.....	78
A&G Pharmaceutical, Inc.....	5	FluGen, Inc.	79
Aciont Inc.	6	FreeMind Group, LLC.....	80
Addex Pharmaceuticals Ltd.	8	Galena Biopharma, Inc. (Formerly RXi Pharmaceuticals)	81
Advaxis, Inc.	10	Gamma Therapeutics, Inc.	83
ADVENTRX Pharmaceuticals, Inc.....	12	Genocea Biosciences, Inc.	85
Aeolus Pharmaceuticals, Inc.	14	Genprex, Inc.	86
Affimed Therapeutics AG	16	GenVec, Inc.	88
Afraxis, Inc.	17	GlaxoSmithKline	90
Akebia Therapeutics, Inc.....	18	Globelimmune, Inc.	91
Allon Therapeutics Inc.....	19	GlycoMimetics, Inc.	93
Anchor Therapeutics, Inc.	21	Glycoregimmune, Inc.	95
AnGes MG, Inc.	22	HemaQuest Pharmaceuticals, Inc.	96
Apeiron Biologics AG.....	24	Heptares Therapeutics Limited.....	97
Aquinox Pharmaceuticals, Inc.	25	Human Genome Sciences, Inc.	98
Aradigm Corporation.....	26	Ikaria, Inc.	100
Arbovax, Inc.....	28	Immune Targeting Systems	101
ASLAN Pharmaceuticals Pte. Ltd.....	29	ImmunoCellular Therapeutics, Ltd.	103
Astellas Pharma Inc.	30	ImmunoGenes AG	105
Astex Pharmaceuticals Inc.	32	ImmusanT Inc.	106
Auspex Pharmaceuticals, Inc.....	34	Indel Therapeutics, Inc.	107
Axikin Pharmaceuticals, Inc.....	35	Inimex Pharmaceuticals, Inc.....	108
BCO Pharma Ltd.....	36	Integrium, LLC.....	109
BioMedTracker.....	37	Intellect Neurosciences, Inc.	110
Bio-Path Holdings, Inc.....	38	Intra-Cellular Therapies, Inc.....	112
BioRelix, Inc.	40	InVasc Therapeutics, Inc.	113
BioSante Pharmaceuticals, Inc.....	41	Jennerex Biotherapeutics, Inc.....	115
BIOTECCanada	43	Kalos Therapeutics, Inc.	116
BMO Capital Markets - Banking	44	Kareus Therapeutics, LLC.....	118
Campbell Alliance	45	LigoCyte Pharmaceuticals, Inc.	119
Catabasis Pharmaceuticals, Inc.	46	Lipocine, Inc.	120
Catalyst Pharmaceutical Partners, Inc.	47	MabVax Therapeutics, Inc.....	121
Cearna, Inc.....	49	MannKind Corporation	123
Cell Therapeutics, Inc.	50	Maruho Co., Ltd.	125
Centella Therapeutics, Inc.	52	Mersana Therapeutics, Inc.....	126
Chelsea Therapeutics, Inc.	53	MetaCyte Business Lab LLC.....	127
CoLucid Pharmaceuticals, Inc.....	55	Metasignal Therapeutics Inc.....	128
Constellation Pharmaceuticals, Inc.....	56	Mirra Therapeutics, Inc.	129
CureFAKtor Pharmaceuticals, LLC.....	57	Mithridion, Inc.	130
Curis, Inc.....	58	Molecular Templates, Inc.	132
Cyclacel Pharmaceuticals, Inc.	60	Muscular Dystrophy Association	133
Dawson James Securities, Inc.....	62	MyeloRx LLC	134
Del Mar Pharmaceuticals, Inc.....	63	Nanocarrier Co., Ltd.	135
Dicerna Pharmaceuticals, Inc.....	64	NeurogesX, Inc.....	137
DLVR Therapeutics Inc.....	65	OncoMed Pharmaceuticals, Inc.....	139
DNA Therapeutics SA	66	OncoSynergy, Inc.....	140
EBD Group	68	P2D Bioscience (P2D, Inc.).....	141
EluSys Therapeutics, Inc.....	69	Palatin Technologies, Inc.....	142
Emisphere Technologies, Inc.	70	PharmaNeuroBoost NV.....	144
Envoy Therapeutics, Inc.....	72	Plx Pharma, Inc.	146
Epiome Therapeutics, Inc.....	74	Progenics Pharmaceuticals, Inc.....	147
Epizyme, Inc.....	75	Prognomix Inc.....	148
Esperion Therapeutics, Inc.	76	ProNAi Therapeutics, Inc.	150
FasterCures	77	Prosensa Therapeutics BV	151

Psyadon Pharmaceuticals, Inc.....	152
Rediens, Inc.	153
Relypsa, Inc.....	154
ResVerlogix Corporation.....	155
Rib-X Pharmaceuticals, Inc.....	157
Rodman & Renshaw, LLC	158
Savara Inc.	159
Senesco Technologies, Inc.	160
Siena Biotech SpA.....	162
Sirius Genomics, Inc.	163
Sorbent Therapeutics, Inc.....	164
Spinifex Pharmaceuticals Pty. Ltd.....	165
STATegics, Inc.	166
SuperNova Diagnostics, Inc.	167
SuppreMol, GmbH.....	168
Susavion Biosciences, Inc.....	169
Sutro Biopharma, Inc.	171
Syndax Pharmaceuticals, Inc.....	172
SynTara LLC	173
Syntaxin Limited	174
TeraDiscoveries, Inc.	175
Tetraphase Pharmaceuticals, Inc.	176
The Salter Group.....	178
Theraclone Sciences, Inc.....	179
Transcept Pharmaceuticals, Inc.....	180
Tranzyme, Inc.	182
Trevena, Inc.	184
Trius Therapeutics, Inc.	185
Unigene Laboratories, Inc.....	187
Xcenda LLC.....	189
XOMA Ltd.....	190
Zalicus Inc.	192
Zymeworks Inc.	193

13therapeutics

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, AutoImmune, Biopharmaceuticals

Thomas Bruggere

Chief Executive Officer

2611 SW 3rd Avenue, Suite 200
Portland, OR 97201
USA

www.13therapeutics.com

1-503-525-4885

Incorporated: 2009

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Completed FDA Pre-IND meeting for P13 in Hearing Disorders. Ready to begin IND-Toxicity trials.
Received 3 year SBIR Phase III grant for P7 in sepsis.

Upcoming

Complete Series A financing, grants, and/or partnership. Start IND-Tox testing in P13.
Receive Army grant for Noise Induced HL.

CORPORATE MISSION

13therapeutics, Inc. is a research and drug development company identifying and characterizing novel anti-inflammatory peptide therapeutics for unmet medical needs with high commercial potential. The company has an innovative platform for isolating novel peptides from immunoregulatory proteins, produced by pathogens, which impact the immune system. 13therapeutics spun out of the Oregon Health and Science University (OHSU) in Portland, Oregon.

The company's peptides have application in treating multiple inflammatory diseases, especially those diseases characterized by over-production of inflammatory cytokines and mediators (e.g., diseases characterized by a "cytokine storm"). These peptides are postulated to have several competitive advantages over current anti-inflammatory therapeutics, including a unique targeting mechanism (inhibition of intracellular TLR signaling), greater efficacy, enhanced safety (based on initial studies), oral and topical bioavailability, ease of manufacturing, and low COGS. Moreover, because testing to date has shown them to be effective inhibitors of multiple inflammatory mediators, greater efficacy may be seen when compared to single mediator inhibitors.

The company is focusing its lead peptide, P13, as a TOPICAL (ear drops) treatment/prevention for hearing disorders: Noise Induced HL, Age Related HL, and Otitis Media. These are multi-billion dollar markets with no effective therapeutics.

The company is self-funded, having received over USD \$7 million from NIH peer reviewed grants, including multiple Phase II and a Phase III SBIR grant. The company's stock is privately held by employees and OHSU. The company is considering a Series A financing or partnership to advance our lead therapeutics through IND Tox testing and clinical trials. 13therapeutics has an experienced management and scientific team capable of developing the company, and a commercialization team that has help bring compounds such as Enbrel and Epogen to market.

PROPRIETARY TECHNOLOGY

The company has a platform for isolating peptides which impact the immune system with application in treating multiple inflammatory diseases, especially those characterized by over-production of inflammatory cytokines. This platform has resulted in a portfolio of over 20 unique peptides which inhibit intracellular TLR signaling, have greater efficacy, enhanced safety, oral & topical bioavailability, ease of manufacturing, and low COGS. They are effective inhibitors of multiple inflammatory mediators so greater efficacy may be seen when compared to single mediator inhibitors. The company is focusing its lead peptide, P13, as a TOPICAL (ear drop treatment) for Noise Induced HL, Age Related HL, Otitis Media, and other hearing disorders.

CORPORATE ALLIANCES

The company has a close alliance with the Oregon Health and Science University (OHSU) where its animal experiments are performed. It also has an experienced commercialization team which has helped to market therapeutics like Epogen, Nepogen and Enbrel.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
P13	Noise Induced Hearing Loss	Lead Series	Shown pre-clinical TOPICAL efficacy for prevention/treatment. P13 has completed an FDA pre-IND meeting.
P13	Age Related Hearing Loss	Preclinical	Shown Pre-clinical efficacy in delaying onset.
P13	Acute Otitis Media	Preclinical	Shown pre-clinical TOPICAL efficacy in reducing fluid buildup and improving hearing.
P13	Otitis Media with Effusion	Preclinical	Shown pre-clinical TOPICAL efficacy in reducing fluid and improving hearing.
P7	Age Related Hearing Loss	Preclinical	Shown pre-clinical TOPICAL efficacy in animal testing.
P7	Sepsis	Preclinical	Shown increased survivability in extreme animal models.
P13	Rheumatoid Arthritis	Preclinical	Oral efficacy in initial animal testing.

SENIOR MANAGEMENT	
Thomas Bruggere, Chief Executive Officer • Steven Hefeneider, Chief Scientific Officer • Sharon McCoy, Vice President	
BOARD OF DIRECTORS	
Thomas Bruggere, 13therapeutics, Inc. • Steven Hefeneider, PhD, 13therapeutics, Inc. • Sharon McCoy, 13therapeutics, Inc.	
SCIENTIFIC ADVISORY BOARD	
Dennis R. Trune, PhD, MBA, Professor, Oregon Health and Science University • Jeffrey A. Gold, MD, Associate Professor of Medicine, Oregon Health and Science University • Carol J. MacArthur, MD, Pediatric Ear, Nose and Throat, Oregon Health and Science University	
FINANCING HISTORY	
Investors:	Employees (76%) • OHSU (10%) • Consultants, etc (4%) • Option pool (10%)

A&G Pharmaceutical, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Autoimmune, Diagnostics

Ginette Serrero, PhD Chief Executive Officer

9130 Red Branch Road
Columbia, MD 21045
USA

www.agpharma.com

1-410-884-4100

Incorporated: 2000

Ownership: Private

HIGHLIGHTS

Recent

A&G finished a 600 breast cancer patient clinical study trial for a new tissue called ONCOSTAIN 88™. GP88 correlates with a HIGH likelihood of breast cancer recurrence. The test is being run on all newly diagnosed breast patients at U. of Maryland.

The ONCO 88™ BLOOD TEST received a major endorsement. The Avon Foundation Breast Cancer Prevention Research Initiative has awarded A&G a three year grant to conduct multicenter monitoring clinical study focused on the measurement of GP88 in blood.

Precision Antibody was selected by SAIC to make "gold-standard" antibodies for NCI's CPTC, which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research.

Upcoming

Expecting distribution deal with large diagnostic multi-national company in 4Q11.

CORPORATE MISSION

A&G Pharmaceutical is based in Columbia, MD and is focused on developing cancer-specific targets that have therapeutic and diagnostic applications. A&G has a biomarker target called GP88/Progranulin which is expressed in breast, lung, and other cancers. A&G has developed neutralizing therapeutic antibody to GP88 that has been validated in animal studies and is entering toxicology study. GP88 has two near-term diagnostic- tissue & blood products- that will improve early detection, diagnosis and treatment of breast cancer and other diseases. A&G is open to partnership for both the therapeutic and diagnostic technologies.

PROPRIETARY TECHNOLOGY

A&G has a PRECISION ANTIBODY technology (www.precisionantibody.com) that rapidly develops customized, high-affinity monoclonal antibodies in as little as 30 to 45 days. This accelerated generation of monoclonal antibodies has been used to conduct thousands of monoclonal projects for large and small biotech and pharmaceutical partners as well as NIH and academic labs. For example, Precision Antibody has been selected as an antibody developer for the National Cancer Institute's Clinical Proteomic Technologies for Cancer (CPTC), which is focused on improving the number and standardizing the quality of monoclonal antibody reagents available for clinical cancer proteomics research. We have also developed and produced numerous custom antibodies for NIAID's Malaria (MR4) program.

CORPORATE ALLIANCES

A&G has an anti-GP88 therapeutic antibody candidate for the treatment of breast & lung cancer. Celltrion, based in South Korea, is performing bioprocess development, scale-up, and cGMP manufacturing to provide material for toxicology studies as well as Phase I and Phase II US clinical studies. We are currently looking for a therapeutic partners for this program.

PRODUCTS

Name	Indication	Phase	Milestone
OncoStain 88	Prognostic for identification of recurrence risk in newly diagnosed cancer patients	Diagnostics	Licensing Opportunity
ONCO 88 Blood Test	Blood Test that Monitors Breast Cancer Recurrence	Diagnostics	Large Clinical Trial Funded by Avon Foundation
GP88 Therapeutic Program	Neutralizing Antibody for Cancer	Preclinical	Ready for Toxicity Trial
RA Compounds	Rheumatoid Arthritis	Optimized Lead	Currently optimizing 3 lead compounds

SENIOR MANAGEMENT

Ginette Serrero, PhD, Chief Executive Officer • **Michael Keefe**, Chief Operating Officer • **Jun Hayashi, PhD**, Senior Vice President • **David Hicks**, Director • **Bing Miller**, Director • **Joe Corvera**, Director

BOARD OF DIRECTORS

Gordon Sato, PhD, Co-Founder, A&G Pharmaceutical • **Tom Hancock**, Nexus Medical Partners • **Lars Hanan**, Broad Oak Capital • **Jennie Mather, PhD**, MacroGenics • **SeungSuh Hong, PhD**, Celltrion • **Ginette Serrero, PhD**, Co-Founder & CEO, A&G Pharmaceutical, Inc.

SCIENTIFIC ADVISORY BOARD

Gordon Sato, PhD, Co-Founder, A&G Pharmaceutical • **Seung-il Shin, PhD**, Founder, Celltrion • **Jennie Mather, PhD**, Senior Vice President, Stem Cell Research, MacroGenics • **Ginette Serrero, PhD**, CEO, A&G Pharmaceutical, Inc.

FINANCING HISTORY

Investors: Maryland Venture Fund (0%) • Olympus (0%) • Emerge Capital (0%) • Celltrion (0%) • Crocker Capital (0%)

Aciont Inc.

BIO Member, Presenting Company

Clinical Foci: Ophthalmic, Drug Delivery, Specialty Pharmaceutical

John Higuchi, MBA, MSIS

President & CEO

350 West 800 North
Salt Lake City, UT 84103
USA

www.aciont.com

1-801-359-3461

Incorporated: 2000

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

We have met with the FDA on the uveitis project and they have in principle agreed with our proposed development plans. This project is funded by the NEI/NIH through a phase II SBIR.

We have demonstrated the delivery of therapeutically relevant levels of a 150KD macromolecule to the posterior section of the eye in rabbit which also showed no discernable adverse effects during and following treatment.

In the past year we have had a couple issued patents; we also have numerous pending and recently filed patents relating to the projects discussed above.

Upcoming

Complete GLP Toxicological Study, File IND and begin phase I clinical trials on first product.

Secure additional commercialization funding for the AMD project which was initially funded by the NEI/NIH.

CORPORATE MISSION

Aciont Inc is an early stage, specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive, controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont endeavors to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance.

There are no current commercialized products that have a non-invasive system that can deliver drugs to the back of the eye. Moreover, our technologies comprise the basis for a platform of high-demand product options that are not limited to only one market opportunity. The back of the eye drug delivery market is driven by an aging population, new research on drugs in the field, and increased understanding of the causes of various eye diseases.

Our own products will focus on innovative therapeutics based on our technologies and off-patent or new commercially available drugs. Combining our technology with the off-patent drugs can help expedite FDA approval because of the known safety profile of an existing commercialized pharmacological agent. Further, Aciont plans to partner with leading pharmaceutical companies involved with ocular therapeutics who may need our technology to deliver their drugs, or who may want to help us market our own products currently in development.

PROPRIETARY TECHNOLOGY

Our two main projects include the topical or non-invasive delivery of small molecules to both the anterior and posterior sections of the eye; and the non-invasive delivery of anti-VEGF macromolecules to the posterior section of the eye for the treatment of age related macular degeneration. We employ a scleral lens shaped eye applicator to deliver passively (during a 5-10 minute treatment) therapeutically relevant levels of small molecules (both water soluble and poorly soluble agents) to the posterior section of the eye. We also have a similar eye applicator employing a novel electroosmotic technology using a mild electrical current to facilitate the transport of macromolecules to the posterior section of the eye during a 10-20 minute treatment.

CORPORATE ALLIANCES

We intend to partner with investors and biopharmaceutical companies in ophthalmology in order to move our projects from a successful preclinical phase to a clinical proof of concept phase. Through SBIR funding, the National Eye Institute has funded both projects and we continue to seek additional development funding through such partnerships. For our uveitis project, we have secured alliances for the GMP manufacturing of our drug and device. Aciont seeks a Series A investment partner (USD \$2-4 million) to help us fund our phase I and II clinical trials. Also, Aciont seeks collaborations with biopharmaceutical companies investigating the development of small molecules or biologics in the ophthalmic industry.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
DSP Visulex	Severe Uveitis	Preclinical	FDA agreed in principle to study plans
Anti-VEGF Visulex	Wet Age Related Macular Degeneration	Preclinical	Completed preclinical proof of concept studies
Transient Analgesia Visulex	Ocular Surface Pain	Preclinical	Preliminary preclinical proof of concept studies completed

SENIOR MANAGEMENT

John Higuchi, MBA, MSIS, President & CEO • **Balbir Brar, DVM, PhD**, Vice President • **Kongnara Papangkorn, PhD**, Manager • **William Higuchi, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

William Higuchi, PhD, Founder, Aciont, Inc. • **John Higuchi, MBA, MSIS**, President & CEO, Aciont, Inc.

SCIENTIFIC ADVISORY BOARD

Gary Novack, Regulatory Consultant • **Paul Laskar**, Drug CMC Consultant • **Paul Bernstein**, AMD Medical Consultant • **Albert Vitale**, Intraocular Inflammation Medical Consultant • **Nick Mamalis**, Eye Surface/Ocular Pathologist Medical Consultant • **Kevin Li**, Pharmaceutical Sciences Consultant

FINANCING HISTORY

Round Date (Amount, US\$) 09/01/2005 (4.00 million)

Investors: William Higuchi (95%)

Addex Pharmaceuticals Ltd.

Presenting Company

Clinical Foci: Drug Discovery • CNS • Metabolic Disease

Bharatt Chowrira Chief Executive Officer

12, chemin des Aulx
1228 Geneva
Switzerland

www.addexpharma.com
41-22-8841555

SIX Swiss: ADXN
Incorporated: 2002
Employees: 85
Ownership: Public

HIGHLIGHTS

Recent

In 1Q11 Phase IIa clinical trials started for two lead products: dipraglurant (ADX48621) for Parkinson's levodopa-induced dyskinesia (PD-LID) and ADX71149 for schizophrenia. ADX71149 is being developed by our partner, Janssen Pharmaceuticals, Inc.

Addex appointed Dr. Bharatt Chowrira as CEO. He has a strong track record, with over 17-years of experience, including senior positions at Nektar, Merck and Sirna, in research, licensing, corporate development, operations & legal responsibilities.

Upcoming

Ph IIa PD-LID and schizophrenia results in 1H12.

Start dipraglurant-ER Phase I testing in 2012.

Clinical candidate selection for at least one program in 1Q12.

Regulatory filing for clinical testing of at least one compound in 4Q12.

CORPORATE MISSION

Addex Pharmaceuticals discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase IIa clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals, Inc., to treat schizophrenia. Addex also is advancing several preclinical programs including: GABA-BR PAM for pain, overactive bladder and other disorders; mGluR4 PAM for Parkinson's, anxiety and other diseases; GLP1R PAM for type 2 diabetes; mGluR2 NAM for treating Alzheimer's disease and depression; and FSHR/LHR NAM for sex hormone dependent tumors & reproductive system disorders. In addition, Addex has discovery programs to identify allosteric modulators of: receptor tyrosine kinase (RTK) superfamily, including TrkB PAM for treating neurodegenerative diseases (e.g. Alzheimer's, Parkinson's and Huntington's diseases); and TNF receptor superfamily, including TNFR1 NAM for inflammation (e.g. rheumatoid arthritis) and other diseases.

PROPRIETARY TECHNOLOGY

Allosteric modulators are an emerging class of orally available small molecule therapeutic agents that may offer a competitive advantage over classical drugs. This potential stems from their ability to offer greater selectivity and better modulatory control at disease mediating receptors. Most marketed drugs bind receptors where the body's own natural molecular activators (i.e. endogenous ligands) bind, specifically to a key part of each receptor's anatomy called the "active site". In short, most drugs must out-compete endogenous ligands in order to bind to the active site. By contrast, allosteric modulators are non-competitive because they bind receptors at a different site and modify receptor function even if the endogenous ligand also is binding. This confers numerous advantages.

CORPORATE ALLIANCES

Our partnership with Janssen Pharmaceuticals, Inc., has demonstrated the strength and success of our platform. The project started in 2005 as a platform-based discovery collaboration around metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulators (PAM). Today the lead product is undergoing Phase IIa testing in schizophrenia.

PRODUCTS

Name	Indication	Phase	Milestone
Dipraglurant-IR	Parkinson's disease levodopa-induced dyskinesia (PD-LID)	Phase II, IIa, IIb	Ph II data 1H12
Dipraglurant-ER	Dystonia	Phase I	
ADX71149 mGluR2 PAM	Schizophrenia + Anxiety	Phase II, IIa, IIb	
mGluR2 NAM	Alzheimer's / Depression	Preclinical	
GABA-BR PAM	Osteoarthritic Pain, Overactive Bladder	Preclinical	
mGluR7 NAM	Depression, Generalized Anxiety Disorder, PTSD	Optimized Lead	
GLP-1R PAM	Type II Diabetes	Optimized Lead	
TNFR1 (CD120a) NAM	Inflammation, Depression, Alzheimer's, MS	Research	
TrkB PAM	Parkinson's, Alzheimer's, Huntington's, Depression, ALS	Research	
mGluR4 PAM	Parkinson's disease, Anxiety	Preclinical	

SENIOR MANAGEMENT


Bharatt Chowrira, Chief Executive Officer • **Tim Dyer**, Chief Financial Officer • **Charlotte Keywood**, Chief Medical Officer • **Sonia Poli**, Managing Director • **Laurent Galibert**, Managing Director • **Jean-Philippe Rocher**, Managing Director • **Robert Lütjens**, Managing Director • **Tatiana Pont Carteret**, Managing Director • **Chris Maggos**, Business Development

BOARD OF DIRECTORS

André J. Mueller, Former CEO, Actelion • **Andrew Galazka**, Sr. Vice President, Scientific Affairs, Merck-Serono • **Ray Hill**, Former Head of EU Licensing, Merck & Co., Inc. • **Vincent Lawton**, Vice Chairman, Former Managing Director, Merck Sharp & Dohme • **Hoyoung Huh**, Chairman, BiPar • **Antoine Papiernik**, Sofinnova Partners • **Oleg Nodelman**, Biotechnology Value Fund

SCIENTIFIC ADVISORY BOARD

George F. Koob • **Bernhard Bettler** • **Mark A. Geyer** • **Barbara J. Mason** • **Jean-Philippe Pin**

TRADING STATUS AS OF OCTOBER 5, 2011**SIX Swiss: ADXN****Market Data**

Current Price	7.76
Currency	Swiss Franc
Net Change	-2.88
Volume	1,881
YTD % Change	-0.21
52Wk Range	7.01–11.95
Avg. Daily Volume (thousands)	3,923

First Call Data

Market Cap (MM)	60.8
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-3.69
EPS (Last Fiscal Year)	-4.75
Consensus Estimate (Y)	-3.69
Consensus Recommend	--
Price/Sales	16.42

Shareholders

<i>Institution</i>	<i>Holding %</i>
BVF, Inc.	30.0%
Hottinger Capital Corp.	6.2%
Medical Strategy GmbH	1.9%
BlackRock Advisors LLC	1.8%
Deka Investment GmbH	0.4%
<i>Mutual Fund</i>	
BVF, Inc.	30.0%
Hottinger Capital Corp.	6.2%
Medical Strategy GmbH	1.9%
BlackRock Advisors LLC	1.8%
Deka Investment GmbH	0.4%

Source: Thomson Reuters

Advaxis, Inc.

BIO Member, Presenting Company

Clinical Foci: Immunology, Oncology, Infectious Disease

Thomas Moore Chief Executive Officer

305 College Road East
Princeton, NJ 08540
USA

www.advaxis.com

1-609-452-9814

OTC BB: ADXS

Incorporated: 2002

Employees: 12

Ownership: Public

HIGHLIGHTS

Recent

Advaxis Completes Pre-IND Meeting for ADXS-PSA
Advaxis Completes Enrollment of Low Dose Cohort in CIN Study
UPenn Initiates Canine Osteosarcoma Study with Advaxis HER2

Upcoming

Results from Phase 2 Cervical Cancer Study 1H12.

CORPORATE MISSION

Advaxis is a biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Our novel platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.

PROPRIETARY TECHNOLOGY

Advaxis immunotherapies are based upon a novel platform technology that utilizes live attenuated *Listeria monocytogenes* (Lm) bio-engineered to secrete an antigen/adjuvant fusion (Lm-LLO) protein. Lm-LLO consists of a truncated fragment of the Lm protein listeriolysin (LLO), fused to target antigens of interest. Lm-LLO stimulates a powerful immune response not only to Lm which is inherent in humans, but redirects this same response to the target antigen(s). Lm-LLO based immunotherapy generates a more comprehensive immune response by serving as its own adjuvant, directing antigen presentation, and changes the tumor microenvironment by increasing tumor infiltrating killer T-cells and decreasing Tregs/MDSCs.

CORPORATE ALLIANCES

Today, the Company has over fifteen (15) distinct constructs in various stages of development, directly developed by the Company and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, and the Department of Homeland Security among others.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>
ADXS-HPV	Cervical Cancer	Phase II, IIa, IIb
ADXS-HPV	CIN	Phase II, IIa, IIb
ADXS-HPV	Head & Neck Cancer	Phase II, IIa, IIb
ADXS-HER2	Canine Osteosarcoma	Phase I
ADXS-PSA	Prostate Cancer	Preclinical
ADXS-HER2	Breast Cancer	Preclinical

SENIOR MANAGEMENT

Thomas Moore, Chief Executive Officer • **Mark Rosenblum**, Chief Financial Officer • **John Rothman**, Chief Operating Officer • **Robert Petit**, Other • **Chris French**, Director • **Diana Moore**, Investor Relations

BOARD OF DIRECTORS

Thomas Moore, Chairman • **Dr. James Patton**, Director • **Roni A. Appel**, Director • **Dr. Thomas McKearn**, Director • **Richard Berman**, Director



Market Data

Current Price	0.13
Currency	US Dollar
Net Change	-0.76
Volume	200,067
YTD % Change	0.05
52Wk Range	0.10-0.25
Avg. Daily Volume (thousands)	588,338

First Call Data

Market Cap (MM)	31.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.03
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	127.63

Shareholders

<i>Institution</i>	<i>Holding %</i>
SFMG LLC	0.1%
Pacific West Financial Consultants, Inc.	0.0%
<i>Mutual Fund</i>	<i>Holding %</i>
SFMG LLC	0.1%
Pacific West Financial Consultants, Inc.	0.0%

Source: Thomson Reuters

ADVENTRX Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Hematology, Specialty Pharmaceutical

Brian M. Culley, MA, MBA Chief Executive Officer

12390 El Camino Real, Suite 150
San Diego, CA 92130
USA

www.adventrx.com

1-858-552-0866

NYSE Amex: ANX

Incorporated: 1997

Employees: 12

Ownership: Public

HIGHLIGHTS

Recent

ADVENTRX to Meet with FDA to Discuss Development Plans for Exelbine™, ANX-514 and ANX-188.

ADVENTRX Receives Complete Response Letter for Exelbine NDA.

ADVENTRX Reports Second Quarter 2011 Financial Results (USD \$42 million In Cash as of June 30, 2011).

Upcoming

Provide Update on Exelbine NDA & Development Plans After meeting with FDA to discuss the Agency's Complete Response Letter.

Provide Development Update on ANX-514 & Anticipated Phase 3 Safety Study After meeting with FDA.

Provide Development Update on ANX-188 & Anticipated Phase 3 Pediatric Study After meeting with FDA.

CORPORATE MISSION

ADVENTRX Pharmaceuticals, Inc. is an oncology and hematology-focused specialty pharmaceutical company focused on acquiring, developing and commercializing proprietary product candidates.

The company's lead product candidates are Exelbine™, or ANX-530, a novel emulsion formulation of the chemotherapy drug vinorelbine (Navelbine®); ANX-514, a novel, detergent-free emulsion formulation of the chemotherapy drug docetaxel (Taxotere®); and ANX-188, a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis. The company is based in San Diego, California.

PROPRIETARY TECHNOLOGY

Two of the Company's lead product candidates, Exelbine™ (vinorelbine injectable emulsion), or ANX-530, and ANX-514 (docetaxel emulsion for injection), are novel emulsion formulations of currently marketed chemotherapy drugs. The Company's other lead product candidate, ANX-188 (purified poloxamer 188), is a novel, purified, rheologic and antithrombotic compound initially being developed as a first-in-class treatment for pediatric patients with sickle cell disease in acute crisis.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
ANX-188 (purified poloxamer 188)	Sickle cell disease	Phase III	Pediatric Phase 3 study planned to begin in 2012
ANX-514 (docetaxel emulsion)	Breast, non-small cell lung, prostate, gastric and head and neck cancers	Phase III	Phase 3 study planned to begin in 2012
Exelbine	Non-small cell lung cancer	NDA/BLA filed, or in process	

SENIOR MANAGEMENT

Brian M. Culley, MA, MBA, Chief Executive Officer • **Patrick L. Keran, JD**, Chief Operating Officer • **Martin R. Emanuele, PhD**, Senior Vice President • **Gregory D. Gorgas**, Senior Vice President • **Brandi L. Roberts, MBA**, Vice President

BOARD OF DIRECTORS

Jack Lief, Arena Pharmaceuticals • **David A. Ramsay**, Halozyme Therapeutics, Inc. • **Lewis J. Shuster**, Shuster Capital



Market Data

Current Price	0.84
Currency	US Dollar
Net Change	-2.33
Volume	273,572
YTD % Change	-0.68
52Wk Range	0.81-4.21
Avg. Daily Volume (thousands).....	751,734

First Call Data

Market Cap (MM)	22.2
Short Interest Shares	1,784,834
Short Interest Ratio	1.03
PE (Trailing 12 Months)	-0.46
EPS (Last Fiscal Year)	-0.75
Consensus Estimate (Y)	-0.46
Consensus Recommend	--
Price/Sales	45.46

Shareholders

<i>Institution</i>	<i>Holding %</i>
RA Capital Management LLC.....	8.9%
Tang Capital Management LLC	8.4%
BlackRock Advisors LLC.....	7.5%
Fidelity Management & Research Co.	4.9%
Barclays Capital, Inc.	3.4%
<i>Mutual Fund</i>	<i>Holding %</i>
RA Capital Management LLC.....	8.9%
Tang Capital Management LLC	8.4%
BlackRock Advisors LLC.....	7.5%
Fidelity Management & Research Co.	4.9%
Barclays Capital, Inc.	3.4%

Source: Thomson Reuters

Aeolus Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology • Biodefense • Biopharmaceuticals

John McManus

Chief Executive Officer

26361 Crown Valley Parkway
Mission Viejo, CA 92691
USA

www.aeoluspharma.com

1-949-481-9825

OTC BB: AOLS

Incorporated: 1994

Employees: 10

Ownership: Public

HIGHLIGHTS

Recent

Presented non-human primate survival data in Lung-ARS.
National Jewish Health received a USD \$12.7 million Grant from NIH/CounterACT to study AEOL 10150 as a potential medical countermeasure for chlorine and sulfur mustard gas exposure.
Awarded contract, worth up to USD \$118 million, from Biomedical Advanced Research and Development Authority ("BARDA") to develop AEOL 10150 as a medical countermeasure to Lung-ARS.

Upcoming

Publication of peer-reviewed article on AEOL 10150 mechanism of action.
Exercise of BARDA contract options.
Commencement of Phase I study in NSCLC.

CORPORATE MISSION

We are developing a novel platform of broad-spectrum, catalytic-antioxidant compounds that protects healthy tissue from the damaging effects of radiation. Our strategy is to leverage the substantial investment by the US Government, in developing AEOL 10150 as a medical countermeasure to Lung-ARS (up to USD \$118 million), to develop it in oncology, where it would be used in combination with radiation therapy. Following the filing of an Emergency Use Authorization (EUA) by mid-2013, the government program will position Aeolus for a potential procurement (potentially worth several hundred million dollars annually) for the national stockpile. Much of the government-sponsored work will be used to support and accelerate the company's oncology development program, thereby reducing the amount of capital that would otherwise be needed from outside investors. The government funding is expected to significantly reduce the dilution to our shareholders.

Published data demonstrate that AEOL 10150 does not interfere with the therapeutic benefit of radiation therapy in prostate and lung cancer preclinical studies.

AEOL 10150 has demonstrated safety in animal studies, been well-tolerated in two human clinical trials, demonstrated efficacy in two species in acute radiation syndrome (ARS) studies, and demonstrated statistically significant survival efficacy in an acute radiation-induced lung injury model. AEOL 10150 has also demonstrated efficacy in validated animal models for GI-ARS, chlorine gas exposure, and sulfur mustard gas exposure.

ARS is caused by exposure to high levels of radiation. There are three relevant sub-syndromes of ARS: 1) Hematopoietic and Bone Marrow (Heme), 2) Gastrointestinal (GI) and 3) Pulmonary/Lung-ARS. The Heme and GI sub-syndromes are generally considered treatable. There are currently no treatments available to treat Lung-ARS, which has been a leading and significant cause of death in industrial radiological accidents over past 20 years.

PROPRIETARY TECHNOLOGY

Discovered at Duke University and National Jewish Health, these compounds, known as metalloporphyrins, scavenge reactive oxygen species ("ROS") at the cellular level, mimicking the effect of the body's own natural antioxidant enzyme, superoxide dismutase ("SOD"). There is evidence that high-levels of ROS can affect gene expression and this may be modulated through the use of metalloporphyrins. We believe this could have a profound beneficial impact on people who are exposed to high-doses of radiation.

Our lead compound, AEOL 10150, is specifically designed to neutralize reactive oxygen and nitrogen species. The neutralization of these species reduces oxidative stress, inflammation, and subsequent tissue damage-signaling cascades resulting from radiation exposure.

CORPORATE ALLIANCES

Duke University; University of Maryland; National Jewish Health; Johnson Matthey; BARDA; NIAID/DAIT; CounterACT; Michael J. Fox; CURE

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
AEOL 10150	Lung-ARS; NSCLC; Head & Neck Cancer; Mesothelioma; GI-ARS; Prostate Cancer	Phase I
AEOL 11207	Parkinson's and Epilepsy	Preclinical
Hexyl	Acute Radiation Syndrome	Preclinical

SENIOR MANAGEMENT


John McManus, Chief Executive Officer • David Cavalier, Chairman • Russell Skibsted, Chief Financial Officer

BOARD OF DIRECTORS

David Cavalier, Principal & COO, Xmark Opportunity Partners, LLC • **Joseph Krivulka**, Chief Executive Officer, Triax Pharmaceuticals, LLC • **John Farah, PhD**, Vice President, Cephalon, Inc. • **Amit Kumar, PhD**, President & CEO, CombiMatrix Corporation • **Chris Rallis**, Pappas Ventures • **Peter Suzdak, PhD**, President, CEO & Founder, Cardioxyl Pharmaceuticals • **Michael Lewis, PhD**, President, BioDiligence Partners, Inc

TRADING STATUS AS OF OCTOBER 5, 2011

OTC BB: AOLS



Market Data

Current Price	0.42
Currency	U.S. Dollar
Net Change	13.51
Volume.....	12,850
YTD % Change	-0.38
52Wk Range	0.29-1.10
Avg. Daily Volume (thousands)	60,604

First Call Data

Market Cap (MM)	25.4
Short Interest Shares	--
Short Interest Ratio.....	--
PE (Trailing 12 Months).....	-0.03
EPS (Last Fiscal Year).....	-0.20
Consensus Estimate (Y)	-0.03
Consensus Recommend	-0.03
Price/Sales	9.42

Shareholders

<i>Institution</i>	<i>Holding %</i>
Xmark Opportunity Partners LLC	65.4%
Cummings Bay Capital Management LP	0.0%

Mutual Fund

	<i>Holding %</i>
Xmark Opportunity Partners LLC	65.4%
Cummings Bay Capital Management LP	0.0%

Source: Thomson Reuters

Affimed Therapeutics AG

Clinical Foci: Oncology, AutoImmune, Immunology

Dr. Rolf Günther Chief Operating Officer

Technologiepark Im Neuenheimer Feld 582
69120 Heidelberg
Germany

www.affimed.com
49-6221-6530710

Incorporated: 2000
Employees: 29
Ownership: Private

HIGHLIGHTS

Recent

AFM13: Filed CTA and IND in 2010; Initiated phase 1/2a in EU and US; In the initial dose the product appeared to be safe and well tolerated.

AFM11: Initiated GMP production and pre-clinical development.

AbCheck, a subsidiary of Affimed, signed partnership with Eli Lilly on human antibody screening and optimization.

Upcoming

AFM13: Report clinical safety and activity data in 2011/12.

AFM11: Finalize IND-Tox studies in 2012.

AFM13: Prepare pivotal trial in HL.

CORPORATE MISSION

Affimed is a clinical stage company developing bispecific RECRUIT-TandAb antibodies in oncology. The lead product AFM13 is currently investigated in Phase I/IIa trials in Hodgkin's lymphoma patients. The product appears to be safe and well tolerated and showed initial activity in patients. AFM13 has potential to be filed in 2014 for 3rd line and in 2016 for 1st line therapy. The market size is well above USD \$1 billion and no immunotherapy is licensed or in development.

A second program, AFM11, is developed for the treatment of NHL, a market with high need and huge potential.

TandAbs possess drug-like properties with excellent product stability. A robust manufacturing process has been established. These antibodies possess increased therapeutic potential compared to monoclonal antibodies or other antibody fragments.

Affimed is backed by a peer group of investors including Orbimed, Aeris, LSP, BioMed Invest and Novo Nordisk A/S.

PROPRIETARY TECHNOLOGY

TandAbs[®] are bispecific, tetravalent human antibody formats that have two binding sites for each antigen and bind the targets with the same avidity as an IgG. In oncology, the RECRUIT-TandAb platform provides an enhanced effector function by directly engaging immune effector cells (T- or NK-cells and macrophages) to induce specific tumor cell killing. Therefore, RECRUIT-TandAbs possess higher activity than Fc-optimised monoclonal antibodies. In addition, RECRUIT-TandAbs evenly address the patient population by overcoming a genetic polymorphism that is responsible for a variable response of monoclonal antibodies.

CORPORATE ALLIANCES

AbCheck, a subsidiary of Affimed, entered partnership with Eli Lilly on human antibody generation.

Affimed is preparing to enter strategic alliances around its proprietary product candidates and its TandAb[®] technology platform.

PRODUCTS

Name	Indication	Phase	Milestone
AFM13	Hodgkin's Lymphoma	Phase I	Safety, tolerability, PK and efficacy
AFM11	Non-Hodgkin's Lymphoma	Preclinical	in vitro and in vivo data

SENIOR MANAGEMENT

Dr. Rolf Günther, Chief Operating Officer • **Dr. Adi Hoess**, Chief Executive Officer • **Prof. Dr. Melvyn Little**, Chief Scientific Officer • **Dr. Florian Fischer**, Chief Financial Officer • **Dr. Miroslav Ravic**, Chief Medical Officer

BOARD OF DIRECTORS

Dr. Thomas Hecht, Hecht Healthcare Consulting • **Dr. Frank Mühlenbeck**, General Partner, aeris CAPITAL • **Dr. Jörg Neermann**, General Partner, Life Sciences Partners • **Dr. Gerhard Ries**, General Partner, BioMedInvest AG • **Dr. Michael Sheffery**, General Partner, OrbiMed • **Dr. Richard B. Stead**, BIOPHARMA Consulting Services LLC

FINANCING HISTORY

Round Date (Amount, US\$) 09/14/2000 (8.00 million) • 03/15/2007 (30.00 million) • 04/15/2010 (20.00 million)

Afraxis, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, CNS

Jay Lichter, PhD

Chief Executive Officer

11099 North Torrey Pines Road, Suite 290
San Diego, CA 92037
USA

www.afraxis.com

1-858-750-4707

Incorporated: 2007

Employees: 6

Ownership: Private

CORPORATE MISSION

Afraxis is discovering and developing drugs to treat rare and neglected diseases through the modulation of p21-activated kinase (PAK). Afraxis' initial indication of interest is Fragile X syndrome with future expansion into other diseases of the central nervous system, including schizophrenia and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines. Dendritic spines constitute the receptive side of a neural synapse and their dysfunction degrades synaptic function leading to deficits in learning, cognition and behavior. The company's lead program targets PAK, a protein that regulates the development and activity of dendritic spines, creating therapies that actually modify the disease rather than just treat symptoms. Modifying the disease produces beneficial changes at the cellular and behavioral level, creating new hope for patients.

In addition to its impact on dendritic spine biology, PAK is also implicated in a number of different oncological settings. Therefore, Afraxis is exploring the potential of PAK inhibitors for the treatment of cancers such as neurofibromatosis, glioblastoma, tamoxifen-resistant breast cancer and lung cancer. Recent work published in PNAS by Genentech illustrates the potential of PAK inhibitors in breast cancer and squamous NSCLC.

Afraxis has developed a high content technology platform to evaluate dendritic spine and synapse function that provides detailed insight into the pharmacological activity of novel treatments. Afraxis is using this platform to optimize the biological activity of its compounds and build a portfolio of its own drug programs. In addition, Afraxis will seek to leverage its dendritic spine analysis platform to help advance external programs in collaboration with partners.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
PAK inhibitor	Fragile X Syndrome	Preclinical
PAK inhibitor	Neurofibromatosis	Preclinical
PAK inhibitor	Glioma	Preclinical
PAK inhibitor	Breast Cancer	Preclinical

SENIOR MANAGEMENT

Jay Lichter, PhD, Chief Executive Officer • **David Campbell, PhD**, Chief Scientific Officer • **Carmine Stengone**, Vice President

BOARD OF DIRECTORS

Jay Lichter, PhD, Avalon Ventures • **Brady Bohrman**, Avalon Ventures • **Steve Heineman, PhD**, The Salk Institute

SCIENTIFIC ADVISORY BOARD

Susumu Tonegawa, PhD, MIT • **Gary Lynch, PhD**, UC-Irvine • **Steve Heinemann, PhD**, The Salk Institute • **Dennis Selkoe, PhD**, Harvard Medical School • **Akira Sawa, PhD**, Johns Hopkins University

Akebia Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Renal • Ophthalmic • Drug Development

Joseph Gardner

President & CEO

9987 Carver Road
Cincinnati, OH 45242
USA

www.akebia.com

1-513-985-1920

Incorporated: 2007

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Completion of Phase 2a study for AKB 6548 demonstrating safety and increased hemoglobin levels in subjects with anemia secondary to Chronic Kidney Disease.

Filed the IND for AKB-9778 for the treatment Diabetic Macular Edema.

Received Department of Defense award supporting preclinical development of AKB-4924 to support wound healing and antimicrobial defense.

Upcoming

Completion of a 100-subject Phase 2 study for the treatment anemia secondary to CKD.

CORPORATE MISSION

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development of small molecules for the treatment of anemia, vascular disease, and wound healing. The company's lead compound, AKB-6548, is a once daily, oral HIF2 stabilizing agent (HIF-PH inhibitor) in phase 2 clinical trials for chronic anemia. Akebia also has a platform of novel HPTP β inhibitors / Angiopoietin 2 modulators which have demonstrated preclinical proof of concept in vascular leak, angiogenesis and as anti-metastatic agents. The first product to be developed from this platform, AKB-9778, is entering phase 1 clinical development. Akebia is based in Cincinnati, Ohio, and is backed by a national syndicate of leading investors.

PRODUCTS

Name	Indication	Phase	Milestone
AKB 6548	Anemia	Phase II, IIa, IIb	Phase 2a completed by 4Q11; Phase 2b starts 1Q12.
AKB 9788	Diabetic Macular Edema	IND Filed	Phase 1 Study to be Completed 4Q11.
AKB4924	Inflammatory bowel disease, wound healing	Preclinical	File IND 4Q12.

SENIOR MANAGEMENT

Joseph Gardner, President & CEO • **Robert Shalwitz, MD**, Chief Medical Officer • **Ian Howes**, Chief Financial Officer • **Kevin Peters, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Paul Weiss, Venture Investors, LLC • **Campbell Murray**, Novartis Venture Funds • **John Rice**, Triathlon Medical Ventures • **Anupam Dalal**, Kearny Ventures Partners • **Joseph Gardner**, Akebia Therapeutics

SCIENTIFIC ADVISORY BOARD

Randall Johnson, PhD, UC San Diego • **Franklin Bunn, MD**, Harvard Medical School • **John Adamson, MD**, UC San Diego • **Anatole Besarab, MD**, Henry Ford Hospital • **Volker Haase, MD**, Vanderbilt University • **Peter Hutt**, Covington and Burling

Allon Therapeutics Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: CNS

Gordon C. McCauley President & CEO

506 - 1168 Hamilton Street
Vancouver, BC V6B 2S2
Canada

www.allontherapeutics.com

1-604-736-0634

Toronto: NPC

Incorporated: 2001

Employees: 18

Ownership: Public

HIGHLIGHTS

Recent

Allon has enrolled 75% in pivotal progressive supranuclear palsy (PSP) study.
Allon wins National Biotech Award as Early Stage Company of the Year (Health) from BIOTECANADA.
Allon enrolling patients in a pivotal davunetide Phase 2/3 clinical trial in progressive supranuclear palsy.

Upcoming

Complete enrollment in pivotal progressive supranuclear palsy (PSP) study.

CORPORATE MISSION

Allon Therapeutics Inc. is a clinical-stage biotechnology company focused on developing the first drugs that impact the progression of neurodegenerative diseases. Allon's lead drug davunetide, is proceeding in a pivotal Phase 2/3 clinical trial in an orphan indication, progressive supranuclear palsy (PSP). This advanced trial is the subject of a Special Protocol Assessment (SPA) with the US FDA and is based upon statistically significant human efficacy demonstrated in amnesic mild cognitive impairment, cognitive impairment associated with schizophrenia, and positive biomarker data. The company is listed on the Toronto Stock Exchange (TSX:NPC) and based in Vancouver.

PROPRIETARY TECHNOLOGY

Allon's two neuroprotective technology platforms are based on two naturally occurring proteins secreted by the brain in response to a range of insults. The platforms are activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF). Because the two platforms are based on different proteins, the drugs from each are different molecules with different therapeutic mechanisms and distinct commercial opportunities. Clinical-stage drug davunetide is derived from ADNP, while preclinical stage drug AL-309 is derived from ADNF.

CORPORATE ALLIANCES

Allon's corporate alliances include The National Institute of Aging, The National Institutes of Health, The Michael J. Fox Foundation, Alzheimer's Drug Discovery Foundation, Tel Aviv University, and TURNS (Treatment Units for Research on Neurocognition and Schizophrenia).

PRODUCTS

Name	Indication	Phase	Milestone
Davunetide	Alzheimer's disease, PSP, and cognitive impairment associated with schizophrenia.	Phase II, Ila, I Ib	Allon is currently enrolling patients in a pivotal phase 2/3 clinical trial in PSP. Davunetide has demonstrated human efficacy in aMCI, a precursor to Alzheimer's disease, and cognitive impairment associated schizophrenia.
AL-309	Neuropathy	Preclinical	Announced that data demonstrate potential for peripheral neuropathy.
AL 408	Neuroprotection	Preclinical	Positive data in pre-clinical models of neuroprotection.
AL 508	Neuroprotection	Preclinical	Positive data in pre-clinical models of neuroprotection.

SENIOR MANAGEMENT


Gordon C. McCauley, President & CEO • **Matthew J. Carlyle, CFA**, Chief Financial Officer • **Bruce H. Morimoto, PhD**, Vice President • **Alistair J Stewart, PhD**, Vice President • **Michael Gold, MS, MD**, Chief Medical Officer

BOARD OF DIRECTORS

James J. Miller, PhD, Managing Partner, NDI Capital Inc. • **Gordon C. McCauley**, President & CEO, Allon Therapeutics Inc. • **Prof. Illana Gozes, PhD**, Co-Founder, Allon Therapeutics Inc. • **Anthony Phillips, PhD**, Professor, Department of Psychiatry, UBC • **Frank Holler**, CEO, Lions Capital Corp. • **Martin Barkin, MD, BSc, MA, FRCSC**, Former President, Draxis Health • **Michael Aldridge, BSc (Hons), MAppFin**, Executive Director, Xenome Inc.

SCIENTIFIC ADVISORY BOARD

Anthony Phillips, PhD, Prof, Department of Psychiatry, UBC • **Esther Shohami, PhD**, Prof, Department of Psychiatry, UBC • **Howard Fillit, MD**, Alzheimer's Drug Discovery Foundation • **Prof. Illana Gozes, PhD**, Allon Therapeutics Inc. • **Keith Black, MD**, Director at Irvine Medical Center • **Mati Fridkin, PhD**, Weizman Institute • **Michael Charness, MD**, Professor, Harvard University • **Michael Moskowitz, MD**, Professor, Harvard Medical School



Market Data

Current Price	0.22
Currency	Canadian Dollar
Net Change	4.88
Volume	127,700
YTD % Change	-0.43
52Wk Range	0.20-0.53
Avg. Daily Volume (thousands)	65,855

First Call Data

Market Cap (MM)	16.9
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.22
EPS (Last Fiscal Year)	-0.22
Consensus Estimate (Y)	-0.22
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
AGF Investments, Inc.	5.6%
Mackenzie Financial Corp.	0.2%
<i>Mutual Fund</i>	
AGF Investments, Inc.	5.6%
Mackenzie Financial Corp.	0.2%

Source: Thomson Reuters

Anchor Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, Metabolic Disease

Frederick (Rick) Jones, MD

President & CEO

67 Rogers Street
Cambridge, MA 02142
USA

www.ascentrx.com

1-617-715-1904

Incorporated: 2006

Employees: 18

Ownership: Private

CORPORATE MISSION

Anchor Therapeutics, Inc. is developing therapeutics for metabolic and cardiovascular diseases using a well-validated platform to identify peptide allosteric G protein-coupled receptor (GPCR) modulators. The company has examples of negative and positive modulators as well as pure agonists. Working on proprietary and partnered projects, Anchor is moving toward identifying first-in-class development candidates targeted at several GPCRs that have been difficult to address with standard technologies.

PROPRIETARY TECHNOLOGY

Anchor has exclusive rights to technology that allows design of lipidated peptides based on the amino acid sequence of the target GPCR. These molecules equilibrate into cell membranes where they interact with their target via an allosteric site. This interaction affects the target GPCR conformation, leading to enhancement or damping of receptor signaling. The mechanism of this interaction has been described in recent PNAS and JCAS publications.

CORPORATE ALLIANCES

Novartis: Anchor entered into an option agreement covering a small set of GPCR targets in 2007.

Ortho-Macneil-Janssen (J&J): Anchor entered into a research collaboration focused on specific metabolic and oncology GPCR targets in 2010.

PRODUCTS

Name	Indication	Phase	Milestone
TGR5 positive modulators and agonists	Metabolic disease	Lead Series	In vivo data 4Q2011
APJ agonists	Cardiovascular and metabolic disease	Lead Series	In vivo data 3Q2011
CXCR4 agonists	Regenerative medicine	Optimized Lead	Outlicense
GLP-1 modulator	Diabetes	Research	Lead optimization 4Q2011
gpr120 modulator	Metabolic disease	Research	Lead optimization 4Q2011
gpr40 modulator	Metabolic disease	Research	
gpr43 modulator	Metabolic disease	Research	

SENIOR MANAGEMENT

Frederick (Rick) Jones, MD, President & CEO • Steve Hunt, PhD, Chief Scientific Officer • Ken Carlson, PhD, Vice President • Tom McMurry, PhD, Vice President

BOARD OF DIRECTORS

Christopher Mirabelli, PhD, HealthCare Ventures • Lauren Silverman, PhD, Novartis Option Fund • Jens Eckstein, PhD, TVM • Mike Webb, Allegro Diagnostics • Robert Kamen, PhD, Biotech Consultant; Past President, Abbott Bioresearch Center, Abbott • Frederick Jones, MD, President & CEO, Anchor Therapeutics, Inc.

SCIENTIFIC ADVISORY BOARD

Graeme Milligan, University of Glasgow • Thomas Sakmar, Rockefeller University • Tom Muir, Princeton • Thue Schwartz, University of Copenhagen • Steve Kunkel, University of Michigan • Athan Kuliopulos, Tufts University • Lidija Covic, Tufts University

FINANCING HISTORY

Investors: HealthCare Ventures (0%) • Novartis Option Fund (0%) • TVM (0%)

AnGes MG, Inc.

Clinical Foci: Biopharmaceuticals, Gene/Cell Therapy, Oncology

Ei Yamada, PhD President & CEO

5-20-14 Shiba
Tokyo 108-0014
Japan

www.anges-mg.com

81-3573-02489

TOKYO: 4563

Incorporated: 1999

Ownership: Public

HIGHLIGHTS

Recent

AnGes and Shionogi executed an exclusive global co-development and licensing agreement for NFkB Decoy in the dermatological field. An equity investment by Shionogi was completed in conjunction with this licensing deal.

AnGes and Midikit executed a Term Sheet for co-development and marketing NFkB Decoy for restenosis, in Japan. Clinical trials a planned to start shortly.

AnGes executed a license agreement with MEDRx Co. Ltd. for a transdermal formulation technology, being developed by MEDRx.

Upcoming

Initiation of Phase 3 of HGF Plasmid in PAD (CLI) as well as partnering of this program.

Advance Development of NFkB Decoy for Atopic Dermatitis.

Phase 3 Results of Allovectin-7 for Metastatic Melanoma.

CORPORATE MISSION

AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on an innovative discovery by researchers of Osaka University. We specialize in development and commercialization of genetic medicine. At present, we are engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and NFkB decoy which controls various inflammations.

We are also making every effort to develop the HVJ Envelope Vector (a new delivery technology for medicines) through our subsidiary, GenomIdea Inc. It is our mission to provide patients, especially those suffering from diseases for which no effective therapy has been available to date, with innovative drugs as soon as possible in order to improve their Quality of Life (QOL).

We are as determined as ever to continue our efforts to satisfy the expectations of patients and families who await new drugs, as well as those of shareholders, investors, and society as a whole.

PROPRIETARY TECHNOLOGY

Essentially our business has two axes: horizontal (genetic medicine) and vertical (lifestyle-related diseases/chronic conditions). The representative agent is the HGF (Hepatocyte Growth Factor) genetic medicine. Applying the HGF's vascularization effects shall provide for better treatment of arteriosclerosis obliterans, which clogs the arteries in the legs, as well as ischemic heart disease (IHD), deteriorating blood circulation in the heart. Unlike cancers, often untraceable due to different gene re-combinations involved, the two disorders listed above can be treated with a method of physics - vascularization. Therefore, among all the genetic medication types, treatment of these diseases represents the field that is nearest to practical applications.

CORPORATE ALLIANCES

- 1) Daiichi Sankyo Co., has been cooperating with us in development of HGF Plasmid in the fields of peripheral arterial disease (PAD) and Ischemic heart disease (IHD). They own marketing rights in Japan.
- 2) Shionogi obtained global marketing rights of NFkB Decoy for skin diseases. Co-development has started by selecting Atopic Dermatitis as the first target indication.
- 3) Vical, Inc. and AnGes executed a collaborative R&D agreement for Allovectin-7 for advanced metastatic melanoma. In addition, AnGes MG obtained development and marketing rights of Allovectin-7 in Asia.
- 4) BioMarin Pharmaceutical Inc. provided AnGes MG with exclusive rights to market and distribute Naglazyme for Mucopolysaccharidosis VI in Japan.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Collatogene	PAD, CLI, Lymphedema	Phase III	Partnering ex-Japan
Allovectin-7(DNA Vaccine)	Metastatic Melanoma	Phase III	Partnering
Naglazyme	Mucopolysaccharidosis VI	On Market	Sales
Functional Peptides	Wound	Optimized Lead	
HGF Plasmid	Lymphedema	Phase I	Partnering
NFkB Decoy	Atopic Dermatitis	Phase II, IIa, IIb	Partnered with Shionogi

SENIOR MANAGEMENT


Ei Yamada, PhD, President & CEO • **Masanori Muryama**, Executive Vice President • **Shunsuke Sami, PhD**, Executive Vice President

BOARD OF DIRECTORS

Shirow Enoki, Former President & Chairman, Seikagaku Corporation

TRADING STATUS AS OF OCTOBER 5, 2011

TOKYO: 4563



Market Data

Current Price	62900.00
Currency	Japanese Yen
Net Change	-3.68
Volume	87
YTD % Change	-0.45
52Wk Range	58,100.00–131000.00
Avg. Daily Volume (thousands).....	273

First Call Data

Market Cap (MM)	7,694.8
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-13206.14
EPS (Last Fiscal Year)	-15925.16
Consensus Estimate (Y)	-13206.14
Consensus Recommend	--
Price/Sales	26.07

Shareholders

<i>Institution</i>	<i>Holding %</i>
Siemens Kapitalanlagegesellschaft mbH	0.0%
Washington State Investment Board.....	0.0%
KBC Fund Management Ltd.	0.0%
--	--
--	--
<i>Mutual Fund</i>	<i>Holding %</i>
Siemens Kapitalanlagegesellschaft mbH	0.0%
Washington State Investment Board.....	0.0%
KBC Fund Management Ltd.	0.0%
--	--
--	--

Source: Thomson Reuters

Apeiron Biologics AG

Presenting Company

Clinical Foci: Oncology • Immunology • Skin/Dermatological

Hans Loibner

Chief Executive Officer

Campus-Vienna-Biocenter 5
1030 Vienna
Austria

www.apeiron-biologics.com

43-1-8656577

Incorporated: 2003

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

Apeiron and the Children's Oncology Group announced a collaboration in a phase II study with Apeiron's APN301 in pediatric neuroblastoma patients. It will be conducted in multiple hospitals in the U.S. and Canada.

June 2011: Apeiron signed agreements with the Children's Cancer Research Institute, Vienna and the European Neuroblastoma Research Network that grant Apeiron the rights to the antibody ch14.18, currently in a phase III in many centers in Europe.

2010: Apeiron signed an exclusive licence agreement with GSK for APN01, a recombinant enzyme (ACE2) for the treatment of ARDS and other diseases. Upfront payment was GBP 11 mio with a total deal volume of GBP 207 mio plus royalties.

Upcoming

Start of phase II with APN01 in Acute Respiratory Distress Syndrome by GSK.

Start of pilot study with APN201 against radiation-induced skin damage.

Entry into man with APN401 (ex-vivo silenced Cbl-b against cancer).

CORPORATE MISSION

Apeiron, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer and related conditions. In addition to an innovative preclinical pipeline, Apeiron presently has one clinical phase III project and three projects in phase II. Apeiron's business strategy is to generate value by applying its know-how to advance projects towards clinical proof of concept. Apeiron's primary customers include all pharmaceutical/biotech companies active in the relevant disease areas. In certain cases, however, Apeiron may complete all development stages and market the final product directly.

PROPRIETARY TECHNOLOGY

Apeiron offers a LC-MS/MS based analytical service that is able to profile peptides in plasma and other biological samples down to concentrations in the low pg/ml range. This diagnostic method is called RAS-fingerprint (originally developed for the renin angiotensin system) has thus unreached sensitivity and is a unique tool for personalized medicine and biomarker discovery.

CORPORATE ALLIANCES

Major licensing deal with GlaxoSmithKline (GSK) since early 2010 (total deal volume up to GBP £207 million plus royalties on sales). GSK licensed Apeiron project APN01 for all territories and indications. Originally, it will be developed in Acute Respiratory Distress Syndrome where it is about to enter phase II.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
APN01	Acute Respiratory Distress Syndrome	Phase I	Start of phase II imminent
APN201	Radiation-induced skin damage	Phase II, IIa, IIb	Efficacy data
APN301	Neuroblastoma	Phase II, IIa, IIb	Phase II recently started in US/Canada
APN311	Neuroblastoma	Phase III	Recruitment in phase III ongoing
APN401	Cancer	Preclinical	Start of clinical trial
APN411	Cancer	Preclinical	
APN501	Cancer	Preclinical	
APN601	Pain	Preclinical	

SENIOR MANAGEMENT

Hans Loibner, Chief Executive Officer • **Manfred Schuster**, Chief Operating Officer • **Lukas Kadawy**, Chief Financial Officer • **Patrick Burgermeister**, Business Development

BOARD OF DIRECTORS

DDr. Manfred Reichl, Entrepreneur & Former Senior Partner, Roland Berger Strategy Consultants • **Josef Penninger, MD**, Founding Scientific Director of the Institute of Molecular Biology (IMBA) • **Martin Bartenstein, PhD**, Politician, Entrepreneur, Former CEO, Lannacher Heilmittel GmbH • **Erwin Rasinger, MD**, Deputy for Healthcare, National Assembly, Municipal Council of Vienna

SCIENTIFIC ADVISORY BOARD

Josef Penninger, Institute for Molecular Biotechnology, Austria • **Ulrich Granzer**, Granzer Consulting • **Friedrich Lottspeich, MPI** • **Gavin Oudit**, Alberta Heart Institute • **Hellmut Samonigg**, University Clinic Graz • **Arthur Slutsky**, University Toronto • **Wolfgang Stoiber**, JSB

Aquinox Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Pulmonary, Immunology, Drug Development

David J. Main

President & CEO

Suite 430 - 5600 Parkwood Way
Richmond, BC V6V 2M2
Canada

www.aqxpharma.com

1-604-629-9223

Incorporated: 2006

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

June 2010: Aquinox completed a USD \$25 million Series B including new investor Pfizer Venture Investments along with all other existing investors: Johnson & Johnson Development Corporation, Baker Brothers Investments and BC Advantage Funds (VCC).

September 2010: Renowned Pharmacologist, Csaba Szabó, MD, PhD, was appointed Vice President, Research and Chief Scientific Officer of Aquinox to lead its world-leading research and development efforts.

Upcoming

January 2012: Aquinox anticipates announcing interim results of its first Phase IIa clinical study of its lead clinical candidate, AQX-1125.

CORPORATE MISSION

Aquinox Pharmaceuticals Inc. is a private, venture-backed biopharmaceutical company committed to the discovery and development of novel and targeted small molecule therapeutics for the treatment of inflammatory disease. The company is focused on developing drugs that act as activators of the enzyme SH2-containing inositol 5'-phosphatase (SHIP1). SHIP1 has been shown to counter-regulate the PI3K pathway in hematopoietic cells and compounds that activate it, such as those being developed by Aquinox, have potential applications in a broad range of inflammatory indications including Asthma, COPD, Arthritis, IBD, and Atopic Dermatitis. Aquinox is currently completing a Phase I clinical study in 52 healthy volunteers for its lead SHIP1 activator, AQX-1125, and anticipates initiating Phase IIa clinical studies in Q4 2011. AQX-1125 can be dosed once-a-day orally.

PROPRIETARY TECHNOLOGY

Aquinox's scientific founders discovered a unique biochemical enzyme called SH2-containing inositol 5'-phosphatase (SHIP1) and have shown that it regulates the critical PI3K pathway in blood cells. They have also demonstrated that small molecule drugs can regulate SHIP1. SHIP1 is unique in that it exclusively regulates blood cells and can be harnessed in the treatment of disorders such as multiple myeloma, leukemia, lymphoma, inflammation, allergy and autoimmune diseases while having no, or minimal, effect on non-blood tissues. SHIP1 is an ideal drug target allowing for the development of a number of potential drug candidates that interact with it. From this discovery, the company has created two research and development programs: the SHIP1 activator program and the SHIP1 inhibitor program

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
AQX-1125	Inflammation	Phase II, IIa, IIb
AQX-1000 Series	Inflammation	Lead Series
AQX-200 Series	Inflammation	Lead Series
AQX-300 Series	Inflammation, Oncology	Lead Series
SHIP1 Activators	Ocular Inflammation	Preclinical

SENIOR MANAGEMENT

David J. Main, President & CEO • **Thomas B. MacRury, PhD**, Chief Operating Officer • **David Chernoff, MD**, Chief Medical Officer • **Csaba Szabo, MD, PhD**, Chief Scientific Officer • **Lloyd Mackenzie**, Director • **Mr. Kamran Alam**, Chief Financial Officer • **Patrick Tam, PhD**, Director • **Jason Robertson**, Business Development

BOARD OF DIRECTORS

David J. Main, President & CEO, Aquinox Pharmaceuticals Inc. • **Kenneth Galbraith**, General Partner, Ventures West Capital • **Daniel Levitt, MD, PhD**, Chief Medical Officer, CytRx Corporation • **Asish Xavier, PhD**, Vice President, Johnson & Johnson Development Corporation • **Elaine Jones, PhD**, Executive Director, Pfizer Venture Investments • **Frank Holler**, President & CEO, Lion's Capital Corp.

FINANCING HISTORY

Round Date (Amount, US\$) 06/12/2007 (14.50 million) • 06/17/2010 (25.00 million)

Aradigm Corporation

BIO Member, Presenting Company

Clinical Foci: Pulmonary, Specialty Pharmaceutical, Drug Delivery

Igor Gonda

President & CEO

3929 Point Eden Way
Hayward, CA 94545
USA

www.aradigm.com

1-510-265-9000

OTC BB: ARDM

Incorporated: 1992

Employees: 13

Ownership: Public

HIGHLIGHTS

Recent

Positive safety and efficacy data from two Phase 2b clinical trials with once daily inhaled ciprofloxacin in patients with non-cystic fibrosis bronchiectasis.

Positive safety and efficacy data from a Phase 2a clinical trial with once daily inhaled liposomal ciprofloxacin in patients with cystic fibrosis.

Proof of principle human study in smokers, showing profound reduction of craving for cigarettes following single breath administration of inhaled nicotine by Aradigm's proprietary palm-size inhaler.

Upcoming

Partnerships on inhaled Ciprofloxacin and on inhaled Nicotine.

CORPORATE MISSION

Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases by pulmonologists. Current activities include development programs addressing the treatments of bronchiectasis, cystic fibrosis, inhaled bioterrorism infections and smoking cessation. In selecting our proprietary development programs, we primarily seek drugs approved by the United States Food and Drug Administration that can be reformulated for both existing and new indications in respiratory diseases. Our intent is to use our pulmonary delivery methods and formulations to improve their safety, efficacy and convenience of administration to patients.

PROPRIETARY TECHNOLOGY

1) AERx Inhalation Technology Platform that can deliver a great variety of drugs and biologics in the form of water solutions and nanodispersions efficiently and precisely into the lung typically in 1-2 breaths. 2) Liposomal nanoencapsulation to provide the convenience of once a day dosing, with potential benefits of improved drug efficacy, safety and tolerability.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Dual release Ciprofloxacin for inhalation	Bronchiectasis	Phase II, IIa, IIb	Partner program prior to Phase 3
Ciprofloxacin for inhalation	Cystic Fibrosis	Phase II, IIa, IIb	
Ciprofloxacin for inhalation	Prevention and treatment of inhaled bioterrorism infections	Phase II, IIa, IIb	Obtain non-dilutive funding for confirmatory non-human primate studies
Inhaled nicotine	Tobacco smoking cessation	Phase II, IIa, IIb	Obtain non-dilutive financing for Phase 2b study or partner
Sumavel (asset sold to Zogenix)	Migraine	On Market	Ongoing receipt of royalties on net sales

SENIOR MANAGEMENT


Igor Gonda, President & CEO • **Nancy Pecota**, Chief Financial Officer

BOARD OF DIRECTORS

Virgil D. Thompson (Chairman), Aradigm, Savient, Questcor • **Frank H. Barker**, Former company group chairman, Johnson & Johnson • **John M. Siebert**, Former Chairman & CEO, Cydex; former President & CEO, CIMA • **Igor Gonda**, CEO & President, Aradigm • **Tamar Howson**, Former Sr. VP, Bristol-Myers Squibb

SCIENTIFIC ADVISORY BOARD

Peter R. Byron, Medical College of Virginia • **Peter S. Creticos**, The Johns Hopkins University School of Medicine • **Stephen J. Farr**, Zogenix • **Michael Konstan**, Rainbow Babies and Children's Hospital • **Babatunde Otulana**, Aerovance • **Adam Wanner**, University of Miami • **Martin Wasserman**, Formerly Roche and AtheroGenics



Market Data

Current Price	0.16
Currency	US Dollar
Net Change	6.67
Volume	47,947
YTD % Change	-0.05
52Wk Range	0.12-0.29
Avg. Daily Volume (thousands)	299,840

First Call Data

Market Cap (MM)	31.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.06
EPS (Last Fiscal Year)	-0.03
Consensus Estimate (Y)	-0.06
Consensus Recommend	--
Price/Sales	36.98

Shareholders

<i>Institution</i>	<i>Holding %</i>
First Eagle Investment Management LLC	36.0%
Conus Partners, Inc.	5.6%
Fidelity Management & Research Co.	0.3%
Nomura Securities Co., Ltd. (Private Banking)	0.2%
Gutmann Kapitalanlage AG	0.1%
<i>Mutual Fund</i>	<i>Holding %</i>
First Eagle Investment Management LLC	36.0%
Conus Partners, Inc.	5.6%
Fidelity Management & Research Co.	0.3%
Nomura Securities Co., Ltd. (Private Banking)	0.2%
Gutmann Kapitalanlage AG	0.1%

Source: Thomson Reuters

Arbovax, Inc.

Presenting Company

Clinical Foci: Vaccines, Veterinary

Malcolm Thomas

President & CEO

617 Hutton Street
Raleigh, NC 27606
USA

www.arbovax.com

1-919-655-0412

Incorporated: 2005

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Completed successful primate trials on Dengue 2 candidate.

Upcoming

Complete animal trials on Chikungunya vaccine.
complete tetravalent Dengue vaccine trials in primates.
GMP Production and Human Phase 1 clinical trials.

CORPORATE MISSION

ARBOVAX™, Inc. has a unique and innovative, proprietary technology that modifies insect-borne viruses (Arboviruses) preventing them from replicating in mammalian cells. ARBOVAX will leverage this technology through partnerships with pharmaceutical companies to facilitate the development of a portfolio of improved human and animal vaccines against the worldwide threat of arthropod-borne diseases.

PROPRIETARY TECHNOLOGY

The technology is based on a modification of the transmembrane portion of the virus which allows it to replicate normally in insect cells while inhibiting its ability to reproduce in mammalian cells. The resulting virus produces immunity in the absence of disease.

CORPORATE ALLIANCES

CRADA US army

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Dengue Fever vaccine	Dengue Fever	Preclinical	Tetravalent vaccine testing in primates
Chikungunya vaccine	Chikungunya fever	Preclinical	Testing in mouse model

SENIOR MANAGEMENT

Malcolm Thomas, President & CEO • **Raquel Hernandez, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Christopher English, Former President, Biometric Imaging, • **Jonathan Lawrie, PhD**, NCBC • **Charlton Owensby, MD, JD, MBA, PAN** • **Jeremy Mario**, MFP • **Leslie Alexandre, DrPH**, Consultant; Adjunct Professor, Dept. of Management, Innovation and Entrepreneurship, North Carolina State University • **Troy Knauss**, Partner, Guardant Partners • **Malcolm Thomas**, President & CEO, Arbovax

FINANCING HISTORY

Round Date (Amount, US\$) 07/01/2008 (1.50 million) • 01/01/2010 (1.70 million)

Investors: Piedmont Angel Network (17%) • Mario Family Partners (11%) • Research Development Foundation (17%) • Wilmington Investor Network (3%) • Emergent Growth Fund (4%)

ASLAN Pharmaceuticals Pte. Ltd.

BIO Member, Presenting Company

Clinical Foci: Oncology • Drug Development • Specialty Pharmaceutical

Carl Firth

Chief Executive Officer

10A Bukit Pasoh Road
Singapore 089824
Singapore

www.aslanpharma.com

65-62-224235

Incorporated: 2010

Employees: 12

Ownership: Private

HIGHLIGHTS

Recent

Licensing of ASLAN001 from Array Biopharma.
Close of Series A financing in April 2011, providing USD \$12 million for first compounds.
Nominated by Scrips for Best Company in an Emerging Market Award.

Upcoming

Soon to announce the in-licensing of our second and third compounds.

CORPORATE MISSION

Headquartered in Singapore, ASLAN is a specialty pharmaceutical company which focuses on oncology, respiratory and inflammatory diseases to develop medicines in Asia for global markets. Our lead compound, licensed from Array Biopharma, is a phase 2 pan-HER inhibitor being developed for gastric cancer. We have a team uniquely qualified in both local and Asia drug development, led by Alan Barge (the former global head of oncology at AstraZeneca) and Mark McHale (the former head of molecular sciences, respiratory / inflammation at AstraZeneca). We are partnering with leading global pharma and biotech companies to build a proprietary portfolio of early clinical compounds, taking advantage of the innovation, quality and efficiency that exists in Asian clinical centers.

CORPORATE ALLIANCES

ASLAN licensed global rights (all territories) to develop a phase 2 oncology compound from Array Biopharma in July 2011.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
ASLAN001	Gastric cancer	Phase II, IIa, IIb

SENIOR MANAGEMENT

Carl Firth, Chief Executive Officer • **Mark McHale**, Chief Scientific Officer • **Alan Barge**, Chief Medical Officer • **Jeff Tomlinson**, Chief Business Officer

BOARD OF DIRECTORS

Carl Firth, ASLAN Pharmaceuticals • **Peter Brooks**, Sagamore Bioventures • **Damien Lim**, Bioveda Capital • **Mike Kleine**, Endogastric solutions

FINANCING HISTORY

Round Date (Amount, US\$) 07/01/2010 (2.40 million) • 04/01/2011 (12.00 million)

Investors: BioVeda Capital (0%) • Sagamore Bioventures (0%)

Astellas Pharma Inc.

BIO Member

Clinical Foci: Oncology • Immunology • Urological

Yoshihiko Hatanaka

Chief Executive Officer

3-11, Nihonbashi-Honcho 2-chome
Tokyo 103-8411
Japan

www.astellas.com

81-33244-3000

Tokyo: 4503

Incorporated: 2005

Employees: 16000

Ownership: Public

CORPORATE MISSION

Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology & Infectious Disease, Oncology, Neuroscience, and DM Complications & Metabolic Diseases. In June, 2010, OSI Pharmaceuticals, Inc. joined Astellas group. OSI is committed to “shaping medicine and changing lives” by discovering, developing and commercializing high-quality, novel and differentiated targeted medicines designed to extend life and improve the quality of life for patients with cancer and diabetes/obesity.

PROPRIETARY TECHNOLOGY

We plan to use multiple NME (New Molecular Entity) platforms for drug discovery across each of Astellas’ focus research areas. The integration of Agensys and the establishment of the joint venture Perseid Therapeutics with US-based Maxygen have helped reinforce our technical research capabilities. In addition to traditional strengths in low-molecule synthesis and fermentation technologies, we have been able to build a base of expertise in antibody/protein drug technologies. As a result, we now have an increased range of drug discovery technologies on which we can draw. In each area of research focus, we can choose the most appropriate drug discovery technology for each project, whether this be low-molecule synthesis, fermentation, antibodies or protein drug technologies.

CORPORATE ALLIANCES


Ambit, AstraZeneca, Basilea, Cardiome, FibroGen, GSK, Ironwood, Maxygen, Medivation, Pfizer, Roche, Sanofi-Aventis, Solvay, Theravance, etc.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Prograf (tacrolimus)	Prevention of rejection after organ transplantation	On Market
Flomax (tamsulosin)	Benign prostatic hyperplasia	On Market
VESIcare (solifenacin)	Overactive bladder	On Market
Micamine (micafungin)	Fungal infection	On Market
mirabegron	Overactive bladder	NDA/BLA filed, or in process
telavancin	infectious disease	NDA/BLA filed, or in process
MDV3100	prostate cancer	Phase III
tivozanib	Renal cell carcinoma	Phase III
OSI-906	Adenocortical cancer	Phase III
isavuconazole	Fungal infection	Phase III

SENIOR MANAGEMENT

Yoshihiko Hatanaka, Chief Executive Officer



Market Data

Current Price	2900.00
Currency	Japanese Yen
Net Change	-1.56
Volume.....	2,408,600
YTD % Change	-0.06
52Wk Range	2,700.00-3345.00
Avg. Daily Volume (thousands)	1,802,622

First Call Data

Market Cap (MM)	1,357,097.0
Short Interest Shares.....	--
Short Interest Ratio.....	--
PE (Trailing 12 Months)	202.65
EPS (Last Fiscal Year).....	115.49
Consensus Estimate (Y)	202.65
Consensus Recommend.....	--
Price/Sales	1.38

Shareholders

<i>Institution</i>	<i>Holding %</i>
Wellington Management Co. LLP	3.1%
First Eagle Investment Management LLC	2.8%
International Value Advisers LLC.....	2.1%
Chuo Mitsui Asset Trust & Banking Co. Ltd.	1.5%
Nomura Asset Management Co., Ltd.	1.4%
<i>Mutual Fund</i>	<i>Holding %</i>
Wellington Management Co. LLP	3.1%
First Eagle Investment Management LLC	2.8%
International Value Advisers LLC.....	2.1%
Chuo Mitsui Asset Trust & Banking Co. Ltd.	1.5%
Nomura Asset Management Co., Ltd.	1.4%

Source: Thomson Reuters

Astex Pharmaceuticals Inc

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Oncology • Hematology • Drug Development

James Manuso, PhD, MBA

Chief Executive Officer

4140 Dublin Boulevard
Dublin, CA 94568
USA

www.astx.com
1-925-560-0100

NASDAQ: ASTX
Incorporated: 1996
Employees: 140
Ownership: Public

HIGHLIGHTS

Recent

Sept 2011: SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website.

July 2011: SuperGen completes acquisition of Astex Therapeutics.

July 2011: FDA Accepts DACOGEN® (Decitabine) sNDA Submission in Acute Myeloid Leukemia.

CORPORATE MISSION

Our corporate mission is to discover, develop and commercialize novel therapeutics with a primary focus in cancer.

We will accomplish this mission through creating "de-risked" products for partnership with leading pharmaceutical companies, developing our proprietary pipeline of novel cancer therapeutics, and selectively in-licensing assets having a strategic fit with an attractive cost-benefit ratio. An important part of our strategy is retention of key assets for late-stage development or potential commercialization with a partner.

PROPRIETARY TECHNOLOGY

The Pyramid™ platform of Astex Pharmaceuticals™ integrates biophysical techniques, such as X-ray crystallography, nuclear magnetic resonance spectroscopy and calorimetry, with fragment library design and a range of computational methodologies. This integration creates a proprietary approach for fragment-based drug discovery. More information can be found at: <http://astx.com/technology/pyramid-platform/>

CORPORATE ALLIANCES


AstraZeneca; Eisai; GSK; Janssen; Johnson & Johnson; Novartis.

PRODUCTS

Name	Indication	Phase	Milestone
Dacogen	MDS	On Market	NDA submitted for elderly AML, 2011
AT13387, HSP-90 inhibitor	GIST	Phase II, IIa, IIb	
SGI-110 DNMT inhibitor	Hypomethylation therapy in MDS, AML	Phase I	
Amuvatinib (MP-470)	Small cell lung cancer or SCLC	Phase II, IIa, IIb	
AT7519, CDK inhibitor	Multiple Myeloma	Phase II, IIa, IIb	
AT9283, Aurora/JAK2 inhibitor	Multiple Myeloma	Phase II, IIa, IIb	
LEE011, CDK4 inhibitor (NVS)	Cancer	Phase I	Ph1 initiated in Jan. 2011
AZD5363, PKB/AKT inhibitor (AZN)	Cancer	Phase I	Ph1 initiated in Apr. 2011

SENIOR MANAGEMENT

James Manuso, PhD, MBA, Chief Executive Officer • Harren Jhoti, PhD, President • Mohammad Azab, MD, MSc, MBA, Chief Medical Officer • Martin Buckland, DPhil, MBA, Chief Business Officer • Michael Molkentin, CPA, Chief Financial Officer



Market Data

Current Price	1.9
Currency	U.S. Dollar
Net Change	-0.52
Volume	257,784
YTD % Change	-0.275
52Wk Range	1.7-3.35
Avg. Daily Volume (thousands)	439,549

First Call Data

Market Cap (MM)	176.29
Short Interest Shares	4,373,132
Short Interest Ratio	11.53
PE (Trailing 12 Months)	0.01
EPS (Last Fiscal Year)	0.27
Consensus Estimate (Y)	0.01
Consensus Recommend	--
Price/Sales	2

Shareholders

<i>Institution</i>	<i>Holding %</i>
BlackRock Fund Advisors	0.04202
Perimeter Capital Management LLC	3.1%
Segall, Bryant & Hamill Investment Counsel	2.5%
Wellington Management Co. LLP	2.5%
Dimensional Fund Advisors, Inc.	1.6%

Mutual Fund

	<i>Holding %</i>
BlackRock Fund Advisors	0.04202
Perimeter Capital Management LLC	3.1%
Segall, Bryant & Hamill Investment Counsel	2.5%
Wellington Management Co. LLP	2.5%
Dimensional Fund Advisors, Inc.	1.6%

Source: Thomson Reuters

Auspex Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS • AutoImmune • Pulmonary

Lawrence C. Fritz, PhD

President & CEO

3366 N. Torrey Pines Court, Suite 225
La Jolla, CA 92037
USA

www.auspexpharma.com

1-858-558-2400

Incorporated: 2001

Ownership: Private

HIGHLIGHTS

Recent

Completed phase 1 clinical trial with SD-809, deuterium-substituted tetrabenazine. SD-809 is being developed for the treatment of chorea associated with Huntington's Disease.

Expanded management team with the appointment of Lawrence C. Fritz, Ph.D. as President and CEO. Dr. Fritz was previously a founder of Athena Neurosciences and Conformia Therapeutics.

CORPORATE MISSION

Auspex Pharmaceuticals is focused on the development of deuterium-substituted analogues of known, validated drugs. Deuterium is a non-radioactive, non-toxic, naturally-occurring form of hydrogen. Our compounds are indistinguishable pharmacologically from the original, hydrogen-containing compounds, but have improved metabolic properties. Importantly, deuterated compounds are new chemical entities (NCE's) eligible for composition-of-matter patent protection. We believe that our drugs can be developed much more quickly and less-expensively than conventional NCE's and with much less risk. Thus, deuterium-substituted compounds constitute a new, unique class of NCE, one with a risk profile similar to that of a generic, but with the patent protection of a new molecule. Our main programs are:

- 1) Deuterium-substituted tetrabenazine (SD-809) for the treatment of the movement disorder (chorea) associated with Huntington's disease. Tetrabenazine is currently marketed by Lundbeck in the US.
- 2) Deuterium-substituted tofacitinib (SD-900) for the treatment of rheumatoid arthritis and other autoimmune diseases. Tofacitinib is the Pfizer small molecule JAK inhibitor that has finished phase 3 testing and is expected to be submitted to the US FDA for NDA approval later this year.
- 3) Deuterium-substituted pirfenidone (SD-560) for the treatment of idiopathic pulmonary fibrosis. Pirfenidone is marketed by Shionogi in Japan and by InterMune in the EU. InterMune is also pursuing the development of pirfenidone in the US, and is currently in phase 3.
- 4) Deuterium-substituted ticagrelor (SD-970) for the treatment of acute coronary syndrome. Ticagrelor (Brilinta) is Astra-Zeneca's new anti-platelet drug that was recently approved in the EU and US.

PROPRIETARY TECHNOLOGY

In each case, we believe that our deuterium-substituted analogue will have significant advantages over the parent compound. The selective substitution of deuterium for hydrogen in these molecules attenuates their rate of metabolism by cytochrome P450 enzymes, providing an increase in drug half-life and systemic exposure (AUC). Thus, equivalent drug exposure can be attained with lower drug doses and/or less frequent dosing. These benefits can lead to improved safety, compliance, and convenience. In addition, deuteration can reduce patient-to-patient variability and drug-drug interactions providing further opportunities for improved safety and more reliable efficacy.

PRODUCTS

Name	Indication	Phase
SD-809: Deuterium-substituted tetrabenazine	Huntington's Disease, chorea	Phase I
SD-900: Deuterium-substituted tofacitinib	Rheumatoid arthritis, other autoimmune diseases	Preclinical
SD-560: Deuterium-substituted pirfenidone	Idiopathic pulmonary fibrosis	Preclinical
SD-970: Deuterium-substituted ticagrelor	Acute coronary syndrome	Preclinical
SD-254: Deuterium-substituted venlafaxine	Neuropathic pain	Phase I

SENIOR MANAGEMENT

Lawrence C. Fritz, PhD, President & CEO • Andreas Sommer, PhD, Chief Operating Officer

BOARD OF DIRECTORS

Pratik Shah, PhD, Thomas Mc Nerney & Partners • David Collier, MD, CMEA Ventures • Lawrence C. Fritz, PhD, President & CEO, Auspex Pharmaceuticals • Samuel R. Saks, MD, Consultant; Former CEO, Jazz Pharmaceuticals • Sep Sarshar, PhD, Founder, Auspex Pharmaceuticals, Inc.

Axikin Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Pulmonary, Drug Development, Immunology

Kevin Bacon, PhD Chief Scientific Officer

10835 Road to the Cure
San Diego, CA 92121
USA

www.axikin.com

1-858-458-1890

Incorporated: 2008

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

Axikin's GPCR inhibitors have proven efficacious in preclinical non-human primate models of allergic asthma.

Axikin's COPD target may have a significant role to play in fibrosis - a common pathology associated with COPD.

Axikin's GPCR inhibitors have shown efficacy in vitro, in models relevant to ocular inflammation, and age-related macular degeneration.

Upcoming

Axikin is on track to file an IND by 4Q11 for AXP1275 in asthma and rhinitis, beginning clinical trials in 1Q12.

Axikin anticipates positive results for the in vivo efficacy of GPCR inhibitors in a non-human primate model of AMD (age-related macular degeneration).

Axikin anticipates positive results for the in vivo efficacy of kinase-specific siRNA in a murine (hu-SCID) model of fibrosis.

CORPORATE MISSION

Axikin Pharmaceuticals, Inc. is focused on small molecule drug discovery and development for respiratory diseases and inflammation. Specifically targeting asthma, rhinitis, and eosinophilic esophagitis, Axikin's targets may also have strong implications in oncology, ophthalmology and neuroinflammation.

PROPRIETARY TECHNOLOGY

Small molecule inhibitors of GPCR and kinase targets.

Novel kinase gene upregulated in COPD.

SENIOR MANAGEMENT

Kevin Bacon, PhD, Chief Scientific Officer • **Peter McWilliams, PhD**, Venture Capitalist • **Kevin B. Bacon, PhD**, President

BOARD OF DIRECTORS

Peter McWilliams, PhD, Principal, Sanderling Ventures • **Kevin Bacon, PhD**, President, Axikin Pharmaceuticals, inc • **Fred Middleton**, Principal, Sanderling Ventures • **Walter Olesiak**, Mitsui Ventures

SCIENTIFIC ADVISORY BOARD

Gary Hardiman, UCSD • **Gerard Manning**, Salk Inst.

FINANCING HISTORY

Round Date (Amount, US\$) 07/11/2011 (3.50 million)

BCO Pharma Ltd.

Clinical Foci: Drug Delivery, Infectious Disease, Cardiovascular Disease

Seamus O'Loan
Chief Executive Officer

Unit 1, Fota Business Park
Carrigtwohill, Cork
Ireland

www.bcopharma.com

1-484-919-8089

Incorporated: 2009

Ownership: Private

CORPORATE MISSION

BCO Pharma focuses on pediatric care and is located in Philadelphia, PA and Cork, Ireland. The company has two products in development. One is a simple way to treat otitis media topically in patients that do not have tympanostomy tubes ("grommets"). This form of drug delivery—which is currently not practical absent an appropriate delivery mechanism—allows for a several hundred-fold increase in the concentration of drug in the middle ear compared to what can be achieved by dosing either orally or by injection. The product is ideal for the one third of patients whose otitis media is severe or recurring.

The other product—a novel presentation of a anti-hypotensive agent for babies and children—is expected to enter a phase III in the fall of this year. Approximately 200,000 children in Europe, disproportionately newborns, will be treated for hypotension each year using drugs not studied in pediatric populations. The trial is being funded in part by the European Union and we expect to be granted a 10-year regulatory exclusivity in the EU by way of a Pediatric Marketing Use Authorizing (PUMA). We believe the product will also qualify as an orphan drug in Europe, the US and Japan.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
BCO 1	Neonatal Hypotension	Phase III	To begin dosing in November 2011
BCO 2	Otitis Media	Other	To initiate phase III trial in mid 2012

SENIOR MANAGEMENT

Seamus O'Loan, Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Joseph E. Dohar, MD, MS, FAAP, FACS, University of Pittsburgh/Children's Hospital, Pittsburgh • **Eugene Dempsey, MB, BCh, BAO, MD, MSc, FRCPI**, Cork University Maternity Hospital • **Michael Harney, MB, BCh, BAO, FRCSI, MD, FRCS (ORL)**, Bon Secours Hospital, Cork

BioMedTracker

Clinical Foci: CNS • Immunology • Oncology

Robert F. Kyle
Chief Executive Officer

3655 Nobel Drive
San Diego, CA 92122
USA

www.biomedtracker.com

1-858-200-2390

Incorporated: 1999

Employees: 50

Ownership: Private

HIGHLIGHTS

Recent

Likelihood of Approval study

CORPORATE MISSION

BioMedTracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and intuitive drug information database. Clients from the pharmaceutical, biotech, and investment industries rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication. Over the last several years, BioMedTracker has become the leader in providing objective information alongside subjective clinical assessments on pipeline drugs worldwide.

CORPORATE ALLIANCES

Clients include pharmaceutical, biotech, hedge funds, mutual funds and options traders.

SENIOR MANAGEMENT

Robert F. Kyle, Chief Executive Officer

Bio-Path Holdings, Inc.

Presenting Company

Clinical Foci: Drug Delivery, Oncology

Peter Nielsen

Chief Executive Officer

2626 South Loop
Houston, TX 77054
USA

www.biopathholdings.com

1-832-971-6616

OTC BB: BPTH

Incorporated: 2000

Ownership: Public

HIGHLIGHTS

Recent

First cohort of Phase I trial with lead compound Grb-2 completed. Compound was well tolerated and activity seen at low starting dose. Second cohort currently enrolling.

Dr. Ana M. Tari joins company as Director, Preclinical Operations and Research.

Completed private placement, raising USD \$1.8 million and received \$244,000 government grant.

Upcoming

Completion of Phase I second cohort.

Potential presentation at American Society of Hematology (ASH) Annual Meeting in December.

CORPORATE MISSION

Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path's lead product candidate, Liposomal Grb-2, is in a Phase I study for blood cancers. Bio-Path's second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors, and its third candidate is a liposomal siRNA cancer drug that is in the final pre-clinical development stage. These product candidates and the delivery technology have been licensed from The University of Texas MD Anderson Cancer Center.

PROPRIETARY TECHNOLOGY

Neutral liposomal delivery technology for nucleic acid drugs.

CORPORATE ALLIANCES

M.D. Anderson Cancer Center

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Liposomal Grb-2	blood cancers	Phase I	First Cohort of study completed; drug well tolerated and activity already seen even at low-starting dose
BP-100-1.02	Lymphoma and solid tumors	Preclinical	Compound is IND ready
BP-101.2.01	Ovarian, colon, thyroid and head & neck cancers	Preclinical	

SENIOR MANAGEMENT


Peter Nielsen, Chief Executive Officer • **Doug Morris**, Business Development • **Ana Maria Tari, PhD, MBA**, Chief Scientific Officer

BOARD OF DIRECTORS

Peter Nielsen, Bio-Path Holdings, Inc. • **Douglas Morris**, Celtic Investment Inc. • **Gillian C. Ivers-Read**, Clovis Oncology • **Thomas Garrison, MD**, Practicing physician

SCIENTIFIC ADVISORY BOARD

Gabriel Lopez-Berestein, MD, MD Anderson Cancer Center • **Anil Sood, MD**, MD Anderson Cancer Center



Market Data

Current Price	0.34
Currency	US Dollar
Net Change	-2.30
Volume	--
YTD % Change	-0.03
52Wk Range	0.25-0.85
Avg. Daily Volume (thousands)	18,964

First Call Data

Market Cap (MM)	19.1
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.04
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	--

Source: Thomson Reuters

BioRelix, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease • Biodefense • Veterinary

Brian R. Dixon, PhD

President & CEO

5 Science Park
New Haven, CT 06511
USA

www.biorelix.com

1-203-785-9282

Incorporated: 2005

Employees: 10

Ownership: Private

CORPORATE MISSION

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective products based on novel patented RNA targets, termed riboswitches, which were identified in the laboratory of BioRelix co-founder, Ronald Breaker, PhD, Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix has a skilled and experienced in-house team, world class external partners, and a well-founded strategy for applying these assets to drug discovery.

BioRelix investors include CHL Medical Partners, New Leaf Venture Partners, Aisling Capital, Novartis Venture Fund, Elm Street Ventures and Alexandria Real Estate Equities.

PROPRIETARY TECHNOLOGY

BioRelix owns a worldwide license to develop and market RiboSwitch targeted medicines. Discovered in the lab of Dr. Ronald Breaker, Riboswitches are short stretches of mRNAs that bind small molecules and control genes that are essential for the survival of many pathogenic microbes. Multiple classes of RiboSwitches have been identified and each has potential as a novel anti-infective drug target.

SENIOR MANAGEMENT

Brian R. Dixon, PhD, President & CEO

BOARD OF DIRECTORS

Ronald W. Lennox, CHL Medical Partners • **Campbell Murray**, Novartis Venture Funds • **Philippe Chambon**, New Leaf Ventures • **William Wiesler**, Yale University • **A. Donny Strosberg**, The Scripps Institute Florida • **Brian R. Dixon**, BioRelix, Inc.

SCIENTIFIC ADVISORY BOARD

Richard White, Half Moon Bay Biotechnology Consulting • **Ronald Breaker**, Yale University • **Robert Moellering**, Harvard University, Beth Israel Deaconess Medical Center • **Robert Batey**, University of Colorado • **Manuel Navia**, Oxford Bioscience Partners • **Frank Sciavolino** • **Mark Velleca**, CGI Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Hormone Therapy • Reproductive • Oncology

Stephen M. Simes Chief Executive Officer

111 Barclay Boulevard
Lincolnshire, IL 60069
USA

www.biosantepharma.com

1-847-478-0500

NYSE: BPAX

Incorporated: 1996

Employees: 58

Ownership: Public

HIGHLIGHTS

Recent

Two pivotal Phase III efficacy trials of LibiGel® in treatment of female sexual completed; Data in 4Q11; LibiGel® increased the number of satisfying sexual events by 238% in Phase II study.

One LibiGel® Phase III study is a cardiovascular and breast cancer safety study; 3,656 women enrolled. The study's DMC has reviewed all unblinded data seven times and has advised BioSante to continue per protocol with no modifications.

Closed USD \$48 million underwritten financing; As of August 31, 2011, approximately \$73.3 million in cash.

Upcoming

LibiGel® efficacy data in 4Q11; safety data in 3Q12.

Submit LibiGel® NDA in 2012.

Bio-T-Gel PDUFA 2/14/12

CORPORATE MISSION

BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.

PROPRIETARY TECHNOLOGY

BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a US Food and Drug Administration (FDA) Special Protocol Assessment. BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the US by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals.

CORPORATE ALLIANCES

AZUR Pharma for marketing rights in the U.S. to Elestrin™ (estradiol gel) for the treatment of hot flashes in menopausal women.

Teva is responsible for regulatory and marketing issues for Bio-T-Gel for hypogonadism.

Pantarhei Biosciences for the development and commercialization of The Pill Plus, triple component contraceptive.

Aduro Biotech for the development of BioSante's pancreatic cancer vaccine in combination with Aduro's platform listeria vaccine.

The Hussman Foundation for development of BioSante's melanoma vaccine.

PRODUCTS

Name	Indication	Phase	Milestone
LibiGel	Female Sexual Dysfunction (FSD)	Phase III	Submit NDA in 2012.
Bio-T-Gel	Male hypogonadism	NDA/BLA filed, or in process	FDA PDUFA date 2/14/12.
Elestrin	Hot Flashes	Cleared for US Marketing	Increase sales.
The Pill Plus	Contraception	Phase II, IIa, IIb	Additional Phase II data.
BioSante Cancer Vaccines	Therapeutic cancer vaccines in pancreatic, breast and prostate cancer, among other cancer types	Phase II, IIa, IIb	Phase II data in various cancer types.

SENIOR MANAGEMENT


Stephen M. Simes, Chief Executive Officer • **Phillip Donenberg**, Chief Financial Officer • **Bill Milling**, Chief Operating Officer • **Michael Snabes, MD, PhD**, Chief Medical Officer • **Joanne Zborowski**, Vice President • **Jeffrey Winkelman, PhD, JD**, Vice President • **Sandy Croak-Brossman, PhD**, Vice President • **Patty Adams**, Vice President

BOARD OF DIRECTORS

Louis W. Sullivan, MD, Morehouse School of Medicine • **Fred Holubow**, William Harris Investors • **Ross Mangano**, JO & Co. • **Edward Rosenow, III, MD**, Mayo Clinic • **Stephen Sherwin, MD**, Chairman BIO • **John Potts, MD**, Mass General • **Stephen M. Simes**, CEO, BioSante Pharmaceuticals, Inc.

TRADING STATUS AS OF OCTOBER 5, 2011

NYSE: BPAX



Market Data

Current Price	55.56
Currency	U.S. Dollar
Net Change	3.18
Volume	1,233,188
YTD % Change	-0.04
52Wk Range	51.83–66.64
Avg. Daily Volume (thousands)	1,042,945

First Call Data

Market Cap (MM)	35,692.5
Short Interest Shares	4,823,476
Short Interest Ratio	4.53
PE (Trailing 12 Months)	5.63
EPS (Last Fiscal Year)	5.21
Consensus Estimate (Y)	5.63
Consensus Recommend	5.64
Price/Sales	1.67

Shareholders

Institution

	<i>Holding %</i>
TD Asset Management, Inc.....	6.7%
RBC Global Asset Management, Inc.....	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.....	2.2%

Mutual Fund

	<i>Holding %</i>
TD Asset Management, Inc.....	6.7%
RBC Global Asset Management, Inc.....	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.....	2.2%

Source: Thomson Reuters

BIOTECanada

BIO Member

Peter Brenders

President & CEO

600 - 1 rue Nicholas St
Ottawa, ON K1N 7B7
Canada

www.biotech.ca

1-613-230-5585

Incorporated: 1987

Employees: 11

Ownership: Private

CORPORATE MISSION

BIOTECanada is dedicated to the sustainable commercial development of biotechnology innovation in Canada. It is the national industry-funded association with over 250 member companies representing the broad spectrum of biotech constituents including emerging and established firms in the health, industrial, and agricultural sectors, as well as academic and research institutions and other related organizations.

SENIOR MANAGEMENT

Peter Brenders, President & CEO • **Lynn Buchanan**, Vice President • **Cate McCready**, Vice President • **Graeme Fraser**, Director • **Mejda Lortie**, Director • **Kira Pejemsky**, Director

BMO Capital Markets - Banking

Sponsor

Thomas V. Milroy
Chief Executive Officer
 3 Times Square, 29th Floor
 New York, NY 10036
 USA

www.bmocm.com
 1-212-702-1160

Toronto: BMO
Incorporated: 2006
Employees: 2000
Ownership: Public

CORPORATE MISSION


BMO Capital Markets is the investment banking arm of the Bank of Montreal. We are part of BMO Financial Group, one of the largest diversified financial service providers in North America with a market capitalization of approximately USD \$35 billion. Our investment banking business provides full services to mid-cap and emerging growth companies. Our healthcare investment banking team is comprised of approximately 30 bankers, many with substantial experience.

SENIOR MANAGEMENT

Thomas V. Milroy, Chief Executive Officer • **Eric C. Tripp**, President • **Perry Hoffmeister**, Other • **Bill Butt**, Managing Director • **Annette Grimaldi**, Managing Director

TRADING STATUS AS OF OCTOBER 5, 2011

TORONTO: TSE:BMO



Market Data

Current Price	57.66
Currency	Canadian Dollar
Net Change	1.28
Volume	1,807,871
YTD % Change	0.00
52Wk Range	55.02–63.94
Avg. Daily Volume (thousands)	1,876,203

First Call Data

Market Cap (MM)	36,738.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	5.62
EPS (Last Fiscal Year)	5.18
Consensus Estimate (Y)	5.62
Consensus Recommend	5.62
Price/Sales	1.74

Shareholders

<i>Institution</i>	<i> Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%
<i>Mutual Fund</i>	<i> Holding %</i>
TD Asset Management, Inc.	6.7%
RBC Global Asset Management, Inc.	6.4%
Bank of Nova Scotia Asset Management	3.1%
CIBC World Markets, Inc.	2.9%
I. G. Investment Management Ltd.	2.2%

Source: Thomson Reuters

Campbell Alliance

Sponsor

Nader Naeymi-Rad

Chief Executive Officer

8045 Arco Corporate Drive
Raleigh, NC 27617
USA

www.campbellalliance.com

1-919-844-7100

Incorporated: 1997

Employees: 325

Ownership: Private

CORPORATE MISSION

Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. Campbell Alliance is the leading management consulting firm specializing in the pharmaceutical and biotechnology industry. The firm's clients include all of the world's top-20 pharmaceutical companies, as well as numerous emerging and midsize firms. Campbell Alliance is organized into practice areas, each specializing in a critical industry function: Brand Management, Business Development, Clinical Development, Pricing and Market Access, Medical Affairs, and Sales. From its locations in Raleigh, NC; Parsippany, NJ; Los Angeles; San Francisco; Chicago; Boston; Philadelphia; New York City; Atlanta; and Zug, Switzerland the firm serves clients throughout North America, Europe, and Japan. For more information please visit www.campbellalliance.com.

SENIOR MANAGEMENT

Nader Naeymi-Rad, Chief Executive Officer • **Darius Naigamwalla**, Managing Director • **Michael Fleming**, Vice President

Catabasis Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Metabolic Disease, Drug Discovery, Drug Development

Jill Milne, PhD

Chief Executive Officer

One Kendall Square, Suite B14202
Cambridge, MA 02139
USA

www.catabasispharma.com

1-617-349-1971

Incorporated: 2008

Employees: 21

Ownership: Private

HIGHLIGHTS

Recent

09.08.11: Catabasis Pharmaceuticals Appoints Joanne M. Donovan, MD, PhD, as Chief Medical Officer.

08.01.11: PharmaVOICE: Michael Jirousek, PhD, Catabasis co-founder and CSO, recognized as one of "the 100 Most Inspiring People" in 2011.

06.14.11: Catabasis Pharmaceuticals Expands Leadership Team and Appoints Leading Experts to Clinical Advisory Board.

CORPORATE MISSION

Catabasis is a private, venture-backed biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids and other clinically validated compounds to create new medicines for the treatment of inflammatory and metabolic diseases. The company's scientific approach harnesses the beneficial effects of the essential omega-3 fatty acids DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid), which have clinical benefits as treatments for a wide range of diseases, including dyslipidemia, atherosclerosis and inflammatory diseases.

Effectively treating complex human disease requires targeting key biological pathways that are dysregulated. Preclinical studies have demonstrated that the company's compounds, which are new chemical entities, specifically modulate key nodes that converge upon a biological axis or disease state pathway, providing amplified efficacy and improved safety.

The company has a rich pipeline of omega-3 conjugated compounds that have the potential to treat a range of metabolic and inflammatory diseases. Its lead compound is in development to treat type 2 diabetes.

Catabasis was founded in 2008 by Chief Executive Officer Jill Milne, PhD; Chief Scientific Officer Mike Jirousek, PhD; Steven Shoelson, MD, PhD; Harvard Medical School and Joslin Diabetes Center on an approach that focuses on targeting inflammation to treat complex human diseases.

In 2010, Catabasis closed a USD \$39.6 million Series A financing. The company is backed by top-tier investors, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

PROPRIETARY TECHNOLOGY

Catabasis' proprietary chemistry platform produces NCEs that are conjugates of an omega-3 fatty acid and another clinically proven entity. The company's SMART linker technology provides an algorithm that enables Catabasis to move rapidly from concept to clinical candidate. This novel approach produces NCEs with superior efficacy and safety. The NCEs superior efficacy is due to targeting two opposing nodes in a disease pathway to produce a synergistic outcome. Superior safety is achieved by utilizing entities with proven clinical safety profiles and creating NCEs that are inactive until hydrolyzed in target tissues.

SENIOR MANAGEMENT

Jill Milne, PhD, Chief Executive Officer • **Joanne Donovan, MD, PhD**, Chief Medical Officer • **Chris Thomajan**, Chief Financial Officer • **Michael Curtis, PhD**, Vice President • **Lucienne Ronco, PhD**, Vice President • **Michael Jirousek, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Michael Ross, PhD, SV Life Sciences • **Jean George**, Advanced Technology Ventures • **Ron Laufer, MD**, MedImmune Ventures, Inc. • **Jeffrey Leiden, MD, PhD**, Clarus Ventures

SCIENTIFIC ADVISORY BOARD

Steve Shoelson, MD, PhD, Harvard Medical School and Joslin Diabetes Center • **Benjamin Cravatt, PhD**, Scripps Research Institute • **Diane Mathis, PhD**, Harvard Medical Center and National Academy of Sciences • **Ruslan Medzhitov, PhD**, Howard Hughes Medical Institute and Yale University • **Jerrold Olefsky, MD**, University of California, San Diego

FINANCING HISTORY

Round Date (Amount, US\$) 04/21/2010 (39.60 million) • 12/08/2010 (14.50 million)

Catalyst Pharmaceutical Partners, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Biopharmaceuticals, Drug Development

Patrick J. McEnany
Chief Executive Officer

355 Alhambra Circle
Coral Gables, FL 33134
USA

www.catalystpharma.com

1-305-529-2522

NASDAQ: CPRX

Incorporated: 2002

Employees: 7

Ownership: Public

HIGHLIGHTS

Recent

Enrolling patients in CPP-109 Phase II(b) trial.
Completed CPP-115 non-clinical studies necessary for IND filing.
Reported positive results of CPP-115 non-clinical Infantile Spasms study at Albert Einstein College of Medicine.

Upcoming

1Q12 - Results of CPP-115 US Phase I(a) study.
2Q12 - Complete enrollment of CPP-109 US Phase II(b) cocaine trial and
initiate CPP-115 US Phase I(b) study.
4Q12 - Top-line results for CPP-109 US Phase II(b) cocaine trial.

CORPORATE MISSION

Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. Catalyst has two products in development, and is currently evaluating its lead product and first-in-class GABA aminotransferase inhibitor candidate, CPP-109 (vigabatrin), for the treatment of cocaine addiction. CPP-109 has been granted "Fast Track" status by the US Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst also expects to evaluate CPP-109 for the treatment of other addictions. Catalyst is also developing CPP-115, another GABA aminotransferase inhibitor that is more potent than vigabatrin and has reduced side effects (e.g., visual field defects, or VFDs) from those associated with vigabatrin. Catalyst is planning to develop CPP-115 for several indications, including drug addiction, epilepsy (initially infantile spasms) and for other selected central nervous disease indications. CPP-115 has been granted orphan-drug designation for the treatment of infantile spasms by the FDA.

PROPRIETARY TECHNOLOGY

CPP-109 & its analog, CPP-115, increase GABA levels by inhibiting GABA-aminotransferase (GABA-AT). In epilepsy, increased GABA decreases overall excitability by raising the action potential threshold of many neurons. In addition, increased GABA dampens the perception of pleasure and reward associated with increased levels of dopamine from drugs of abuse, most notably by stimulants like cocaine & methamphetamine. Diseases like addiction and epilepsy that result from excessive neuronal activity are treatable by enhancing endogenous GABA in the brain through the blockade of GABA-AT. CPP-109 & CPP-115 have no addictive liability and are not receptor active; consequently, they do not appear to affect baseline levels of dopamine, nor variations in dopamine levels caused by normal stimuli.

CORPORATE ALLIANCES

Catalyst and the National Institute On Drug Abuse (NIDA) are jointly conducting a 200 subject, 11 site, US Phase II(b), double-blind, placebo-controlled clinical trial evaluating CPP-109 for the treatment of cocaine addiction. The Trial is designed to confirm the safety and efficacy of CPP-109 for the treatment of cocaine addiction and, if successful, Catalyst believes it will qualify as one of the adequate and well controlled trials required to support approval of an NDA for CPP-109. Catalyst expects to have top-line data from the Trial in the fourth quarter of 2012. NIDA, under their agreement with the Veterans Administration Cooperative Studies Program, has agreed to provide approximately 70% of the resources necessary to complete the Trial.

PRODUCTS

Name	Indication	Phase	Milestone
CPP-109	Cocaine & Methamphetamine Addiction	Phase II, IIa, IIb	Top-line Phase II(b) cocaine data in 4Q12.
CPP-115	Addiction and Epilepsy (Infantile Spasms)	Preclinical	Phase I(a) safety data in 1Q12.

SENIOR MANAGEMENT

Patrick J. McEnany, Chief Executive Officer • **Steven R. Miller, PhD**, Chief Operating Officer • **Jack Weinstein**, Chief Financial Officer • **Douglas Winship**, Vice President • **Charles Gorodetzky, MD, PhD**, Chief Medical Officer

BOARD OF DIRECTORS


Patrick J. McEnany, President, CEO & Co-Founder, Catalyst Pharmaceutical Partners, Inc. • **Philip H. Coelho**, President & CEO, Synergenesis Inc. • **Hubert E. Huckel, MD**, Co-Founder, Catalyst Pharmaceutical Partners, Inc. • **Charles B. O'Keeffe**, Professor, Virginia Commonwealth University • **David S. Tierney, MD**, President, COO and Director, Oceana Therapeutics • **Milton J. Wallace**, BOD Chairman, Renal Care Partners, Inc.

SCIENTIFIC ADVISORY BOARD

Stephen L. Dewey, PhD (SAB Chairman), Center for Behavioral & Molecular Imaging, Feinstein Institute, North Shore LIJ • **Jonathan Brodie, PhD, MD**, Marvin Stern Professor of Psychiatry, New York University School of Medicine • **Robert D. Fechtner, MD**, Professor of Ophthalmology, UMDNJ–New Jersey Medical School • **Thomas Kosten, MD**, Waggoner Professor of Psychiatry & Neuroscience at Baylor College of Medicine • **Eugene Laska, PhD**, Professor, Department of Psychiatry at New York University • **Richard A. Rawson, PhD**, Professor-in-residence, University of California, Los Angeles (UCLA) Department of Psychiatry • **Richard B. Silverman, PhD**, John Evans Professor of Chemistry, Northwestern University

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: CPRX



Market Data

Current Price	1.37
Currency	US Dollar
Net Change	3.79
Volume	18,260
YTD % Change	0.38
52Wk Range	0.89–2.25
Avg. Daily Volume (thousands).....	63,068

First Call Data

Market Cap (MM)	29.7
Short Interest Shares	126,928
Short Interest Ratio	1.21
PE (Trailing 12 Months)	-0.27
EPS (Last Fiscal Year)	-0.23
Consensus Estimate (Y)	-0.27
Consensus Recommend	--
Price/Sales	--

Shareholders

Institution

Holding %

Federated Investment Management Co.	9.5%
Fidelity Management & Research Co.	7.2%
Federated Global Investment Management Corp.	5.3%
Hudson Bay Capital Management LP.....	3.2%
The Vanguard Group, Inc.	0.4%

Mutual Fund

Holding %

Federated Investment Management Co.	9.5%
Fidelity Management & Research Co.	7.2%
Federated Global Investment Management Corp.	5.3%
Hudson Bay Capital Management LP.....	3.2%
The Vanguard Group, Inc.	0.4%

Source: Thomson Reuters

Cearna, Inc.

Clinical Foci: Skin/Dermatological • Medical Device • Regenerative Medicine

Josephine Polich Chief Executive Officer

29 S. Webster St.
Naperville, IL 60540
USA

www.cearna.com
1-630-740-4580

Incorporated: 2010
Employees: 4
Ownership: Private

HIGHLIGHTS

Recent

Patent of Cearna Prototype filed in 48 countries filed and 2nd Provisional Patent filed for high potency topical Arnica gel filed March 2011.
Regulatory Path verified by three leading FDA consultants/attorneys
Production capability of high potency topical gel achieved. No further pre-launch FDA filings required.
Completion of over 50 surgical procedures evaluating product.

Upcoming

Quality compliance - GMP certification of manufacturer - 03/12
First production lot complete and certified - 03/12
Beta test of key plastic surgeons - 04/12; Double blind placebo controlled clinical trial, data collection - 04/12;
Product launch - 05/12

CORPORATE MISSION

Cearna® Healing Products will become the market leader for topical products used to reduce bruising, swelling, pain, and inflammation due to plastic surgery. Cearna offers the most effective product on the market for the reduction of bruising, pain and swelling. Bruising and swelling are unmet needs resulting in a two-week recovery from plastic surgery. Patients using the Cearna Healing Gels are typically back to work in a week.

Bruising, swelling and pain are symptoms of plastic surgery and prevent the patient from returning to work and other activities for two weeks or more. Patients, particularly facial surgery patients, are greatly concerned with the appearance of bruising and swelling which severely limits their ability to be seen in public. There are 1.2 million plastic surgery procedures performed annually in the USA representing USD \$5+ billion in procedure spending. The U.S. market for Cearna® Healing Products is estimated at USD \$475 million.

There are few remedies which address bruising, swelling, and pain. Analgesics are commonly used to address pain, but bruising and swelling have been neglected complications. Cearna® Healing Products provides first-of-its-kind high potency topical Healing Gels to the plastic surgery market.

The company is seeking a cash infusion of USD \$2 million to launch the product in May of 2012, train the sales force, conduct additional studies, participate in trade shows, build product inventory, and market the selling program. Our regulatory path has been verified by three leading FDA consultants (including FDA legal specialists Hogan & Lovells) who have verified that the product does not need additional testing prior to commercialization.

PROPRIETARY TECHNOLOGY

Arnica has long been used in the plastic surgery market for its impact on bruising. Our patent pending composition creates gels 10,000X stronger than any other topical gel on the market and delivers it directly to the site of the injury. These disposable "peel-and-place" products reduce the bruising, swelling, and pain by 50+%. The moist cooling "peel-and-place" healing gels are easy to apply, cooling to the skin, stick lightly to the face, and minimally impact the surgeon's procedure. Our improvement in recovery time has been demonstrated in more than 50 plastic surgery procedures. Our four surgeons tested prototypes on over 30 facelift subjects as well as multiple eye lift, nose reconstruction, and liposuction patients and observed over a 50% improvement.

PRODUCTS

Name	Indication	Phase	Milestone
Cearna Eye Lift	Plastic surgery recovery	Cleared for US Marketing	Successfully tested in case studies
Cearna Facelift	Plastic surgery recovery	Cleared for US Marketing	Successfully tested in case studies
Cearna Nose Reconstruction	Plastic surgery recovery	Cleared for US Marketing	Successfully tested in case studies
Cearna Abdominoplasty	Plastic surgery recovery	Research	In development
Cearna Liposuction	Plastic surgery recovery	Cleared for US Marketing	Successfully tested in case studies
Cearna Breast Augmentation	Plastic surgery recovery	Research	In development

SENIOR MANAGEMENT

Josephine Polich, Chief Executive Officer • **Russell Effrig**, Chief Operating Officer

SCIENTIFIC ADVISORY BOARD

Dr. Brian Biesman, The Nashville Centre for Laser and Facial Surgery • **Dr. Riley Rees**, University of Michigan

FINANCING HISTORY

Round Date (Amount, US\$) 08/31/2011 (1.20 million)

Investors: Founder (98%) • Others (2%)

Cell Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology • Drug Development • Oncology

James A. Bianco, MD Chief Executive Officer

501 Elliott Avenue West
Seattle, WA 98119
USA

www.cticseattle.com

1-206-282-7100

NASDAQ: CTIC

Incorporated: 1991

Ownership: Public

HIGHLIGHTS

Recent

Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial.

Cell Therapeutics Submits Day 120 Response for Pixantrone Marketing Authorization Application to European Medicines Agency.

New OPAXIO and Tosedostat Data Selected for Oral Discussion Sessions at the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting.

Upcoming

Potential Opinion on Pixantrone Marketing Authorization Application from the European Medicines Agency in 1Q12.

Re-submission of Pixantrone NDA.

CORPORATE MISSION

Cell Therapeutics, Inc. is committed to being a biopharmaceutical-industry leader with a diversified portfolio of proprietary oncology drugs. What makes us different is our personalized approach to cancer therapy that focuses on treating the right patient with the right drug at the right dose.

PROPRIETARY TECHNOLOGY

- Our polyglutamate delivery technology may open the way to the selective delivery of cancer therapies to tumor tissue, potentially reducing the toxic side effects of widely used and well-characterized therapies.
- Our Genetic Polymer™ technology supports the need for new rDNA-derived protein-based drugs by potentially extending plasma half-life. This could reduce the time and cost of developing new drugs, so patients can benefit sooner from breakthrough scientific discoveries.
- Our advanced systems biology platform addresses context of vulnerability. Every tumor and every patient has a specific set of genomic and clinical characteristics. Potentially, these characteristics can be used in synchrony to accelerate drug development and identify patients who will respond to treatment.

CORPORATE ALLIANCES

Novartis:

We have an exclusive worldwide licensing agreement with Novartis for the development and commercialization of OPAXIO™ (paclitaxel poliglumex, CT-2103, formerly known as XYOTAX), which also provides Novartis with an option to develop and commercialize pixantrone based on agreed terms.

PG-TXL Company, LP:

We have an agreement with PG-TXL Company, LP granting us an exclusive worldwide license for the rights to PG-TXL, now known as OPAXIO™, and to all potential uses of PG-TXL's polymer technology.

Chroma Therapeutics, Ltd.

We have a co-development and license agreement providing CTI with exclusive marketing and co-development rights to Tosedostat in North, Central, and South America.

PRODUCTS

Name	Indication	Phase	Milestone
OPAXIO(TM)	Lung Cancer	Phase III	Closed to accrual
Brostallicin	Ovarian, Breast, Colorectal	Phase II, IIa, IIb	On-going
OPAXIO(TM)	Breast Cancer	Phase III	Enrolling
Pixantrone	Diffuse Large B-Cell Lymphoma (DLBCL)	Phase III	Enrolling

SENIOR MANAGEMENT


James A. Bianco, MD, Chief Executive Officer • Craig W. Philips, President • Louis A. Bianco, Chief Financial Officer • Dan Eramian, Corporate Communications • Jack W. Singer, MD, Chief Medical Officer

BOARD OF DIRECTORS

John H. Bauer, DigiPen Institute of Technology • **James A. Bianco, MD**, Cell Therapeutics, Inc. • **Vartan Gregorian, PhD**, Carnegie Corporation • **Richard L. Love**, Translational Accelerator LLC • **Mary O’Neil Munding, DPH, RN**, Columbia University School of Nursing • **Phillip M. Nudelman, PhD**, The Hope Heart Institute • **Jack W. Singer, MD**, Cell Therapeutics, Inc. • **Frederick W. Telling, PhD**, Pfizer

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: CTIC



Market Data

Current Price	1.08
Currency	U.S. Dollar
Net Change	-1.82
Volume.....	710,253
YTD % Change	-0.51
52Wk Range	0.95–3.33
Avg. Daily Volume (thousands)	1,623,437

First Call Data

Market Cap (MM)	208.3
Short Interest Shares.....	19,422,716
Short Interest Ratio.....	12.83
PE (Trailing 12 Months)	-0.25
EPS (Last Fiscal Year).....	-12.28
Consensus Estimate (Y)	-0.25
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i> Holding %</i>
The Vanguard Group, Inc.....	3.8%
Ayer Capital Management LP	1.6%
Hudson Bay Capital Management LP.....	1.4%
State Street Global Advisors.....	1.4%
Northern Trust Investments	1.0%
<i>Mutual Fund</i>	<i> Holding %</i>
The Vanguard Group, Inc.....	3.8%
Ayer Capital Management LP	1.6%
Hudson Bay Capital Management LP.....	1.4%
State Street Global Advisors.....	1.4%
Northern Trust Investments	1.0%

Source: Thomson Reuters

Centella Therapeutics, Inc.

BIO Member

Clinical Foci: Oncology • Diagnostics • Drug Development

Thorsten Melcher Chief Executive Officer

c/o Varian Medical Systems
Palo Alto, CA 94304
USA

www.centellatx.com
1-650-251-5543

Incorporated: 2008
Ownership: Private

HIGHLIGHTS

Recent

Licensing agreements related to CEN-109 and CEN-209.
Partnership agreement with Cancer Research UK providing non-dilutive funding for CEN-209/-109 co-development.
Launch of several CEN-109 Phase 2 trials.

Upcoming

File IND for CEN-209.
Complete a first-in-human Phase 1 study for CEN-209, including proof-of-mechanism using CEN-109 PET imaging.
Enhance pipeline, including completion of partnerships around CEN-111 and CEN-211.

CORPORATE MISSION

The Radiotherapy-Drug Company: Centella Therapeutics is combining molecular targeted therapeutics with spatially targeted external-beam radiation therapy to improve survival of patients with solid tumors, making Centella the first Radiation Oncology Biotech company.

Centella Therapeutics is a California-based company jointly founded and incubated by Varian Medical Systems (Varian; NYSE: VAR) and the Auckland Cancer Society Research Centre (ACSRC) at the University of Auckland, New Zealand. Varian is the leading provider of technologies to treat cancer using External Beam Radiation Therapy (EBRT), and the ACSRC is a premier cancer research and drug discovery center with a proven track record in identifying and characterizing promising small-molecules for cancer treatment.

Although over 50% of solid tumor patients are treated using EBRT with curative intent, only 1 targeted drug is approved in combination with EBRT. The biotechnology and pharmaceutical industry is beginning to embrace EBRT as a spatially targeted and personalized cancer treatment with distinct advantages. Centella will focus on combining state-of-the-art EBRT with targeted cancer therapeutics derived from academic centers and the biotechnology and pharmaceutical industries. Centella is positioned to benefit from Varian's technology leadership in radiation oncology and Varian's marketing channel to the radiation oncologist, a channel that is presently unavailable to the pharmaceutical industry.

Centella's first product candidate, CEN-209, targets hypoxic tumors in combination with fractionated EBRT using a stratified medicine approach with initial focus on non-small-cell lung cancer. Centella capitalizes on its partnerships with Varian, the technology leader in radiation oncology, and the ACSRC, a proven developer of targeted drugs in the context of EBRT, to emerge as the strategic leader in combining EBRT and drug therapies.

PROPRIETARY TECHNOLOGY

CEN-209/CEN-109:

Centella's first products are,

- (1) the hypoxia-targeted drug CEN-209 in conjunction with
- (2) the PET hypoxia imaging agent CEN-109, a companion diagnostic for patient selection and response assessment

CEN-111:

CEN-111 is a small-molecule to be repositioned for development in combination with Stereotactic Ablative Radiotherapy ("SABR") for the treatment of early-stage lung cancer, oligometastatic disease, and brain metastases.

CORPORATE ALLIANCES

Varian Medical Systems, Inc, Palo Alto, CA;
Auckland Cancer Society Research Centre, Auckland, New Zealand;
Cancer Research UK, London, UK;
Pacific BioDevelopment, Millbrae, CA;
Certus International, Bedford, NH.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
CEN-109	Companion Diagnostic	Phase II, IIa, IIb
CEN-209	Solid Tumors	Preclinical

SENIOR MANAGEMENT

Thorsten Melcher, Chief Executive Officer • **Jim Mervis**, Business Development • **Dan Hoth, MD**, Consultant

Chelsea Therapeutics, Inc.

BIO Member

Clinical Foci: Neurology • CNS • AutoImmune

Simon Pedder, PhD

President & CEO

3530 Toringdon Way
Suite 200
Charlotte, NC 28277
USA

www.chelseatherapeutics.com

1-704-341-1516

NASDAQ: CHTP

Incorporated: 2004

Employees: 30

Ownership: Public

HIGHLIGHTS

Recent

Recent Phase III data shows that Parkinson's patients with neurogenic orthostatic hypotension treated with Northera demonstrate 60% reduction in falls.

Northera NDA in Neurogenic Orthostatic Hypotension was submitted in 3Q11 based on completed Studies 301 & 302.

Northera Study 301 meets primary endpoint and demonstrates significant improvement in symptoms associated with neurogenic orthostatic hypotension.

Upcoming

Northera (droxidopa) new drug application currently under review by FDA.

Unblinded Interim analysis of CH-4051 Phase II in rheumatoid arthritis patients that demonstrate inadequate response to methotrexate.

Results from Droxidopa Phase 2 Study in fibromyalgia 4Q11.

CORPORATE MISSION

Chelsea Therapeutics, Inc. is a biopharmaceutical company developing prescription products in multiple therapeutic categories such as RA, psoriasis and other inflammatory conditions. In addition to its autoimmune pipeline, Chelsea is pursuing an orphan drug strategy for the accelerated development of Droxidopa, an orally active synthetic precursor of norepinephrine currently approved and marketed in Japan, for the treatment of orthostatic hypotension and freezing of gait in Parkinson's Disease.

CORPORATE ALLIANCES

In May 2006, Chelsea established a strategic partnership with Dainippon Sumitomo Pharma to develop and commercialize droxidopa.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Droxidopa	Symptomatic Neurogenic Orthostatic Hypotension	NDA/BLA filed, or in process
CH-4051	Rheumatoid Arthritis	Phase II, IIa, IIb
Droxidopa	Fibromyalgia	Phase II, IIa, IIb
Droxidopa	Intradialytic Hypotension	Phase II, IIa, IIb
Droxidopa	Adult ADHD	Phase II, IIa, IIb
Droxidopa	Chronic Fatigue Syndrome	Phase II, IIa, IIb

SENIOR MANAGEMENT

Simon Pedder, PhD, President & CEO • **Arthur Hewitt, PhD**, Chief Scientific Officer • **William Schwieterman, MD**, Chief Medical Officer • **Nick Riehle, MBA**, Chief Financial Officer • **Keith Schmidt, MBA**, Vice President • **Joe Oliveto, MBA**, Vice President • **Michael Roberts, PhD**, Vice President

BOARD OF DIRECTORS

Kevan Clemens, PhD, Former Exec. VP, Hoffmann-La Roche Inc. (Retired)



Market Data

Current Price	4.03
Currency	U.S. Dollar
Net Change	3.07
Volume	550,281
YTD % Change	-0.46
52Wk Range	3.25-8.20
Avg. Daily Volume (thousands)	592,035

First Call Data

Market Cap (MM)	249.3
Short Interest Shares	5,682,220
Short Interest Ratio	15.22
PE (Trailing 12 Months)	-1.20
EPS (Last Fiscal Year)	-0.97
Consensus Estimate (Y)	-1.20
Consensus Recommend	-1.20
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
Columbia Wanger Asset Management LLC	10.8%
TCW Asset Management Co., Inc.	7.5%
VHCP Management LLC	6.3%
Pyramis Global Advisors LLC	5.7%
Fidelity Management & Research Co.	5.3%
<i>Mutual Fund</i>	<i>Holding %</i>
Columbia Wanger Asset Management LLC	10.8%
TCW Asset Management Co., Inc.	7.5%
VHCP Management LLC	6.3%
Pyramis Global Advisors LLC	5.7%
Fidelity Management & Research Co.	5.3%

Source: Thomson Reuters

Colucid Pharmaceuticals, Inc.

BIO Member, BIO Board Member

Clinical Foci: CNS, Neurology

Thomas P. Mathers

Chief Executive Officer

2530 Meridian Parkway, Suite 300
Durham, NC 27713
USA

www.colucid.com

1-919-806-4304

Incorporated: 2005

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

August 30, 2011 — Colucid raised USD \$7.5 million of planned \$9.5 million.
August 18, 2011 — Colucid received clearance for IND Application for Lasmiditan for the treatment of Acute Migraine.

Upcoming

Colucid conducts End of Phase 2 meeting with FDA confirming Phase 3 development plan.
Colucid doses first patient in Phase 3 study.

CORPORATE MISSION

Colucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatments for CNS disorders. The company's investors include Pappas Ventures, Domain Associates, Care Capital, Pearl Street Venture Funds and Triathlon Medical Ventures. The company's pipeline includes lasmiditan, a novel treatment for migraine headache, COL-204 for wake promotion, and a conjugated stigmime platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders.

Lasmiditan is a first-in-class Neurally Acting Anti-Migraine Agent (NAAMA) designed to deliver efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies. Lasmiditan is a member of a novel chemical class called "ditans" and, unlike triptans, penetrates the central nervous system (CNS) and selectively targets 5-HT_{1F} receptors expressed in the trigeminal pathway. Lasmiditan does not interact with vasoconstrictor 5-HT_{1B/1D} receptors activated by triptans.

Five clinical studies have been successfully completed outside of the US, including a Phase 2b double blind placebo controlled oral dose ranging study treating a single migraine attack which was completed in 2010. In the Phase 2b study, lasmiditan achieved its primary endpoint of reducing a moderate or severe headache at baseline to mild or none 2 hours after dosing ($p < 0.0001$) in 391 patients. Differentiation of individual doses from placebo was seen as early as 30 minutes after dosing. Lasmiditan also achieved secondary endpoints, including relief of nausea, photophobia and phonophobia. Importantly, because there was no evidence of drug-related cardiovascular effects or chest symptoms in the previous five clinical studies, Colucid expects the pivotal Phase 3 studies to confirm that lasmiditan's side effect profile is highly differentiated from triptans and ergotamines.

PROPRIETARY TECHNOLOGY

Conjugated Stigmime Platform — Concept:

Conjugate pharmaceutically active entities to stigmime acetylcholinesterase inhibitors to allow delivery of 2 active agents to the CNS.

- Stigmimes are carbamate based cholinesterase inhibitors
- Enzyme inhibition occurs when carbamate binds to active site of enzyme.
- The bound carbamate enzyme is hydrolyzed, releasing carbonic acid that disassociates, releasing an inactive amine.
- Replacing the inactive amine with a therapeutically active amine can be accomplished by conjugating the stigmime.
- Results in two active drugs being released in the CNS.
- Also results in an NCE, providing commercial exclusivity.

PRODUCTS

Name	Indication	Phase	Milestone
Lasmiditan (COL-144)	acute migraine	Phase III	Initiation of Phase III registration trials
COL-204	wake promotion	Optimized Lead	

SENIOR MANAGEMENT

Jim White, PhD, Other • Thomas P Mathers, Chief Executive Officer • Nadia Rupniak, PhD, Vice President • Alison Pilgrim, BM, BCh, DPhil, Chief Medical Officer • Linda C Hogan, Business Development • Barry Dussault, Director • Tim Gupton, CPA, Chief Financial Officer • Dan Boeglin, General Counsel

BOARD OF DIRECTORS

Art Pappas, Pappas Ventures • Jesse Treu, PhD, Domain Partners • Richard Markham, Care Capital

SCIENTIFIC ADVISORY BOARD

Peter Goadsby, UCSF • Richard Lipton, Albert Einstein • David Dodick, Mayo • Stephen Silberstein, University of Pennsylvania

FINANCING HISTORY

Round Date (Amount, US\$) 12/01/2005 (16.50 million) • 08/30/2011 (32.50 million)

Investors: Domain Associates (100%) • Pappas Ventures (100%) • Care Capital (100%)

Constellation Pharmaceuticals, Inc.

Presenting Company

Mark A. Goldsmith, MD, PhD

President & CEO

215 First Street, Suite 200
Cambridge, MA 02142
USA

www.constellationpharma.com

1-617-714-0555

Incorporated: 2008

Employees: 60

Ownership: Private

CORPORATE MISSION

Constellation's scientific founders represent the core thought leaders in the field of Epigenetics, responsible for key advances, insights and discoveries in the burgeoning field. Their deep scientific insights and those of our strong internal scientific team drive the company's mission and success in developing a robust pipeline of drug products aiming to treat a wide array of important diseases, including cancer and autoimmune diseases. Constellation has built a sophisticated technology platform to explore multiple targets broadly in multiple therapeutic areas. Constellation leverages this platform to build a diversified product pipeline of small molecules designed to modulate key epigenetic players – including chromatin writers, erasers and readers -- responsible for human disease. Its lead programs are progressing toward the clinic.

SENIOR MANAGEMENT

Mark A. Goldsmith, MD, PhD, President & CEO • **Garen Bohlin**, Chief Financial Officer • **James Audia, PhD**, Chief Scientific Officer • **Michael Cooper, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Mark Levin, Third Rock Ventures • **Bob Tepper, MD**, Third Rock Ventures • **Anthony Evnin, PhD**, Venrock • **Dave Goeddel, PhD**, The Column Group • **Tom Maniatis, PhD**, Columbia University • **Steven M. Paul, MD, PhD**, Weill Cornell Medical College • **Mark A. Goldsmith, MD, PhD**, Constellation Pharmaceuticals, Inc.

SCIENTIFIC ADVISORY BOARD

Danny Reinberg, PhD, NYUSOM / SMILOW Research Center • **Arnold Levine, PhD**, Institute for Advanced Studies • **David Livingston, MD**, Dana Farber Cancer Institute • **Thomas Jenuwein, PhD**, Max-Planck Institute • **Scott Lowe, PhD**, Cold Spring Harbor Laboratory • **Rick Klausner, MD**, The Column Group • **Stephen Baylin, MD**, Johns Hopkins University • **Arul M. Chinnaiyan, MD, PhD**, University of Michigan Health System • **Steve Gamblin, PhD**, MRC National Institute for Medical Research

FINANCING HISTORY

Round Date (Amount, US\$) 04/29/2008 (32.00 million) • 06/30/2010 (22.00 million) • 06/30/2011 (15.00 million)

Investors: Third Rock Ventures (0%) • The Column Group (0%) • Venrock (0%) • Altitude (0%) • SROne (0%)

CureFAKtor Pharmaceuticals, LLC

Presenting Company

Clinical Foci: Drug Development, Oncology

H. Shepardson Wild

President & CEO

14 Rock Dove Lane
Buffalo, NY 14127
USA

www.curefaktor.com

1-716-445-4918

Incorporated: 2008

Employees: 9

Ownership: Private

HIGHLIGHTS

Recent

The company's technology developments have been the subject of more than 115 peer-reviewed publications. Dr. William Cance and CureFAKtor have been featured on the CBS Radio Network and WCBS-AM.com. Podcasts available on our Web site.

CureFAKtor has been featured in the following publications (linked on our Web site): Life Science Leader Magazine, Buffalo Business First, Oncology Times, Pharmaceutical Business Review, and OnLive TechSector Q&A.

Key members of the CureFAKtor Staff have been selected to present at National Conferences including University of Florida Technology Showcase, The ASCO Gastrointestinal Cancers Symposium and Bright Buffalo

CORPORATE MISSION

CureFAKtor Pharmaceuticals, LLC has unlocked one of the basic molecular mechanisms which drive cancer and found ways to disrupt it.

CureFAKtor Pharmaceuticals has developed technology which the company believes will lead to significant advances in the therapy for all solid tumors. Preclinical results are dramatic with startling efficacy in even the most deadly and difficult indications, such as pancreatic cancer and melanoma, and the company's compounds are showing similar remarkable results against every type of tumor addressed.

The company's ground breaking research has been continuously funded by a total of over \$15 million in National Institute of Health peer reviewed grants for more than 15 years, recently again reviewed and continuing until 2015.

CureFAKtor Pharmaceuticals has an exclusive worldwide license to all of the technology and is engaged in its commercialization. The company is preparing for its first human trials for pancreatic cancer scheduled to begin in early 2012. The company's objective is to address the USD \$1.4 billion franchise for treating pancreatic cancer established by Lilly, whose chemotherapy Gemzar (Gemcitabine) goes off patent in 2011, with a CureFAKtor patented combination that has proven to be much more effective in pre-clinical models.

The company is also advancing extremely promising compounds for melanoma, breast, lung, colorectal and brain cancer which are expected to be the next indications addressed in human trials.

CureFAKtor's work has been and continues to be supported by more than USD \$15 million in NIH and other grants. As it enters human trials, the company seeks additional investments by private placement of its securities, adding to the funds already raised from high net worth individuals, families and trusts and from the Roswell Park Cancer Institute.

PROPRIETARY TECHNOLOGY

The company's Senior Scientist, Dr. William Cance and his team discovered that a protein, focal adhesion kinase (FAK) plays a central role in the growth and spread of cancer and that at the same time protects the tumors from chemotherapy, radiation and the body's natural defenses.

The company has developed a unique way of disabling the activity of FAK binding sites where the protein communicates with tumors, finding small molecules that disrupt the signaling.

CureFAKtor has found 13 such sites that interact with cancer in different ways and has a pipeline of 40 efficacious compounds that disrupt the activity of each of them, for example disrupting the growth of tumor blood vessels, retarding metastasis and allowing the body's natural death mechanisms to reach and destroy the tumors.

CORPORATE ALLIANCES

The company's scientific operations are located at the Roswell Park Cancer Institute in Buffalo, NY, which holds the National Cancer Institute designation of "comprehensive cancer center."

Roswell Park is a CureFAKtor Pharmaceuticals investor.

The University of Florida Research Foundation has provided grants to CureFAKtor.

The company's research has been continuously funded by a total of over USD \$15 million in National Institutes of Health peer reviewed grants for more than 15 years, recently again reviewed and continuing until 2015.

CureFAKtor has also been supported by grants from the Susan Komen for the Cure Foundation.

SENIOR MANAGEMENT

H. Shepardson Wild, President & CEO • **William Cance, MD**, Chief Scientific Officer

BOARD OF DIRECTORS

William G. Cance, MD, Roswell Park Cancer Institute • **H. Shepardson Wild**, President & CEO, CureFAKtor Pharmaceuticals, LLC • **David Keiser**, Alexion Pharmaceuticals, Former President and Founder • **George Potter**, Quality Systems International • **Daniel Kleiner, MD**, Instructor, University of Virginia, Board Certified Surgeon

Curis, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Daniel R. Passeri President & CEO

4 Maguire Road
Lexington, MA 02421
USA

www.curis.com

1-617-503-6500

NASDAQ: CRIS

Incorporated: 2000

Employees: 40

Ownership: Public

HIGHLIGHTS

Recent

September 2011: Curis collaborator Genentech submitted an NDA to the FDA seeking approval for vismodegib (GDC-0449, RG3616) to treat people with advanced basal cell carcinoma (BCC), which includes metastatic and locally advanced BCC.

August 2011: Curis treated the first patient in a Phase I clinical trial of CUDC-101 in combination with cisplatin and radiation in head and neck cancer patients. Curis plans conduct a Phase II trial in head and neck cancer following this study.

January 2011: Curis selected CUDC-907 as a proprietary PI3K/HDAC inhibitor from our pipeline of targeted cancer drug candidates to advance into formal development.

Upcoming

Genentech's EU regulatory submission with EMA for vismodegib in advanced basal cell carcinoma and potential approval of US and EU submissions in this indication. Results from Genentech's ongoing Phase II study of vismodegib in operable BCC.

Progress CUDC-101: complete Phase Ib study in 2011 and progress through dose escalation of a Phase I HNC study with CUDC-101 in combination with cisplatin and radiation in head and neck cancer patients. Launch Phase I study of oral form of CUDC-101.

Complete IND-enabling work and initiate Phase I study with CUDC-907 in 1H12.

CORPORATE MISSION

Curis, Inc. is a biotechnology company focused on the development of targeted small molecules in oncology. These programs include vismodegib (GDC-0449; RG3616), a Hedgehog pathway inhibitor that is under collaboration with Genentech. Genentech reported positive results from a pivotal Phase II clinical trial in advanced basal cell carcinoma patients earlier in 2011 and filed an NDA in the US in September 2011 based on these results. Vismodegib is also being tested by Genentech in a Phase II clinical trial in operable basal cell carcinoma as well as in several NCI- and investigator-sponsored Phase I and Phase II clinical trials in other indications.

Curis' other targeted cancer programs include CUDC-101, an EGFR, Her2 and HDAC inhibitor in Phase Ib clinical testing in several cancers as well as in a Phase I study in locally advanced head and neck cancer in combination with cisplatin and radiation; Debio 0932 (formerly CUDC-305), a Phase Ib Hsp90 inhibitor under collaboration with Debiopharm; and CUDC-907, a PI3K/HDAC inhibitor that is in preclinical development. We also expect to select additional development candidates from a broad pipeline of preclinical programs in the future. For more information, please visit www.curis.com

PROPRIETARY TECHNOLOGY

Curis internal research and development efforts are focused on the development of targeted small molecule drugs for cancer applications. Curis' approach is to develop novel small molecules that seek to disrupt cancer resistance networks, which could lead to a more durable response for the cancer patient. We believe that this approach represents a potential breakthrough in cancer therapy and differentiates Curis from other cancer-focused companies.

CORPORATE ALLIANCES

Hedgehog Pathway Inhibitor (June 2003): Genentech and Roche are responsible for the clinical development and commercialization of vismodegib (GDC-0449, RG3616). Curis is eligible to receive cash payments upon the achievement of specified objectives and royalties on product sales of vismodegib by Genentech and its sublicensees.

Heat Shock Protein (HSP) 90 (August 2009): Debiopharm is responsible for all development and commercialization of Debio 0932. Curis is eligible to receive additional cash payments upon the achievement of specified objectives and royalties on product sales by Debiopharm or its sublicensees.

PRODUCTS

Name	Indication	Phase	Milestone
GDC-0449 (Hedgehog Pathway Inhibitor)	Advanced basal cell carcinoma	NDA/BLA filed, or in process	US NDA submitted Sept. 2011; future EU submission expected.
GDC-0449 (Hedgehog Pathway Inhibitor)	Operable basal cell carcinoma	Phase II, IIa, IIb	Phase II data.
GDC-0449 (Hedgehog Pathway Inhibitor)	Various-multiple NCI studies through NCI-Genentech collaboration	Phase II, IIa, IIb	Data from NCI studies.
CUDC-101 (HDAC, EGFR, Her2 Inhibitor)	Gastric, NSCLC, head and neck, liver and breast cancers	Phase I	Phase Ib enrollment completed 1H11.
CUDC-101 (HDAC, EGFR, Her2 Inhibitor)	Head and neck cancer	Phase I	Continue enrollment in combination with radiation and cisplatin (complete study in 2012).

PRODUCTS			
Name	Indication	Phase	Milestone
CUDC-101 (oral formulation)	cancers	Preclinical	Initiate Phase I dose escalation study with oral formulation in 1H12.
CUDC-907 (HDAC, PI3K inhibitor)	cancers	Preclinical	Initiate Phase I dose escalation study in 1H12.
Various network-targeted cancer programs	cancers	Research	Select additional development compounds.

SENIOR MANAGEMENT
Daniel R. Passeri, President & CEO • **Michael P. Gray**, Chief Operating Officer • **Mark Noel**, Vice President • **Changgeng Qian, PhD**, Senior Vice President

BOARD OF DIRECTORS
James R. McNab, Jr., Chairman & CEO, Palmetto Pharmaceuticals, Executive Chairman, FirstString Research • **Susan Bayh**, Director; Dyax, Dendreon, Wellpoint, Emmis Communications • **Martyn D. Greenacre**, Director; Acusphere, former Director; Cephalon • **Kenneth I. Kaitin, PhD**, Director of Tufts Center for the Study of Drug Development • **Robert E. Martell, MD, PhD**, Tufts Medical Center Cancer Center, Director Neely Cancer for Clinical Cancer, former positions at BMS, Bayer, Methylgene • **Daniel R. Passeri**, President & CEO, Curis • **Marc Rubin, MD**, Titan Pharmaceuticals, Executive Chairman, Board of Directors • **James R. Tobin**, Former President & CEO, Boston Scientific Corporation

SCIENTIFIC ADVISORY BOARD
Kenneth J. Pienta, MD, CAB/SAB Chairman; Director, Translational Medicine Committee, South West Oncology Group • **Stuart A. Aaronson, MD**, Chairman, Dept. of Oncological Sciences, Mount Sinai Medical Center, NY • **James D. Griffin, MD**, Dana Farber Cancer Institute • **Philip A. Philip, MD, PhD, FRCP**, Clinical Professor, Oncology, Barbara Ann Karmanos Cancer Institute • **Samir E. Witt, MD, PhD**, Rocky Mountain Cancer Care Center

TRADING STATUS AS OF OCTOBER 5, 2011	NASDAQ: CRIS																																																																			
	<p>Market Data</p> <table border="0"> <tr><td>Current Price</td><td>3.26</td></tr> <tr><td>Currency</td><td>US Dollar</td></tr> <tr><td>Net Change</td><td>2.19</td></tr> <tr><td>Volume</td><td>338,677</td></tr> <tr><td>YTD % Change</td><td>0.65</td></tr> <tr><td>52Wk Range</td><td>1.28–4.42</td></tr> <tr><td>Avg. Daily Volume (thousands)</td><td>567,452</td></tr> </table> <p>Shareholders</p> <table border="0"> <tr><td colspan="2"><i>Institution</i></td><td><i> Holding %</i></td></tr> <tr><td>First Eagle Investment Management LLC</td><td></td><td>22.9%</td></tr> <tr><td>BlackRock Fund Advisors</td><td></td><td>5.7%</td></tr> <tr><td>Baillie Gifford & Co.</td><td></td><td>4.4%</td></tr> <tr><td>The Vanguard Group, Inc.</td><td></td><td>2.4%</td></tr> <tr><td>State Street Global Advisors</td><td></td><td>1.7%</td></tr> <tr><td colspan="2"><i>Mutual Fund</i></td><td><i> Holding %</i></td></tr> <tr><td>First Eagle Investment Management LLC</td><td></td><td>22.9%</td></tr> <tr><td>BlackRock Fund Advisors</td><td></td><td>5.7%</td></tr> <tr><td>Baillie Gifford & Co.</td><td></td><td>4.4%</td></tr> <tr><td>The Vanguard Group, Inc.</td><td></td><td>2.4%</td></tr> <tr><td>State Street Global Advisors</td><td></td><td>1.7%</td></tr> </table>	Current Price	3.26	Currency	US Dollar	Net Change	2.19	Volume	338,677	YTD % Change	0.65	52Wk Range	1.28–4.42	Avg. Daily Volume (thousands)	567,452	<i>Institution</i>		<i> Holding %</i>	First Eagle Investment Management LLC		22.9%	BlackRock Fund Advisors		5.7%	Baillie Gifford & Co.		4.4%	The Vanguard Group, Inc.		2.4%	State Street Global Advisors		1.7%	<i>Mutual Fund</i>		<i> Holding %</i>	First Eagle Investment Management LLC		22.9%	BlackRock Fund Advisors		5.7%	Baillie Gifford & Co.		4.4%	The Vanguard Group, Inc.		2.4%	State Street Global Advisors		1.7%	<p>First Call Data</p> <table border="0"> <tr><td>Market Cap (MM)</td><td>249.5</td></tr> <tr><td>Short Interest Shares</td><td>6,214,568</td></tr> <tr><td>Short Interest Ratio</td><td>17.44</td></tr> <tr><td>PE (Trailing 12 Months)</td><td>-0.04</td></tr> <tr><td>EPS (Last Fiscal Year)</td><td>-0.24</td></tr> <tr><td>Consensus Estimate (Y)</td><td>-0.04</td></tr> <tr><td>Consensus Recommend</td><td>0.04</td></tr> <tr><td>Price/Sales</td><td>64.44</td></tr> </table>	Market Cap (MM)	249.5	Short Interest Shares	6,214,568	Short Interest Ratio	17.44	PE (Trailing 12 Months)	-0.04	EPS (Last Fiscal Year)	-0.24	Consensus Estimate (Y)	-0.04	Consensus Recommend	0.04	Price/Sales	64.44
Current Price	3.26																																																																			
Currency	US Dollar																																																																			
Net Change	2.19																																																																			
Volume	338,677																																																																			
YTD % Change	0.65																																																																			
52Wk Range	1.28–4.42																																																																			
Avg. Daily Volume (thousands)	567,452																																																																			
<i>Institution</i>		<i> Holding %</i>																																																																		
First Eagle Investment Management LLC		22.9%																																																																		
BlackRock Fund Advisors		5.7%																																																																		
Baillie Gifford & Co.		4.4%																																																																		
The Vanguard Group, Inc.		2.4%																																																																		
State Street Global Advisors		1.7%																																																																		
<i>Mutual Fund</i>		<i> Holding %</i>																																																																		
First Eagle Investment Management LLC		22.9%																																																																		
BlackRock Fund Advisors		5.7%																																																																		
Baillie Gifford & Co.		4.4%																																																																		
The Vanguard Group, Inc.		2.4%																																																																		
State Street Global Advisors		1.7%																																																																		
Market Cap (MM)	249.5																																																																			
Short Interest Shares	6,214,568																																																																			
Short Interest Ratio	17.44																																																																			
PE (Trailing 12 Months)	-0.04																																																																			
EPS (Last Fiscal Year)	-0.24																																																																			
Consensus Estimate (Y)	-0.04																																																																			
Consensus Recommend	0.04																																																																			
Price/Sales	64.44																																																																			
<i>Source: Thomson Reuters</i>																																																																				

Cyclacel Pharmaceuticals, Inc.

Bio Member, Presenting Company

Clinical Foci: Hematology, Oncology, AutoImmune

Spiro Rombotis

President & CEO

200 Connell Drive Suite 1500
Berkeley Heights, NJ 07922
USA

www.cyclacel.com

1-908-517-7330

NASDAQ: CYCC

Incorporated: 1996

Employees: 22

Ownership: Public

HIGHLIGHTS

Recent

Initiation of the pivotal Phase 3 SEAMLESS randomized trial of oral sapacitabine as a front-line treatment in elderly patients aged 70 years or older with newly diagnosed AML who are not candidates for intensive induction chemotherapy.

Reported interim results from an ongoing, multicenter, Phase 1/2 clinical trial examining the safety and effectiveness of sapacitabine administered sequentially with decitabine.

Initiation of a Phase 2 trial of sapacitabine in patients with CLL or SLL hematological malignancies and 11q22-23 deletion

Upcoming

Interim recommendation by DSMB of SEAMLESS pivotal randomized Phase 3 study of sapacitabine in AML.

Interim data from Phase 2 study of sapacitabine in patients with NSCLC.

Patient biomarker analysis from the APPRAISE Phase 2b randomized discontinuation study of seliciclib in patients with NSCLC.

CORPORATE MISSION

Cyclacel is a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious diseases. Sapacitabine (CYC682), an oral cell cycle modulating nucleoside analog, is in Phase 3 development for the front-line treatment of acute myeloid leukemia in the elderly and Phase 2 studies for myelodysplastic syndromes, lung cancer and chronic lymphocytic leukemia. Seliciclib (CYC202 or R-roscovitine), an oral CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. Cyclacel's ALIGN Pharmaceuticals subsidiary markets directly in the US Xclair® Cream for radiation dermatitis, Numoisyn® Liquid and Numoisyn® Lozenges for xerostomia. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.

PROPRIETARY TECHNOLOGY

Cyclacel is a leader in cell cycle biology including the use of biomarker analysis to help evaluate whether drug candidates are having their intended effect on their assumed mechanisms. Cyclacel relies on proprietary genomic technology to identify gene targets, which are then advanced to the discovery stage by means of structure-based design techniques. Cyclacel scientists have discovered nine (9) new chemical entity classes to date.

CORPORATE ALLIANCES

2007, ALIGN Pharmaceuticals, LLC: asset acquisition (Xclair® Cream, Numoisyn® Liquid and Lozenges);

2005, Altana Pharma AG: research collaboration applying Cyclacel's expertise in mitosis to identify the molecular targets of certain Altana Pharma compounds.;

2004, Corgentech: Out license Penetratin drug delivery technology for transcription factor decoy drugs;

2003, Sankyo Co., Ltd: In-license CYC682 (nucleoside analog prodrug).

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Sapacitabine (CYC682)	AML	Phase III	SEAMLESS Phase 3 trial initiated in AML under SPA.
Sapacitabine (CYC682)	MDS	Phase II, IIa, IIb	Phase 2 MDS extended survival data.
Sapacitabine (CYC682)	NSCLC	Phase II, IIa, IIb	NSCLC Phase 2 interim data.
Sapacitabine (CYC682)	CLL	Phase II, IIa, IIb	
Seliciclib (CYC202)	NSCLC	Phase II, IIa, IIb	APPRAISE Phase 2b biopsy analysis data.
Seliciclib (CYC202)	NPC nasopharyngeal cancer	Phase II, IIa, IIb	Phase 2 lead-in completed.
CYC116 Aurora & VEGFR2 inhibitor	Cancer	Phase I	
CYC065 CDK Inhibitor	Cancer	Preclinical	
PLK-1 inhibitor	Cancer	Preclinical	
GSK-3 inhibitor	Diabetes Type 2	Preclinical	

SENIOR MANAGEMENT

Spiro Rombotis, President & CEO • **Paul McBarron**, Chief Operating Officer • **Judy Chiao, MD**, Chief Medical Officer • **Robert Sosnowski**, Vice President

BOARD OF DIRECTORS


David U'Prichard, PhD, Druid Consulting LLC; 3-D Therapeutics, SmithKlineBeecham, Zeneca • **Nicholas Bacopoulos, PhD**, Mersana Therapeutics, Aton Pharma; OSI Pharmaceuticals; Pfizer • **Sir John Banham**, Spacelabs; Johnson Matthey; Amvescap • **Christopher S. Henney, PhD, DSc**, Co-Founder, Dendreon; ICOS; Immunex • **Gregory T. Hradsky**, Sielox; Avenue Capital Group; Bellport Capital; UBS Securities, T. Rowe Price • **Paul McBarron**, Cyclacel; Shire; SmithKlineBeecham; Sterling Drug • **Spiro Rombotis**, Cyclacel; Liposome; Bristol-Myers Squibb; Centocor; Novartis • **Lloyd Sems**, Sems Capital, LLC; Selectica, Inc.; Sport-Haley, Inc • **Daniel K. Spiegelman**, CV Therapeutics; Genentech

SCIENTIFIC ADVISORY BOARD

Professor Kenneth Harrap, PhD, Institute of Cancer Research, Sutton, Surrey & London • **Professor Stanley Kay, MD**, Institute of Cancer Research, The Royal Marsden Hospital • **Professor Michel Marty, MD**, University of Paris VII; Institut Gustave Roussy • **Professor Enrico Mihich, MD**, Roswell Park Cancer Institute, Buffalo • **Professor Karol Sikora, MD**, Brunel-Buckingham University Medical School, AstraZeneca, Imperial College School of Medicine; Hammersmith Hospital, London

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: CYCC



Market Data

Current Price	0.44
Currency	US Dollar
Net Change	10.00
Volume	1,828,017
YTD % Change	-0.70
52Wk Range	0.36–1.95
Avg. Daily Volume (thousands)	617,545

First Call Data

Market Cap (MM)	23.9
Short Interest Shares	258,160
Short Interest Ratio	1.13
PE (Trailing 12 Months)	-0.34
EPS (Last Fiscal Year)	-0.36
Consensus Estimate (Y)	-0.34
Consensus Recommend	--
Price/Sales	31.25

Shareholders

<i>Institution</i>	<i>Holding %</i>
AWM Investment Co., Inc.	5.2%
Manatuck Hill Partners LLC	2.8%
Redmile Group LLC	1.1%
Millennium Management LLC	0.9%
The Vanguard Group, Inc.	0.9%
<i>Mutual Fund</i>	<i>Holding %</i>
AWM Investment Co., Inc.	5.2%
Manatuck Hill Partners LLC	2.8%
Redmile Group LLC	1.1%
Millennium Management LLC	0.9%
The Vanguard Group, Inc.	0.9%

Source: Thomson Reuters

Dawson James Securities, Inc.

Clinical Foci: Biopharmaceuticals • Diagnostics • Medical Device

Albert James Poliak

President & CEO

925 South Federal Highway, 6th Floor
Boca Raton, FL 33432
USA

www.dawsonjames.com

1-408-524-2941

Incorporated: 2002

Ownership: Private

CORPORATE MISSION

Whether you're an institutional investor seeking expert guidance, a corporation requiring timely financial transactions or an individual investor needing superior service, Dawson James Securities, Inc. aims to deliver. From investment banking and institutional research to private client services and wealth management . . . our reputation for quality and integrity is earned one client at a time.

Dawson James Securities set out to create the highest-quality, full service investment firm specializing in the complex and fast-moving healthcare, biotechnology, technology and clean-tech sectors.

With this goal in mind, we've assembled an experienced team of investment professionals whose expertise in these areas is well respected in the industry.

Our professionals have many years investment and industry experience combined with an unending passion for excellence and service.

SENIOR MANAGEMENT

Albert James Poliak, President & CEO • **Thomas W. Hands**, Chief Operating Officer • **Donald Shek**, Chief Financial Officer • **Joseph Balagot (Head of Investment Banking)**, Partner

Del Mar Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Oncology

Jeffrey Bacha, BSc, MBA

Chief Executive Officer

887 Great Northern Way - Suite 115
Vancouver, BC V5T 4T5
Canada

www.delmarpharma.com

1-604-689-5989

Incorporated: 2010

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

Opened IND and initiated Phase II study in GBM.
First closing of private financing.
Received National Research Council (Canada) Grant to support research.

Upcoming

Final closing of private financing.
Reconfirm safety & efficacy of VAL-083 in GBM.
Potential investor exit opportunity.

CORPORATE MISSION

Del Mar Pharmaceuticals was founded in 2010 around a drug, VAL-083, which has been studied extensively in clinical trials sponsored by the National Cancer Institute in the United States (NCI), and approved as a cancer chemotherapy in China. Clinical activity has been demonstrated in a wide range of tumor types, including glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.

PROPRIETARY TECHNOLOGY

VAL-083. Small-molecule anticancer therapy.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
VAL-083	Glioblastoma multiforme	Phase II, IIa, IIb	2012

SENIOR MANAGEMENT

Jeffrey Bacha, BSc, MBA, Chief Executive Officer • **Dennis Brown, PhD**, Chief Scientific Officer • **Bill Garner, MD**, Director

SCIENTIFIC ADVISORY BOARD

Victor Levin, MD, PhD, Prof. Emeritus, MD Anderson Cancer Center • **James Perry, MD**, Chair, Canadian Brain Tumor Consortium

Dicerna Pharmaceuticals, Inc.

Presenting Company

Clinical Foci: Oncology, Drug Discovery

Douglas Fambrough, PhD *Chief Executive Officer*

480 Arsenal Street
Watertown, MA 02472
USA

www.dicerna.com

1-617-612-6222

Incorporated: 2007

Employees: 30

Ownership: Private

HIGHLIGHTS

Recent

Dicerna's alliance with KHK has been highly successful to date and has been expanded from oncology to include immunology and inflammation, including an exercised optioned right, and has also been expanded to include additional delivery technologies.

Dicerna's DsiRNA and delivery technologies are achieving efficacy in multiple tumor models using clinically relevant delivery directed at classically undruggable targets.

CORPORATE MISSION

Dicerna is an oncology-focused next generation RNA interference company developing therapies based on Dicer Substrate siRNA (DsiRNA) molecules and proprietary RNAi drug delivery systems. Dicerna's Dicer Substrate Technology™ utilizes 25bp and longer RNA duplexes which are the natural substrate for Dicer, the entry point to the RNAi pathway. This structure provides enhanced activity, facilitates delivery formulation, defines a distinct IP estate, and positions Dicerna to realize the promise of RNAi therapeutics. Dicerna's programs are focused on high value otherwise undruggable targets in oncology, for diseases such as hepatocellular carcinoma and pancreatic adenocarcinoma. Dicerna's delivery system achieves RNAi delivery to these solid tumors and others, enabling RNAi to be broadly used within oncology. In addition, Dicerna has programs focused on the therapeutic areas of endocrinology, immunology and inflammation with its pharmaceutical partners Kyowa Hakko Kirin and Ipsen.

PROPRIETARY TECHNOLOGY

Dicerna's DsiRNA Technology offers significant advantages over earlier RNAi technologies, in terms of potency and longevity of gene silencing, achieved in in vitro and in vivo experiments to date, and in its enhanced delivery potential. Dicerna delivers these DsiRNAs to solid tumors via a proprietary targetable lipid nanoparticle technology that has been tuned to accumulate in tumors, bind and internalize into tumor cells, and escape from endosomes into the cytoplasm. This technology has proven effective in solid tumors of both liver and non-liver origin, and we continue to expand the breadth of applicability of this technology.

CORPORATE ALLIANCES

Dicerna has a major alliance in oncology with Kyowa Hakko Kirin, which has been expanded to include immunology and inflammation. Dicerna also has an alliance with Ipsen involving both oncology and endocrinology.

SENIOR MANAGEMENT

Douglas Fambrough, PhD, Chief Executive Officer • **Bob Brown, PhD**, Senior Vice President

BOARD OF DIRECTORS

David Madden, Narrow River Management • **Jonathan MacQuitty, PhD**, Partner, Abingworth Management • **Steve Hoffman, MD, PhD**, Managing Director, Skyline Ventures • **Brian Halak, PhD**, Partner, Domain Associates • **Jonathan Fleming**, Oxford Bioscience Partners • **Dennis Langer, MD, JD**, Professor, Dept. of Psychiatry, Georgetown University School of Medicine; Former Senior VP, R&D, GlaxoSmithKline • **Jim Jenson, PhD**, Dicerna Co-Founder • **Douglas Fambrough, PhD**, CEO, Dicerna Pharmaceuticals, Inc.

SCIENTIFIC ADVISORY BOARD

Frank McCormick, PhD, FRS, DSc (Hon), UCSF • **Thomas Roberts, PhD**, Dana-Farber Cancer Institute • **John Rossi, PhD**, City of Hope • **Mark Behlke, MD, PhD**, Integrated DNA Technologies • **Ronald Kahn, MD**, Joslin Diabetes Center • **Joseph Bonventre**, Harvard Medical School • **Carlo Croce, MD**, Ohio State University

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2008 (21.40 million) • 08/01/2010 (29.00 million)

Investors: Domain Associates (18%) • Skyline Ventures (18%) • Oxford Bioscience Partners (18%) • Abingworth Management (13%) • SR One (6%)

DLVR Therapeutics Inc.

Presenting Company

Clinical Foci: Oncology, Drug Delivery

Frank Gleeson

Chief Executive Officer

MaRS Centre, South Tower, 101 College St.,
Suite 800
Toronto, ON M5G 0A3
Canada

www.dlvtherapeutics.ca

1-647-237-3691

Incorporated: 2011

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Company co-founded by University Health Network, MaRS Innovation and Ontario Institute for Cancer Research in 2011. Initial seed funding of CAD \$1 million secured.

Execution of initial corporate collaboration with a major pharmaceutical company to evaluate HPPS technology for siRNA delivery.

Upcoming

Selection of initial clinical candidate in 2012.

Completion of proof of concept evaluation and initiation for first co-development collaboration in 2012.

Securing of Series A equity financing in 2H12.

CORPORATE MISSION

DLVR Therapeutics Inc. is a privately held biotechnology company based in Toronto. Founded in 2011, the company is focused on developing a novel, HDL-mimicking nanoparticle delivery system suitable for a variety of different payloads: in particular small molecule lipophilic therapeutics and siRNA, initially for oncology indications. The company has two principal programs: the first is focused on improving the therapeutic index of chemotherapeutic drugs and advancing them into clinical development; the other is focused on the targeted delivery of siRNA in collaboration with biopharmaceutical partners. The company will be seeking Series A financing in H2, 2012.

PROPRIETARY TECHNOLOGY

DLVR's innovative technology is based on the synthesis and use of an HDL-mimetic phospholipid-based nanoparticle called HPPS (HDL-like Peptide-Phospholipid Scaffold). Exploiting the property of HDL to create a hydrophobic channel in the cell membrane, HPPS delivers its payload directly into the cytosol of its target cells. It further mimics the natural targeting of HDL to the scavenger receptor class B type I (SR-BI) which is upregulated in several cancers including breast, prostate and colon. HPPS exhibits similar pharmacokinetics as plasma-derived HDL with a long stable circulating time and favourable biodistribution. HPPS nanoparticles are ultra-small (10-25 nm), nontoxic, nonimmunogenic, biocompatible, easy to synthesize and customizable.

CORPORATE ALLIANCES

The company has entered into its first relationship with a major pharmaceutical corporation to undertake a proof of concept evaluation of the HPPS technology in siRNA delivery.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Chemotherapeutic development	Oncology	Lead Series	Advance HPPS - Gemcitabine into clinical candidate
Chemotherapeutic development	Oncology	Lead Series	Advance HPPS - Bendamustine into preclinical development
Chemotherapeutic development	Oncology	Research	Advance HPPS - SN-38 into preclinical development

SENIOR MANAGEMENT

Frank Gleeson, Chief Executive Officer • **Dr. Bev Incedon**, Vice President • **Dr. Malik Slassi**, Consultant • **Dr. Gang Zheng**, Chief Scientific Officer

BOARD OF DIRECTORS

Dr. Brian Barber • **Dr. Eric Rowinsky** • **Dr. Jeff Edelson**

FINANCING HISTORY

Round Date (Amount, US\$) 09/10/2011 (1.00 million)

DNA Therapeutics SA

Presenting Company

Clinical Foci: Oncology

Jian-Sheng Sun Chief Executive Officer

4 rue Pierre Fontaine
91058 Evry
France

www.dna-therapeutics.com

33-6-2475 3239

Incorporated: 2006

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

Initiating DRIIM trial to evaluate the safety, PK, preliminary anti-tumor activity and PD (using biomarkers) of locally administered DT01 in combination with radiotherapy in patients suffering metastatic melanoma with relapsed cutaneous tumors.

August 22, 2011, French Health Authority (AFSSAPS) issued its Clinical Trial Authorization for DNA Therapeutics' First-in-Human trial, without any question on the safety, quality of the investigational medicinal product - DT01, and trial protocol.

April 4, 2011, Japanese Patent Office notified its decision to grant the 1st Dbait patent in Japan. So far, the princeps patent of Dbait has been already granted in the major pharmaceutical territories, such as USA, Europe, Japan and Australia.

Upcoming

2H12 - clinical safety, PK/PD & preliminary efficacy of DT01.

1H13 - clinical Proof of Concept of Dbait to achieve validation of siDNA concept & technology.

1H15 - preliminary efficacy of DT01 in 2 major cancer indications in order to trigger a strategic partnership

CORPORATE MISSION

DNA Therapeutics is an emerging clinical stage biopharmaceutical company. It develops a paradigm-shift concept named signal interfering DNA (siDNA) and siDNA-based first-in-class small molecular drugs to address unmet needs in oncology. It primarily focuses on the treatment-related resistance of cancer. Anticancer therapies, such as radiotherapy and chemotherapy, often are inefficient in the treatment of relapsed cancer, due to tumor cells' enhanced capacity to repair DNA lesions caused by DNA damaging treatments.

DNA Therapeutics is a spin-off of 4 renowned French research institutions (Institut Curie, CNRS, INSERM, MNHN). It acts as an integrator of life science technologies and a business-driven drug developer, through its strong interactions with renowned research institutions for translational research, and biotech companies, and worldwide outsourcing to top tier CRO/CMO for drug development.

DNA Therapeutics has been successfully organized as a Virtually Integrated Pharmaceutical Company (VIPCo). This minimizes burning rate, keeps flexibility and optimizes value creation. Its management relies on the expertise of professionals from pharmaceutical and biotechnology industries, and on top notch consultants in chemistry-manufacture-control (CMC), early stage drug development and regulatory affairs, as well as Key Opinion Leaders in oncology.

The lead investigational medicinal product DT01 has a high therapeutic index as MTD was not reached, nor CNS & CVS disorder were observed in the ICH9 compliant 4-week animal toxicology studies with 2-week recovery in rat and in monkey. This provides high safety margin for 1st-in-human dosing.

The 1st trial of DT01 (combined with radiotherapy) in melanoma-in-transit is starting in France. It was specially designed to establish not only the safety and tolerance, but also the clinical proof of concept of DT01 with limited patients at early stage of clinical development. "THINK DIFFERENT" is also its credo!

PROPRIETARY TECHNOLOGY

The originality of siDNA is to use a short DNA fragment mimicking DNA damage. It acts by jamming DNA damage sensing and signaling, ultimately inhibiting DNA repair during its treatment. Therefore siDNA-based drugs sensitize anticancer therapies. This is a technology platform capable of generating multiple products – Dbait is its 1st family which interferes with the repair pathways of double strand break (DSB), a major DNA damage.

Dbait is not classical inhibitor, but a novel class of target therapy drugs which acts on a cascade of proteins involved in DSB repairs, the 1st example of SUPRA-MOLECULAR therapy. Only Dbait can block all DSB repair pathways without toxicity to normal cells. This prevents tumor cells from escaping the inhibition of targeted pathway through an alternative pathway.

CORPORATE ALLIANCES

DNA Therapeutics aims at bridging the gap between translational research and late stage drug development. After having achieved the clinical proof of concept of its products, it will look for strategic partner(s) in oncology field for late stage drug development, market approval and commercialization. It is also looking for the partners for regional, emerging, or veterinary markets through early stage licensing-out/co-development.

PRODUCTS

Name	Indication	Phase	Milestone
DT01	Oncology	Phase I	Safety, anticancer activity, clinical proof of concept
Pbait	Oncology	Lead Series	Lead optimization

SENIOR MANAGEMENT

Jian-Sheng Sun, Chief Executive Officer • **Marie Dutreix**, Chief Scientific Officer • **Alan Irvine**, Chief Medical Officer • **Bruno Cervera**, Chief Financial Officer • **Denis Ravel**, Consultant • **Brian Sproat**, Consultant • **Sidonie Hill**, General Counsel • **Valérie Gallois**, Attorney

BOARD OF DIRECTORS

Jian-Sheng Sun, CEO, DNA Therapeutics • **Béatrice Denys**, Partner, SGAM SEFTI • **Bernard Majoie**, BA; Former CEO, Fournier Pharma (now Abbott) • **Michel Raoult**, Chandra Capital; Formerly with Paul Capital, Crédit Lyonnais, Innolion • **Eric Viaud**, CEO, Gene Signal

SCIENTIFIC ADVISORY BOARD

Michel Marty, Saint Louis Hospital, Paris • **Alban Denys**, CHUV, Lausanne

FINANCING HISTORY

Round Date (Amount, US\$) 06/05/2006 (1.10 million) • 01/29/2009 (3.00 million) • 05/17/2011 (2.70 million)

Investors: SGAM SEFTI (VC) (55%) • Genopole 1er Jour Ile-de-France (Institutional seed) (5%) • Inserm-Transfert Initiative (Institutional seed) (3%) • Business angels (Belgian, Chinese, French) (20%) • Founders and management (17%)

EBD Group

BIO Member

Carola Schropp

President

2032 Corte del Nogal
Carlsbad, CA 92009
USA

www.ebdgroup.com

1-760-930-0500

Incorporated: 1993

Employees: 45

Ownership: Private

HIGHLIGHTS

Recent

BIO-Europe Spring® 2011: 1,803 attendees from 1,123 companies participated in 9,202 one-to-one meetings and 120 company presentations on products and technologies.

The next BIO-Europe Spring® will be, March 19–21, 2012 in Amsterdam, The Netherlands

ChinaBio® Partnering Forum 2011: 658 attendees participated in 807 one-to-one meetings, 38 biotech company presentations and 29 "Innovation Showcase" presentations.

Next year's ChinaBio® Partnering Forum will be in Suzhou, China; May 23–24, 2012

EuroMedtech™ 2011

261 attendees from more than 205 companies participated in 741 one-to-one meetings and 45 company presentations on products and technologies.

Save the date for EuroMedtech 2012 in Grenoble, France : May 31–June 1, 2012

Upcoming

BioPharm America™, Boston, USA

September 7–9, 2011 is where biotech industry partnerships get started.

<http://www.ebdgroup.com/bpa/index.php>

BIO-Europe® is Europe's largest partnering conference, serving the global biotechnology industry.

Will be held in Duesseldorf, Germany on October 31–November 02, 2011

<http://www.ebdgroup.com/bioeurope/index.php>

Biotech Showcase™: private and public life science companies present to an audience of investors and business development executives during the course of the world's largest annual healthcare investor conference.

<http://www.ebdgroup.com/bts/index.php>

CORPORATE MISSION

EBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group's partnering conferences, technology and services to identify business opportunities and develop strategic relationships essential to their success.

EBD Group's conferences are run with the support of leading corporations and international trade associations and include:

- BIO-Europe® and BIO-Europe Spring®, the world's largest stand-alone life science partnering conferences, supported by the Biotechnology Industry Organization (BIO)
- BioPharm America™, the fastest growing partnering event in North America
- EuroMedtech™, EBD Group's partnering event for the innovative medical technology industry
- BioEquity Europe, the investor conference co-organized with BioCentury Publications and BIO
- ChinaBio® Partnering Forum, the first dedicated biotech/pharma partnering conference in China.
- Biotech Showcase™, a unique forum in San Francisco for presenting to investors and business development executives, co-produced with Demy-Colton Life Science Advisors

EBD Group's sophisticated web-based partnering service, partneringONE®, is used as the partnering engine at numerous third-party events around the world. Outside of the conference format, EBD Group's consultants provide hands-on assistance for firms seeking to in- or out-license products and technologies.

EBD Group has offices in the USA and Europe.

For more information please visit www.ebdgroup.com

PROPRIETARY TECHNOLOGY

EBD Group's partnering software, bundled into its partneringONE® services, is available to event organizers around the world, helping your delegates connect. Move your event to the next level by adding professional partnering services.

For a list of upcoming and past client events please visit: <http://www.ebdgroup.com/ebd/partneringone/events.htm>

EBD Group's Business Development consultants are experienced in a wide variety of partnering deals including out-licensing, in-licensing and R&D collaborations. Their services encompass identification of potential partners, initial introductions, location of in-licensing opportunities, identification of clients for CRO/CMO and support of deal negotiations.

CORPORATE ALLIANCES

In addition to EBD Group's own events, partneringONE services are used at numerous third-party events worldwide.

For a list of upcoming and past client events please visit <http://www.ebdgroup.com/ebd/partneringone/events.htm>

SENIOR MANAGEMENT

Constantine Theodoropoulos, Corporate Communications • **Carola Schropp**, President • **Philip Ledger**, Vice President • **Katharina Schropp**, Director • **Florian Schönhammer**, Director • **Karin Dierkes**, Director

EluSys Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease, Biodefense

Elizabeth Posillico, PhD

Chief Executive Officer

25 Riverside Drive
Pinebrook, NJ 07058
USA

www.elusys.com

1-973-808-0222

Incorporated: 1999

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

Awarded USD \$69 million, five (5) year, government advanced development contract for pre- and post-exposure indication of Anthim, anthrax anti-toxin to supplement previous \$143 million contract.

Initiated dose escalating human safety study.

CORPORATE MISSION

EluSys Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the development of antibody-based therapies for the treatment of infectious disease. The company has pioneered the development of a rapid injection, anti-toxin antibody, Anthim®, for the prophylaxis and treatment of anthrax disease following a biowarfare attack. Anthim has consistently demonstrated significant efficacy in multiple non-clinical animal studies and has been successfully evaluated in two clinical safety trials.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Anthim monoclonal anthrax anti toxin	prophylaxis and treatment of anthrax infection	Phase II, IIa, IIb

SENIOR MANAGEMENT

Elizabeth Posillico, PhD, Chief Executive Officer • **Robert Love, MBA**, Chief Financial Officer • **Greg Torre, PhD**, Vice President • **Leslie Casey, PhD**, Vice President • **Jeremy Middleton**, Vice President • **James Porter**, Vice President • **Debra Duffy**, Director

BOARD OF DIRECTORS

Ron Eastman, Essex Woodlands Healthcare Ventures • **Johnson Evans**, Invesco • **Clinton Musil**, Essex Woodlands Healthcare Ventures • **Tyrell Rivers, PhD**, Medimmune • **Jeffrey Wolf**, Heat Biologics • **Frank Young, MD, PhD**, Essex Woodlands Health Ventures

Emisphere Technologies, Inc.

Clinical Foci: Drug Delivery

Michael R. Garone
Interim Chief Executive Officer &
Chief Financial Officer

240 Cedar Knolls Road
Cedar Knolls, NJ 07927
USA

www.emisphere.com

1-973-532-8000

OTC BB: EMIS

Incorporated: 1986

Ownership: Public

HIGHLIGHTS

Recent

Novartis Pharma AG is conducting Phase III trials of oral salmon calcitonin using Eligen® for the treatment of osteoporosis and osteoarthritis. Data from both trials is expected 2011. Novartis plans to file for regulatory approval of OP in 2012.

Novo Nordisk A/S is conducting clinical Phase I testing of an oral formulation of their GLP-1 receptor agonist and preclinical testing of oral formulations of their proprietary insulins using Eligen® Technology for Type 2 diabetes.

Emisphere completed a successful clinical trial that demonstrated its oral formulation of B12 using the Eligen® Technology was comparable in efficacy to the IM injection which is the current standard of care.

Upcoming

Emisphere's Eligen® Technology is a leading contender to be the first technology to successfully deliver a therapeutic peptide molecule orally in a commercial product.

Eligen® Technology facilitates and improves absorption of molecules which are otherwise poorly absorbed. We have demonstrated improved delivery and Tmax reduction for several pre-clinical candidates in pain, migraine and other therapeutic areas.

Emisphere can launch a B12 medical food product right now and is currently evaluating the feasibility of continuing development of a drug product.

CORPORATE MISSION

Emisphere Technologies Inc. is a biopharmaceutical company that focuses on improving the delivery of active pharmaceutical ingredients, medical foods and dietary supplements using its proprietary Eligen® Technology. The company's core focus is on oral delivery of molecules which are currently administered by injection. Emisphere's Eligen® Technology overcomes several major obstacles to effective oral delivery including degradation of the active and poor absorption. The major advantages of the technology include broad applicability, stand alone delivery approach – eliminating the need for penetration enhancing excipients, versatility of formulation design, ease of scale up and manufacture and cold chain elimination. In addition to enhancing the bioavailability of compounds, a key feature of the technology is an advantageous pharmacokinetic profile. This feature can be extremely valuable in certain therapeutic areas like pain, migraine, etc. Oral delivery has been shown with Eligen® in clinical trials of solid dosage forms of Unfractionated Heparin, two low molecular weight heparins, Salmon Calcitonin, Insulin, Parathyroid Hormone fragment 1-34, recombinant growth hormone, Cromolyn, Acyclovir and a bisphosphonate. Emisphere has also demonstrated oral delivery of over 60 other compounds in pre-clinical studies. Emisphere recently conducted a clinical trial that demonstrated complete repletion of cyanocobalamin - a vitamin that is poorly absorbed upon oral administration. To date, the Eligen® Technology has been evaluated in more than 140,000 human dosings in different clinical studies ranging in duration from a single dose up to 3 months of daily doses with no adverse events attributed to the technology. Eligen® Technology can be applied to the oral route of administration as well as other delivery pathways, such as buccal, rectal, nasal, ophthalmic, otic, intra vaginal or transdermal.

PROPRIETARY TECHNOLOGY

Eligen® Technology is based upon proprietary, synthetic chemical compounds known as carriers or delivery agents that facilitate the transport of therapeutic macromolecules and other compounds across biological membranes. The Eligen® Technology only changes the physical nature of the molecule without chemically altering the molecule being delivered. We have designed and synthesized a library of over 2000 delivery agents and continue to evaluate these agents for their ability to facilitate the delivery of drugs without altering their ability to exert their pharmacological effect. In addition to improving the absorption of various therapeutic molecules, the technology has been shown to significantly reduce the time to maximum concentration when compared to the marketed formulations.

CORPORATE ALLIANCES

Novo Nordisk has licensed Eligen® Technology for use in combination with its proprietary GLP-1 and insulin analogs. This partnership with Novo Nordisk has the potential to offer new and significant solutions to millions of people with diabetes worldwide. Novartis Pharma AG has licensed Eligen® Technology for use in an oral Calcitonin formulation to treat osteoporosis and osteoarthritis. For osteoarthritis, Novartis completed on Phase III trial and a second Phase III clinical study is ongoing. Novartis is planning a regulatory submission for oral Calcitonin for the treatment of osteoporosis during 2012. These programs serve to validate Eligen® Technology in addition to providing oral delivery as an option for drugs that would otherwise require an invasive route of administration.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Salmon Calcitonin	Osteoporosis and Osteoarthritis	Phase III
Oral GLP-1 Analogues	Type 2 Diabetes	Phase I
Oral Insulin	Type 1 and Type 2 Diabetes	Preclinical
Oral Eligen B12	repletion of B12 levels in deficient patients	Other

SENIOR MANAGEMENT


Michael R. Garone (CFO), Interim Chief Executive Officer • **M. Gary I. Riley, DVM, PhD**, Vice President • **Ron Zesch**, Vice President • **David Gschneider**, Director • **Karen Brazzillo**, Director

BOARD OF DIRECTORS

Mark Rachesky, MHR Fund Management • **Michael Weiser**, Actin Biomed • **John Harkey**, Consolidated Restaurant Operations • **Tim Rothwell**

TRADING STATUS AS OF OCTOBER 5, 2011

OTC BB: EMIS



Market Data

Current Price	1.72
Currency	U.S. Dollar
Net Change	-3.91
Volume	45,784
YTD % Change	-0.29
52Wk Range	0.75–2.68
Avg. Daily Volume (thousands)	100,430

First Call Data

Market Cap (MM)	104.4
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.33
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	1828.00

Shareholders

Institution

Holding %

MHR Fund Management LLC	30.5%
Dimensional Fund Advisors, Inc.	0.7%
Jamison, Eaton & Wood, Inc.	0.0%
Mellon Capital Management Corp.	0.0%
Manulife Asset Management Ltd.	0.0%

Mutual Fund

Holding %

MHR Fund Management LLC	30.5%
Dimensional Fund Advisors, Inc.	0.7%
Jamison, Eaton & Wood, Inc.	0.0%
Mellon Capital Management Corp.	0.0%
Manulife Asset Management Ltd.	0.0%

Source: Thomson Reuters

Envoy Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Drug Discovery, CNS, Metabolic Disease

Brad Margus Chief Executive Officer

555 Heritage Drive
Jupiter, FL 33458
USA

www.envoytherapeutics.com

1-561-210-7705

Incorporated: 2009

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

August, 2011 – Awarded "Mega Market" Newcomer award from State of Florida, citing the company's "outstanding contributions toward improving and diversifying Florida's economy plus distinctive community investment efforts".

July, 2011 – Awarded grant from The Michael J. Fox Foundation to develop compounds targeting a motor circuit compromised in Parkinson's disease via modulation of a receptor recently identified by Envoy.

May, 2011 – Harvard Medical School pain expert, Clifford Woolf, MD, PhD, joins Envoy's scientific advisory board. Dr. Woolf is a professor of neurology and neurobiology focusing on the development of somatosensory circuits, pain and regeneration.

CORPORATE MISSION

Envoy was founded in 2009 to apply a powerful new technology that greatly improves target identification and drug discovery. The technology allows us to measure, in vivo, the expression of each protein within any given cell type and to identify targets selectively expressed in cell populations important to diseases. With highly selective targets in-hand, we believe we can advance novel compounds through preclinical and clinical activities with lower rates of attrition.

In October 2009, we raised \$8 million from 5AM Ventures, Takeda and Roche. We subsequently formed research collaborations with Merck, focused on diabetes and obesity, and with Takeda focused on schizophrenia. These collaboration agreements provide up-front payments and non-dilutive, cash-flow positive research funding and potential milestone payments and royalties. We have also obtained non-dilutive funding from the US government for programs focused on Parkinson's disease and schizophrenia, and from the Michael J. Fox Foundation.

In the year ahead, as we advance compounds from our internal pipeline into lead optimization, we expect to complete a Series B financing. Our goal at the BIO Investor Forum is to introduce the company to investors and potential collaborators.

Our business model has three pillars: using our technology to profile cell types and identify specifically expressed drug targets, discovering new compounds that act on a number of those targets, and forming cash-flow-positive research collaborations with a handful of global pharmaceutical companies.

As our internal drug discovery programs achieve pre-clinical proof of concept in animal models, we expect our business model to gain a fourth pillar as we partner a subset of our compounds to pharmaceutical companies for further development and commercialization.

PROPRIETARY TECHNOLOGY

The pharmaceutical industry's pipeline for innovative therapies to treat neurological and psychiatric diseases is sparse. Envoy's technology holds the promise of bringing forth new, more effective medicines. Our patented bacTRAP translational profiling technology enables us to analyze in vivo all the proteins expressed in specific cell types that play critical roles in complex disease circuits, enabling us to identify novel, cell-type-specific drug targets that are less likely to cause off-mechanism side effects. The platform also enables us to identify the molecular adaptations that occur in specific cell types as a result of disease and drug treatment.

CORPORATE ALLIANCES

In December 2009, less than three months after closing our initial financing, Envoy formed a multi-year research alliance with Merck & Company to discover novel diabetes and obesity drug targets and advance new compounds that modulate them. Merck has thus far paid Envoy an upfront fee, research funding and a milestone payment; additional success-based milestones and royalties may be earned.

In October 2010, Envoy signed an additional collaboration agreement with Takeda to identify proteins selectively expressed in specific cell types known to be involved in schizophrenia. Takeda made a USD \$3 million upfront payment and is providing \$2.25 million per year to Envoy in research funding and fees. Envoy may earn additional success-based milestones and royalties.

PRODUCTS

Name	Indication	Phase
D130	Cognition	Preclinical
D110	Parkinson's disease	Preclinical
D150	Schizophrenia	Preclinical
D180	Parkinson's disease	Preclinical
D170	Addiction & Pain	Preclinical

SENIOR MANAGEMENT

Brad Margus, Chief Executive Officer • **Robert Middlebrook**, Chief Financial Officer • **Stephen Hitchcock, PhD**, Senior Vice President • **Matt Britz**, Business Development

BOARD OF DIRECTORS

John Diekman, PhD, 5AM Ventures • **Fmr. Senator William Bradley**, Allen & Company, LLC • **Mason Freeman, MD**, Mass General Hospital, Harvard Medical School & 5AM Ventures • **Brad Margus**, Envoy Therapeutics, Inc.

SCIENTIFIC ADVISORY BOARD

Nathaniel Heintz, PhD, The Rockefeller University, Howard Hughes Medical Institute • **Paul Greengard, PhD**, The Rockefeller University, The Fischer Center for Alzheimer's Research • **Jeffrey Friedman, MD, PhD**, The Rockefeller University, Howard Hughes Medical Institute • **Scott Biller, PhD**, Agios Pharmaceuticals • **Mark Gallop, PhD**, Former Senior Vice President and Co-founder, Xenoport • **Patrick Griffin, PhD**, The Scripps Research Institute • **Myriam Heiman, PhD**, Broad Institute of MIT and Harvard University, Picower Institute of Learning and Memory • **Eugene Johnson, PhD**, Washington University School of Medicine • **Clifford Woolf, MD, PhD**, Harvard Medical School, Children's Hospital Boston

FINANCING HISTORY

Round Date (Amount, US\$) 10/09/2009 (8.00 million)

Epiomed Therapeutics, Inc.

Presenting Company

Clinical Foci: Drug Development, Drug Discovery, CNS

David R. Helton
Chief Executive Officer

25 Mauchly, Ste 316
Irvine, CA 92618
USA

www.epiomed.com

1-949-398-7359

Incorporated: 2010

Employees: 2

Ownership: Private

CORPORATE MISSION

Epiomed Therapeutics, Inc., is a development-stage pharmaceutical organization focused on the discovery, development and partnering of novel central nervous system (CNS) drugs with a primary focus on anti-emetic (anti-vomiting and anti-nausea) and anxiety. Over a multi-year period and at a cost of several million dollars, the basic research and technology development leading to the discovery and pre-clinical characterization of a lead clinical compound, platform screening technology and discovery compound library has already been completed. Epiomed is poised to initiate human clinical studies of its lead compound within 6 months. In June 2011 the company completed its first round of venture funding with NDI Capital (Vancouver, Canada). The raise includes funding for a Phase I proof of concept human clinical study of its lead compound, ETI-385. Epiomed also has a genus of chemical compounds whose profile is believed to address multiple novel receptor targets. In addition to emesis and anxiety, these receptors modulate pathways for depression, psychosis, cognition, attention, pain and neurodegenerative disease. Epiomed is currently seeking capital to expand the scope of its Phase I clinical trials and to begin development of novel compounds as potential therapeutics for both human and veterinary applications.

PROPRIETARY TECHNOLOGY

Epiomed Therapeutics has acquired technology and assets from Cenomed, Inc. (technology developed by Cenomed BioSciences, LLC) relating to the discovery of a previously unknown but important inter-play between several receptors essential for development of potent anti-emetic, anti-anxiety therapeutic compounds. Epiomed Therapeutics' lead product is ETI-385 (formerly, CM-2,385), a novel anti-emetic, non-anxiogenic with multi-receptor pharmacology acting in the CNS at the common final pathway for emesis. Unlike all currently marketed anti-emetic drugs, ETI-385 blocks all emetic stimuli (motion, chemical, conditioned, etc.) in preclinical models. ETI-385 establishes the proof of the theory behind the Company's proprietary and broad ESP Discovery technology.

CORPORATE ALLIANCES

The Institute of Palliative Medicine (IPM) at the San Diego Hospice (www.sdhospice.org);
ChemPacific (www.chempacific.com) in Baltimore, MD (USA) and China (ChemPacific Zhapu);
MicroConstants (www.microconstants.com) in San Diego, California 92121;
NDI Capital (NDI) (www.ndicapital.com) in Vancouver, BC Canada, and Wright State University in Dayton Ohio.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
ETI-385	Emesis	Phase I	
ETI-601	PTSD	Preclinical	IND

SENIOR MANAGEMENT

David R. Helton, Chief Executive Officer • **Ernie Pfdenhauer**, Chief Operating Officer

BOARD OF DIRECTORS

James Miller, NDI Capital • **David R. Helton**, Epiomed Therapeutics • **Gordon McCauley**, NDI Capital • **Theodore Ming-Teh Yang**, ChemPacific

SCIENTIFIC ADVISORY BOARD

James Lucot, PhD, Wright State University • **Lakshmi Putcha**, PhD, NASA • **Marit I. Piacente**, DVM, DABT, Allergan • **Ernest H. Pfdenhauer**, MA, Epiomed Therapeutics • **Charles Von Gunten**, MD, San Diego Hospice • **Jay Huff**, MD, Consultant • **Laurence R. Meyerson**, PhD, Epiomed Therapeutics • **Douglas Harpel**, Aerospace Industry • **David Fleisher**, MD, University of Missouri School of Medicine

Epizyme, Inc.

BIO Member, Presenting Company

Robert J. Gould

Chief Executive Officer

325 Vassar Street, Suite 2B
Cambridge, MA 02139
USA

www.epizyme.com

1-617-229-5872

Incorporated: 2007

Employees: 42

Ownership: Private

CORPORATE MISSION

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of targeted therapeutics for the treatment of genetically-defined cancer patients, based on breakthroughs in the field of epigenetics. Epigenetic enzymes are strongly associated with the underlying causes of multiple human diseases and have been broadly validated as viable drug targets by the FDA approval of histone deacetylase and DNA methyltransferase enzyme inhibitors. Our hypothesis-driven approach to the creation of personalized therapeutics represents the future of cancer therapy creating better therapeutics for the right patients more quickly and at lower cost than traditional approaches. Epizyme's personalized therapeutics are exemplified by our two most advanced therapeutic product programs, targeting the HMTs DOT1L and EZH2.

CORPORATE ALLIANCES

GlaxoSmithKline (GSK), Multiple Myeloma Research Foundation (MMRF), Eisai, The Leukemia & Lymphoma Society (LLS)

SENIOR MANAGEMENT

Robert J. Gould, Chief Executive Officer • **Jason P. Rhodes**, Chief Business Officer • **Robert A. Copeland**, Chief Scientific Officer • **Victoria M. Richon**, Vice President • **Mikel Moyer**, Vice President

Esperion Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease, Metabolic Disease, Biopharmaceuticals

Roger S. Newton, PhD President & CEO

46701 Commerce Center Drive
Plymouth, MI 48170
USA

www.esperion.com

1-734-862-4856

Incorporated: 2008

Employees: 15

Ownership: Private

HIGHLIGHTS

Recent

ETC-1002, completed Phase 2 Lipid POC - August 2011.
Lead protein selection for oxidation-resistant apoA-I program.
Lead selection for follow-on small molecule program.

Upcoming

ETC-1002 - Top-line results and additional data analysis.
Collaborative research agreement with biopharmaceutical company for the oxidation-resistant apoA-I program.
ETC-1002 - Initiate a Phase 2 Glucose study in 1Q12.

CORPORATE MISSION

Esperion Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies to prevent, treat and reverse cardiovascular and metabolic diseases. We are developing novel therapies that enhance the body's ability to regulate lipid and carbohydrate metabolism as well as reduce inflammation, leading to improved health outcomes. Located in Plymouth, Michigan, Esperion is funded by top tier venture capital investors. Esperion Founder, President and CEO, Roger Newton, PhD, co-discovered and was the product champion of Lipitor®, while at Warner Lambert. Dr. Newton was also the co-founder and President/CEO of the original Esperion, purchased by Pfizer in 2004 for USD \$1.3 billion. Several members of the current Esperion team are accomplished drug developers from across the industry, including Warner Lambert/Pfizer and the original Esperion.

Esperion's most advanced product candidate just completed a Phase 2 Lipid POC. ETC-1002 -- a novel, once-daily, oral drug -- is being developed for patients who have, or are at risk for cardiovascular and metabolic diseases. ETC-1002 is a metabolic regulator of imbalances in carbohydrate and lipid metabolism and inflammation, unique in its ability to modulate LDL and HDL cholesterol, triglycerides, free fatty acids, glucose and other cardio-metabolic risk factors. Mechanistic studies indicate that treatment with ETC-1002 increases AMP-kinase phosphorylation, inhibits fatty acid and cholesterol synthesis and also enhances fatty acid oxidation. In addition, Esperion has completed discovery research on a number of promising follow-on candidates and has selected a lead compound.

PROPRIETARY TECHNOLOGY

In 2003 Esperion was the original developer of recombinant apoA-I Milano (ETC-216) and demonstrated regression of atherosclerotic plaques, after 5 weekly infusions, in stable ACS patients, via Intravascular Ultrasound (IVUS). This seminal moment in cardiovascular drug development led Pfizer to purchase the company in 2004.

Combining its legacy of innovation with significant advancements in recombinant protein production as well as improved sourcing, formulation and manufacturing, all factors leading to reductions in cost of goods, the new Esperion is developing a Proprietary, Optimized MPO Oxidation-Resistant ApoA-I Mimetic. The oxidation-resistant HDL mimetic therapy will preserve the function of HDL and its primary apolipoprotein (apoA-I).

PRODUCTS

Name	Indication	Phase	Milestone
ETC-1002	Dyslipidemia, diabetic dyslipidemia, pre-diabetic dyslipidemia	Phase II, IIa, IIb	Phase 2 Lipid POC completed in August 2011
Oxidation-Resistant ApoA-I - HDL Mimetic Therapy	Acute Coronary Syndrome	Optimized Lead	Pre-clinical, in vivo proof of concept completed in October 2011
Follow-on Small Molecule Compound	Dyslipidemia, diabetic dyslipidemia, pre-diabetic dyslipidemia	Optimized Lead	Evaluating partnerships

SENIOR MANAGEMENT

Roger S. Newton, PhD, President & CEO • **Troy Ignelzi**, Vice President

BOARD OF DIRECTORS

Alison Kiley, Alta Partners • **Dov Goldstein**, Aisling Capital • **Nicole Vitullo**, Domain Associates • **Lou Lange**, Asset Management • **Tim Mayleben**, Aastrom Biosciences • **Roger Newton**, Esperion Therapeutics

SCIENTIFIC ADVISORY BOARD

Michael Davidson, MD, Radiant Research • **Robert Eckel, MD**, University of Colorado, Denver • **Stephen Nicholls, MBBS, PhD, FRACP, FACC**, Cleveland Clinic • **Christie Ballantyne, MD**, Baylor College • **Lorenzo DiCarlo**, BioDev, LLC • **Stan Hazen, MD, PhD**, Cleveland Clinic

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2008 (22.75 million)

Investors: Alta Partners (28%) • Aisling Capital (28%) • Domain Associates (28%) • Arboretum Ventures (9%) • Asset Management Company (3%)

FasterCures

Presenting Company

Clinical Foci: Drug Development, Biopharmaceuticals, Drug Discovery

Margaret Anderson

Other

1101 New York Avenue NW, #620
Washington, DC 20005
USA

www.fastercures.org

1-202-336-8900

Incorporated: 2003

Employees: 13

Ownership: Patient Advocacy Group

HIGHLIGHTS

Recent

Partnering for Cures 2010: More than 800 medical leaders convened for this unique cross-sector partnering meeting, presentations on innovative collaborative initiatives, consultations with experts, and one-on-one partnering meetings.

"Crossing the Valley of Death" whitepaper: Highlights the importance of translational research in the therapeutic development process, identifies some of the major challenges to its conduct, and points the way toward possible solutions.

TRAIN Central Station: Online platform for venture philanthropists in medical research to come together to share best practices, exchange ideas, and find relevant tools and resources.

Upcoming

Partnering for Cures 2011: Scheduled for November 6-8 in New York City. Save the date for this one-of-a-kind partnering event.
www.partneringforcures.org

CORPORATE MISSION

FasterCures/The Center for Accelerating Medical Solutions is a nonprofit think tank and catalyst for action that works across sectors and diseases to improve the effectiveness and efficiency of the medical research enterprise. Our mission is to accelerate the progress of discovery and development of new medical solutions for deadly and debilitating diseases. FasterCures, a center of the Milken Institute, is nonpartisan and independent of interest groups.

Since 2003, FasterCures has been working on breaking down the barriers that exist across the research continuum - from basic research to drug development - to clear the path to faster medical progress. We are committed to facilitating a medical research culture that encourages innovation, collaboration, outcomes, effective and efficient use of resources and transparency.

Our strategic goals are:

1. To increase innovative, cross-sector collaborative science among all players in the medical research system;
2. To increase patient engagement in research and optimize use of patient data;
3. To improve the research policy and process to support efficient development and approval of new therapies;
4. Greater access to and strategic allocation of capital to support medical research.

SENIOR MANAGEMENT

Margaret Anderson, Other • **Cecilia Arradaza**, Other • **Kristin Schneeman**, Other • **Melissa Stevens**, Other • **Lisa Simms**, Other

BOARD OF DIRECTORS

Michael Milken, Milken Institute • **David Baltimore, PhD**, California Institute of Technology • **Ernest Bates, MD**, American Shared Hospital Services • **Gary Becker, PhD**, University of Chicago • **Leon D. Black**, Apollo Management • **Nancy G. Brinker**, Susan G. Komen for the Cure • **Larry Flax**, California Pizza Kitchen • **Shmuel Meitar**, Aurec Group • **Richard Merkin, MD**, Heritage Provider Network • **David A. Steinberg**, CAIVIS Acquisition Corp.

Flexion Therapeutics, Inc.

Presenting Company

Clinical Foci: Specialty Pharmaceutical, Biopharmaceuticals, Drug Development

Mike Clayman Chief Executive Officer

300 Trade Center
Woburn, MA 01801
USA

www.flexiontherapeutics.com

1-781-897-9977

Incorporated: 2007

Employees: 10

Ownership: Private

CORPORATE MISSION

Flexion has three novel assets in development for the treatment of Osteoarthritis (OA). Our approach combines local delivery (intra-articular injection) with sustained release technology to ensure high therapeutic concentrations at the site of disease. Two of our assets are in Phase II clinical trials and will have defining clinical data in 2012. Our programs will initially focus on relief of symptomatic OA pain, but both assets have disease modifying potential.

PROPRIETARY TECHNOLOGY

Flexion's approach combines local delivery (via injection) with sustained release technology to ensure high therapeutic concentrations at the site of disease. This also guarantees vanishingly low systemic concentrations and improves the safety profile of our molecules.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
FX005	Relief of symptomatic OA pain	Phase II, IIa, IIb	Proof of Concept Study completes 1Q12
FX006	Relief of symptomatic OA pain	Phase II, IIa, IIb	Dose Ranging Study completes 3Q12
FX007	Relief of symptomatic OA pain	Research	Preclinical testing in progress

SENIOR MANAGEMENT

Mike Clayman, Chief Executive Officer • **Neil Bodick**, Chief Medical Officer • **Lisa Davidson**, Vice President

BOARD OF DIRECTORS

Patrick Mahaffy, Clovis Oncology • **Sam Colella**, Versant • **Elaine Jones**, Pfizer • **Andy Schwab**, 5AM • **Brad Bolzon**, Versant • **Rafaele Tordjman**, Sofinnova

SCIENTIFIC ADVISORY BOARD

Virginia Kraus, Duke School of Medicine • **Tim Mcalindon**, Tufts School of Medicine • **Mark Genovese**, Stanford School of Medicine

FINANCING HISTORY

Round Date (Amount, US\$) 10/16/2009 (42.00 million)

Investors: Sofinnova Partners (0%) • Versant Ventures (0%) • Pfizer Ventures (0%) • 5AM Ventures (0%)

FluGen, Inc.

BIO Member, Presenting Company

Clinical Foci: Medical Device, Vaccines, Immunology

Paul V. Radspinner

President & CEO

545 Science Drive
Madison, WI 53711
USA

www.flugen.com

1-608-658-6095

Incorporated: 2007

Employees: 11

Ownership: Private

HIGHLIGHTS

Recent

Series A funding of USD \$7.8 million in February of 2011.
Manufacture and sterilization of devices for fill/finish validation, GLP toxicology studies and IRB saline human study.
REDEE FLU™ kinetics comparable to wild-type influenza without replication. In addition, heterosubtypic protection in mice.

Upcoming

Human IRB saline study with microneedle device to be completed in December 2011.
IND for microneedle device submitted by April 2012 with Phase I clinical trial to start thereafter.
REDEE FLU™ pivotal efficacy trials in animals initiated November 2011.

CORPORATE MISSION

FluGen is driving the combination of the engineering of intradermal delivery with the biology of vaccine development. Through the intradermal delivery of vaccines patients can receive substantially more efficacy as well as convenience. Targeted patient groups include those with compromised immune systems such as the elderly, cancer patients, the very young and the very sick.

PROPRIETARY TECHNOLOGY

FluGen's proprietary technologies include its intradermal delivery device which allows health care professionals to easily apply and deliver vaccines to diverse patient groups. In addition, the patchlike nature of the FluGen device would allow for patients to self administer vaccines and other payloads.

FluGen is also aggressively moving to the clinic with its REDEE FLU replication deficient influenza vaccine. This vaccine has shown in vivo results indicating a flu vaccine with all of the benefits of a live attenuated vaccine without the concerns of recombination, reversion and lack of efficacy in the elderly.

CORPORATE ALLIANCES

The company currently has alliances with the University of Wisconsin- Madison and the US Department of Defense, USAMRIID and TATRC.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Intradermal Delivery Device	Influenza	Preclinical	Phase I Clinical Trial
REDEE FLU™ Influenza Vaccine	Prevention of Influenza	Preclinical	Pivotal Animal Efficacy Studies
Multiple Vaccine Delivery Device	Intradermal Delivery of Multiple Vaccines at Once	Preclinical	Pivotal Animal Efficacy Studies

SENIOR MANAGEMENT

Paul V. Radspinner, President & CEO • **Dr. Pamuk Bilse**, Vice President • **Dr. Trent Gu**, Director • **Renee Herber**, Director

BOARD OF DIRECTORS

Paul V Radspinner, Founder, President & CEO • **Frederick Mancheski**, Investor • **David Walsh**, Investor • **Terence Kelly**, Investor • **Russel Smestad**, Independent • **Scott Klug**, Independent • **Deven McGlenn**, Founder Representative • **Bryan Renk**, Founder Representative

SCIENTIFIC ADVISORY BOARD

Dr. Yoshihiro Kawaoka, Founder • **Dr. Gabriele Neumann**, Founder • **Dr. Pamuk Bilse**, VP R&D

FINANCING HISTORY

Round Date (Amount, US\$) 12/27/2008 (2.20 million) • 02/26/2011 (7.80 million)

Investors: Knox Investment Group (24%) • P. Radspinner (13%) • Y. Kawaoka (13%) • G. Neumann (13%) • WARF (6%)

FreeMind Group, LLC

Eyal Schmidt

President & CEO

423 Brookline Avenue
Boston, MA 02215
USA

www.freemindconsultants.com

1-617-648-0340

Incorporated: 1999

Employees: 25

Ownership: Private

CORPORATE MISSION

FreeMind is the premier worldwide consultancy firm for Non Dilutive Funding and a proud member of the Bio Strategic Alliance Program. Over the past decade we have assisted hundreds of companies and academic institutions to secure grants and contracts, mainly from the NIH and DOD. FreeMind's systematic and methodological process, taking advantage of our experienced 25 full-time analysts and writers supports our clients' needs. On average we triple our clients' chances for success in comparison to the common statistics. We aim to turn non-dilutive funding to a strategic source of funding bringing millions of dollars to our clients annually. These awards average at over USD \$1.5 million per project and include large scale, multi-PI and multi-disciplinary mechanisms leading to over USD \$20 million awards per project.

SENIOR MANAGEMENT

Eyal Schmidt, President & CEO • **Ram May-Ron**, Vice President • **Ariel Shatz**, Vice President

Galena Biopharma, Inc. (Formerly RXi Pharmaceuticals)

BIO Member, Presenting Company

Clinical Foci: Oncology • Skin/Dermatological • Ophthalmic

Mark J. Ahn, PhD

President & CEO

310 N. State Street, Suite 208
Lake Oswego, OR 97034
USA

www.galenabiopharma.com

1-503-400-6636

NASDAQ: RXII

Incorporated: 2006

Employees: 15

Ownership: Public

HIGHLIGHTS

Recent

Company Strengthens Strategic Focus by Separating Into Two Publicly Traded Companies: Galena Biopharma and RXi Pharmaceuticals.

Licenses Folate Binding Protein (FBP), a Novel, Targeted Cancer Vaccine for Gynecological Cancers.

Hires Hana B. Moran as Vice President, Regulatory Affairs and Compliance.

Upcoming

NeuVax™ is slated to commence Phase 3 clinical trials under a Special Protocol Agreement in 1H12 in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®.

Folate Binding Protein-E39 (FBP), a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers, is expected to start a Phase 1/2 trial by 4Q11.

CORPORATE MISSION

Galena Biopharma, Inc. (Nasdaq: RXII) is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care.

PROPRIETARY TECHNOLOGY

Developing NeuVax for the treatment of HER2 1+ & 2+ breast cancer patients in the adjuvant setting. The company anticipates initiating its Phase 3 trial under an approved SPA in first half 2012. NeuVax consists of the E75 peptide derived from HER2 combined with the immune adjuvant granulocyte macrophage colony stimulating factor (GM-CSF). Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2.

Folate Binding Protein-E39 (FBP) is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers. The FBP vaccine consists of the E39 peptide derived from the folate binding protein combined with GM-CSF. A Phase 1/2 trial is expected to commence by 4Q11.

PRODUCTS

Name	Indication	Phase	Milestone
NeuVax (E75)	Adjuvant breast cancer with low to intermediate HER2 expression	Phase III	Initiate Phase 3 in 1H12.
Folate Binding Protein-E39 (FBP)	ovarian, endometrial, and breast cancers	Phase I	Phase 1/2 initiation in 4Q12.

SENIOR MANAGEMENT


Mark J. Ahn, PhD, President & CEO • Mark W. Schwartz, PhD, Chief Operating Officer • Hana Moran, Vice President

BOARD OF DIRECTORS

Sanford J. Hillsberg, TroyGould PC • Richard Chin, MD, Chief Executive Officer, Institute for OneWorld Health • Stephen S. Galliker, Former Executive VP & CFO, Dyax Corp. (Retired) • Steven A. Kriegsman, President & CEO, CytRx Corporation • Rudolph Nisi, MD, New York Westchester Square Medical Center • Mark J. Ahn, PhD, President & CEO, Galena Biopharma

SCIENTIFIC ADVISORY BOARD

George Peoples, MD, Chief Medical Advisor



Market Data

Current Price	0.9
Currency	U.S. Dollar
Net Change	1.12
Volume	38,986
YTD % Change	-0.651
52Wk Range	0.61-4.08
Avg. Daily Volume (thousands)	734,967

First Call Data

Market Cap (MM)	38.42
Short Interest Shares	3,593,980
Short Interest Ratio	5.59
PE (Trailing 12 Months)	-0.55
EPS (Last Fiscal Year)	-0.51
Consensus Estimate (Y)	-0.55
Consensus Recommend	-0.55
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
Tang Capital Management LLC	0.04239
BlackRock Fund Advisors	3.5%
BAM Capital LLC	0.9%
The Vanguard Group, Inc.	0.7%
DAFNA Capital Management LLC	0.7%
<i>Mutual Fund</i>	<i>Holding %</i>
Tang Capital Management LLC	0.04239
BlackRock Fund Advisors	3.5%
BAM Capital LLC	0.9%
The Vanguard Group, Inc.	0.7%
DAFNA Capital Management LLC	0.7%

Source: Thomson Reuters

Gamma Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease • Diagnostics • Medical Device

David H. Farrell, PhD Chief Scientific Officer

2611 SW Third Avenue
Portland, OR 97201
USA

www.gamma-therapeutics.com

1-503-222-2313

Incorporated: 2009

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

Named Finalist in 18th Annual Tom Hulce Entrepreneurship Awards as Development Stage Venture.

Honored as one of Oregon's fastest growing Early Stage Development Companies by the Portland Oregon Business Journal.

Won full U.S. Patent for GammaSeal Surgical Incision and Wound Closure Sealant.

Upcoming

Expect to win USD \$1.5 million Air Force Expeditionary Medicine Grant for the development of a new medical device designed to address issues of diffuse coagulopathy during warfighter battlefield resuscitation.

Expect to win USD \$1.5 million Army Medical Research and Materiel Command Grant for the development of a fast-clotting hemostatic dressing to address hemorrhaging wounds on the battlefield.

Expect to win USD \$1.52 million NIH/SBIR Grant for the development of an incision sealant for wound closure, healing, and tissue regeneration based upon Gamma Prime Fibrinogen, a high tensile strength naturally occurring protein in the human body.

CORPORATE MISSION

Gamma Therapeutics is an Oregon-based early-stage venture developing novel CVD risk diagnostic assays, surgical therapy and combat casualty care solutions based upon the application of human compatible proteins responsible for the clotting mechanism in human blood.

PROPRIETARY TECHNOLOGY

Gamma Therapeutics holds the IP to the monoclonal antibody, Gamma Prime Fibrinogen a naturally occurring protein in human blood responsible for the clotting mechanism and the technology platform for its CVD risk and inflammation biomarkers, anticoagulant blood thinners and surgical incision and wound closure products.

CORPORATE ALLIANCES

Gamma Therapeutics currently has strategic partnerships with Healthcare Diagnostic Laboratories, Pharming Technologies NV and the Armed Forces Institute of Pathology. It is in partnership discussions with Alere Medical, Luminex, Baxter BioSurgery, Diagnostica Stago, Zeus Scientific, Merck Pharmaceuticals, EMD Millipore, Novartis and a host of other small biopharmaceutical and biotechnology companies in the cardiovascular disease diagnostic assay, surgical therapy and combat casualty care market segments.

PRODUCTS

Name	Indication	Phase	Milestone
GammaCoeur CVD Risk Assay	a novel analyte for heart attack and stroke risk to capture at-risk patients mizzed by traditional cardiac biomarkers, i.e., cholesterol	Diagnostics	Presenting GammaCoeur to FDA OIVD on Sept. 27 and beginning (3) BETA tests with Coronary Heart Stud (Framingham Cohort)
GammaSeal Surgical Incision and Wound Closure Sealant	a natural non-immunogenic, pathogen-free, degradation resistant recombinantly derived sealant for surgery and trauma	Preclinical	signed partnership with Pharming to develop the recombinant gamma prime fibrinogen sealant, signed NDA with Baxter Healthcare
Gammarin Anticogulant Blood Thinner	a natural blood thinner for use during and after surgery to prevent venous thromboembolisms and avoid problems seen with heparin-induced thrombocytopenia	Research	Signed CDA and in discussions with Merck
GammaTF Warfighter Hemostatic Dressing	addresses military medicine need for a fast-clotting dressing that clots hemorrhaging wound in under 120 seconds.	Research	developed working prototypes and presented to US Army. Navy and Air Force medical research groups for assessment, submitted DARPA, BAA and AF grants

SENIOR MANAGEMENT

David H. Farrell, PhD, Chief Scientific Officer • **Steve Kazmierczak, PhD (Director, OHSU Division of Pathology)**, Consultant • **David Forman (Tonkon Torp Law Firm)**, Attorney • **Sheila Ramerman, PhD, FDA Regulatory**, Consultant • **Candace Clement (Comptroller)**, Corporate Finance • **David F. Eastman, MS**, Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Sanjiv Kaul, MD, Head, OHSU Division of Cardiovascular Medicine • **Martin Schreiber, MD**, Chief, OHSU Trauma Surgery, Adult and Acute Care • **Steve Kazmierczak, PhD**, Head, OHSU Department of Pathology • **Jose Lopez, MD**, Head, Research, Puget Sound Blood Center • **Kent Thornburg, PhD**, Director, OHSU Heart Institute • **Michelle Guinness, PhD**, OHSU Technology Transfer and Business Development

FINANCING HISTORY

Round Date (Amount, US\$) • 10/01/2010 (1.52 million)

Investors: David H. Farrell, PhD, Founder and CSO (67%) • Oregon Health Sciences University (OHSU) (15%) • David F. Eastman, CEO (5%) • Employee Pool (13%)

Genocea Biosciences, Inc.

Presenting Company

Clinical Foci: Vaccines, Infectious Disease, Oncology

Chip Clark

Chief Executive Officer

161 First St 2C
Cambridge, MA 02142
USA

www.genocea.com

1-781-876-8191

Incorporated: 2006

Employees: 40

Ownership: Private

HIGHLIGHTS

Recent

HSV-2 Tx: successful pre-IND meeting to set tox package and 1st clinical trial protocol; start of pre-IND tox studies; animal PoC demonstrating that unique mechanism of action provides significant benefits against spectrum of infection symptoms

Pneumococcus vaccine: publication of data from PATH/Children's Hospital of Boston in Cell; animal PoC with unique mechanism, showing that three proteins can prevent infection caused by spectrum of known Pneumococcus strains

Corporate:

Hired new CEO, CMO, and VP of BD - all with significant and relevant experience

Completed USD \$35 million Series B, co-led by JJDC and Skyline, with significant insider participation as well.

Upcoming

HSV-2 vaccine: 2012 start and completion of first human trial, investigating safety, immunology, and efficacy.

Pneumococcus: initiation of IND-enabling studies in 1Q12.

Chlamydia: initiation of IND-enabling studies in 3Q12.

CORPORATE MISSION

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), pneumococcus, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The most advanced program, a therapeutic vaccine for HSV-2, will enter the clinic in 2012.

The company, founded in 2006, has raised more than USD \$60 million to date in two venture rounds, from investors including Polaris, Johnson & Johnson Development Corp, SR One, Skyline, and Lux.

PROPRIETARY TECHNOLOGY

Each of Genocea's five vaccine programs (HSV2 Tx and Px, Pneumococcus, Chlamydia and Malaria) is wholly owned. They are the product of a technology invented by Darren Higgins, PhD, of Harvard Medical School. This proprietary technology, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations.

CORPORATE ALLIANCES

Pneumococcus: We collaborate with PATH and Children's Hospital of Boston.

Malaria: We collaborate with the Naval Medical Research Center.

Chlamydia: We collaborate with the University of Pittsburgh.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
HSV-2 vaccine	Herpes simplex-2 (therapeutic)	Preclinical	IND filing expected in 1Q12.
Pneumococcus vaccine	Pneumococcus	Preclinical	IND-enabling studies to start in 1Q12.
Chlamydia vaccine	Chlamydia	Preclinical	IND-enabling studies to start in 3Q12.
Malaria vaccine	Malaria	Research	

SENIOR MANAGEMENT

Chip Clark, Chief Executive Officer • **Seth Hetherington, MD**, Chief Medical Officer • **Bob Farrell (finance)**, Vice President • **Jessica Flechtner, PhD (research)**, Vice President • **Paul Giannasca, PhD (manufacturing)**, Vice President • **Ravi Venkatramani, PhD (BD)**, Vice President

BOARD OF DIRECTORS

George Siber, MD • **Kevin Bitterman, PhD**, Polaris Venture Partners • **Dalton Einhorn, JJDC** • **Simeon George, MD**, SR One • **Steve Hoffman, MD, PhD**, Skyline • **Rob Paull**, Lux • **Chip Clark**, CEO, Genocea Biosciences, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 01/01/2009 (23.00 million) • 01/01/2011 (35.00 million)

Genprex, Inc.

Presenting Company

Clinical Foci: Oncology, Genetic Disorders, Drug Delivery

David G. Nance

Chairman

6034 West Courtyard Drive
Austin, TX 78730
USA

www.genprex.com

1-512-597-5945

Incorporated: 2010

Employees: 12

Ownership: Private

HIGHLIGHTS

Recent

Positive data reported from phase I dose escalation trial evaluating intravenous Oncoprex™ (TUSC2/FUS1) monotherapy in stage IV, metastatic lung cancer patients. Drug well tolerated, dose established, responses in lung, liver, pancreas tumors.

Compelling in vivo study data with Oncoprex combined with multiple TKIs. Synergistic activity with EGFR TKIs in both EGFR mutation negative (EGFR wild type) cancers and EGFR mutation positive cancers as well as Kras-related cancers.

Ph II trial designed for Oncoprex + erlotinib in stage IV NSCLC without EGFR mutation. Represents 85% of America/Europe population & 70% Asian population.

Upcoming

Initiation of Ph II Oncoprex + erlotinib trial in 2012.

One or more corporate alliances for Oncoprex development.

Journal publication of Ph I Oncoprex monotherapy trial and interim data from Ph II trial.

CORPORATE MISSION

We are a clinical-stage biopharmaceutical company developing oncology products designed to unlock the unrealized potential of targeted therapies and currently available cancer drugs. We are initiating a phase II clinical trial of our lead product candidate Oncoprex™ used in combination with Tarceva® (erlotinib) in stage IV lung EGFR wildtype cancer patients who are not candidates for erlotinib monotherapy due to their EGFR status.

Oncoprex (CNVN202) harnesses the TUSC2 tumor suppressor to overcome genomic limitations and reduce drug resistance. Our tumor suppression technologies work to induce apoptosis in cancer cells and to control cell signaling and inflammatory pathways to treat cancer at the molecular level, without harming normal cells. TUSC2 (FUS1), the subject of more than 20 peer-reviewed journal publications, is associated with most major cancers including >85% of lung cancers. In early 2011 we completed and reported positive results from a phase I, dose escalation clinical study evaluating Oncoprex monotherapy in stage IV metastatic patients. The trial showed for the first time that a tumor suppressor gene can be delivered intravenously and selectively to human cancer cells using a nanoparticle vector, express high levels of mRNA and protein in cancer cells in the primary tumor and distant metastatic sites, alter relevant pathways in the cancer cell and mediate clinically beneficial anti-cancer activity. The study provided a therapeutic dosage and demonstrated that Oncoprex therapy was well tolerated.

We believe our product candidates can address unmet medical needs of cancer patients by making existing agents more effective and relevant to more patients. Our discoveries, research, technologies and product candidates have been supported by more than USD \$40 million from investigator grant awards and corporate funding.

PROPRIETARY TECHNOLOGY

Oncoprex™ has shown synergistic cancer killing activity when combined with a variety of Tyrosine Kinase Inhibitors (TKIs) including EGFR, VEGFR and PDGF targeted TKIs. Oncoprex™ works synergistically with EGFR TKIs (erlotinib and gefitinib) in both EGFR mutation negative (EGFR wild type) cancers and resistant EGFR mutation positive cancers, as well as Kras-related cancers. Oncoprex employs the TUSC2 (FUS1) tumor suppressor delivered via intravenous lipid nanoparticles to selectively kill cancer cells. By inducing apoptosis and controlling cell signaling and inflammatory pathways, Oncoprex can be combined with targeted therapies to overcome genomic limitations of receptor targets and can re-sensitize cancer to mutation targeted therapies to surmount intrinsic or acquired drug resistance.

CORPORATE ALLIANCES

We hold license, sponsored research and collaboration alliances with The University of Texas MD Anderson Cancer Center.

We seek commercial development collaborations and marketing partnerships.

PRODUCTS

Name	Indication	Phase	Milestone
Oncoprex	NSCLC and other solid tumors	Phase II, IIa, IIb	Ph. I complete; Initiating Ph II in combination with EGFR TKIs
GPRX203	NSCLC and other solid tumors	Preclinical	Developing protocols for combination use with platinum drugs and DNA damaging agents

SENIOR MANAGEMENT

David G. Nance, Chairman • Greg J. Heinlein, Chief Operating Officer

BOARD OF DIRECTORS

David Nance, Technology Capital Corporation

SCIENTIFIC ADVISORY BOARD

Jack Roth, MD, FACS, MD Anderson Cancer Center, Houston TX • **Dr. Nagahiro Saijo**, Deputy Director, National Cancer Center Hospital East, Chiba Japan • **Dr. Tony Mok**, Department of Clinical Oncology, Prince of Whales Hospital, Hong Kong, China

FINANCING HISTORY

Round Date (Amount, US\$) 05/01/2009 (0.20 million) • • 07/01/2011 (4.50 million)

Investors: Four Founding Investors (100%)

GenVec, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Biopharmaceuticals, Vaccines, Veterinary

Paul H. Fischer, PhD President & CEO

65 West Watkins Mill Road
Gaithersburg, MD 20878
USA

www.genvec.com

1-240-632-0740

NASDAQ: GNVC

Incorporated: 1992

Employees: 83

Ownership: Public

HIGHLIGHTS

Recent

Hearing loss program:

- (1) Novartis - global development and commercialization partnership;
- (2) Novartis - clinical supply manufacture partnership;
- (3) New research published.

New appointees to the GNVC Board of Directors:

Edward M. Connor, Jr., MD, former Chief Medical Officer and Exec. Vice President of MedImmune; and Adel A.F. Mahmoud, MD, PhD, former President of Merck Vaccines.

Animal health program:

- (1) Merial (animal health division of sanofi-aventis) - commercialization partnership, foot and mouth disease (FMD) vaccine;
- (2) Merial - agreement to explore indications in addition to FMD, beginning with swine disease.

Upcoming

Advance the hearing loss program to clinical testing under the Novartis partnership.

RSV Vaccine Program: Form corporate partnership for development and commercialization of the product.

HSV Vaccine Program: Generate proof of concept data.

Advance the Foot and Mouth Disease vaccine to Field Safety Testing under our collaboration with the US Dept of Homeland Security.

CORPORATE MISSION

GenVec's lead therapeutic product program is for the common, and poorly addressed, problem of hearing loss. This fully-funded program, based on our proprietary technology, is the subject of a global development and commercialization agreement with Novartis. Our vaccine programs, also based on our core technology, are for major medical needs including Respiratory Syncytial Virus and Herpes Simplex Virus. Our vaccine program for dengue fever is supported through a collaboration with the Naval Medical Research Center and malaria is the subject of a relationship with the US Military Malaria Vaccine Program. In animal health, we work with the Department of Homeland Security to develop vaccines for foot and mouth disease (FMD). We have partnered with Merial, the animal health division of sanofi-aventis, to commercialize FMD vaccines globally. Swine diseases are being targeted under a second agreement with Merial.

PROPRIETARY TECHNOLOGY

GenVec's technology delivers genes to cells of the body in order to produce desired proteins. Our core technology facilitates the rapid discovery and testing of new therapeutic and vaccine candidates designed to solve critical problems. Extensive production experience and clinical testing has demonstrated the clear manufacturing, stability and safety advantages conveyed by our technology.

CORPORATE ALLIANCES

Novartis - global development and commercialization of hearing loss biotherapeutic, including a second agreement with Novartis for clinical supply manufacture;

Naval Medical Research Center - dengue fever vaccine development;

US Military Malaria Vaccine Program - malaria vaccine development;

US Department of Homeland Security - foot and mouth disease vaccine development;

Merial (animal health division of sanofi-aventis) - foot and mouth disease vaccine commercialization;

Merial - swine disease vaccine research and development.

PRODUCTS


Name	Indication	Phase	Milestone
Hearing loss therapeutic	Hearing loss	Preclinical	Clinical testing under our collaboration with Novartis.
Respiratory Syncytial Virus (RSV) vaccine	RSV	Preclinical	Corporate partnership to develop and commercialize the vaccine.
Herpes Simplex Virus-2 (HSV-2) vaccine	genital herpes	Preclinical	Proof concept preclinical data.
Dengue fever vaccine	dengue fever	Preclinical	Generate immunological data in animal models in collaboration with the Naval Medical Research Center.
Malaria vaccine	malaria	Phase I	Vaccine optimization working with the US Military Malaria Vaccine Program.

PRODUCTS			
Name	Indication	Phase	Milestone
Foot and Mouth Disease vaccine	foot and mouth disease in herd animals	Other	Field Safety Testing under our collaboration with the US Department of Homeland Security.
Swine disease vaccine or vaccines	swine diseases	Pre-Target Validation	Exploratory data generated with Meril.

SENIOR MANAGEMENT
Paul H. Fischer, PhD, President & CEO • **Douglas J. Swirsky, CPA, CFA**, Chief Financial Officer • **Bryan T. Butman, PhD (Vector Operations)**, Senior Vice President • **Douglas E. Brough, PhD (Research)**, Vice President • **Michael Tucker (Business Development)**, Vice President

BOARD OF DIRECTORS
Zola P. Horovitz, PhD, Bristol-Myers Squibb, retired • **Edward M. Connor, Jr., MD**, Children's National Medical Center & George Washington University • **Paul H. Fischer, PhD**, GenVec • **Wayne T. Hockmeyer, PhD**, MedImmune, Inc., retired • **William N. Kelley, MD**, University of Pennsylvania • **Adel A.F. Mahmoud, MD, PhD**, Princeton University • **Kevin Rooney**, Beacon Consulting • **Marc R. Schneebaum**, Predictive Biosciences

TRADING STATUS AS OF OCTOBER 5, 2011 **NASDAQ: GNVC**



Market Data	First Call Data
Current Price 2.88	Market Cap (MM) 37.2
Currency US Dollar	Short Interest Shares 145,569
Net Change 0.70	Short Interest Ratio 3.08
Volume 35,397	PE (Trailing 12 Months) -0.71
YTD % Change -0.49	EPS (Last Fiscal Year) -0.57
52Wk Range 2.00–6.57	Consensus Estimate (Y) -0.71
Avg. Daily Volume (thousands) 115,263	Consensus Recommend --
	Price/Sales 1.83

Shareholders

Institution	Holding %
The Vanguard Group, Inc.	2.6%
BlackRock Fund Advisors 2.6%	
BAM Capital LLC 1.0%	
Dimensional Fund Advisors, Inc. 0.4%	
The California Public Employees Retirement System 0.3%	

Mutual Fund	Holding %
The Vanguard Group, Inc.	2.6%
BlackRock Fund Advisors 2.6%	
BAM Capital LLC 1.0%	
Dimensional Fund Advisors, Inc. 0.4%	
The California Public Employees Retirement System 0.3%	

Source: Thomson Reuters

GlaxoSmithKline

Clinical Foci: Neurology • Pulmonary • Specialty Pharmaceutical

Andrew Witty Chief Executive Officer

Five Moore Drive
Research Triangle Park, NC 27709
USA

www.gsk.com
1-919-483-5921

NYSE: GSK
Incorporated: 2000
Employees: 99000
Ownership: Public

HIGHLIGHTS

Recent

GlaxoSmithKline (GSK) and McLaren Group announce innovative strategic partnership.
GlaxoSmithKline (GSK) commits USD \$1 million in cervical cancer vaccine to new cooperative effort aimed at reducing deaths from women's cancers.
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease.

CORPORATE MISSION

GlaxoSmithKline, one of the world's leading research-based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

PRODUCTS


Name	Indication	Phase
Seretide/Advair	Asthma	On Market
Valtrex	Anti-Viral	On Market
Relenza	Anti-Viral	On Market
Arixtra	Cardiovascular	On Market
Tyverb/Tykerb	Oncology	On Market
Synflorix	Vaccine	On Market

SENIOR MANAGEMENT

Andrew Witty, Chief Executive Officer • Ian Tomlinson, Senior Vice President

TRADING STATUS AS OF OCTOBER 5, 2011

NYSE: GSK



Market Data

Current Price	41.83
Currency	U.S. Dollar
Net Change	1.83
Volume	3,238,156
YTD % Change	0.07
52Wk Range	36.28–45.34
Avg. Daily Volume (thousands)	2,609,483

First Call Data

Market Cap (MM)	105,719.0
Short Interest Shares	5,940,922
Short Interest Ratio	1.81
PE (Trailing 12 Months)	3.60
EPS (Last Fiscal Year)	2.04
Consensus Estimate (Y)	3.60
Consensus Recommend	3.60
Price/Sales	2.47

Shareholders

Institution	Holding %
Dodge & Cox, Inc.	3.0%
Fidelity Management & Research Co.	0.6%
Royal Bank of Canada (Channel Islands) Ltd.	0.5%
State Street Global Advisors	0.5%
Fisher Asset Management LLC	0.5%
Mutual Fund	Holding %
Dodge & Cox, Inc.	3.0%
Fidelity Management & Research Co.	0.6%
Royal Bank of Canada (Channel Islands) Ltd.	0.5%
State Street Global Advisors	0.5%
Fisher Asset Management LLC	0.5%

Source: Thomson Reuters

Globelimmune, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Infectious Disease, Oncology, Vaccines

Timothy C. Rodell, MD
Chief Executive Officer

1450 Infinite Drive
Louisville, CO 80027
USA

www.globeimmune.com

1-303-625-2700

Incorporated: 1996

Employees: 35

Ownership: Private

HIGHLIGHTS

Recent

Positive SVR data from the GI-5005 phase 2b trial in treatment-naïve HCV patients. The greatest improvement in SVR occurred in IL28B T/T patients, those genetically predisposed to be hardest to treat (60% SVR / GI-5005+SOC vs. 0% SVR / SOC alone).

The GI-5005 phase 2b study is being expanded by 20 patients having the IL28B T/T genotype to better quantify the treatment effect seen in this high-need patient population.

In the GI-5005 phase 2b trial, in patients that had previously failed treatment with SOC including null responders, poor responders, and partial responders, GI-5005+SOC demonstrated a three-fold improvement in SVR over SOC alone (17% vs 5%).

Upcoming

Top line efficacy results from GI-4000-02, a randomized, active control, adjuvant trial in resected pancreas cancer year end 2011.

End of treatment virologic efficacy data from the 20-patient expansion of GI-5005 in chronically infected HCV patients with the IL28B T/T genotype in 1Q12.

Initiation of a phase 2 study of GI-6207 in patients with medullary thyroid cancer year end 2011.

CORPORATE MISSION

Globelimmune, Inc. is a private biopharmaceutical company developing therapeutic vaccines called Tarmogens® for the treatment of cancer and infectious diseases. The company's lead infectious disease product candidate, GI-5005, is a Tarmogen being developed for the treatment of chronic hepatitis C infection (HCV). The company's lead oncology programs, GI-4000 and GI-6207, target cancers caused by mutated versions of the Ras oncoprotein and CEA expressing

tumors, respectively. GI-4000 is being investigated in clinical trials for the treatment of cancers expressing mutated Ras, including non-small cell lung cancer, pancreatic cancer and colorectal cancer. GI-6207 is being evaluated in clinical trials in patients with CEA expressing tumors. In clinical trials, Tarmogens have been well-tolerated, generated antigen-specific T cell immune responses and improved clinical outcomes in patients. Tarmogens are produced using fermentation processes which can be simply and economically scaled up to commercial levels.

PROPRIETARY TECHNOLOGY

All of the Company's Tarmogen® products are developed from its proprietary platform technology. Tarmogens, a contraction of targeted molecular immunogens, are whole, heat-killed recombinant *Saccharomyces cerevisiae* yeast that have been engineered to produce one or more target disease proteins, or antigens, inside the yeast. These target antigens distinguish diseased cells from normal cells, and can include viral proteins, mutated proteins unique to cancer cells and proteins that are over-expressed in cancer cells. Tarmogens activate T cells capable of locating and destroying the target cancer or virally-infected cells containing the same target antigen.

CORPORATE ALLIANCES

- 1) National Cancer Institute (NCI) / July 2008 – Globelimmune and NCI are jointly developing multiple Tarmogen® products under a Cooperative Research and Development Agreement (CRADA) intended to treat a variety of cancers.
- 2) Celgene Corporation (NASDAQ: CELG) / May 2009 – Global alliance with the Celgene Corporation in oncology that includes USD \$40 million upfront, >\$500 million in milestone payments, plus royalties.

PRODUCTS

Name	Indication	Phase	Milestone
GI-5005	Chronic HCV infection	Phase II, IIa, IIb	End of treatment virologic efficacy data from the 20 patient IL28B T/T expansion 1Q12.
GI-4000	Tumors expressing mutated Ras (pancreas, CRC, NSCLC)	Phase II, IIa, IIb	Preliminary survival data year end 2011.
GI-6207	Tumors expressing carcinoembryonic antigen (CEA)	Phase II, IIa, IIb	Initiation of phase 2 trial in medullary thyroid cancer
GI-6301	Brachyury expressing cancers	Preclinical	IND 2011
GI-13000	Chronic hepatitis B (HBV) infection	Preclinical	IND 2012

SENIOR MANAGEMENT

Timothy C. Rodell, MD, Chief Executive Officer • **David Apelian, MD, PhD, MBA**, Chief Medical Officer • **John Frenz, PhD**, Vice President • **Jeffrey Dekker**, Vice President

BOARD OF DIRECTORS

Timothy C. Rodell, MD, Chief Executive Officer, GlobalImmune, Inc. • **Ralph Christoffersen, PhD**, Morgenthaler • **Ehud Geller, PhD**, Medica Venture Partners • **Augustine Lawlor**, Healthcare Ventures • **Paul Mieyal, PhD, CFA**, Wexford Capital • **Dan Mitchell**, Sequel Venture Partners • **Edward Torres**, Lilly Ventures • **William Freytag, PhD**, Independent Director

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2003 (8.00 million) • 09/01/2005 (38.30 million) • 07/01/2007 (41.20 million)

Investors: Celgene, Inc. (0%) • Morgenthaler Ventures (0%) • HealthCare Ventures (0%) • Wexford Capital (0%) • Sequel Venture Partners (0%)

GlycoMimetics, Inc.

BIO Member, BIO Board Member

Clinical Foci: Hematology • Oncology • Drug Discovery

Rachel K. King

Chief Executive Officer

401 Professional Drive, Suite 250
Gaithersburg, MD 20879
USA

www.glycomimetics.com

1-240-243-1201

Incorporated: 2003

Employees: 22

Ownership: Private

HIGHLIGHTS

Recent

GlycoMimetics entered exclusive worldwide licensing agreement with Pfizer for the GlycoMimetics investigational compound GMI-1070 for all indications. The potential value of the agreement is approximately USD \$340 million plus royalties on sales.

GMI has designed and synthesized a family of compounds that are antagonists of both CXCR4 and E-selectin. A lead series has been identified. These are in preclinical testing in models of hematologic malignancies.

GMI has discovered a family of potent small molecule anti-inflammatories which are being optimized for oral availability. One compound has been shown to improve blood flow and reduce leukostasis in diabetic mice (an early marker of retinopathy.)

Upcoming

The Phase 2 study for GMI-1070 for vaso-occlusive crisis is now enrolling patients at 18 sites in the US and Canada. Data is expected in 2012.

Three oral presentations have been selected for the 2011 ASH meeting on the GMI-1070 compound.

Preclinical studies for the company's second program, an E-selectin-CXCR4 antagonist, are underway. These proprietary compounds are initially intended to target hematologic malignancies. Lead selection is pending.

CORPORATE MISSION

GlycoMimetics, Inc. is developing small molecule drugs targeting unmet clinical needs in orphan disease indications, with an initial focus in hematology/oncology. GlycoMimetics closed a USD \$38 million venture round in late 2009 led by New Enterprise Associates and with new investor Genzyme Ventures. The company's lead product, GMI-1070, is initially being developed for the treatment of vaso-occlusive crisis in sickle cell disease and has been granted Orphan Drug Status and Fast Track designation by the U.S. Food and Drug Administration. Phase 1 clinical trials and a pilot study in sickle cell patients are complete. A Phase 2 trial in vaso-occlusive crisis ("VOC") in sickle cell disease is underway. GMI-1070 is also being evaluated in preclinical studies for use in hematologic malignancies and other orphan indications. GlycoMimetics has generated a pipeline of promising carbohydrate mimic ("glycomimetic") compounds representing an important new class of drugs. In addition to GMI-1070, GlycoMimetics has identified a family of high affinity, small molecule E-selectin specific antagonists which are currently being optimized for oral availability. GlycoMimetics has also designed and synthesized compounds that are antagonists of both E-selectin and CXCR4 which are being evaluated in preclinical models.

In October 2011 GlycoMimetics entered into an exclusive worldwide licensing agreement with Pfizer Inc. for the GlycoMimetics investigational compound GMI-1070.

PROPRIETARY TECHNOLOGY

GlycoMimetics is positioned to lead the emerging field of carbohydrate mimics, or "glycomimetics" with world-class drug discovery and optimization technologies. (The company's chemistry approach was recently described in a review article published in Nature Reviews Drug Discovery: Aug. 2009, vol. 8, no. 8) While native carbohydrates are generally not good drug candidates, glycomimetics can be designed to function with drug-like characteristics that serve to enhance the key biological activity of the native structures. GlycoMimetics' lead compound (GMI-1070) inhibits binding of E-, P-, and L-selectins. The selectins are a family of adhesion molecules involved in a number of disease processes involving inflammation and cell trafficking.

CORPORATE ALLIANCES

On October 11, 2011, GlycoMimetics, Inc. entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) for the GlycoMimetics investigational compound GMI-1070.

Pfizer will receive an exclusive worldwide license to GMI-1070 for vaso-occlusive crisis associated with sickle cell disease and for other diseases for which the drug candidate may be developed.

The potential value of the agreement for GlycoMimetics is approximately USD \$340 million, including an upfront payment as well as development, regulatory and commercial milestones. GlycoMimetics is also eligible for royalties on any sales.

PRODUCTS

Name	Indication	Phase	Milestone
GMI-1070	Sickle Cell Crisis	Phase II, IIa, IIb	Data from Phase 2 in 2012
GMI-1070	hematologic malignancies, e.g. Myeloma	Phase I	Pre- IND meeting upcoming
GMI-1257 family	AML, mobilization	Lead Series	Lead selection, IND preparation
E-selectin antagonist	anti-inflammatory	Lead Series	
GMI-1051	Pseudomonas infection	Optimized Lead	Seeking to partner

SENIOR MANAGEMENT	
Rachel K. King, Chief Executive Officer • John L. Magnani, Chief Scientific Officer • Helen Thackray, Vice President	
BOARD OF DIRECTORS	
M. James Barrett, PhD, New Enterprise Associates • Mike Henos, Alliance Technology Ventures • Bill Gust, Anthem Capital • Jack Baldwin, PhD, Vitae, Merck • Frank Top, MD, MedImmune • Rachel King, Chief Executive Officer, GlycoMimetics, Inc. • John L. Magnani, PhD, Chief Scientific Officer, GlycoMimetics, Inc.	
SCIENTIFIC ADVISORY BOARD	
Beat Ernst, PhD, University of Basel, Pharmacenter • Bruce Bochner, MD, FAAI, Johns Hopkins University School of Medicine • Paul Frenette, MD, Enstein College of Medicine • Dietmar Vestweber, PhD, Max Planck Institute for Vascular Biology	
FINANCING HISTORY	
Round Date (Amount, US\$) 05/01/2003 (9.60 million) • 06/01/2006 (15.40 million) • 10/20/2009 (38.00 million)	
Investors:	New Enterprise Associates (0%) • Genzyme Ventures (0%) • Anthem Capital Management, Inc. (0%) • Alliance Technology Ventures (0%) • Novartis Venture Fund (0%)

Glycoregimmune, Inc.

Presenting Company

Clinical Foci: Gastroenterology, Autoimmune, Immunology

Marc Hertz

President & CEO

3550 General Atomics Court, TPIMS 2-203
San Diego, CA 92121
USA

www.glycoregimmune.com

1-858-597-3859

Incorporated: 2009

Ownership: Private

HIGHLIGHTS

Recent

Identified pathway important in NKT I cell activation, previously unknown to be active in NKT cells, in collaboration with the Torrey Pines Institute for Molecular Studies; and licensed the world-wide rights to the subsequent intellectual property.

6/29/2011 - Entered into collaborative partnership with RxMD to expedite drug development in a highly efficient and cost effective risk-sharing model.

7/25/2011 - USPTO Notice of Allowance for US Patent Application No. 11/529,793.

Upcoming

Complete GRI-001 Phase 2b study in alcoholic liver disease patients by 4Q12, and initiate pivotal studies in 1H13.

File GRI-003 Sulfatide IND in 3Q2012 and initiate Phase 1b studies in 2Q13.

CORPORATE MISSION

Glycoregimmune, Inc. ("GRI") is a privately held startup biotech firm seeking to raise Series A financing to develop Natural Killer T ("NKT") cell targeted therapeutics for alcoholic liver disease ("ALD") and autoimmune disorders. GRI's lead program is a Type I NKT ("NKT I") cell inhibitor that is FDA-approved for an unrelated indication. A single generic oral formulation is marketed for an unrelated oncology indication and is priced around USD \$30/cap. GRI's medical use patents, and the significant cost of the available generic, would preclude generic bleed into the ALD indication. In addition, GRI is developing highly potent selective agonists active in the same pathway as follow-on and/or backup programs to the lead NKT I cell inhibitor program. The NKT I cell inhibitors address the USD \$30 billion ALD market, for which today there is no FDA approved drug, and GRI expects to file a 505b2 submission with the FDA by the second half of 2013. GRI is also developing Type II NKT ("NKT II") cell modulators as novel therapeutics for treating autoimmune disorders. GRI's lead NKT II cell modulator program is a glycolipid, cis-tetracosenoyl ("sulfatide"), that is a natural ligand for activating NKT II cells. GRI is also developing small molecule mimetics of sulfatide as follow-on and/or backup programs to the lead NKT II cell modulator program. The NKT II cell modulators address the USD \$25 billion autoimmune market, and will complete Phase 2 proof of concept clinical trials by the end of 2014. GRI is seeking to raise USD \$25 million to fund operations through 2012; to initiate pivotal trials of an NKT I cell inhibitor and file an IND for our NKT II cell modulator.

PROPRIETARY TECHNOLOGY

GRI develops novel Natural Killer T (NKT) cell targeted therapies, and has programs focused on Type I NKT (NKT I) cell inhibitors and Type II NKT (NKT II) cell modulators. NKT cells share properties of both NK and T cells, are a functional link between the innate and adaptive immune responses, regulate the expression of key cytokines and are critical in modulating the immune response. GRI's NKT I cell inhibitors act through a novel, currently undisclosed, pathway GRI recently discovered to be active in NKT cells. The pathway is independent of the NKT cell TCR. GRI's NKT II cell modulators activate NKT II cells in a CD1d-dependent manner. Cis-tetracosenoyl ("sulfatide"), a natural glycolipid ligand for NKT II cells, binds to CD1d and activates NKT II cells via their TCR.

CORPORATE ALLIANCES

GRI has a current alliance with RxMD to develop NKT targeted therapeutics. Under the alliance, RxMD will use its global drug development expertise, including its team of physician-scientists in Chennai, India, to advance GRI's portfolio of drug candidates. The collaboration represents a new model for risk-sharing, success-based drug development, and allows GRI to preserve resources for ongoing drug discovery while advancing our development candidates much more rapidly and efficiently than we could on our own.

PRODUCTS

Name	Indication	Phase	Milestone
GRI-001	Alcoholic Liver Disease	Other	Expect to initiate pivotal trials 1Q13.
GRI-002 Sulfatide	Autoimmunity	Preclinical	Expect file IND 3Q12.
GRI-003	Alcoholic Liver Disease	Other	Back-up molecule to GRI-001, in-licensed 1Q12.
GRI-004	Autoimmunity	Optimized Lead	Back-up to GRI-002; expect to file IND 3Q13.

SENIOR MANAGEMENT

Marc Hertz, President & CEO • **Albert Agro**, Chief Medical Officer • **Vipin Kumar**, Chief Scientific Officer

BOARD OF DIRECTORS

Marc Hertz, President & CEO, Glycoregimmune, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2011 (0.30 million)

HemaQuest Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Hematology

John P. Longenecker, PhD
Chief Executive Officer

11995 El Camino Real
San Diego, CA 92130
USA

www.hemaquest.com

1-858-356-5590

Incorporated: 2007

Ownership: Private

HIGHLIGHTS

Recent

HemaQuest is conducting a multicenter Phase 2 clinical trial to evaluate HQK-1001 taken orally at higher doses (30, 40, and 50 mg/kg daily) and for longer duration (up to six months) than previously evaluated. Data will be available in late 2011.

HemaQuest will support two investigator-sponsored Phase 2 clinical trials to evaluate HQK-1001 taken orally at 20 mg/kg daily for 6 months in patients with moderately severe beta thalassemia. Data is expected to be available in 1Q12.

Upcoming

Interim data is expected from the multicenter Phase 2 clinical trial to evaluate HQK-1001 in patients with sickle cell disease in late 2011 with final data expected during 1Q12.

CORPORATE MISSION

HemaQuest Pharmaceuticals, Inc., founded in 2007, is a San Diego and Seattle-based biopharmaceutical company focused on developing small molecule therapeutics based on its proprietary Short Chain Fatty Acid Derivatives (SCFADs) technologies to treat hemoglobin diseases. HemaQuest is also developing a proprietary multi-drug therapeutic approach for treating viral-associated malignancies, with a primary focus on Epstein-Barr virus associated lymphomas. The Company's lead drug candidate, HQK-1001, belongs to the class of compounds, SCFADs, originally discovered at Boston University School of Medicine. These compounds have been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory and in small clinical trials in patients with hemoglobin disorders, including sickle cell disease and beta thalassemia. Increased fetal hemoglobin production in red blood cells was shown to ameliorate the outcome of patients with these diseases. HQK-1001 is an orally administered SCFAD, which has shown an excellent safety profile and biologic effects on fetal hemoglobin induction and red blood cell production in the laboratory, relevant animal models, and in clinical trials carried out in healthy human subjects as well as patients with sickle cell disease and beta thalassemia. Additionally, the compound has received Orphan Drug Designation in the United States and Europe for both sickle cell disease and beta thalassemia. Early preclinical studies have also shown the molecule may have activity in models of cystic fibrosis. HemaQuest initiated a Phase 2 multi-dosing clinical trial testing HQK-1001 in patients with sickle cell disease in April 2011 and expects to have data available in late 2011.

PROPRIETARY TECHNOLOGY

HQK-1001 is an orally administered short chain fatty acid (SCFA) derivative, which has a unique combination of biological effects - induction of fetal globin and stimulation of red blood cell production - that addresses the underlying pathological mechanisms in sickle cell disease and beta thalassemia. Extensive studies in both the laboratory and relevant animal models carried out in transgenic mice and non-human primates have demonstrated the potential therapeutic effects of this compound in treating these serious, chronic illnesses. HemaQuest has obtained an exclusive worldwide license for a series of patents and patent applications from Boston University for these technologies that give it a strong proprietary position.

PRODUCTS

Name	Indication	Phase	Milestone
HQ-1001	Sickle Cell Disease and Beta Thalassemia	Phase II, IIa, IIb	Phase II data available late 2011

SENIOR MANAGEMENT

John P. Longenecker, PhD, Chief Executive Officer • **Tamara A. Seymour, MBA**, Chief Financial Officer • **Richard G. Ghalie, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Fred Dotzler, De Novo Ventures • **Armen Shanafelt**, Lilly Ventures • **Ivor Royston MD**, Forward Ventures • **James Woody MD**, Latterell Venture Partners • **Naheed Misfeldt**, Aberdare Ventures • **Wayne Roe** • **George Stamatoyannopoulos MD**, Founder • **Paul Goddard** • **John P. Longenecker, PhD**, CEO, HemaQuest Pharmaceuticals, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 12/18/2008 (20.60 million) • 07/21/2010 (16.00 million)

Investors: Lilly Ventures (18%) • De Novo Ventures (18%) • Forward Ventures (18%) • Aberdare Ventures (11%) • Latterell Venture Partners (11%)

Heptares Therapeutics Limited

Presenting Company

Clinical Foci: CNS, Metabolic Disease, Oncology

Malcolm Weir, PhD

Chief Executive Officer

BioPark, Broadwater Road
Welwyn Garden City
AL7 3AX
United Kingdom

www.heptares.com

44-170-7358629

Incorporated: 2007

Employees: 60

Ownership: Private

HIGHLIGHTS

Recent

- Four-year collaboration with AstraZeneca (2011) focused on developing small molecule and antibody candidates targeting specific GPCRs linked to CNS/pain, CV/metabolic and inflammatory disorders
- Exclusive option agreement with Shire (2011) for novel small molecule adenosine A2A antagonist with best-in-class potential for the treatment of CNS diseases. To our knowledge, this is the first-ever GPCR candidate to arise solely from SBDD.
- Approximately USD \$100 million drug discovery collaboration with Takeda (2011) focused on a GPCR linked to CNS disorders.

CORPORATE MISSION

Heptares Therapeutics Limited is a drug discovery company creating new medicines targeting G-protein-coupled receptors (GPCRs). The Company is currently leveraging its GPCR expertise and proprietary StaR® technology to build a best-in-class and first-in-class pipeline focused on CNS and metabolic disease.

GPCRs represent the single most important family of drug targets in the human body, yet, due to their inherent instability when removed from cell membranes, little or no structural information about these valuable targets has been available to drive structure-based drug discovery (SBDD) programmes.

PROPRIETARY TECHNOLOGY

Heptares' StaR® (Stabilised Receptor) technology enables the first-ever thermo-stabilisation of GPCRs. This breakthrough allows Heptares scientists to resolve GPCR structures and deploy structure-based drug discovery techniques to identify potent and selective drug candidates to previously undruggable targets.

CORPORATE ALLIANCES

AZ, Novartis, Takeda, Shire

PRODUCTS

Name	Indication	Phase
Adenosine A2a antagonist	Neurology/Parkinson's	Preclinical
Muscarinic M1 agonist	Cognition	Preclinical
Orexin (DORA)	Insomnia	Preclinical

SENIOR MANAGEMENT

Malcolm Weir, PhD, Chief Executive Officer • Fiona Marshall, PhD, Chief Scientific Officer • Barry Kenny, PhD, Chief Business Officer

BOARD OF DIRECTORS

John Berriman, Independent • Michael Steinmetz, Clarus • Anja Koenig, NOF • Martin Murphy, MVM • Richard Henderson, MRC

SCIENTIFIC ADVISORY BOARD

Richard Henderson, MRC LMB • David Brown • Chris Tate, MRC LMB • Patrick Humphrey • Mike Tarbit • Paul Leeson • Greg Winter, MRC LMB • Gebhard Schertler, Paul Scherrer Institute

FINANCING HISTORY

Investors: MVM Life Science (0%) • Clarus Ventures (0%) • Novartis Bioventures (0%) • Takeda Research Investments (0%)

Human Genome Sciences, Inc.

BIO Member, BIO Board Member

Clinical Foci: Immunology • Oncology

H. Thomas Watkins President & CEO

14200 Shady Grove Road
Rockville, MD 20850
USA

www.hgsi.com
1-301-309-8504

NASDAQ: HGSI
Incorporated: 1992
Ownership: Public

CORPORATE MISSION

At Human Genome Sciences, we believe that solving critical medical challenges takes careful planning, relentless resilience, the best scientific minds, and rigorous clinical trials. Success will come by design – and by working systematically to achieve breakthrough results one careful step at a time. We received our first product approval in the United States from the FDA on March 9, 2011 – when BENLYSTA® became the first new approved drug for lupus in more than fifty years. The FDA approval of BENLYSTA® was based on data from the largest clinical trial program ever conducted in patients with systemic lupus. We and GlaxoSmithKline (GSK) are developing BENLYSTA® under a co-development and co-commercialization agreement entered into in 2006. GSK submitted a Marketing Authorization Application (MAA) for BENLYSTA® to the European Medicines Agency (EMA) in June 2010, and a decision on European approval is expected in 2H11. Regulatory applications have also been submitted and are currently under consideration in Canada, Australia, Switzerland, Russia, Brazil and The Philippines. Raxibacumab is being developed under a contract with the U.S. Government and represents a new way to address the threat of inhalation anthrax. In 2009, we submitted a BLA to FDA for raxibacumab for the treatment of inhalation anthrax. We received a Complete Response Letter from the FDA in November 2009 and are working closely with the FDA to obtain approval. In the first half of 2009, we achieved our first product sales by delivering 20,000 doses of raxibacumab to the U.S. Strategic National Stockpile for use in the event of an emergency to treat inhalation anthrax. In July 2009, we secured a new purchase order for 45,000 additional doses to be delivered over a three-year period. Approximately 21,000 doses have been delivered to date under the new purchase order, and we expect to deliver approximately 15,000 additional doses to the Stockpile in 2011.

PROPRIETARY TECHNOLOGY

HGS has acquired rights to a variety of human antibody technologies. We have integrated these technologies into our research and development program, and continue to collaborate with a number of antibody companies. Our albumin-fusion technology allows us to create long-acting forms of protein drugs by fusing the gene that expresses human albumin to the gene that expresses a therapeutically active protein. We and our partners are actively pursuing the development of albumin-fusion drugs based on therapeutic proteins already on the market, as well as albumin-fusion versions of therapeutic proteins that we are developing ourselves. For example, albiglutide results from the genetic fusion of human albumin and glucagon-like peptide-1 (GLP-1).

CORPORATE ALLIANCES


Strategic collaborations and partnerships are a key aspect of the HGS business strategy. We have co-development and commercialization agreements with prominent pharmaceutical companies for two of our late-stage products, and our third late-stage product is being developed under a contract with the U.S. Government. Strategic collaborations are an important source of revenues and clinical development cost-sharing. They also allow us to leverage our strengths and gain access to sales and marketing infrastructure, international distribution, or complementary technologies.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
BENLYSTA®	Systemic Lupus (Initiation of Phase 3 trial in Asia planned 2011, initiation of Phase 3 trial of subcutaneous formulation planned 2011)	On Market
Raxibacumab	Inhalation Anthrax (Sales to Strategic National Stockpile under U.S. Government Contract)	Phase III
Darapladib (GSK)	Cardiovascular disease	Phase III
Albiglutide (GSK)	Type 2 Diabetes	Phase III
BENLYSTA	Vasculitis (Initiation of Phase 2 trial planned 2011)	Other
BENLYSTA	Additional autoimmune	Other
Mapatumumab	Cancer	Phase II, IIa, IIb
HGS-1029	Cancer	Phase I
HGS-1036	Cancer	Phase I

SENIOR MANAGEMENT

H. Thomas Watkins, President & CEO • **James H. Davis, PhD, JD**, Executive Vice President • **Barry A. Labinger**, Executive Vice President • **David P. Southwell**, Chief Financial Officer • **David C. Stump, MD**, Executive Vice President • **Susan Bateson**, Senior Vice President • **Curran Simpson**, Senior Vice President • **Craig C. Parker**, Senior Vice President



Market Data

Current Price	12.43
Currency	U.S. Dollar
Net Change	1.72
Volume	3,357,377
YTD % Change	-0.48
52Wk Range	11.05–30.25
Avg. Daily Volume (thousands)	3,374,362

First Call Data

Market Cap (MM)	2,370.0
Short Interest Shares	16,593,595
Short Interest Ratio	3.59
PE (Trailing 12 Months)	-1.33
EPS (Last Fiscal Year)	-1.80
Consensus Estimate (Y)	-1.33
Consensus Recommend	-1.32
Price/Sales	19.19

Shareholders

<i>Institution</i>	<i>Holding %</i>
Fidelity Management & Research Co.	14.9%
T. Rowe Price Associates, Inc.	13.3%
Capital Research Global Investors	5.0%
Taube Hodson Stonex Partners LLP	4.1%
The Vanguard Group, Inc.	3.9%

Mutual Fund

<i>Mutual Fund</i>	<i>Holding %</i>
Fidelity Management & Research Co.	14.9%
T. Rowe Price Associates, Inc.	13.3%
Capital Research Global Investors	5.0%
Taube Hodson Stonex Partners LLP	4.1%
The Vanguard Group, Inc.	3.9%

Source: Thomson Reuters

Ikaria, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Pulmonary, Cardiovascular Disease, Other

Daniel Tassé <i>Chief Executive Officer</i> Perryville III Corporate Park 53 Frontage Road Hampton, NJ 08827 USA	www.ikaria.com 1-908-238-6600	<i>Incorporated:</i> 2007 <i>Employees:</i> 440 <i>Ownership:</i> Private
--	--	---

CORPORATE MISSION

Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies designed to address the significant needs of critically ill patients in the hospital and ICU settings. The company's lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug delivery system, on-site training and 24/7/365 technical assistance and support. Ikaria alone, or through partners, also markets the INOMAX therapy package in Puerto Rico, Canada, Australia, Mexico and Japan. The company is pursuing a number of new indications for INOMAX. Ikaria's late-stage pipeline also is comprised of LUCASSIN® (terlipressin), a potential treatment for hepatorenal syndrome Type 1, as well as IK-5001, a potential treatment for preventing cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction. Ikaria is headquartered in Hampton, NJ, with research facilities in Seattle, WA and Madison, WI, and manufacturing facilities in Port Allen, LA and Madison, WI. Please visit www.ikaria.com.

PROPRIETARY TECHNOLOGY

As the first and only endogeneous signalling molecule in gas form approved for use as a drug in humans, INOMAX® (nitric oxide) for inhalation is used to treat newborns suffering from hypoxic respiratory failure (HRF). INOMAX drug therapy is delivered through Ikaria's proprietary drug-delivery systems, the INOMAX DS and INOMAX DSIR. Next-generation drug-delivery systems are on the horizon.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
INOMAX (nitric oxide) for inhalation	Hypoxic Respiratory Failure in term and near-term infants >36 weeks gestational age	Cleared for US Marketing
INOMAX (nitric oxide) for inhalation	Bronchopulmonary Dysplasia (BPD) in pre-term infants	Phase III
INOMAX (nitric oxide) for inhalation	Pulmonary Arterial Hypertension	Phase II, IIa, IIb
INOMAX (nitric oxide) for inhalation	Chronic Obstructive Pulmonary Disease (Phase IIb/III)	Phase II, IIa, IIb
LUCASSIN (terlipressin)	Hepatorenal Syndrome Type 1	Phase III
IK-5001	Prevention of Ventricular Remodeling and Congestive Heart Failure Post-AMI	Phase II, IIa, IIb

SENIOR MANAGEMENT

Daniel Tassé, Chief Executive Officer • **Douglas Greene, MD**, Executive Vice President • **Matthew M. Bennett**, Senior Vice President • **James Briggs**, Senior Vice President • **Lien-Lung (L.L.) Sheu, PhD**, Senior Vice President • **Stephen Ross**, Senior Vice President

BOARD OF DIRECTORS

Daniel Tassé, Chairman & CEO, Ikaria, Inc.

Immune Targeting Systems

Presenting Company

Clinical Foci: Infectious Disease, Oncology, Immunology

<p>Carlton Brown Chief Executive Officer 2 Royal College Street London NW1 0NH United Kingdom</p>	<p>www.its-innovation.com 44-20-76914908</p>	<p><i>Incorporated:</i> 2003 <i>Ownership:</i> Private</p>
--	---	---

HIGHLIGHTS	
Recent	Upcoming
<p>Successful completion of Phase-I for the lead program culminating in decision to progress to Phase-Ib / 2a studies in 2012.</p> <p>Initiation of 2nd candidate - a unique universal HBV immunotherapy targeting all major globally relevant viral genotypes relevant to the 7MM and China</p> <p>Development of oncology vaccine platform - one vaccine for multiple cancer indications whilst eliminating the need for HLA subtyping.</p>	<p>Series-B funding targeting USD \$28 million.</p>

CORPORATE MISSION

Immune Targeting Systems is a London-based biotech company developing vaccines for mutating viruses and cancer underpinned by its DepoVaccine™ & Densigen™ technology platforms. ITS' lead program, a synthetic universal influenza vaccine (Flunisyn™) targeting all potential seasonal and pandemic flu strains, has completed phase-I clinical testing. Phase-1b / 2a clinical studies will initiate in 2012.

ITS seeks to raise a USD \$28 million Series-B funding to expedite its universal Hepatitis-B therapeutic vaccine (targets major genotypes relevant to 7MM & China) through phase-I, lead optimise an oncology indication (potential to expedite IND) and provide a commercialisation run-way whilst a commercialisation partner is sought. ITS lead investors the Novartis Venture Fund, HealthCap and Truffle Capital will support this round.

Flunisyn will be used as an add on to the seasonal flu vaccine in the elderly to ensure a full complement of immunological correlates of protection are provided at immunisation. Today's seasonal flu vaccine is <30% effective and only generates antibodies, limiting its clinical benefit.

Phase-I data highlights an excellent safety profile and it's best-in-class potential when assessing key immunological performance parameters; vaccine responder frequency (eliminating need for HLA selection), breadth & magnitude of response, booster amplification (no requirement for a heterologous prime-boost strategy). The induced immune responses are able to target multiple variants of H1N1, H2N2, H3N2, H5N1, H7N7 & H9N2 strains including all pandemic / zoonotic flu strains. The Densigen platform fully predicts the human immune response.

Oncology: Overexpressed tumour associated antigens shared by 10 high unmet need cancers were mined for Densigens. Such Densigens frequently contain clinically validated peptides including those associated with survival benefits. Cancer vaccines will offer broad cancer indication utility whilst eliminating HLA sub-typing.

PROPRIETARY TECHNOLOGY

DepoVaccines deliver Densigens™ to the immune system by promoting a short-term vaccine injection site depot resulting in potent T-cell immunity. DepoVaccine™ delivered Densigens™ contain multiple different rationally selected long peptide antigen sequences (35aa) which are conjugated to a fluorocarbon molecule yielding a thermostable freeze dried nanoparticle formulation. Densigens are highly conserved (all strains/genotypes) immunoprevalent antigens. By combining 6-8 different Densigens we ensure a T-cell response capable of providing broad population coverage without restrictive HLA sub-type selection, a multi-peptide breadth of response exceeding best-in-class and a potent-durable magnitude of response. Immunogenesis can be significantly enhanced with proprietary depot forming adjuvants

PRODUCTS			
Name	Indication	Phase	Milestone
Flunisyn	Universal influenza-A vaccine	Phase I	Phase-I complete - progressing to Phase-Ib / 2a in 2012
FP-02	Universal Hepatitis-B immunotherapy	Optimized Lead	Progressing through lead optimisation (human in-vitro validation of Densigen selection)
FP-03	Oncology	Pre-Target Validation	In-silico optimised leads

SENIOR MANAGEMENT

Carlton Brown, Chief Executive Officer • **Dr. Campbell Bunce (R&D Director)**, Other • **Dr. Bertrand Georges**, Chief Technology Officer • **Dr. Jill Makin**, Other • **Tim Cowper**, Chief Financial Officer • **Florent Gros**, Chairman

BOARD OF DIRECTORS

Florent Gros, Novartis Venture Fund (Investor) • **Carlton Brown**, CEO • **Marten Steen**, HealthCap (Investor) • **Philippe Pouletty**, Truffle Capital (Investor) • **Sandy Primrose**, nominated director by the London Technology Fund

SCIENTIFIC ADVISORY BOARD

Professor John Treanor, University of Rochester (USA) • **Dr. Peter Patriarca**, Biologics Consulting Group (USA) • **Dr. Arthur Krieg**, Entrepreneur in residence (Atlas Ventures) • **Professor Hakan Mellstedt**, Professor of Oncologic Biotherapy, Karolinska University Hospital Solna • **Professor Mark Thursz**, Professor of hepatology at Imperial College, London (UK)

FINANCING HISTORY

Round Date (Amount, US\$) 06/28/2007 (21.50 million)

Investors: Novartis Venture Fund (co-lead) (0%) • HealthCap (co-lead) (0%) • Truffle Capital (co-lead) (0%) • Esperante Ventures (0%) • London Technology Fund (0%)

ImmunoCellular Therapeutics, Ltd.

BIO Member, Presenting Company

Clinical Foci: Oncology, Vaccines

Manish Singh, PhD

President & CEO

21900 Burbank Blvd
Woodland Hills, CA 91367
USA

www.imuc.com

1-818-992-2907

OTC BB: IMUC

Incorporated: 2006

Employees: 4

Ownership: Public

HIGHLIGHTS

Recent

Completed a Phase I clinical trial for glioblastoma with encouraging clinical outcomes. Data demonstrates significant improvements in PFS and OS which was presented at ASCO.

Initiated a randomized, double blinded, placebo controlled Phase II clinical Trial in glioblastoma.

Upcoming

Complete patient enrollment in phase II trial in 1Q12 and interim analysis in 3Q12.

Filing of an IND to initiate a cancer stem cell vaccine, 3Q11

Out-licensing of antibody technology platform for novel antibody and antigen expression.

CORPORATE MISSION

ImmunoCellular Therapeutics, Ltd. develops and commercializes new immune based products to treat cancers. Our approach is to harness the body's immune system to provide therapeutics with the ability to fight cancer. There are two arms of the adaptive immune system that provide natural protection to the body: the cellular immune system (T-cell based) and the humoral immune system (B-cell based), which uses antibodies to fight foreign invaders.

- Dendritic Cell Based Cancer Vaccine: Dendritic cells are critical facilitators of a T-cell response but are often not present in sufficient numbers and are often not aggressive enough against malignant tumors to permit an adequately potent immune response to fight cancer. Our lead product, ICT-107, is currently in a phase II clinical trial for Glioblastoma.
- Cancer Stem Cell Therapeutics for Brain and Other Cancers: The characterization of cancer stem cells from glioblastoma has provided an opportunity to study the etiology of this dreaded disease and to be engaged in the development of product candidates that would be able to target the cancer stem cells which are believed to be responsible for the initiation and maintenance of glioblastoma.
- Antibody ImmunoTherapy: The second strategy for our product development, which is in preclinical development, is to harness the other arm of the adaptive immune system, which uses antibodies that can bind and neutralize any foreign antigen. The antibody candidates that we acquired bind to certain tumor antigens which may be useful for the potential detection and treatment for multiple myeloma, small cell lung, pancreatic and ovarian cancers.

PROPRIETARY TECHNOLOGY

Our approach is to harness the body's immune system to provide therapeutics with the ability to fight cancer. There are two arms of the adaptive immune system that provide natural protection to the body: the cellular immune system (T-cell based) and the humoral immune system (B-cell based), which uses antibodies to fight foreign invaders. Our strategy is to utilize both of these mechanisms in our product development programs. Currently, we have three programs: Dendritic Cell Based Cancer Vaccine, Cancer Stem Cell Therapeutics for Brain and Other Cancers, and Antibody Immunotherapy.

CORPORATE ALLIANCES

Cedars-Sinai Technology License, MD Anderson Technology License
University of Pennsylvania License on Dendritic Cell technology

PRODUCTS

Name	Indication	Phase	Milestone
ICT-107	Glioblastoma (Brain cancer)	Phase II, IIa, IIb	Initiate Phase IIb in 1Q11.
ICT-121 (cancer stem cell vaccine)	Solid Tumors	Preclinical	IND in 3Q11.
ICT-109	Small cell lung cancer	Preclinical	Antibody humanization
ICT-69	Multiple Myeloma	Preclinical	Partnered with Roche Pharmaceuticals

SENIOR MANAGEMENT

Manish Singh, PhD, President & CEO • **John Yu, MD**, Chief Scientific Officer • **James Bender, PhD**, Vice President • **David Fractor, CFO**, Chief Financial Officer

BOARD OF DIRECTORS


John Yu, MD, Director, Dept. of Neuro-Oncology, Cedars-Sinai Medical Center • **Jacqui Brandwynne**, President & CEO, Brandwynne Corporation • **Col. Richard Cowell**, Principal, Booz Allen Hamilton Inc. • **Helen Kim**, Chief Business Officer, NGM Biopharmaceuticals • **Manish Singh, PhD**, President & CEO, ImmunoCellular Therapeutics • **Navdeep Jaikaria, PhD**, President & CEO, SGN Advisors • **Rahul Singhvi, DSc**, President and CEO of Novavax

SCIENTIFIC ADVISORY BOARD

Keith L. Black, MD, Chairman, Dept. of Neurosurgery, Cedars-Sinai Medical Center • **Cohava Gelber, PhD**, Chief Scientific Officer, ATCC • **Peter Brooks, PhD**, Senior Scientist, Maine Medical Center Research Institute for Molecular Medicine • **Sherie Morrison, PhD**, Professor, UCLA • **Constantin Ioannides, PhD**, Professor, MD Anderson Cancer Center • **Col George Peoples, MD**, US Military Cancer Institute • **John Bockavar, MD**, Cornell Medical Center • **Zvi Ram, MD**, Tel Aviv Medical Center

TRADING STATUS AS OF OCTOBER 5, 2011

OTC BB: IMUC



Market Data

Current Price	1.60
Currency	US Dollar
Net Change	5.96
Volume	19,383
YTD % Change	0.18
52Wk Range	0.89–2.55
Avg. Daily Volume (thousands)	103,770

First Call Data

Market Cap (MM)	45.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.41
EPS (Last Fiscal Year)	-0.41
Consensus Estimate (Y)	-0.41
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
DAFNA Capital Management LLC	0.2%
Yellowstone Partners	0.1%
<i>Mutual Fund</i>	<i>Holding %</i>
DAFNA Capital Management LLC	0.2%
Yellowstone Partners	0.1%

Source: Thomson Reuters

ImmunoGenes AG

BIO Member, Presenting Company

Clinical Foci: Drug Development, Drug Discovery, Immunology

Imre Kacs Kovics

Chief Executive Officer

Innere Guterstrasse 4
CH-6304 Zug
Switzerland

www.immunogenes.com

1-917-327-6423

Incorporated: 2008

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

We have published three new articles in well respected journals indicating the scientific community's acceptance of the power of our tg mice.

A patent was issued on June 22, 2011, by the European Patent Office, number EP209744, and additional patent applications have been filed and are pending in all other major jurisdictions.

Additional experiments have demonstrated that the technology works in species other than mice.

Upcoming

Patent issuance in US

Publication of an article in a scientific journal showing increased diversity of the immune response.

CORPORATE MISSION

ImmunoGenes is a biotech company based in Hungary that specializes in the generation of monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) using animals that have been genetically modified to overexpress the neonatal Fc Receptor (FcRn). As a result of this overexpression, the company's animals produce a greater number of B cell clones than normal animals because of FcRn's role in antigen presentation. In addition, because of the improved antigen presentation, they are able to mount a strong immune response against weakly immunogenic targets. Also, in response to immunization, they produce 3-10x the quantity of antigen specific polyclonal antibody made by normal animals. As a result, this technology is of value for developers of antibodies against weakly immunogenic targets and for those interested in the production of a higher number of hybridomas than would be possible with a standard mouse process. In addition, it is attractive to those who would benefit from the capability of the animals to express a more diverse immune response against epitopes of an antigen (AG) that are typically not part of the standard response pattern.

PROPRIETARY TECHNOLOGY

The company's genetically modified animals result from the insertion of a specially chosen gene (the FcRn gene) that is delivered to a fertilized egg via a Bacterial Artificial Chromosome (BAC). The effects of neonatal Fc receptor (FcRn) overexpression result in a significant improvement of the humoral immune response in the generation of antibodies for immunotherapy, diagnostics and other uses. These improvements include: 1) improved IgG protection; 2) augmented antigen-specific humoral immune response with larger numbers of antigen specific B cells, offering a wider spectrum of clones; 3) generation of antibodies against weakly immunogenic antigens; 4) significant improvements in the number and diversity of hybridomas.

CORPORATE ALLIANCES

We have signed agreements and shipped our mice to a number of top 10 pharma companies as well as additional antibody producing companies. The first of these experiments have been completed and have confirmed that our partners were able to reproduce the success that we described with the experiments in their facilities demonstrating that our mice produce higher quantity of antibodies, greater numbers of antigen specific B cells and greater numbers of hybridomas than their control mice. We are currently discussing licensing terms with these companies.

SENIOR MANAGEMENT

Imre Kacs Kovics, Chief Executive Officer • **Lee Schalop**, Chief Operating Officer • **Zsuzsanna Bosze**, Chief Scientific Officer • **Wolfgang Oster**, Chairman • **Tonio Barlage**, Chief Financial Officer

SCIENTIFIC ADVISORY BOARD

Anna Erdei, PhD, DSc, Chair Immunology, Eötvös Loránd University • **John E. Butler, PhD**, Professor Immunology, University of Iowa • **Lennart Hammarström, MD, PhD**, Professor, Clinical Immunology, Karolinska Institute (Sweden) • **Richard A. Goldsby, PhD**, Professor of Biology, Amherst College • **Bruce Whitelaw, PhD**, Head of Division of Developmental Biology, The Roslin Institute (UK)

ImmusanT Inc.

Presenting Company

Clinical Foci: AutoImmune, Drug Development, Biopharmaceuticals

Leslie J Williams

Chief Executive Officer

One Broadway, 14th Floor
Cambridge, MA 02142
USA

www.immusant.com

1-617-401-2154

Incorporated: 2010

Employees: 3

Ownership: Private

CORPORATE MISSION

ImmusanT, Inc. is a privately-held emerging biotechnology company focused on restoring tolerance to gluten in celiac disease by harnessing new discoveries in immunology that improve diagnosis and treatment and return patients to a normal diet, good health and improved quality of life. The Company, that acquired the technology from Australia based Nexpep Pty. Ltd., has a strong intellectual property position and foundational science which provides the basis for their peptide-based immunotherapy and diagnostics.

PROPRIETARY TECHNOLOGY

The Company is harnessing the specificity of the immune reaction to gluten (protein in wheat, rye and barley) to develop diagnostics and therapeutics. Nexvax2, a peptide-based therapeutic vaccine, consists of 3 immuno-dominant peptides which are designed to induce tolerance to the toxic effects of gluten in Celiac Disease. This introduces a new treatment paradigm for celiac disease by leveraging the immune response to gluten.

PRODUCTS

<u>Name</u>	<u>Indication</u>	<u>Phase</u>	<u>Milestone</u>
Nexax2	HLA DQ2 Celiac Disease	Phase II, IIa, IIb	PreIND meeting
Companion Diagnostic	Identify and Monitor response	Diagnostics	
Stand alone diagnostic	Diagnose DQ2 CD	Diagnostics	

SENIOR MANAGEMENT

Leslie J Williams, Chief Executive Officer • **Bob Anderson**, Chief Scientific Officer

SCIENTIFIC ADVISORY BOARD

Peter Green, MD, Columbia University • **Bana Jabri, MD, PhD**, University of Chicago • **Ludvig Sollid, MD, PhD**, University of Oslo • **Knut Lundin, MD, PhD**, University of Oslo • **Markku Maki, MD, PhD**, University of Tampere • **Joseph Murray, MD**, Mayo Clinic • **Ciaran Kelly, MD**, Beth Israel • **Wally Binder, PhD**, INOVA Diagnostics • **Michelle Pietzak, MD**, University of Southern California

Indel Therapeutics, Inc.

Presenting Company

Clinical Foci: Infectious Disease, Biodefense, PGH – Neglected Diseases

Malcolm Kendall

Chief Executive Officer

Suite 100, 4068 West 11th Avenue
Vancouver, BC V6R 2L#
Canada

www.indelrx.com

1-604-551-8464

Incorporated: 2008

Employees: 5

Ownership: Private

CORPORATE MISSION

Founded in 2008, Indel Therapeutics, Inc. is a privately-held biopharmaceutical company focused on the discovery, development and commercialization of new antibiotics to address the global health crisis caused by antibiotic resistance.

The company has a growing pipeline of novel small-molecule antibiotic drug discovery programs that aim to cure serious, life-threatening infections. These programs are based on Indel's paradigm-changing antimicrobial drug discovery platform, a patented technology that has opened a rich, new area of drug targets for the treatment of bacterial and parasitic infections and, potentially, fungal and viral infections.

The Indel platform technology allows it to identify and target discrete amino acid insertion/ deletion differences ("indels") between essential homologous proteins that are evolutionarily conserved across the pathogen (bacteria) and humans. Based on these structural differences, the company can selectively target the pathogen protein with small molecules without hitting the human counterpart protein, thereby reducing toxicity concerns.

Indel targets are considered one of the first new major classes of antimicrobial targets identified in decades and provide a way to attack drug-resistant microbes by inhibiting indel-differentiated targets with novel drugs.

Indel's lead program focuses on the treatment of methicillin resistant *Staphylococcus aureus* (MRSA), a multidrug resistant super bug responsible for a growing proportion of hospital-acquired and community-acquired infections that result in significant morbidity and mortality. The company is also working on a number of indel-related Gram Negative antibiotic drug discovery programs.

PROPRIETARY TECHNOLOGY

The Indel platform technology:

- Identifies novel targets in bacterial, fungal, parasitic, and viral pathogens – a truly novel, broad-based antimicrobial technology platform.
- Leverages a distinct advantage conferred against resistance – targeting highly conserved, critical hub bacterial targets that may have an advantage against the development of drug resistance.
- Allows for selection of targets with either broad spectrum or narrowly defined spectra of activity against one or a few pathogens that are clinically advantageous to combat resistance.
- Produces exact knowledge of the target every time.
- Enables quick, economical identification and validation of targets using an in silico (computer based) discovery platform.

CORPORATE ALLIANCES

The Indel platform technology has the ability to create a large and growing pipeline of novel antimicrobial drugs. The company is currently advancing a number of antibacterial programs and one anti-parasitic program internally and is continuing to enhance its antibacterial indel target database, which contains hundreds of attractive indel differentiated targets from a range of clinically and commercially interesting pathogens. Given the breadth of its platform, Indel is interested in establishing strategic relationships to advance its platform and programs to develop novel treatments for serious bacterial, fungal, parasitic and viral infections.

SENIOR MANAGEMENT

Malcolm Kendall, Chief Executive Officer • **Neil Reiner, MD**, Chief Scientific Officer • **Roger Leger, PhD**, Vice President

BOARD OF DIRECTORS

Michael Abrams, PhD, Inimex Pharmaceuticals Inc. (Anormed Inc.) • **Allan Collings, CGA**, ACM Advisors Ltd. • **Charles "Chuck" Fisher, MD**, CEO, Margaux Biologics Inc. (Cardiome, Abbot, Lilly, Cleveland Clinic) • **Malcolm Kendall, MBA**, CEO, Indel Therapeutics Inc. (MDS Capital, Intersouth Partners) • **Simon Pimstone, MD, PhD**, CEO, Xenon Pharmaceuticals Inc. • **Neil Reiner, MD**, CSO, Indel Therapeutics Inc. (Vancouver General Hospital, University of British Columbia) • **Patrick Scannon, MD, PhD**, CSO, Xoma Ltd. • **Richard White, PhD**, Half Moon Bay Biotechnology Consulting (Vicuron, BMS)

SCIENTIFIC ADVISORY BOARD

Neil Reiner, MD (Chairman), CSO, Indel Therapeutics Inc. (Vancouver General Hospital, University of British Columbia) • **Julian Davies, PhD**, Emeritus Professor of Microbiology & Immunology at the University of British Columbia • **Brett Finlay, PhD**, Peter Wall Distinguished Professor at the University of British Columbia • **Irwin Kuntz, PhD**, Professor Emeritus of Pharmaceutical Chemistry at the University of California San • **David Shlaes, MD, PhD**, Anti-infectives Consulting LLC (Idenix, Wyeth)

FINANCING HISTORY

Round Date (Amount, US\$) 03/23/2011 (1,400,000.00 million)

Inimex Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease, Drug Development, Pulmonary

Michael J. Abrams, PhD

President & CEO

8540 Baxter Place
Burnaby, BC V5A 4T8
Canada

www.inimexpharma.com

1-604-225-2251

Incorporated: 2001

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

Phase 1 completed
Pre IND meeting completed
Phase II IND submitted

Upcoming

Release of clinical hold for Phase II
Series C VC funding Closed

CORPORATE MISSION

Inimex Pharmaceuticals, Inc. is a clinical-stage, venture-backed Canadian company developing a new class of drugs, Innate Defense Regulators (IDRs). IDRs are host-directed agents that protect against – and improve recovery from - damage caused by a variety of insults including pathogens, trauma and chemo- or radiation-therapy. IDRs increase survival after challenge with a broad range of pathogens and ameliorate tissue damage by selective modulation of the body's innate defenses.

Inimex' lead development candidate, IMX942, has shown excellent safety in Phase 1. An IND has been filed for a Phase 2 trial in Acute Bacterial Skin and Skin Structure Infections (ABSSSI). A Phase 2 trial has also been designed for the amelioration of mucositis in head and neck cancer patients undergoing radiotherapy. Preclinical data indicate that IDRs are active in models of a wide range of indications including life threatening and antibiotic-resistant bacterial infections and the severe side-effects of chemo- and radiation-therapy.

The Company wishes to secure further financing and to initiate discussions with both North American and overseas potential partners in order to maximize the development opportunities for its R&D portfolio.

PROPRIETARY TECHNOLOGY

Extensive in vivo preclinical studies have shown that IMX942 and its analogs accelerate pathogen clearance and increase host survival in a broad spectrum of bacterial infections (including Gram positive and negative bacteria and both drug sensitive and resistant strains), while having no direct antibacterial activity and suppressing inflammation. As host-directed agents, IDRs do not select for antibiotic resistance. IMX942 also reduces tissue damage associated with chemotherapy, radiation, trauma and inflammation. While IDR action depends on monocytes and macrophages, there is no dependence on the presence of either the adaptive immune system (e.g., T cells) or neutrophils. IDRs are effective following immunosuppression.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
IMX942	ABSSSI	Phase II, IIa, IIb	Phase II IND filed

SENIOR MANAGEMENT

Michael J. Abrams, PhD, President & CEO • **John R. North, PhD**, Chief Operating Officer • **Marty McConnell, CA**, Chief Financial Officer

BOARD OF DIRECTORS

Robert Fildes, PhD, SB2 Inc. • **Michael Abrams, PhD**, Inimex • **Patrick Brady, MBA**, Growthworks • **Brenda Irwin, MBA**, BDC Venture Capital • **Stephanie O'Brien**, Morningside

SCIENTIFIC ADVISORY BOARD

B. Brett Finlay, PhD, University of British Columbia • **David Fitzpatrick, PhD**, Biotech Clarity • **Philippe Gros, PhD**, McGill University • **Eric Pamer, MD**, Memorial Sloan-Kettering Cancer Center • **G.Ralph Corey, MD**, Duke Clinical Research Institute • **Vance Fowler, MD**, Duke Clinical Research Institute

FINANCING HISTORY

Round Date (Amount, US\$) 06/28/2004 (6.50 million) • 05/23/2008 (22.00 million)

Integrium, LLC

Clinical Foci: Cardiovascular Disease • Metabolic Disease • Drug Development

Joel Neutel, MD

Partner

500 Hills Drive
Bedminster, NJ 07921
USA

www.integrium.com

1-908-255-4130

Incorporated: 1997

Employees: 137

Ownership: Private

HIGHLIGHTS

Recent

Integrium's Expertise in Ambulatory Blood Pressure Monitoring Helps Assess and Demonstrate Drug Safety and Efficacy. More at: www.integrium.com/Press.asp

Advancing Diabetes Therapies, Integrium Clinical Research Finds the Sweet Spot. More at: www.integrium.com/Press.asp

CORPORATE MISSION

Integrium, LLC is a full-service clinical research organization (CRO), headquarters in Tustin, CA, focused on the therapeutic areas of cardiovascular disease, metabolic disease, wound healing, and dermatology. The Integrium team understands biotech companies' need for reliable, accurate data to make informed decisions, reach inflection points, and make go-no go decisions on development compounds. We conduct Phase 1/PK studies, and help many companies move from IND creation to topline results in as few as 90 days.

PRODUCTS

Name	Indication	Phase
Integrium QT (Quick Turn-Around)	All	Phase I

SENIOR MANAGEMENT

Joel Neutel, MD, Partner • Eileen McAuley, Chief Operating Officer • Mark Powers, Chief Financial Officer • Michael Loftus, Director • Laura Robinson, Director • David Smith, MD (Chief Medical Officer), Partner

Intellect Neurosciences, Inc.

Presenting Company

Clinical Foci: CNS • PGH – Neglected Diseases • Biopharmaceuticals

Daniel G. Chain, PhD <i>Chief Executive Officer</i> 45 West 36th Street New York, NY 10018 USA	www.intellectns.com 1-212-448-9300	OTC BB: ILNS <i>Incorporated:</i> 2005 <i>Ownership:</i> Public
---	--	--

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
The company recently announced it has granted an exclusive license to ViroPharma Incorporated related to Intellect's clinical stage drug candidate, OX1, a multimodal, metal-binding, antioxidant molecule.	Phase 3 data for Bapineuzumab in 2012. US patent for ANTISENILIN technology.

CORPORATE MISSION

Founded in 2005, Intellect Neurosciences is pioneering the discovery and development of innovative treatment approaches to address the large and unmet clinical need for drugs that can slow down, arrest and ultimately prevent Alzheimer's and other neurological diseases. The company's core expertise lies in immunotherapy approaches, especially neoepitope immunotherapy stemming from Dr. Chain's discovery in 1997 of a novel method for treating Alzheimer's disease that is at the forefront of Alzheimer's drug development today. Intellect Neurosciences is currently focused on developing next generation antibody based therapeutics to address Alzheimer's and other proteinopathies.

PROPRIETARY TECHNOLOGY

The company has several proprietary technology platforms: (1) ANTISENILIN® using highly specific monoclonal antibodies against beta amyloid underlies Bapineuzumab, Ponezumab and other drug products in development. (2) Recall-Vax is an active vaccine technology that similarly produces highly specific monoclonal antibodies against beta amyloid and other internal cleavage sites of proteins. It is being developed to target beta amyloid and tau proteins for treatment of AD and other tauopathies. (3) A method of immunotherapy against the cleavage products of tau protein. (4) Novel platform regarding antibody drug conjugates. (5) Humanized beta amyloid specific monoclonal antibody. (6) OX1 a multimodal anti-oxidant small molecule licensed to ViroPharma Inc; (7) OX2 a multimodal anti-oxidant.

CORPORATE ALLIANCES

Intellect maintains an internal preclinical and clinical-stage pipeline, as well as multiple licenses with major pharmaceutical companies covering products in late-stage clinical trials for Alzheimer's disease. In addition, the company recently announced it has granted an exclusive license to ViroPharma Incorporated related to Intellect's clinical stage drug candidate, OX1, a multimodal, metal-binding, antioxidant molecule, which has been demonstrated to protect nerve cells from highly oxidizing neurotoxins. ViroPharma plans to develop and commercialize OX1 as a treatment of Friedreich's Ataxia. In addition, Intellect has acquired technologies from Immuno-Biological Laboratories (Japan), MRCT (UK), NYU Medical School and University South Alabama Research Foundation.

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Licensed Mab A	Alzheimer's disease	Phase III	US patent
Licensed Mab B	Alzheimer's disease	Phase II, IIa, IIb	US patent
Optioned Mab C	Alzheimer's disease	Phase II, IIa, IIb	NA
OX1	Friedreich's Ataxia	Phase II, IIa, IIb	Regulatory
IN-N01-ADC	Alzheimer's, TBI, ARMD	Lead Series	NA
RV-02/03	Alzheimer's, EOFAD, Prefrontal Dementia	Research	NA

SENIOR MANAGEMENT


Daniel G. Chain, PhD, Chief Executive Officer • **Elliot M. Maza, CPA, JD**, Chief Financial Officer

BOARD OF DIRECTORS

Daniel Chain, PhD, CEO, Intellect Neurosciences, Inc. • **Isaac Onn, BSc, LLB**, Independent Director; Former CEO & Partner, Erez Tal Bar - Fueling Services Ltd. • **Elliot M. Maza, JD, CPA**, CFO, Intellect Neurosciences, Inc.

SCIENTIFIC ADVISORY BOARD

Kelvin Davies, PhD, University of Southern California • **Benjamin Chain, PhD**, University College, London • **Cheryl Fitzer-Attas, PhD**, Teva Pharmaceuticals • **Michael Grundman, MD, MPH**, Global R&D Partners, LLC • **Donald Price, MD**, Johns Hopkins University • **Paul Bendheim, MD**, Banner Good Samaritan Medical Center, Phoenix, AZ • **Steven H. Ferris, PhD**, NYU School of Medicine • **Douglas R. Galasko, MD**, University of California, San Diego • **Eric Reiman, MD**, Banner Good Samaritan Medical Center, Phoenix, AZ



Market Data

Current Price	0.06
Currency	U.S. Dollar
Net Change	5.36
Volume.....	1,138,969
YTD % Change.....	-0.49
52Wk Range	0.05-1.13
Avg. Daily Volume (thousands)	311,662

First Call Data

Market Cap (MM)	--
Short Interest Shares.....	--
Short Interest Ratio.....	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year).....	-0.43
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	--

Source: Thomson Reuters

Intra-Cellular Therapies, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Drug Development, Drug Discovery

Sharon Mates, PhD Chief Executive Officer

3960 Broadway
New York, NY 10032
USA

www.intracellulartherapies.com

1-212-923-3344

Incorporated: 2002

Employees: 28

Ownership: Private

HIGHLIGHTS

Recent

Completed Phase Ib/II MAD study for ITI-007 in patients with schizophrenia demonstrating safety, tolerability and early signals for efficacy. ITI-007 is currently in Phase II studies.

February 2011: ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders.

Company identified a novel target for drug discovery in the Alzheimer's disease field called GSAP. GSAP participates in the formation of amyloid beta through the interaction with amyloid precursor protein and gamma secretase without inhibiting NOTCH.

CORPORATE MISSION

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the Central Nervous System (CNS). Compounds in clinical development include ITI-007 for the treatment of schizophrenia, bipolar disorder, depression, sleep disturbances in psychiatric and neurodegenerative diseases and other CNS disorders. The Company has concluded a positive Phase I/II study demonstrating the safety and tolerability of ITI-007 across a broad range of doses in patients with stable schizophrenia. Additionally, exploratory clinical measures revealed signals consistent with antipsychotic and antidepressant efficacy for ITI-007. ITI-007 is currently in Phase II studies for the treatment of schizophrenia. In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders. ITI has preclinical programs in the area of cognitive dysfunction in schizophrenia, depression, Parkinson's disease, Alzheimer's disease and Women's Health.

CORPORATE ALLIANCES

In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop PDE1 inhibitors for the treatment of schizophrenia and other CNS disorders.

PRODUCTS

Name	Indication	Phase
ITI-007	schizophrenia, bipolar disorder, depression, sleep disturbances in psychiatric and neurodegenerative diseases	Phase II, IIa, IIb
ITI-002	cognitive dysfunction in schizophrenia and Alzheimer's disease, Parkinson's disease	Preclinical
ITI-009	Alzheimer's disease	Optimized Lead
ITI-014	Vasomotor Symptoms, Major Depressive Disorder, Fibromyalgia	Lead Series

SENIOR MANAGEMENT

Sharon Mates, PhD, Chief Executive Officer • Lawrence Wennogle, PhD, Vice President • Kimberly Vanover, PhD, Vice President • Allen A. Fienberg, PhD, Business Development • Lawrence Himeline, Chief Financial Officer

InVasc Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Renal, Cardiovascular Disease, Metabolic Disease

William D. Schaeffer

Chief Operating Officer

3562 Habersham at Northlake
Tucker, GA 30084
USA

www.invasc.net

1-678-736-5903

Incorporated: 2006

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

June 2011: We announced the initiation of an 80 patient phase IIa clinical trial in hypertensive diabetic patients with chronic kidney disease. The primary endpoint is a reduction of proteinuria.

June 2011: The completion of a worldwide exclusive license with a exclusive supply agreement with the only cGMP manufacturer of the API for our lead drug, INV-144 for CKD. The license give us rights to 6 issued and 1 pending patent.

April 2011: We announce a worldwide exclusive license a salt of the R(+) enantiomer alpha lipoic acid, a component used in INV-144. This includes a pending patent filed in the primary CKD markets global.

Upcoming

Completion of the Phase IIa clinical trial of INV-144 in CKD patients. This will facilitate the initiation of one or more Phase IIa trials in 2012.

Filing of an IND for either our 400 Series for atherosclerosis, or for the 300 Series, a myeloperoxidase inhibitor that will most likely be evaluated in patients with an acute MI.

Completion of a Series B financing by early 2012.

CORPORATE MISSION

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a virtual biopharmaceutical company developing drugs for the treatment and prevention of chronic kidney (CKD) and cardiometabolic diseases. Due to the advancing age of baby-boomers and the obesity epidemic within western societies, the number of patients requiring drug intervention for these conditions is expanding significantly and enlarging global markets. Hypertensive diabetics, including those with CKD, account for the single largest segment of the US Medicare budget at 28%. InVasc's lead product, INV-144, is being developed for CKD. INV-144 is the combination of two distinct chemical entities: alpha Lipoic Acid (ALA), a powerful antioxidant and an approved drug in Europe with Generally Recognized as Safe (GRAS) nutraceutical status in the US, and a widely used generic antihypertensive drug, Losartan. The company has already demonstrated statistical significance for key endpoints in a placebo controlled, double-blind Phase II study in hypertensive diabetics with CKD utilizing an alternative antihypertensive agent. The company has an active IND with the Food & Drug Administration (FDA), which is a 505(b)(2) filing. Based on FDA's input, a well defined development plan through Phase III has been designed. A Phase IIa clinical trial involving 80 patients will begin near the end of 2Q11. The company believes the safety risk of this combination product is minimal based on prior human exposure to the two components. The need for new therapeutics for CKD is very strong as manifested by the USD \$450 million investment by Abbott this past fall.

PROPRIETARY TECHNOLOGY

INV-144, being developed for CKD, is the combination of two distinct chemical entities: alpha Lipoic Acid (ALA), a powerful antioxidant and an approved drug in Europe with Generally Recognized as Safe (GRAS) nutraceutical status in the US, and Losartan. The company has already demonstrated statistical significance for key endpoints in a placebo controlled, double-blind Phase II study in hypertensive diabetics with CKD utilizing an alternative antihypertensive agent. The company has an active IND with the Food & Drug Administration (FDA), and a Phase IIa clinical trial involving 80 patients will begin near the end of June. InVasc has a family of NMEs/NCEs directed at atherosclerosis, stroke, acute MI and inflammation. Two series of compounds are beginning ADME studies.

CORPORATE ALLIANCES

InVasc has two worldwide exclusive licenses. The first is with Labochim S.A., a subsidiary of Infa S.A. Under this license InVasc has exclusive rights to all IP associated with alpha lipoic acid for use in combination with any RAS inhibitor, anti-hypertensive for the treatment or prevention in chronic kidney disease. This license included 6 issued and 1 pending patent. The license also includes an exclusive supply agreement.

InVasc has a WW exclusive in-license from the magnesium salt of R(+) ALA for use in combination with antihypertensives for the prevention or treatment of chronic kidney disease.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
INV-144	Chronic kidney disease	Phase II, IIa, IIb	Completion of 80 patient IIa in mid-2012
400 Series	Atherosclerosis	Pre-Target Validation	IND filing near the end of 2012
300 Series	Acute MI, Inflammation	Pre-Target Validation	IND filing near the end of 2012

SENIOR MANAGEMENT

William D. Schaeffer, Chief Operating Officer • **Sang Le**, Director • **William D. Johnston, PhD**, Chief Executive Officer

BOARD OF DIRECTORS

William D. Johnston, PhD, InVasc Therapeutics, Inc. • **William D. Schaeffer**, InVasc Therapeutics, Inc. • **Daniele Cardoso**, Infa S.A. / Trois I Investments • **Larry Dillaha, MD**, Former Executive VP and CMO, Sciele/Shionogi • **Frank Kelly**, Retired Coke Cola Officer

SCIENTIFIC ADVISORY BOARD

Bobby Khan, MD, PhD, St. Joesph's Hospital, Atlanta • **Sanjay Rajagopalin, MD, PhD**, University of Ohio School of Medicine • **Sampath Parthasarathy, PhD**, University of Ohio School of Medicine • **Bertran Pitt, MD**, University of Michigan Medical School • **W. Virgil Brown**, Emory University School of Medicine

FINANCING HISTORY

Round Date (Amount, US\$) 06/01/2010 (3.20 million)

Investors: Trois I Investissements Industriels Internationaux S.A. (24%) • Bobby Khan - Founder (10%) • William D. Johnston - CEO (10%) • Sampath Parthasarthy - Founder (9%) • Sanjay Rajagopalin - Founder (8%)

Jennerex Biotherapeutics, Inc.

Presenting Company

Clinical Foci: Oncology, Immunology, Drug Delivery

Ken Newport

Chief Executive Officer

450 Sansome St, 16th Floor
San Francisco, CA 94111
USA

www.jennerex.com

1-415-281-8886

Incorporated: 2003

Employees: 35

Ownership: Private

HIGHLIGHTS

Recent

Presented positive JX-594 clinical data in combination with sorafenib in liver cancer.
Presented positive randomized Phase 2 clinical data showing survival benefit in liver cancer.

Published proof of concept data in Nature showing the ability to deliver JX-594 intravenously.

Completed private financing providing cash balance at 8/31/11 of ~\$18 million USD.

Upcoming

Presenting randomized Phase 2 data of JX-594 in oral presentation at AASLD Meeting in November.

Launching Phase 2b clinical trial (TRAVERSE) of JX-594 in patients with hepatocellular carcinoma.

Completing enrollment in Phase 1/2 trial of JX-594 in colorectal cancer.

CORPORATE MISSION

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.

PROPRIETARY TECHNOLOGY

JX-594 is a proprietary, engineered oncolytic poxvirus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the reduction of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into tumors or systemically, induces tumor shrinkage and/or necrosis and is well-tolerated by patients (over 115 treated to date). Objective tumor responses have been demonstrated in a variety of cancers.

CORPORATE ALLIANCES

Transgene (NYSE Euronext Paris: FR0005175080), a bio-pharmaceutical company specialized in the development of immunotherapeutic products, holds an exclusive license to develop and commercialize JX-594 in Europe and neighboring countries. Green Cross Corporation, a leading company in the development, manufacturing, and commercialization of viral vaccines and other biological products, holds an exclusive license to develop and commercialize JX-594 in South Korea, and Lee's Pharmaceutical Ltd. holds an exclusive license to develop and commercialize JX-594 in China.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
JX-594	Liver Cancer	Phase II, IIa, IIb	Initiate Phase 2b trial in 4Q11.
JX-594	Colorectal Cancer	Phase II, IIa, IIb	Present interim clinical data
JX-929	Pancreatic Cancer	Phase I	
JX-1395	Prostate Cancer	Preclinical	

SENIOR MANAGEMENT

Ken Newport, Chief Executive Officer • **David Kirn, MD**, Chief Medical Officer • **Gregory Schafer**, Chief Financial Officer • **John Bell**, Chief Scientific Officer • **Lara Longpre**, Chief Operating Officer

BOARD OF DIRECTORS

Brennan Mulcahy, Energy Saving Income Fund • **Hoyoung Huh**, BiPar Sciences • **Martin Murphy**, American Society for Clinical Oncology (Chairman) • **Ken Newport**, PRA International • **David Kirn**, Jennerex • **John Bell**, Jennerex • **Daniel Spiegelman**, Affymax, Inc.

SCIENTIFIC ADVISORY BOARD

David Bartlett, MD, University of Pittsburgh Medical Center • **Malcolm Brenner, MD, PhD**, Baylor College of Medicine • **William Dupere, MBA**, Five Points Therapeutics • **Douglas Hanahan, PhD**, UCSF • **Terry Hermiston, PhD**, Bayer Healthcare Pharmaceuticals • **Thomas Lynch, MD**, Yale Comprehensive Cancer Center • **Frank McCormick, PhD**, UCSF • **Grant McFadden, PhD**, University of Florida, College of Medicine • **Paul Polakis, PhD**, Genentech

Kalos Therapeutics, Inc.

Presenting Company

Clinical Foci: Oncology • Ophthalmic • Cardiovascular Disease

George Colberg (Co-Founder)

Chairman

4370 La Jolla Village Drive, Suite 400
San Diego, CA 92122
USA

www.kalostherapeutics.com

1-858-385-1290

Incorporated: 2005

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

AMD breakthrough.
Addition of Dr. David Shalinsky, Translational Medicine, Onc and AMD from Pfizer.
Involvement In BIO Exec institute, incredible professional interactions with Leaders from big Pharma and potential collaborators, and VC's.

Upcoming

Next round of financing to complete late-stage preclinical work.
File IND.
Phase 1.

CORPORATE MISSION

Kalos is a unique biomedical company whose family of peptide therapeutics has previous successful clinical experience. Kalos is pioneering an approach to cancer treat by developing peptides made primarily in the heart, as a cytostatic therapeutic for treating aggressive cancers by engaging known pathway receptors more efficiently without the side effects associated with chemotherapeutic or small molecule compounds. By raising to therapeutic levels of peptides that circulate naturally in the body we reduce potential safety and toxicological issues based on the recognized function of these peptides. Based on a previous Investigator IND these proven clinical effects of increased natriuresis, and diuresis with our therapeutic will reduce edema and bloating in abdominal cancer patients. Kalos will initiate clinical trials to treat pancreatic and ovarian cancers for which new therapies are sorely needed. Response times to standard regimens are short, leading to a shorter time to progression, and a poor survival time. Both cancers are typically diagnosed in advanced stages and patient populations actively seek experimental therapies. Kalos expects to extend survival time, to reduce or retard disease progression, mitigate issues related to ascites and improve the quality of life for these patients by eliminating the fluid accumulation associated with organ failure, our approach while innovative in concept will provide for an improved QOL with no chemotoxic side effects. The company has recently discovered an application of its therapy in Adult Macular Degeneration (AMD) which may provide a therapeutic and prophylactic application in this eye disease with a formulation aimed at topical (eye drop) delivery rather than injected directly into the eye. The company acknowledges the fact that it represents the potential to provide a relatively quick exit for investors with a return based on a licensing or sale of the company and or its assets based on good clinical data.

PROPRIETARY TECHNOLOGY

Our peptide therapeutic inhibits MAPK activation. This inhibition appears to take place at the level of ERK1/2, although one study suggests that it may occur further upstream at MEK1/2. Inhibition of the MAPK pathway has also been reported by KT-220 and shorter peptide chains that share its anti-cancer motif. The specificities of these peptides suggest that the inhibition is mediated by the NPRC receptor, one of three specific receptors for ANP. Its action on the MAPK pathway may explain why KT-220 inhibits the growth of cancer cells, whose proliferation is often Mitogen-dependent, but not that of normal cells. We have identified the active region of these peptides, the anticancer motif (ACM), and intellectual property position around this motif provides a clear commercialization path.

CORPORATE ALLIANCES

Kalos has just entered into an agreement with the Arizona College of Optometry at Midwestern University (MWU) to develop novel therapies for AMD using our peptides. MWU has both an experimental laboratory conducting research on model systems of AMD as well as a clinical facility (MWU Eye Institute) that could participate in the management and performance of clinical research. Kalos also has a preferred provider agreement to manufacture to this point with Covidien.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
KT 228	Pancreatic Cancer	Target Validated
KT 236	Ovarian Cancer	Target Validated
KT- A	AMD	Research

SENIOR MANAGEMENT

George Colberg (Co-Founder), Chairman • **Jay Merritt, MD**, Chief Medical Officer • **Michael Kozlowski, PhD**, Chief Scientific Officer • **Michael Krupp, PhD**, Chief Business Officer • **David Shalinsky, PhD**, Chief Technology Officer • **Greg Witchel**, Executive Vice President

BOARD OF DIRECTORS

George Colberg, Co-Founder • **Greg Witchel**, Co-founder • **Michael Mitrow**, Largest Investor

SCIENTIFIC ADVISORY BOARD

Daniel Von Hoff, MD, US Oncology; University of Arizona Health Sciences Center • **Marc Garnick, MD**, Paecis Pharmaceuticals; Harvard Medical School • **Patrice Rioux, MD, PhD**, Edison Pharmaceuticals, Inc.

FINANCING HISTORY

Round Date (Amount, US\$) 02/01/2007 (760,000.00 million) • • 03/01/2010 (249,000.00 million)

Investors: George Colberg (29%) • Greg Witchel (22%) • Dylan Witchel (11%) • Michael Kozlowski (8%) • Michael Krupp (8%)

Kareus Therapeutics, LLC

Presenting Company

Clinical Foci: CNS, Metabolic Disease, Drug Discovery

Dr. Patrick Doyle Chief Executive Officer

40 Rue Fritz-Courvoisier
2300 La Chaux-de-Fonds
Switzerland

www.kareustherapeutics.com

44-7871-309056

Incorporated: 2010

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Positive in vivo PK/PD and efficacy in Alzheimer's models. Decrease in transgenic mouse brain A β -42 with significant improvement in water maze cognition tests in same group.

GLP TOX & IND enabling started June 2011.

CMC scale-up completed.

In vivo Proof of Concept in Diabetes program with optimised lead.

Non GLP Tox package completed.

Positive in vivo proof of concept in Pain models for proprietary novel small molecules.

Upcoming

Alzheimer's program GLP box & IND studies completed end 2011.

Alzheimers IND file 3Q12.

KU-5001 to enter GLP box & CMC scale-up 4Q11.

In vivo Proof of concept on 2 novel small molecule series in Pain program.

CORPORATE MISSION

Kareus Therapeutics is a privately held company focused on discovery and development of novel small molecule drugs based upon its proprietary KARLECT chemistry platform. The technology allows novel combinations of drugs to be created with improved therapeutic and safety profiles using a new approach. Kareus also has small molecule drug discovery in Diabetes and Pain

Proof of concept in vivo animal model studies have been successfully completed in Alzheimer's and Cardiovascular diseases.

The KARLECT platform approach is applicable to any therapeutic area.

PROPRIETARY TECHNOLOGY

KARLECT chemistry platform for development of novel combination drug therapies.

Platform to facilitate brain entry

CORPORATE ALLIANCES

Quintiles Strategic Development Alliance signed June 2011

PRODUCTS

Name	Indication	Phase	Milestone
KU046	Alzheimer's	Preclinical	IND 1Q12.
KU-5001	Diabetes	Preclinical	IND 2H12.
Arthritis Discovery	Pain	Optimized Lead	GLP Tox 4Q11.

SENIOR MANAGEMENT

Dr. Patrick Doyle, Chief Executive Officer • Dr. Anji Reddy, Chairman • Dr. Uday Saxena, Chief Operating Officer

BOARD OF DIRECTORS

Dr. K. Anji Reddy, Dr. Reddys Laboratories • Dr. Uday Saxena, Kareus Therapeutics, SA • Dr. Patrick Doyle, Kareus Therapeutics, SA

SCIENTIFIC ADVISORY BOARD

Akella Venkateswarlu

FINANCING HISTORY

Investors: Dr. K Anji Reddy (1%) • Management (1%) • Quintiles (1%)

LigoCyte Pharmaceuticals, Inc.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Vaccines

Donald P Beeman
Chief Executive Officer

2155 Analysis Drive
Bozeman, MT 59718-6831
USA

www.ligocyte.com

1-406-585-2733

Incorporated: 1998

Employees: 37

Ownership: Private

HIGHLIGHTS

Recent

LigoCyte has shown in a Phase I/II human vaccination plus live virus challenge study that its Norwalk VLP vaccine effectively reduced clinical illness. The full results will be presented at the IDSA conference in October.

The Company also initiated a Phase I study of a bivalent intramuscular norovirus vaccine in 2010.

CORPORATE MISSION

LigoCyte Pharmaceuticals, Inc. is a private, biopharmaceutical company focused on the development of innovative vaccine products based on the company's proprietary virus-like particle (VLP) platform technology. LigoCyte's lead candidate recently completed a Phase I/IIa clinical trial designed to study the prevention of norovirus acute gastroenteritis (AGE), a ubiquitous and prostrating illness characterized by a fever, vomiting and diarrhea. This proof-of-principle study tested the company's VLP Norwalk vaccine candidate in conjunction with a live-virus challenge in healthy adult volunteers. Notably, the trial met its primary endpoints of statistically significant reductions of illness, infection and severity. LigoCyte also has a novel respiratory syncytial virus vaccine in preclinical development that has demonstrated protection in cotton rat challenge studies - without vaccine-associated histopathology. Utilizing the company's core VLP expertise, LigoCyte's vaccine development programs focus on gastrointestinal and respiratory targets in commercially attractive markets.

PROPRIETARY TECHNOLOGY

LigoCyte's core expertise is virus-like particle, or VLP, based vaccines. VLP technology presents vaccine antigens in a highly immunogenic, native form for anti-viral protection without the complexity associated with live viruses. The company has developed simple, scalable and high-yield production processes to support advanced development. Additionally, the VLP platform technology can be rapidly engineered for emerging targets or to add other vaccine antigens for multivalent, combination products. LigoCyte has also developed dry powder, intranasal-delivery vaccine formulations for enhancing mucosal immune responses. These formulations can improve commercial cold-chain distribution options, address stockpile constraints and do not require needles or trained personnel for delivery.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
VLP Norwalk Vaccine	Human Proof-of-Principal for Vaccination against Norwalk Infection	Phase II, IIa, IIb	Met primary study objectives
Intramuscular, Bivalent VLP Norovirus Vaccine	Prevention of Norovirus Acute Gastroenteritis	Phase I	
Intranasal, Bivalent VLP Norovirus Vaccine	Prevention of Norovirus Acute Gastroenteritis	Preclinical	

SENIOR MANAGEMENT

Donald P Beeman, Chief Executive Officer • **Robert R Goodwin, PhD**, Chief Operating Officer • **Robert F Bargatze, PhD**, Chief Scientific Officer • **Charles E Richardson, PhD**, Executive Vice President • **Paul M Mendelman, MD**, Chief Medical Officer • **Larry W Mikkola**, Director

BOARD OF DIRECTORS

Ivor Royston, MD, Forward Ventures • **Donald Beeman**, CEO, LigoCyte Pharmaceuticals, Inc. • **J. Donald deBethizy, PhD**, CEO, Targacept, Inc. • **Markus Goebel, PhD, MD**, Novartis Ventures • **Hironori Hozoji**, JAFCO Life Science Investment • **Ben Auspitz**, Fidelity Biosciences • **C. Boyd Clarke**, Chairman, QLT Inc. and Mersana Therapeutics • **Peter Greenleaf**, MedImmune, LLC

SCIENTIFIC ADVISORY BOARD

Harry Greenberg, MD, Joseph D. Grant Professor and Co-Chairman, Department of Medicine, Stanford University • **Jerry R McGhee, PhD**, Profeseor of Microbiology, University of Alabama, Birmingham • **Charles Russell Middaugh, PhD**, A. & T. Higuichi Distinguished Professor of Pharmaceutical Chemistry, University of Kansas • **Bryan S Finkle, PhD**, Director of Pharmacology (retired), Genetech, Inc. • **Marian Neutra, PhD**, E. & M. Gordon Distinguished Professor of Pediatrics, Children's Hospital Harvard University • **George R Siber, MD**, Executive Chairman of Genocea Biosciences

FINANCING HISTORY

Round Date (Amount, US\$) • 03/15/2008 (28.00 million)

Lipocine, Inc.

Presenting Company

Clinical Foci: Hormone Therapy, Specialty Pharmaceutical, Drug Delivery

Mahesh Patel Chief Executive Officer

675 Arapeen Drive
Salt Lake City, UT 84108
USA

www.lipocine.com

1-801-994-7383

Incorporated: 1997

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Completed license out of the first oral testosterone (Abbott Products). Second milestone received.
Phase I data for first oral progesterone product (Development for Pre Term Birth)
Phase I data for first oral testosterone for females (Development for Hypoactive Sexual Desire Disorder - HSDD)

Upcoming

Phase II data for Preterm Birth
Phase II data for HSDD
Marketing partner for cough/cold products (LPCN 1084,1087, and 1090)

CORPORATE MISSION

Specialty Pharmaceutical Company with eight products in clinical development. Therapeutic Focus: Womens's health (first oral progesterone for Pre-Term Birth and first oral treatment for Female Sexual Disorder/HSDD). Male Hormone treatment (first oral testosterone). Cough/Cold (three unique 505(b)(2) candidates).

Lipocine products are available for out-licensing/partnering. Lipocine is also actively looking to in-license Proof of Concept verified products in the Men's Health, Women's Health and Urology sectors.

PROPRIETARY TECHNOLOGY

21 issued patents for the improved oral delivery of poorly water soluble drugs.

CORPORATE ALLIANCES

Abbott Products, UCB, Elan

PRODUCTS

Name	Indication	Phase
LPCN 1021	First oral Oral testosterone for male hypogonadism	Phase I
LPCN 1098	First oral for HSDD (Hypoactive sexual desire disorder)	Phase I
LPCN 1084	First long acting combination of a safe narcotic and a antihistamine to treat runny nose symptoms	Phase I
LPCN 1090	First long acting Rx combination product for Productive Cough	Optimized Lead
LPCN 1087	First long acting RX combo for productive cough	Optimized Lead
LPCN 1002	Hormone Replacement Therapy	Phase I
LPCN 1110	First oral for Preterm Birth	Phase I
LPCN 1022	Natural Progesterone/Natural Estradiol combination oral	Phase I
LPCN 1109	Progesterone Only Pill (ER)	Phase I

SENIOR MANAGEMENT

Mahesh Patel, Chief Executive Officer • **Srinivasan Venkateshwaran**, Chief Scientific Officer • **Jerry Simmons**, Chief Business Officer • **Robert Merrell**, Corporate Finance

BOARD OF DIRECTORS

Dr. William Higuchi, Retired Head of Department of Pharmaceutics (U of U) • **Gordhan Patel**, Entrepreneur • **John Higuchi**, CEO Acliont Pharmaceuticals • **Dr. Mahesh Patel**, CEO Lipocine Inc.

FINANCING HISTORY

Investors: Management/founders (73%) • UCB (23%) • Elan (4%)

MabVax Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Immunology, Vaccines

David Hansen

President & CEO

11588 Sorrento Valley Road, Suite 20
San Diego, CA 92121
USA

www.mabvax.com

1-858-259-9405

Incorporated: 2006

Employees: 7

Ownership: Private

HIGHLIGHTS

Recent

Initiated Phase II sarcoma and ovarian cancer vaccine trials July 2010. Both studies have more than 14 sites enrolling patients in the US. Enrollment is on track for both studies.

Multiple NCI/NIH Grant Awards: STTR 2 Grant for antibody research USD \$1.1 million and SBIR Fast-Track Award for sarcoma vaccine research. Phase 1 is USD \$150,000 and Phase 2 award was \$1.8 million.

SCLC vaccine manufactured and revised IND submitted to FDA. Phase I trial initiated in July 2011.

Upcoming

SCLC Vaccine: Phase 1 trial complete end of 2011 and Phase II trial initiated in 1H12.

Achieve target enrollment for both the sarcoma and ovarian cancer Phase 2 clinical trials by 3Q12.

Completion of early preclinical development, including animal model testing, of anti-sialyl Lewis(a) antibody by 3Q. Complete characterization of additional antibody candidates from the 11 antigens incorporated into the vaccines licensed from MSKCC

CORPORATE MISSION

MabVax Therapeutics, Inc. is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address the unmet medical need of preventing recurrent cancer. Certain types of cancer have high metastatic potential and therefore very high recurrence rates even after patients have initially been rendered free of detectable disease using optimal current therapies. The company believes that passively administered or vaccine induced antibodies against selected tumor cell surface antigens are ideally suited for eradication of free tumor cells and micrometastases that remain after initial treatment and cause cancer recurrence. Successful development of our therapeutic products will result in significantly improving patient quality of life and prolonging overall survival.

We have established multiple licenses with Memorial Sloan Kettering Cancer Center (MSKCC) which has already established proof of principal for both its cancer vaccine products. MabVax is focused on the clinical development of our sarcoma, small cell lung cancer, and ovarian cancer vaccine products which entered Phase 2 clinical trials in July 2010.

MabVax is leveraging the ongoing clinical programs along with the antigenic components of the vaccines to create a pipeline of monoclonal antibody products based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers. MabVax has already demonstrated the ability to isolate and preserve the antibody responses from patients immunized with a monovalent breast cancer vaccine as well as a bivalent melanoma vaccine. These fully human monoclonal antibodies have high affinity, specificity, and pronounced cytotoxic activity against cells displaying the targeted antigens on their surface. We will continue to build our library of high potential antibodies as both MSKCC and MabVax continue the planned vaccine clinical program.

PROPRIETARY TECHNOLOGY

The company has secured rights from Memorial Sloan-Kettering Cancer Center to a series of highly immunogenic vaccines against cancers of neuroectodermal and epithelial origin as well as small cell lung cancer. These vaccines target extensively expressed carbohydrates molecules on malignant cells on these types of cancers. These vaccines have been tested and refined in multiple clinical trials establishing immunogenicity, tolerability, and therapeutic utility. MabVax is leveraging the ongoing clinical programs along with the antigenic components of the vaccines to create a pipeline of monoclonal antibody products based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers.

CORPORATE ALLIANCES

Multiple licenses in place with Memorial Sloan-Kettering Cancer Center

PRODUCTS

Name	Indication	Phase	Milestone
Trivalent Sarcoma Vaccine	Sarcoma	Phase II, IIa, IIb	Initiated Phase II trial in July 2010.
Tetavalent SCLC Vaccine	Small Cell Lung Cancer	Phase I	Initiated Phase I trial in July 2011 at MSKCC. Phase II to be initiated 1H12.
Ovarian Cancer Vaccine	Ovarian Cancer	Phase II, IIa, IIb	Initiated Phase II trial in July 2010.
Fully Human Monoclonal Antibody 5B1	Metastatic pancreatic, colon and breast cancer	Preclinical	Completion of animal model testing 3Q11.

SENIOR MANAGEMENT

David Hansen, President & CEO • Philip Livingston, MD, Chief Scientific Officer • Wolfgang Scholz, PhD, Vice President • Govind Ragupathi, MD, Vice President

BOARD OF DIRECTORS

David Hansen, MabVax Therapeutics, Inc. • **Douglas Lind, MD**, Greenwich Biotech Partners • **Philip Livingston, MD**, MabVax Therapeutics, Inc. • **Nicholas Stephens**, RTP Venture Fund

SCIENTIFIC ADVISORY BOARD

Philip Livingston, MD, Memorial Sloan Kettering Cancer Center • **Samuel Danishefsky, PhD**, Memorial Sloan Kettering Cancer Center • **Jeff Gildersleeve**, National Cancer Institute

FINANCING HISTORY

Round Date (Amount, US\$) 02/01/2008 (2,000,000.00 million) • 08/01/2009 (4,000,000.00 million) • 09/01/2011 (2,500,000.00 million)

MannKind Corporation

BIO Member

Clinical Foci: Metabolic Disease, Oncology, Drug Delivery

Alfred Mann

President & CEO

28903 North Avenue Paine
Valencia, CA 91355
USA

www.mannkindcorp.com

1-661-775-5300

NASDAQ: MNKD

Incorporated: 1991

Employees: 250

Ownership: Public

CORPORATE MISSION

MannKind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, metabolic disorders and cancer.

PROPRIETARY TECHNOLOGY

- (1) Technosphere® Insulin [CRL - Restarting pivotal studies].
- (2) Technosphere GLP-1 [Phase 1].
- (3) MKC-1106MT active immunotherapy for melanoma [Phase 2].
- (4) MKC-1106PP active immunotherapy for solid-tumor cancers [Phase 1].
- (5) IRE-1 alpha small molecule program for multiple myeloma and autoimmune disease [Preclinical].

CORPORATE ALLIANCES


Multiple

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
AFREZZA	Diabetes	NDA/BLA filed, or in process
MKC1106-MT	Melanoma	Phase II, IIa, IIb
MKC1106-PP	Select solid tumors	Phase I
MKC1106-NS	Hematological malignancies	Preclinical
MKC204 (IRE-1 alpha inhibitor)	Multiple myeloma	Preclinical
Technosphere Technology	Pulmonary Drug Delivery Platform	NDA/BLA filed, or in process

SENIOR MANAGEMENT

Alfred Mann, President & CEO • **Matthew Pfeffer**, Chief Financial Officer



Market Data

Current Price	3.49
Currency	U.S. Dollar
Net Change	-5.68
Volume	675,654
YTD % Change	-0.57
52Wk Range	2.20-10.05
Avg. Daily Volume (thousands)	2,030,710

First Call Data

Market Cap (MM)	457.1
Short Interest Shares	25,075,272
Short Interest Ratio	27.45
PE (Trailing 12 Months)	-1.25
EPS (Last Fiscal Year)	-1.44
Consensus Estimate (Y)	-1.25
Consensus Recommend	-1.26
Price/Sales	9137.21

Shareholders

<i>Institution</i>	<i>Holding %</i>
BlackRock Fund Advisors	3.7%
The Vanguard Group, Inc.	3.1%
Chou Associates Management, Inc.	1.9%
State Street Global Advisors	1.0%
Northern Trust Investments	0.7%
<i>Mutual Fund</i>	<i>Holding %</i>
BlackRock Fund Advisors	3.7%
The Vanguard Group, Inc.	3.1%
Chou Associates Management, Inc.	1.9%
State Street Global Advisors	1.0%
Northern Trust Investments	0.7%

Source: Thomson Reuters

Maruho Co., Ltd.

Clinical Foci: Skin/Dermatological, Drug Delivery, Specialty Pharmaceutical

Koichi Takagi President & CEO

1-5-22, Nakatsu, Kita-ku
Osaka 531-0071
Japan

www.maruho.co.jp/english

81-6-63718438

Incorporated: 1915

Employees: 1076

Ownership: Private

HIGHLIGHTS

Recent

Dainippon Sumitomo Pharma and Maruho entered into a License Agreement for a Novel Topical Analgesic Drug (DSR18424) (Apr 2011).

Marketing Collaboration with Astellas Pharma on Protopic® Ointment for Atopic Dermatitis in Japan (Dec 2010).

Maruho received Gold Triangle Awards 2010 by American Academy of Dermatology. This award recognizes Maruho Derma Report Issue #3 "Vitiligo Advancements" for raising public awareness of dermatologic issues (Mar 2010).

CORPORATE MISSION

Maruho Co., Ltd. is a specialty pharmaceutical company focused on dermatology and topical products. Maruho ranks #1 in dermatology market in Japan and #1 as a manufacturer of ethical semi-solid products in Japan. We have oversea offices in New York, London and Düsseldorf to expand its business globally now. We are looking for in-license development pipelines in the field of dermatology from early stage to late stage including ethical drugs, diagnostic drugs, cosmeceuticals, skin care products, aesthetic dermatology products, medical devices and research programs with academia.

CORPORATE ALLIANCES

Maruho has been collaborating in dermatology field with many leading pharmaceutical companies including MSD, Abbott, Novartis, Astellas, Chugai, Mitsubishi Tanabe Pharma and Dainippon Sumitomo Pharma in several business structures, for example, sales alliance, co-development, and so on.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
M5180	Anti-psoriasis	Phase II, IIa, IIb
M5160	Anti-pruritic	Phase II, IIa, IIb
M5120	Anti-acne	Phase II, IIa, IIb
M5200	Anti-allergic dermatitis	Phase I
DSR18424	Anti-pain	Preclinical
M5210	Anti-herpes simplex	Phase III

SENIOR MANAGEMENT

Koichi Takagi, President & CEO

Mersana Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Nick G. Bacopoulos, PhD

Chief Executive Officer

840 Memorial Drive
Cambridge, MA 02139
USA

www.mersana.com

1-617-715-8236

Incorporated: 2005

Employees: 25

Ownership: Private

HIGHLIGHTS

Recent

Achieved high potency in vivo POC for antibody drug conjugates.
Initiation of Phase IB extension study in NSCLC Cancer, March 2011.
Initiation of Phase I study for XMT-1107 in refractory, advanced solid tumors, April 2010.

Upcoming

1-2 high impact antibody drug conjugate collaborations with pharma in 2011/2012.
Completion of XMT-1001 Phase Ib extension study, 1H12.
Initiation of Phase II study for XMT-1107, 2H12.

CORPORATE MISSION

Mersana engineers novel drug conjugates to maximize the potential of new and established therapeutic classes. Our technology harnesses the power and synergy of nanotechnology, biologics and small molecules. Mersana is advancing its own pipeline of next generation drugs with best-in-class potential to address multiple unmet needs in oncology. Our versatile conjugation system integrates Fleximer, a clinically validated biodegradable polymer, with a broad array of customizable linker chemistries matched to therapeutic payloads. Our technology is being leveraged in multiple therapeutic areas through partnerships with major pharmaceutical companies.

PROPRIETARY TECHNOLOGY

Mersana's proprietary platform, Fleximer, is a novel, biodegradable and biocompatible polymer that can be covalently conjugated to biologics, small molecules, peptides, and nucleic acids to enhance their pharmacokinetic and safety profiles, as well. Fleximer has been proven to transform existing and experimental agents into new, patentable drugs with superior properties. The Fleximer platform has broad and versatile applications across therapeutic categories and enhances the delivery of small molecule, protein, and nucleic acid therapeutics. Two such Fleximer conjugates, XMT-1001, a novel camptothecin-based cytotoxic conjugate, and XMT-1107, a novel fumagillin-based anti-angiogenic conjugate, are both in Phase 1 trials and are each the subject of their own composition of matter patents.

CORPORATE ALLIANCES

Mersana has an alliance with Teva Pharmaceuticals for the development and commercialization of XMT-1107 on a world-wide basis excluding Japan where Mersana has retained rights. Mersana is currently pursuing alliances with companies to advance its next generation antibody drug conjugate technology.

PRODUCTS

Name	Indication	Phase	Milestone
XMT-1001	oncology, multiple tumor types	Phase I	Phase II start in 2H12.
XMT-1107	oncology, multiple tumor types	Phase I	Outlicense Japanese Rights in 1H12.
Antibody Drug Conjugates	Oncology, multiple tumor types	Preclinical	Major collaborations with pharma in 2011/2012
Antibody Drug Conjugate	Oncology, multiple tumor types	Preclinical	In-license novel antibody technology in 2011/2012

SENIOR MANAGEMENT

Nick G. Bacopoulos, PhD, Chief Executive Officer • **Michael A. Metzger**, Chief Operating Officer • **Timothy B. Lowinger, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Boyd Clarke • **Nick G. Bacopoulos** • **Thomas Beck**, Fidelity Biosciences • **Joyce Tsang**, ProQuest Investments • **Martin Vogelbaum**, Rho Ventures

MetaCyte Business Lab LLC

Clinical Foci: Biopharmaceuticals • Vaccines • Gene/Cell Therapy

Steven R. Gailar
Chief Executive Officer

201 East Jefferson Street
Louisville, KY 40202
USA

www.metacyte.biz

1-502-569-1020

Incorporated: 2002

Employees: 7

Ownership: Private

CORPORATE MISSION

MetaCyte Business Lab creates “investment grade” life science companies. MetaCyte co-founds companies in partnership with researchers and clinicians.

CORPORATE ALLIANCES

MetaCyte Business Lab, founded in late 2002, is owned by the University of Louisville Foundation, Inc.

PRODUCTS

Name	Indication	Phase	Milestone
Pradama Inc.	MRSA osteomyelitis; other bone/musculoskeletal diseases	Preclinical	Pradama has a novel bone-targeting moiety. We have data from a rat tibial model of chronic osteomyelitis.
RhinoCyte, Inc.	Human adult olfactory-derived neural progenitors to treat a variety of neurodegenerative disorders.	Preclinical	First indication will be spinal cord injury. Other indications will include Parkinson's, ALS, MS.
AllTranz Inc.	Transdermal drug delivery	Preclinical	AllTranz uses a proprietary prodrug strategy for enhancing drug delivery via the skin.
EndoProtech, Inc.	Novel technology that rapidly incorporates therapeutic molecules on the surface of the endothelium/cells.	Preclinical	One application of this technology consists of delivering an anti-complement therapy to protect grafts from ischemia reperfusion injury.
Intrepid Bioinformatics Solutions, Inc.	Cloud-based system to store, access and relate genetic data.	On Market	Just launched an NGS data solution.
TrackFive Diagnostics, Inc.	Gene expression signature of response to EGFR inhibitors.	Diagnostics	Validation; also looking at PI3K inhibitors.
Gnarus Systems, Inc.	Cloud-based expert system for toxicity prediction.	On Market	Advantages include the ability to modify sensitivity/specificity of the analysis; open and transparent predictions; and ability to connect biological responses to molecules in the learning set.
ApoVax, Inc.	Immunostimulatory adjuvant construct based on 4-1BBL.	Preclinical	Differentiated from other adjuvants; effects on Treg cells (including overcoming Treg-mediated suppression), activates innate and adaptive immunity (CD4 and CD8 T cells), directs antigens to dendritic cells and promotes a Th1 response.
Pharos Medicine, Inc.	Dosing of ESAs.	Other	Software to control dosing in anemia management. Additionally, developing complementary biomarkers.

SENIOR MANAGEMENT

Steven R. Gailar, Chief Executive Officer • **Andrew Steen**, Business Development • **Teresa Leezer**, Vice President • **Gina Lankswert**, Vice President • **Sean Kuntz**, Other • **Jessica Sharon**, Other • **Deanna Husted**, Administrative Assistant

Metasignal Therapeutics Inc.

Presenting Company

Clinical Foci: Oncology, Drug Development, Drug Discovery

Dr. Jasbinder Sanghera

President & CEO

8880 Sidaway Road
Richmond, BC V6W 1G8
Canada

www.metasignal.ca

1-604-790-5623

Incorporated: 2010

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

MST 100 Program: Three lead candidate small molecule compounds in assessment to select optimum IND Candidate. To conclude within four months of securing CAD\$1.25 million financing and cGMP Pre-Clinical Studies to support an IND submission will begin.

MST 200 Program: Three lead candidate small molecule compounds in assessment to select optimum IND Candidate. To conclude within four months of securing CAD\$1.25 million financing and cGMP Pre-Clinical Studies to support an IND submission will begin.

Upcoming

One IND submission completed with US FDA 10 months after securing a CAD \$2.5 million investment. One or more IND Candidates will move to cGMP preclinical studies with \$1.25 million. First IND Candidate will be submitted to FDA with 2nd \$1.25 million.

Successful IND candidate will move to two Principal Investigator Phase I trials using the 3rd tranche of investment CAD \$3 - \$5.25 million to be completed within 24 to 36 months from the seed financing.

CORPORATE MISSION

MetaSignal Therapeutics Inc. is a private drug development company developing innovative targeted therapies to block metastasis and cancer cell survival. Cancer metastasis is the cause of mortality in 90% of cancer patient deaths. Currently marketed anticancer treatments and therapeutics do NOT specifically or adequately treat metastasis and cancer stem cell survival. MetaSignal develops drugs that address this unmet therapeutic need by targeting druggable cell surface enzyme proteins that are unique to the cancer stem cells that are normally resistant to current treatments and therapeutics. MetaSignal's drug candidates kill these cancer stem cells that are the driving force for metastasis. Current data indicates that MetaSignal's therapies and drugs may have application in >10 different major cancers and that they may be used as monotherapy and combination therapy with cytotoxic agents and other cancer treatments. Presently MetaSignal has three drug development programs each targeting a separate mechanism of action of cancer stem cell survival. MetaSignal is seeking seed investment to advance the first small molecule lead compound in its Hypoxia program from its preclinical stage of development to a completed Phase I Clinical trial.

PROPRIETARY TECHNOLOGY

First-in-class small molecule compounds and antibody therapeutics targeted to block one or more of three driving forces of cancer cell metastasis and cancer cell survival. These driving forces are hypoxic environments created within primary tumors, altered cell metabolism of cancer stem cells, invasion/migration of tissues at remote sites from the primary tumor by cancer stem cells. Also biomarkers of these altered cellular metabolic states that are useful in patient selection for treatment with MetaSignal's therapies and for assessing the effects of the therapy during and after treatment of the patient.

CORPORATE ALLIANCES

SignalChem Pharmaceutical Ltd. for assessment and validation of biological targets, screening, assay reagent production, biomarker reagent production. Advinus Therapeutics Inc. for medicinal chemistry services, preclinical testing services, preparation and submission of IND. BC Cancer Agency service agreement for assay services. University of Florence for medicinal chemistry small molecule design. BC Cancer Agency, MD Anderson Cancer Centre, Ontario Cancer Research Institute for Phase I clinical trials.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
MST 100	Cancer	Lead Series	IND Candidate Selection
MST 200	Cancer	Lead Series	IND Candidate Selection

SENIOR MANAGEMENT

Dr. Jasbinder Sanghera, President & CEO • **Kevin McDuffie**, Chief Business Officer • **Dan DeBeyer**, Chief Operating Officer

FINANCING HISTORY

Investors: Dr. Jasbinder Sanghera (Founder) (20%) • Dr. Shoukat Dedhar (Founder) (20%) • Dr. Claudiu Supuran (Founder) (20%) • Mr. Jun Yan (Founder) (20%)

Mirna Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Ophthalmic, Skin/Dermatological

Paul Lammers, MD, MSc

President & CEO

2150 Woodward Street
Austin, TX 78744
USA

www.mirnatherapeutics.com

1-512-901-0900

Incorporated: 2007

Employees: 12

Ownership: Private

HIGHLIGHTS

Recent

August 2010: Mirna Therapeutics Announces USD \$10.3 million Award from the Cancer Prevention and Research Institute of Texas (CPRIT).

August 2011: Mirna completes USD \$1.5 million financing round.

July 2011: Mirna Therapeutics Announces Allowance of Multiple Patents

for Therapeutic Use of Tumor Suppressor miRNAs.

Upcoming

Selection of optimal systemic delivery technology by End of 2011, based on strong data out of the Company's delivery program for its miRNA mimics.

Initiation of IND-enabling tox program 4Q11.

IND filing late 2012.

CORPORATE MISSION

Mirna Therapeutics, Inc. (Mirna) is a biotechnology company founded in late 2007 as a spin-off from Asuragen Inc. and is located in Austin, Texas. Mirna is focused on the development of miRNA-directed therapeutics for the treatment of cancer and other diseases. Mirna is developing "MicroRNA Replacement Therapy" approaches which involves introducing microRNAs back into tumors to boost cellular tumor suppressor abilities, ultimately leading to cancer cell death and tumor shrinkage. For more information, visit www.mirnax.com.

PROPRIETARY TECHNOLOGY

Mirna is focused on the discovery and development of microRNA (miRNA) therapeutics called miRNA mimics. The Company possesses extensive research capabilities in the miRNA field, and has identified to date eight miRNA mimics as potential therapeutics against a wide range of cancer types.

CORPORATE ALLIANCES

Working with several top 10 pharmaceutical companies interested in testing the efficacy and safety of several of Mirna's miRNA mimic product candidates.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
miR-34a	Solid and hematological cancers	Optimized Lead	IND Submission late 2012

SENIOR MANAGEMENT

Paul Lammers, MD, MSc, President & CEO • **Lynne Hohlfeld**, Chief Financial Officer • **Ana Ward**, General Counsel • **David Brown, PhD**, Director • **Jay Stoudemire, PhD**, Director • **Andy Bader, PhD**, Other

BOARD OF DIRECTORS

Dr. Matt Winkler, CEO/CSO Asuragen • **Dr. Corey Goodman**, Partner, VenBio • **Dr. Chris Earl** • **Dr. Evan Melrose**, Partner, PTV Sciences • **Dr. Paul Lammers**, President & Chief Executive Officer

SCIENTIFIC ADVISORY BOARD

Dr. Daniel Von Hoff, TGen; US Oncology, University of Arizona, Scottsdale, AZ • **Dr. David Johnson**, UT Southwestern, Dallas, TX • **Dr. Steve McKnight**, UT Southwestern, Dallas, TX • **Dr. Frank Slack**, Yale University, New Haven, CT • **Dr. Arthur Krieg**, Entrepreneur in Residence, Atlas Ventures

FINANCING HISTORY

Round Date (Amount, US\$) • 08/01/2011 (1.50 million)

Mithridion, Inc.

BIO Member, Presenting Company

Clinical Foci: CNS, Drug Development, Other

Trevor M Twose, BSc, PhD

Chief Executive Officer

505 Science Drive, Ste C
Madison, WI 53711
USA

www.mithridion.com

1-608-443-2430

Incorporated: 2004

Ownership: Private

HIGHLIGHTS

Recent

Completion of Phase Ib for MCD-386CR in 57 subjects; safety, tolerability, food-effect, pharmacokinetic, metabolism and cognition studies; proof-of-concept for sustained release; successful dose-ranging for low parasympathetic side-effect incidence.

Selection of MI-10-022 as a drug candidate; preparing for IND-enabling studies

Demonstrated disease-modifying potential. MCD-386 and MI-10-022 reduced hippocampal A-beta in transgenic Tg-2576 mice. Demonstrated potent anti-psychotic activity of MI-10-022. Orphan status for MCD-386 for Progressive Supranuclear Palsy (PSP).

Upcoming

Exploratory Phase II for MCD-386CR in PSP, Parkinson's disease dementia, Dementia with Lewy Bodies, Autosomal Dominant Inherited Alzheimer's. Acute, statistically powerful cross-over studies using specific neuropsych test and biomarker endpoints.

Corporate partnership and Series C funding

MI-10-022 into IND enabling studies.

CORPORATE MISSION

Mithridion, Inc. develops drugs for the unmet needs of serious CNS disorders, initially for neurodegenerative diseases (ND), which are multi-billion drug and market opportunities. Lead drug candidate MCD-386CR has completed Phase I clinical evaluations and is being prepared for exploratory Phase II proof-of-pharmacology trials. MCD-386CR is a controlled-release oral formulation of a small molecule NCE, potentially a first-in-class disease-modifying drug for ND and to treat memory/cognition impairment.

Drug candidate MI-10-022 is being prepared for IND-enabling studies. It is potentially a first-in-class single agent for schizophrenia (S) and ND, addressing cognition/memory, psychosis/behavior in S and ND and underlying disease processes in ND.

Mithridion has in house medicinal chemistry, neuropharmacology, PK/ADME and other preclinical development capabilities, and a virtual early clinical development capabilities.

Mithridion has demonstrated preclinical proof-of-concept of therapeutic potential for S and cognition/disease-modifying potential for ND of its drug leads in laboratory models, and has announced several exciting partnering opportunities created with our platform technology.

We aim to add great value in preclinical and clinical development, partnering drugs with major pharma or biotech companies at latest after demonstrating proof-of-concept in Phase II.

Mithridion is capital efficient. It has raised US\$8.6m to date from Rosetta Partners, Wisconsin Investment Partners, Venture Investors LLC, State of Wisconsin Investment Board (SWIB), Rocket Ventures.

PROPRIETARY TECHNOLOGY

Oral, small-molecule muscarinic receptor sub-type selective M1 agonists(MCD-386CR). M1 agonists improve cognition./memory and have potentially beneficial actions on several ND disease mechanisms, including Amyloid Protein Precursor/A-beta metabolism, Tau phosphorylation, GSKIII-beta inhibition, PKC activation and apoptosis - effectively several drug actions in one molecule.

Oral, small-molecule muscarinic receptor sub-type selective M1/M4 agonists (MI-10-022). Potent, powerful potential anti-psychotic actions by a novel mechanism driven by the M4 agonist activity. Also has all the actions of M1 agonists (above). Potential first-in-class.

Oral controlled-release tablet dosage forms.

Forte high-dose drug product options.

Transdermal dosage options.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
MCD-386CR (oral controlled release)	Cognition, memory, disease-modification in neurodegenerative diseases	Phase I	Phase II
MCD-386CR	Cognition in schizophrenia	Preclinical	IND
MI-08-016 Series	MCD-386 follow-on	Preclinical	IND
MCD-386CR Forte (/glycopyrrolate combination)	Cognition, memory, disease-modification in neurodegenerative diseases	Preclinical	IND
MI-10-022	Cognition, primary, secondary symptoms in schizophrenia; cognition, memory, disease-modification in neurodegenerative diseases	Preclinical	IND

SENIOR MANAGEMENT

Trevor M Twose, BSc, PhD, Chief Executive Officer • **Alex Kasper**, Chief Financial Officer • **Wayne Hoss, PhD**, Director • **Patti Twose, BSc**, Chief Operating Officer • **William S. Messer, Jr., PhD**, Chief Scientific Officer • **Richard Copp, PhD**, Vice President

BOARD OF DIRECTORS

Trevor M Twose, BSc, PhD, Mithridion, Inc. • **Wayne P Hoss, PhD**, University of Toledo; Cognitive Pharmaceuticals Ltd • **John Neis**, Venture Investors LLC • **Paul Weiss, PhD, MBA**, Venture Investors LLC • **Frederick A. Robertson MD MBA**, Independent

SCIENTIFIC ADVISORY BOARD

William S. Messer, Jr., PhD, Professor, University of Toledo • **Franklin P. Bymaster**, Independent; Formerly with Eli Lilly

FINANCING HISTORY

Round Date (Amount, US\$) 02/01/2006 (2.20 million) • 01/09/2009 (5.20 million) • 01/06/2011 (1.30 million)

Molecular Templates, Inc.

Presenting Company

Clinical Foci: Biopharmaceuticals, Oncology, Hematology

Eric Poma

Chief Executive Officer

111 W. Cooperative Way
Georgetown, TX 78626
USA

www.moleculartemplates.com

1-512-930-0304

Incorporated: 2009

Ownership: Private

CORPORATE MISSION

Molecular Templates (MTEM) is a biopharmaceutical company focused on the development of a new class of biologics called Engineered Toxin Bodies (ETBs) for a variety of oncology indications. ETBs derive their biologically active properties from a toxin-based scaffold that possesses a differentiated mechanism of action over traditional antibody based or small molecule approaches. MTEM's lead ETB program is being developed for hematological cancer indications. The company plans to be in the clinic in the next 12-18 months.

CORPORATE ALLIANCES

ImClone/Lilly, Alnylam Pharmaceuticals, Memorial Sloan Kettering, NYU Cancer Institute

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
MT-3724	Hematological	Preclinical

SENIOR MANAGEMENT

Eric Poma, Chief Executive Officer • **Jason Kim**, Chief Financial Officer

Muscular Dystrophy Association

Presenting Company

Clinical Foci: Genetic Disorders, Drug Discovery, Drug Development

Gerald C. Weinberg

President & CEO

3300 E Sunrise Dr
Tucson, AZ 85718
USA

www.mdausa.org

1-520-615-6702

Incorporated: 1952

Ownership: Patient Advocacy Group

HIGHLIGHTS

Recent

Since initiating the MVP program in 2009, MVP has funded 15 projects. All but two of these projects have proceeded as planned, and the therapeutics are moving forwards in development.

With MVP funding, three potential therapeutics either have just entered the clinic for the first time, or will very soon.

CORPORATE MISSION

MDA Venture Philanthropy (MVP) is the Muscular Dystrophy Association's drug development program, which operates within MDA's Translational Research program. MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases.

MVP does not provide traditional grants, but rather makes targeted investments in drug development for neuromuscular disease. Projects will be milestone-driven, contract-mediated and a return on investment will be negotiated. MVP utilizes a professional diligence process and is committed to a 16-week turnaround on investment decisions.

Investment Profile: MVP invests in small pharmaceutical and biotech companies and in academics developing treatments and therapies for neuromuscular diseases. Companies may be public or private, and MVP does not discriminate between US and international projects. MVP funds academic investigators doing appropriate studies but encourages corporate collaboration. MVP seeks to apply funding where it will achieve the greatest leverage to increase the number of effective drugs in development for neuromuscular diseases. As such, well-financed projects that will proceed without MVP investment may not be selected for funding.

SENIOR MANAGEMENT

Gerald C. Weinberg, President & CEO • **Valerie Cwik, MD**, Senior Vice President • **Sanjay Bidichandani, MBBS, PhD**, Vice President • **Jane Larkindale, DPhil**, Director • **Gerald C. Weinberg**, President & CEO • **Valerie Cwik, MD**, Senior Vice President • **Sanjay Bidichandani, MBBS, PhD**, Vice President • **Jane Larkindale, DPhil**, Director

BOARD OF DIRECTORS

R. Rodney Howell, MD • **Olin Morris** • **Lori West** • **Timmi Masters** • **Suzanne Lowden** • **Stanley Appel** • **Lous Kunkel** • **Christopher J Rosa** • **Charles D Schoor** • **Brad Henry**

SCIENTIFIC ADVISORY BOARD

Stanley Appel, Methodist Neurological Institute • **Cristina Csimma** • **Merit Cudkowicz**, Massachusetts General Hospital • **Kenneth Fischbeck**, National Institute of Neurological Disorders and Stroke • **Louis Kunkel**, Harvard Medical School • **Elizabeth McNally**, University of Chicago Medical School • **John Porter**, National Institute of Neurological Disorders and Stroke • **Jeffrey Rothstein**, Johns Hopkins School of Medicine • **Charles Thornton**, University of Rochester

MyeloRx LLC

Clinical Foci: Oncology, Hematology, AutoImmune

John H. Musser Chief Executive Officer

941 Railroad Avenue
Vallejo, CA 94592
USA

www.myelorex.com

1-650-759-3595

Incorporated: 2007

Employees: 4

Ownership: Private

HIGHLIGHTS

Recent

Awarded Fast Track SBIR contract from National Cancer Institute worth US\$2.0 million in September, 2009 to fund development of MRx102; Phase I and Phase II, Year 1 successfully completed; and Phase II, Year 2 initiated in March, 2011.

Allowance of MRx102 patent in the US and other patents in US, EU and China

Publication of paper in Nature Chemistry Biology on the target of triptolide in February, 2011 and publication of a paper describing MRx102 in the journal Leukemia in September, 2011 by members of the MD Anderson Cancer Center and MyeloRx

Upcoming

Complete all preclinical work in 2012 and file an IND
Additional funding via government sources

Generation of data demonstrating utility of MRx102 in combination with radiation as well as in models of melanoma

CORPORATE MISSION

MyeloRx LLC is a Northern California biotechnology company which develops drugs for oncology and immune-based diseases based on the natural product triptolide. Triptolide has been shown clinically active in acute leukemias as well as in immune-based diseases. As shown in a recent Nature Chemistry Biology paper triptolide binds to a protein termed XPB leading to an inhibition RNA polymerase II thereby affecting a number of cell signaling pathways. The nuclear excision repair (NER) pathway is also blocked leading to inhibition of DNA repair following damage caused by a variety of anti-cancer modalities including cisplatin treatment and perhaps radiation exposure as well. The lead compound, MRx102, is being developed initially for acute myeloid leukemia (AML) and is expected to be active in other leukemias including Gleevec-insensitive CML. Our clinical consultant, Dr. Michael Andreeff of the MD Anderson Cancer Center, found MRx102 effective in killing blast cells from AML patients as well as AML stem cells. Based on preliminary safety and efficacy studies MyeloRx was awarded a US\$2.0 million SBIR contract by the National Cancer Institute to develop MRx102 for AML. MRx102 also demonstrated significant activity in a variety of melanoma screens performed by the NCI and is undergoing tertiary testing by that organization as well as testing by investigators at UCSF Helen Diller Family Comprehensive Cancer Center. The company plans to have MRx102 enter clinical trials in AML patients in 2013. The second triptolide-based product in the pipeline is MRx109. It has demonstrated activity in a series of transplantation models performed in rodents and primates as well as in a rodent collagen arthritis model. It has undergone extensive toxicology studies in rodents and primates. The principals in the company have extensive experience in both large pharmaceutical companies (Pfizer, Wyeth, DuPont) as well as in the biotechnology industry (Cetus/Chiron, Glycomed, Pharmagenesis).

PROPRIETARY TECHNOLOGY

Three of the company principals have been working with triptolide for more than 15 years. They have a strong understanding of the structure-activity of the core compound and have developed five patent families consisting of numerous prodrugs and derivatives of triptolide which have been exclusively licensed to MyeloRx. They also have extensive manufacturing experience and have produced cGMP drug supply.

CORPORATE ALLIANCES

The company has an alliance with the MD Anderson Cancer Center as well as with a number of subcontractors which are performing IND-enabling R&D. It also has been awarded a Fast Track SBIR contract from the National Cancer Institute to fund development of MRx102.

PRODUCTS

Name	Indication	Phase	Milestone
MRx102	Acute Myeloid Leukemia	Optimized Lead	Completed preclinical efficacy in AML models and pilot toxicology in rodents.
MRx109	Immune based diseases	Optimized Lead	Completed efficacy in organ transplantation and RA as well as pilot toxicology in rodents and monkeys.

SENIOR MANAGEMENT

John H. Musser, Chief Executive Officer • John M. Fidler, Vice President • Jinhua An, Vice President • Neil R. Ackerman, Vice President

SCIENTIFIC ADVISORY BOARD

Michael Andreeff, M.D., Ph.D., MD Anderson Cancer Center • Adil Daud, M.D., UCSF Helen Diller Family Comprehensive Cancer Center • Anne Welton, Ph.D., Consultant

FINANCING HISTORY

Investors: John H. Musser (25%) • John M. Fidler (25%) • Jinhua An (25%) • Neil R. Ackerman (25%)

Nanocarrier Co., Ltd.

Presenting Company

Clinical Foci: Drug Delivery, Drug Development, Biopharmaceuticals

Ichiro Nakatomi <i>President & CEO</i> Yaesu Yamagata Bldg. Tokyo 103 0027 Japan	www.nanocarrier.co.jp 81-3-3548-0213	Tokyo: 4571 <i>Incorporated:</i> 1996 <i>Employees:</i> 40 <i>Ownership:</i> Public
---	--	---

HIGHLIGHTS <i>Recent</i> NanoCarrier has completed PI of DachPlatin Micelles in Europe and is looking for a development partner worldwide.

CORPORATE MISSION NanoCarrier is a pharmaceutical company that focuses on development of drug delivery systems based on micellar technology. In addition to its proprietary drug delivery platform, NanoCarrier developed several products such as NK105, NC-6004, or NC-4016 that are in clinical development as far as PIII for treatment of different cancer indications. The company was founded in 1996 and is located in Tokyo, Japan. In 2008 NanoCarrier was listed on Tokyo stock exchange. NanoCarrier's core technology, micellar nanoparticles technology, was proposed and has been researched by Professor Kazunori Kataoka of University of Tokyo, Professor Teruo Okano of Tokyo Women's Medical University. The aforementioned professors demonstrated that when drug-encapsulating micellar nanoparticles were intravenously administered, the micellar nanoparticles could function as stable drug carriers in the bloodstream and they accumulated in cancerous tissues. It is hoped that, if efficacy and safety of drugs are further improved by utilizing our technology, we will be able to contribute to the advance in medication of cancer and other intractable diseases. NanoCarrier has been working on the design of advanced Biomaterials for drug delivery using its proprietary processes. NanoCarrier has more than 10-years of experience in the design and development of polymeric micellar drugs and a broad intellectual property position. NanoCarrier is consolidating its position as the leading pharmaceutical company focused on the application of polymeric micelle technology to drug development. NanoCarrier's leading projects, includes a Paclitaxel (NK105), a Cisplatin-analogue (NC-6004) and a Dachplatin-analogue (NC-4016) formulations that are ongoing in clinical development. The pre-clinical development program includes an Epirubicin based formulation. Moreover the technology was used successfully with client's API to deliver different products that had low solubility or its use was limited by high toxicity.

PROPRIETARY TECHNOLOGY NanoCarrier has three broad product technology platforms. First, NanoCarrier developed the NanoCap™ system to encapsulate Poorly Water-Soluble Drugs, such as Paclitaxel, for intravenous administration. Second, the MediCelle™ system provides a highly versatile technology that addresses Hydrophilic compounds, including peptides, proteins, metal-chelating conjugates, and genes, for incorporation in the polymeric micelles. Third, the NanoCoat™ system is designed to have specialized functionality on the surface of the micelles by attachment of a specific ligand. Micellar nanoparticles are composed of biocompatible block copolymers, comprising of hydrophilic polyethylene glycol (PEG) and hydrophobic polyamino acids.

CORPORATE ALLIANCES NK105 – Nippon Kayaku; NC-6004 – Oriental Europharma; NC-4016 – Self development/Partner identified for Japan, undisclosed; NC-6300 – Japan partner identified, undisclosed; Dozen of other undisclosed alliances were established mainly for the use of technology.
--

PRODUCTS																												
<table border="1"> <thead> <tr> <th><i>Name</i></th> <th><i>Indication</i></th> <th><i>Phase</i></th> <th><i>Milestone</i></th> </tr> </thead> <tbody> <tr> <td>NK105</td> <td>Gastric Cancer</td> <td>Phase II, IIa, IIb</td> <td>Completed PII</td> </tr> <tr> <td>NC-6004 Micelle</td> <td>Pancreatic cancer</td> <td>Phase II, IIa, IIb</td> <td>Completed PI in EU</td> </tr> <tr> <td>NC-4016 DachPlatin Micelle</td> <td>Undisclosed</td> <td>Phase I</td> <td>Finished PI in EU</td> </tr> <tr> <td>NC-6003 Epirubicin Micelle</td> <td>Undisclosed</td> <td>Preclinical</td> <td></td> </tr> <tr> <td>Protein Micelles Delivery Platform</td> <td>Hemophilia; others</td> <td>Research</td> <td></td> </tr> <tr> <td>siRNA Micelle Delivery Platform</td> <td>Cancer</td> <td>Research</td> <td></td> </tr> </tbody> </table>	<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>	NK105	Gastric Cancer	Phase II, IIa, IIb	Completed PII	NC-6004 Micelle	Pancreatic cancer	Phase II, IIa, IIb	Completed PI in EU	NC-4016 DachPlatin Micelle	Undisclosed	Phase I	Finished PI in EU	NC-6003 Epirubicin Micelle	Undisclosed	Preclinical		Protein Micelles Delivery Platform	Hemophilia; others	Research		siRNA Micelle Delivery Platform	Cancer	Research	
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>																									
NK105	Gastric Cancer	Phase II, IIa, IIb	Completed PII																									
NC-6004 Micelle	Pancreatic cancer	Phase II, IIa, IIb	Completed PI in EU																									
NC-4016 DachPlatin Micelle	Undisclosed	Phase I	Finished PI in EU																									
NC-6003 Epirubicin Micelle	Undisclosed	Preclinical																										
Protein Micelles Delivery Platform	Hemophilia; others	Research																										
siRNA Micelle Delivery Platform	Cancer	Research																										

SENIOR MANAGEMENT


Ichiro Nakatomi, President & CEO • **Takuma Nakatsuka**, Chief Financial Officer • **Hiroyuki Hanada**, Chief Business Officer • **Yasuki Kato**, Chief Scientific Officer • **Okano Teruo**, Academic

BOARD OF DIRECTORS

Akira Ohashi

TRADING STATUS AS OF OCTOBER 5, 2011

TOKYO: 4571



Market Data

Current Price	22930.00
Currency	Japanese Yen
Net Change	-4.06
Volume	1,618
YTD % Change	0.81
52Wk Range	9,258.33–64100.00
Avg. Daily Volume (thousands)	5,391

First Call Data

Market Cap (MM)	5,133.7
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-2215.20
EPS (Last Fiscal Year)	-3354.08
Consensus Estimate (Y)	-2215.20
Consensus Recommend	--
Price/Sales	65.46

Shareholders

Institution

Holding %

Siemens Kapitalanlagegesellschaft mbH	0.0%
Nikko Asset Management Co. Ltd.	0.0%
Nomura Asset Management Co., Ltd.	0.0%
.....	--
.....	--

Mutual Fund

Holding %

Siemens Kapitalanlagegesellschaft mbH	0.0%
Nikko Asset Management Co. Ltd.	0.0%
Nomura Asset Management Co., Ltd.	0.0%
.....	--
.....	--

Source: Thomson Reuters

NeurogesX, Inc.

Clinical Foci: Biopharmaceuticals, Specialty Pharmaceutical, Neurology

Anthony DiTonno President & CEO

2215 Bridgepointe Parkway, Suite 200
San Mateo, CA 94404
USA

www.neurogesx.com

1-650-358-3300

NASDAQ: NGSX

Incorporated: 2000

Employees: 106

Ownership: Public

HIGHLIGHTS

Recent

Completed USD \$40 million financing comprised of \$20 million private placement to a group of institutional accredited investors and \$20 million loan with Hercules Technology Growth Capital.

Following FDA approval in November 2009, accelerating US launch of Qutenza® (capsaicin) 8% patch with dedicated sales force and established Medicare Part B / commercial payer coverage.

Completed enrollment in Phase 2 clinical study for NGX-1998, a topical formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN) and top-line data expected by year end 2011.

Upcoming

Report data from Phase 2 study of NGX-1998 by year end 2011.

FDA acceptance of sNDA for Qutenza, for the management of pain associated with HIV-associated neuropathy (HIV-AN).

Approval of Qutenza sNDA.

CORPORATE MISSION

NeurogesX, Inc., a biopharmaceutical company focused on developing and commercializing novel pain management therapies, was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. NeurogesX has leveraged its passion for helping people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental new drug application (sNDA) to expand the US label for Qutenza for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN) also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).

The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and patient enrollment has been completed in a Phase 2 clinical trial of NGX-1998 in PHN patients.

The Company's early-stage pipeline includes pre-clinical compounds, including a number of acetaminophen prodrugs. The Company has evaluated certain of these compounds in vitro and in vivo.

PROPRIETARY TECHNOLOGY

Qutenza (capsaicin) 8% patch: localized, dermal delivery system that contains prescription strength capsaicin, approved and commercially available in the United States and European Union. Qutenza is designed to reduce the pain associated with PHN or other peripheral neuropathic pain syndromes after a single one-hour administration.

NGX-1998: topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. Enrollment in the Phase 2 study has been completed and three Phase 1 studies were previously completed.

Acetaminophen Prodrugs and Opioid Analgesic Prodrugs: pre-clinical product pipeline evaluated in vitro and in vivo, for which NeurogesX seeking development partners.

CORPORATE ALLIANCES

June 2009: NeurogesX entered agreement with Astellas Pharma Europe Ltd., for commercialization of Qutenza in Europe, Middle East and Africa, including licensing option and development funding for NGX-1998. NeurogesX received two upfront payments, €30 million (~\$42 million USD) for Qutenza commercialization rights and €5 million (~\$7 million USD) for NGX-1998 option and Phase 2 development. In addition, NeurogesX is eligible to receive up to €70 million (~\$97 million) total potential milestone payments; and royalties based on double-digit percentage of Qutenza net sales. Astellas is responsible for funding and conducting post-marketing studies to support Qutenza EU marketing. If Astellas takes option for NGX-1998, the companies anticipate collaborating on Phase 3 clinical development.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Qutenza (capsaicin) 8% patch	Pain associated with postherpetic neuralgia	Cleared for US Marketing	sNDA filed for management of pain due to HIV-associated peripheral neuropathy (HIV-PN)
NGX-1998	Pain associated with postherpetic neuralgia	Phase II, IIa, IIb	Report data from Phase 2 study

SENIOR MANAGEMENT


Anthony DiTonno, President & CEO • **Stephen Ghiglieri**, Chief Financial Officer • **Jeffrey Tobias, MD**, Chief Medical Officer • **Michael Markels**, Business Development

BOARD OF DIRECTORS

Gary A. Lyons, Existing Director, Neurocrine Biosciences Inc. • **Jean-Jacques Bienaimé**, CEO, BioMarin • **Bradford Goodwin**, President and CEO, Keren Pharmaceutical • **Neil Kurtz, MD**, President & CEO, Golden Living • **Robert Nelsen**, ARCH Ventures • **Steven Nelson**, CEO, Western Region, UnitedHealthcare • **John Orwin**, CEO, Affymax, Inc. • **Anthony DiTonno**, CEO, NeurogesX

SCIENTIFIC ADVISORY BOARD

Allan I. Basbaum, PhD, Professor and Chair of the Department of Anatomy at the University of California, San Francisco • **Gary Bennett, PhD**, Faculty, Dept. of Anesthesia, McGill University; Director of Pain Research, Montreal General Hospital • **Robert Dworkin, PhD**, Professor of Anesthesiology, Neurology, Oncology and Psychiatry, University of Rochester Medical Center • **Nathaniel Katz, MD**, Adjunct Assistant Professor of Anesthesia, Tufts University School of Medicine • **Marco Pappagallo, MD**, Professor, Dept. of Anesthesiology and Pain Medicine; Director, pain medicine R&D, Mount Sinai School of Medicine

TRADING STATUS AS OF OCTOBER 5, 2011**NASDAQ: NGSX****Market Data**

Current Price	0.78
Currency	US Dollar
Net Change	-2.50
Volume	38,400
YTD % Change	-0.88
52Wk Range	0.66–7.55
Avg. Daily Volume (thousands)	78,257

First Call Data

Market Cap (MM)	23.2
Short Interest Shares	411,912
Short Interest Ratio	10.38
PE (Trailing 12 Months)	-1.75
EPS (Last Fiscal Year)	-2.97
Consensus Estimate (Y)	-1.75
Consensus Recommend	-1.75
Price/Sales	2.30

Shareholders

<i>Institution</i>	<i> Holding %</i>
Wasatch Advisors, Inc.	18.8%
The Dow Chemical Co. Pension Fund	1.5%
Sphera Fund Management Ltd.	0.5%
Dimensional Fund Advisors, Inc.	0.5%
GRT Capital Partners LLC	0.5%
<i>Mutual Fund</i>	<i> Holding %</i>
Wasatch Advisors, Inc.	18.8%
The Dow Chemical Co. Pension Fund	1.5%
Sphera Fund Management Ltd.	0.5%
Dimensional Fund Advisors, Inc.	0.5%
GRT Capital Partners LLC	0.5%

Source: Thomson Reuters

OncoMed Pharmaceuticals, Inc.

BIO Member, BIO Board Member

Clinical Foci: Drug Development, Biopharmaceuticals

Paul J. Hastings

President & CEO

800 Chesapeake Drive
Redwood City, CA 94063
USA

www.oncomed.com

1-650-995-8200

Incorporated: 2004

Employees: 81

Ownership: Private

HIGHLIGHTS

Recent

April 2011: Initiate phase I for OMP-18R5, OncoMed's third clinical antibody and first targeting the Wnt pathway under the collaboration with Bayer. Milestone generated USD \$20 million payment.

Dec. 2010: Initiate phase I for OMP-59R5, OncoMed's second antibody to enter the clinic targeting the Notch pathway.

Dec. 2010: Third clinical candidate selected by GSK in the Notch pathway collaboration.

CORPORATE MISSION

OncoMed Pharmaceuticals is a clinical-stage biotechnology company dedicated to improving cancer treatment, by developing therapeutics that target the pathways critical to tumor initiating cells, also known as cancer stem cells. The company has leveraged its robust scientific platform to generate a rich pipeline of compounds inhibiting cancer stem cell proteins for the treatment of solid tumors. OncoMed's lead candidate, OMP-21M18, is currently in Phase 1 and Phase Ib clinical trials. In addition, OncoMed has initiated a clinical study for the company's second and third anti-cancer stem cell candidates, OMP-59R5 and OMP-18R5.

A leader in cancer stem cell research, OncoMed has established a library of antibodies targeting multiple cancer stem cell pathways for the treatment of solid tumors such as pancreatic, breast, colorectal and lung cancers.

PROPRIETARY TECHNOLOGY

OncoMed utilizes proprietary tumor models created with human primary tumor xenografts. These models, developed under intellectual property licensed exclusively to OncoMed, are much more representative of human tumors than the cell line approach relied upon in traditional cancer research. Candidate therapeutics active against these primary human tumor xenografts are much more likely to also be effective against these tumors in the clinic. The ability to measure and purify tumor initiating cells has enabled OncoMed to assess the importance of specific target proteins implicated in human cancer and associated with biological pathways that regulate stem cell biology.

CORPORATE ALLIANCES

In December 2007, OncoMed and GlaxoSmithKline entered into a strategic where OncoMed is eligible to receive USD \$1.4 billion from GSK based on the achievement of specified discovery, development, regulatory and commercial milestones as well as double-digit royalties on all product sales.

In June of 2010, OncoMed entered into strategic alliance with Bayer Schering Pharma AG (BSP). BSP made an upfront payment of USD \$40 million to OncoMed and the company is eligible to receive milestone payments on up to five compounds. For each of three biotherapeutics, OncoMed is eligible for up to USD \$387.5 million, and for two small molecules up to \$112 million as well as double-digit royalties on net product sales.

PRODUCTS

Name	Indication	Phase
OMP-21M18	Anti-DLL4, Oncology	Phase I
OMP-59R5	Notch pathway, Oncology	Phase I
OMP-18R5	Wnt pathway, Oncology	Phase I
OMP-52M51	Notch pathway, Oncology	Preclinical

SENIOR MANAGEMENT

Paul J. Hastings, President & CEO • **John Lewicki, PhD**, Chief Scientific Officer • **Sunil Patel**, Senior Vice President • **Austin Gurney, PhD**, Senior Vice President • **Steven E. Benner, MD**, Chief Medical Officer • **Timothy Hoey**, Senior Vice President • **William D. Waddill**, Chief Financial Officer • **Michael Mulkerin, PhD**, Vice President • **Jakob Dupont**, Vice President • **Alicia J. Hager, JD, PhD**, Vice President

BOARD OF DIRECTORS

James N. Woody, MD, PhD, Latterell Venture Partners • **James Broderick, MD**, Morgenthaler Partners • **Terry Gould**, Adam Street Partners • **Jack Lasersohn, JD**, Vertical Group • **Jonathan D. Root, MD**, US Venture Partners • **Paul J. Hastings**, OncoMed Pharmaceuticals, Inc. • **Laurence A. Lasky, PhD**, US Venture Partners • **Denise Pollard-Knight, PhD**, Phase4 Ventures Limited • **Deepa Pakianathan, PhD**, Delphi Ventures

FINANCING HISTORY

Round Date (Amount, US\$) 04/01/2006 (17.80 million) • 08/01/2006 (43.10 million) • 12/01/2008 (126.20 million)

Investors: US Venture Partners (16%) • Latterell Venture Partners (11%) • Verticle Fund (10%) • Morgenthaler Partners (10%) • Phase4 Ventures Limited (8%)

OncoSynergy, Inc.

Clinical Foci: Oncology • Drug Development • Diagnostics

W. Shawn Carbonell, MD, PhD

Chief Executive Officer

1700 4th Street Byers Hall Ste 214
QB3 MC: 2522
San Francisco, CA 94158-2330
USA

www.OncoSynergy.com

1-617-755-9156

Incorporated: 2011

Ownership: Private

HIGHLIGHTS

Recent

The molecular target has been shown to promote resistance to certain existing therapies for glioblastoma multiforme (GBM).

OS2996 has been shown to significantly inhibit growth of therapy-resistant GBM in both in vitro and in vivo models.

Recent funding will support the completion of preclinical testing.

Upcoming

IND in 18 months.

CORPORATE MISSION

OncoSynergy is a UCSF spin-out developing a family of drugs targeting mechanisms of treatment resistance in cancer both for monotherapy and as a complement to existing therapies. Our lead product, OS2996, is directed to recurrent glioblastoma multiforme (GBM) and breast cancer; however, the product family holds promise for therapy of other solid and metastatic cancers, retinal diseases and inflammatory diseases.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
OS2996	glioblastoma multiforme (GBM)	Preclinical	preclinical proof of concept (in vitro and in vivo)
OS6264	cancer	Preclinical	
OS7275	cancer	Preclinical	
OS2966DX	cancer	Research	

SENIOR MANAGEMENT

W. Shawn Carbonell, MD, PhD, Chief Executive Officer • **Robert Dunkle**, Chief Operating Officer

P2D Bioscience (P2D, Inc.)

Presenting Company

Clinical Foci: Drug Development • CNS • Infectious Disease

Frank Zemlan, PhD Chief Executive Officer

3130 Highland Avenue
Cincinnati, OH 45219
USA

www.p2dinc.com

1-513-475-6618

Incorporated: 2006

Employees: 8

Ownership: Private

HIGHLIGHTS

Recent

September 2011: P2D Bioscience received USD \$1.3 million in funding from the National Institutes of health to develop its lead attention deficit/hyperactivity disorder (ADHD) lead drug candidate.

September 2011: P2D Bioscience announced a strategic alliance and co-development agreement with Advinus Therapeutics for funding IND-enabling studies for P2D's series of dopamine transport inhibitors.

July 2011: P2D Bioscience received USD \$1.5 million in funding from the National Institute of Diabetes, Digestive and Kidney Disease to develop its lead obesity/diabetes lead drug candidate.

CORPORATE MISSION

P2D Bioscience (P2D) is a specialty pharmaceutical company focused on developing innovative "first in class" drugs that fulfill unmet medical needs. Our primary focus is small molecule R&D. P2D currently has a pipeline of nine drug candidates, all with novel mechanisms of action. Based in Cincinnati, Ohio with a satellite office in Mumbai, India we offer capabilities for bringing proprietary molecules through the "valley of death" to clinical stage development in a leveraged schema that de-risks projects and makes even de-prioritized assets economically feasible for strategic partners. Our therapeutic focus areas are the treatment of central nervous system (CNS) disorders including attention deficit/hyperactivity disorder (ADHD) and pulmonary disorders (COPD).

At P2D, we have an experienced drug development team with expertise that spans preclinical to clinical development including lead optimization, toxicology, pharmacokinetics, safety and regulatory affairs. Through our strategic partners we have access to GMP manufacture and GLP resources within a risk-sharing model that maximizes our chances of getting a lead candidate into the clinic. Once in the clinic, our proven expertise in study design and implementation helps insure taking our selected drug candidate through clinical proof of concept and then out-license to complete the commercialization process. P2D's business strategy is to acquire IP at an early stage of development and to map out a customized commercialization plan with strategic co-development partners having predetermined end-stage licensees identified early in clinical development.

PROPRIETARY TECHNOLOGY

P2D Bioscience has received funding to complete IND studies for its lead proprietary ADHD drug candidate. Additional funding has been obtained for early stage Phase 1A human studies. Additional funding is being sought to complete human Phase 2A proof-of-efficacy clinical studies.

CORPORATE ALLIANCES

P2D Biosciences currently has alliances with Advinus Therapeutics, University of California Los Angeles and Cincinnati Children's Hospital Medical Center.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PD9475	AttentionDeficit/Hyperactivity Disorder (ADHD)	Phase I	Phase 1B/2A Study Completed 2011
PD2007	AttentionDeficit/Hyperactivity Disorder (ADHD)	Optimized Lead	IND-enabling studies initiated
PD3766	Pulmonary Disease (COPD)	Pre-Target Validation	
PD2005	Obesity/Diabetes	Optimized Lead	IND-enabling studies initiated
PD2015 and PD2016	Alzheimer's Disease	Target Validated	

SENIOR MANAGEMENT

Frank Zemlan, PhD, Chief Executive Officer • **Prasad Gabbita, PhD**, Chief Scientific Officer • **Sekhar Tatapudy**, Vice President • **Guru Dhareshwar, PhD**, Vice President

FINANCING HISTORY

Round Date (Amount, US\$) 09/01/2008 (10.50 million)

Investors: Four Founding Owners (100%)

Palatin Technologies, Inc.

Presenting Company

Clinical Foci: Drug Development • Specialty Pharmaceutical • Biopharmaceuticals

Carl Spana, PhD

President & CEO

4-C Cedar Brook Drive
Cranbury, NJ 08512
USA

www.palatin.com

1-609-495-2200

SIX Swiss: PTN

Incorporated: 1996

Employees: 19

Ownership: Public

HIGHLIGHTS

Recent

Initiated enrollment in multicenter at home Phase 2B clinical trial with bremelanotide in pre-menopausal women with female sexual dysfunction.

Announced commencement of a Phase 1 trial of AZD2820 by AstraZeneca. AZD2820, which resulted from the license and collaboration between Palatin and AstraZeneca, is under development for the treatment of obesity.

March 2011: Closed on a USD \$23 million firm commitment public offering consisting of 23 million units at a price to the public of \$1.00. Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were \$21 million.

Upcoming

Completion of enrollment of 400 patient, at-home dose-finding Phase 2B trial of bremelanotide for female sexual dysfunction in premenopausal women expected in first quarter of 2012. Top-line data expected 2H12.

Completion of Phase 1 trial of AZD2820 expected in 4Q11. Initiation of Phase 2 trial as early as 1H12.

Corporate collaboration on development of PL-3994 for acute asthma indications targeted for 1Q12.

CORPORATE MISSION

Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our primary product in development is bremelanotide for the treatment of female sexual dysfunction (FSD). In addition, we have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, heart failure and inflammatory diseases. We have the following drug candidates actively under development:

- Bremelanotide, a peptide melanocortin receptor agonist, for treatment of FSD. This subcutaneous drug candidate is in Phase 2B clinical trials.
- AZD2820, a melanocortin receptor-based compound for treatment of obesity, under development by AstraZeneca pursuant to our research collaboration and license agreement. This drug candidate is in Phase 1 clinical trials.
- An inhalation formulation of PL-3994, a peptide mimetic natriuretic peptide receptor A (NPR-A) agonist, for treatment of acute exacerbations of asthma. This PL-3994 formulation is in preclinical research.

PROPRIETARY TECHNOLOGY

Palatin developed a series of proprietary technologies used in its drug development programs. One technology employs novel amino acid mimetics in place of selected amino acids. These mimetics provide the receptor-binding functions of conventional amino acids, while providing structural, functional and physicochemical advantages. The amino acid mimetic technology was employed in PL-3994, our compound for treatment of acute asthma, heart failure and related cardiovascular indications. The patent-pending amino acid mimetic technology can potentially be used with a wide range of peptide-based compounds.

CORPORATE ALLIANCES

In 2007, we entered into an exclusive global licensing and research collaboration agreement with AstraZeneca to discover, develop and commercialize compounds that target melanocortin receptors for the treatment of obesity, diabetes and related metabolic syndrome. We have received license and milestone payments of USD \$21.6 million from AstraZeneca, and are eligible for milestone payments totaling up to \$145.2 million, with up to \$85.2 million contingent upon development and regulatory milestones and the balance on achievement of sales targets, plus royalties on sales of approved products.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Bremelanotide	Erectile Dysfunction	Phase II, IIa, IIb	Completed subcutaneous safety studies in target population
PL-3994	Acute Asthma	Phase II, IIa, IIb	IND for Phase 2 trial with subcutaneous PL-3994 submitted to FDA; protocol approved
PL-3994	Acute Asthma	Preclinical	Developing inhalation formulation and designed inhalation toxicity and related preclinical studies
AZD2820	Obesity	Phase I	Initiated Phase 1 clinical trial

SENIOR MANAGEMENT


Carl Spana, PhD, President & CEO • **Stephen T. Wills**, Chief Financial Officer • **Jeffrey Edelson, MD**, Chief Medical Officer

BOARD OF DIRECTORS

John K.A. Prendergast, PhD • **Carl Spana, PhD**, Palatin Technologies • **Perry B. Molinoff, MD**, University of Pennsylvania (Retired) • **Robert K. deVeer, Jr.**, deVeer Capital LLC • **Zola P. Horovitz, PhD**, Bristol-Myers Squibb (Retired) • **Robert I. Taber, PhD**, Message Pharmaceuticals and Synaptic Pharmaceuticals (Retired) • **Alan W. Dunton, MD**, Danerius, LLC • **J. Stanley Hull**, GlaxoSmithKline (Retired)

TRADING STATUS AS OF OCTOBER 5, 2011

SIX Swiss: PTN



Market Data

Current Price	2.18
Currency	Swiss Franc
Net Change	7.39
Volume	8,440
YTD % Change	-0.83
52Wk Range	1.55–15.30
Avg. Daily Volume (thousands)	16,286

First Call Data

Market Cap (MM)	11.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-3.42
EPS (Last Fiscal Year)	-4.30
Consensus Estimate (Y)	-3.42
Consensus Recommend	--
Price/Sales	5.99

Shareholders

Institution

	<i>Holding %</i>
Vontobel Holding AG (Investment Management)	4.3%
InCentive Asset Management AG	2.2%
Swisscanto Asset Management AG	0.7%
Pictet Asset Management SA	0.4%
UBS AG (Investment Management)	0.3%

Mutual Fund

	<i>Holding %</i>
Vontobel Holding AG (Investment Management)	4.3%
InCentive Asset Management AG	2.2%
Swisscanto Asset Management AG	0.7%
Pictet Asset Management SA	0.4%
UBS AG (Investment Management)	0.3%

Source: Thomson Reuters

PharmaNeuroBoost NV

Presenting Company

Clinical Foci: CNS, Specialty Pharmaceutical, Biopharmaceuticals

Remi Van Den Broeck, MD, MSc

Chief Operating Officer

Alkerstraat 30a
3570 Alken
Belgium

www.pharmaneuroboost.com

32-473-861 079

Incorporated: 2006

Employees: 10

Ownership: Private

HIGHLIGHTS

Recent

February 2011: Grant US Composition of Matter Patent on PNB01, the Fixed Dose Combination (FDC) comprising 5-15 mg pipamperone and 10-40 mg citalopram.

March 2011: FDA Special Protocol Approval (SPA) of the Phase III PNB01-C301 Acute Efficacy Trial in Major Depression with agreement on the new primary end point Early and Sustained Response Rate (ESR) to demonstrate superiority over standard of care.

August 2011: Central IRB approval of the Phase III PNB01-C301 Clinical Trial in Major Depression

Upcoming

October 2012: First randomized patient in the Phase III PNB01-C301 Clinical Trial in Major Depression (n=555), a centrally randomized, double-blind, multicenter, 3-arm, fixed dose study with a 10-week treatment phase and 1-week safety follow-up.

December 2012: Expected Top Line Results of the Phase III PNB01-C301 Clinical Trial in Major Depression (n=555).

December 2012: Expected Top Line Results of the Phase IIa PNB02-C201 Clinical Trial in Schizophrenia with Residual Stage (n=60).

CORPORATE MISSION

PharmaNeuroBoost (PNB), founded in 2006 by Dr. Erik Buntinx, psychiatrist and inventor of PNB's technology, is a specialty biopharmaceutical company dedicated to developing best in class CNS therapeutics. As such, PNB is specialized in boosting current standard of care on major CNS disorders addressing high unmet medical needs.

PNB has brought two proprietary Fixed Dose Combinations (FDC) in late and mid clinical development stage: the antidepressant PNB01 in Phase III and the antipsychotic PNB02 in Phase IIa.

These two front-running projects result from discoveries made using PNB's unique IP platform claiming the use of high selective Serotonin 2A / Dopamine 4 receptor antagonists. In that respect, PNB has globally granted Composition of Matter (CoM) and use patents for the individual compounds in its pipeline.

The lead product PNB01, a novel antidepressant (AD) with an early and sustained response (ESR), has entered globally (US, Canada and Europe) phase III in August 2011 after FDA and IRB approval of the study protocol. This includes ESR as the new, unique primary end point demonstrating the superiority of PNB01 over standard of care. If successful, PNB01 would be the first AD claiming a faster antidepressant effect and addressing the unmet medical need of latency of response of current AD's.

PNB's second FDC product PNB02, has entered phase II in September 2011 and is targeted against the residual phase of schizophrenia, a high unmet medical need up until date.

PNB' Business Plan is oriented to collaborate with high value partners for co-development and/or commercialization of the late stage products. Like any drug development company, PharmaNeuroBoost needs to show the efficacy of its products. PNB faces the additional challenge of that need to demonstrate superiority over standard of care, rather than placebo. However, if PNB can achieve this, the PNB products could have a potential step up into a large and lucrative market.

PROPRIETARY TECHNOLOGY

The MOA of PNB's technology is based on the induction of a highly selective antagonism on the 5-HT_{2A} and D₄ receptors in the CNS resulting in a boosting effect on the efficacy of different standard of care CNS compounds by adding low dose pipamperone (5-15 mg/day).

PNB01 is the Fixed Dose Combination (FDC) with the SSRI citalopram. This generates additive and potentially synergistic antidepressant effects by restoring the dopamine-serotonin balance in the limbic system and cortical areas of the CNS, thus increasing both dopamine and serotonin tonus.

PNB02, the FDC with the atypical antipsychotic risperidone, mimics the receptor occupancy profile of the first in class antipsychotic clozapine, without the unwanted antagonism towards receptors responsible for important adverse events.

CORPORATE ALLIANCES

The PharmaNeuroBoost team is currently working with J&J to initiate and lead discussions with interested investors regarding a Development Stage Company focused on a mid stage Fast Dissociating D₂ Antagonist for the Treatment of Early Stage Schizophrenia.

PRODUCTS

Name	Indication	Phase	Milestone
PNB01	Major Depressive Disorder	Phase III	December 2012: Top Line Results of the first Phase III study PNB01-C301 (n=555) showing a superior Early and Sustained Response Rate over standard of care
PNB02	Schizophrenia, residual stage	Phase II, IIa, IIb	December 2012: Top Line Results of the Phase IIa study PNB02-C201 (n=60) showing a clinical relevant effect over standard of care.
PNB03	Parkinson Disease	Preclinical	Validation of the concept

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PNB04	Alzheimer Disease	Preclinical	Validation of the concept
PNB05	Obsessive-Compulsive Disorder	Preclinical	Results first Phase III study with PNB01 in Major Depression

SENIOR MANAGEMENT
Remi Van Den Broeck, MD, MSc , Chief Operating Officer • Ludo Haazen, MD, QPPV , Chief Medical Officer • Didier de Chaffoy, PhD , Chief Scientific Officer • Lieven Baert, PhD - MBA , Director • Philippe Lemmens, PhD , Director • Erik Buntinx, MD-Psychiatrist , Chief Operating Officer • Patricia Baede, PhD , Director • Arthur Noach, PhD , Director

BOARD OF DIRECTORS
Peter Verhaeghe, LL.M Harvard • Ruth Devenyns, KBC PE • Rudi Mariën, Biovest Life Science • Jos Sluys, Saffelberg Investments • Erik Buntinx, Anima bvba • Floris Vansina, KBC PE • Roger Pinder, Independent • John Fullen, Biopharma Investment Ltd.

SCIENTIFIC ADVISORY BOARD
Prof. Dr. Charles Nemeroff, MD, PhD , University of Miami • Prof. Dr. Thomas E. Schlaepfer, MD , University of Bonn and John Hopkins University, Baltimore • Prof. Dr. Alan F. Schatzberg, MD , Stanford University • Dr. Erik Buntinx, MD , Anima Research Centre - PharmaNeuroBoost

FINANCING HISTORY
<i>Round Date (Amount, US\$)</i> 01/12/2006 (2.70 million) • 01/10/2008 (8.78 million) • 09/28/2011 (23.52 million)
<i>Investors:</i> Saffelberg Investments/PNBSaffel NV (23%) • KBC PE NV (21%) • KBC ARKIV NV (7%) • Biovest Comm VA (20%) • Finanima GmbH (13%)

PLx Pharma, Inc.

BIO Member, Presenting Company

Clinical Foci: Cardiovascular Disease, Musculoskeletal, Drug Delivery

Ron Zimmerman

President & CEO

8285 El Rio, Suite 130
Houston, TX 77054
USA

www.plxpharma.com

1-713-842-1249

Incorporated: 2002

Ownership: Private

CORPORATE MISSION

PLx Pharma uses its proprietary PLxGuard technology to delivery GI safer formulations of drugs. The lead product is a GI safer aspirin formulation in late stage of development nearing an NDA submission. Another product with clinical data is a GI safer ibuprofen. Other GI safer NSAIDs are in the pipeline. These products are for OTC and Rx markets and include oral and parenteral dose forms.

PROPRIETARY TECHNOLOGY

The PLxGuard technology complexes a soy derived oil rich in phosphatidylcholine with an API to mitigate its GI toxicity.

CORPORATE ALLIANCES

Have licensed the PLxGuard technology for use by Cambrex Corporation and Tillotts Pharma for use with a 5-ASA mesalamine based product.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PL2200 Aspirin 325 mg	cardiovascular, antiplatelet agent, analgesic, anti-inflammatory, anti-pyretic and colorectal cancer prevention	Phase III	Preparing for NDA submission
PL 1200 Ibuprofen 200 mg - OTC	analgesic, anti-inflammatory, arthritis	Other	
PL1100 Ibuprofen - Rx	analgesic, anti-inflammatory, arthritis	Other	
PL4500 Indomethacin	patent ductus arteriosus, post operative pain	Preclinical	
Multiple NSAID-PC products	analgesic, anti-inflammatory	Preclinical	

SENIOR MANAGEMENT

Ron Zimmerman, President & CEO • **Gary Mossman**, Chief Operating Officer • **Upendra Marathi, PhD**, Senior Vice President • **Jason Moore, MS, MBA, RAC**, Vice President

BOARD OF DIRECTORS

David Anderson, formerly COO with Tanox • **Tim Black**, Partner with Integra Ventures • **David Jorden**, Director with Opexa Therapeutics and Cytomedix • **Lenard M. Lichtenberger, Ph.D.**, Professor with University of Texas Health Science Center at Houston, scientific founder of PLx • **Gary Mossman**, PLx • **Ron Zimmerman**, PLx • **Mike Valentino**, formerly CEO of Adams Respiratory and Xanodyne Phama and head of Novartis Consumer Health worldwide

SCIENTIFIC ADVISORY BOARD

Barry Marshall, MD, Nobel Laureate, Founder of Ondek Pharma • **Ferid Murad, MD, PhD**, Nobel Laureate, formerly VP of R&D Abbott Labs • **Haile Debas, MD**, Former Chancellor and Dean of the Medical School with UCSF • **Joe Wernicke, MD, PhD**, Senior Reseacher with Eli Lilly • **Brendan Whittle, PhD, DSc**, NSAID expert • **Kim Rainsford, PhD**, NSAID expert • **Susumu Okabe, PhD**, NSAID expert • **Tom Gutshall**, Cepheid Chairman of the Board, formerly with CV Therapeutics, Syntex and Mallinckrodt

Progenics Pharmaceuticals, Inc.

Clinical Foci: Oncology • Biopharmaceuticals

Mark R. Baker

Chief Executive Officer

777 Old Saw Mill River Road
Tarrytown, NY 10591
USA

www.progenics.com

1-914-789-2800

NASDAQ: PGNX

Incorporated: 1986

Employees: 113

Ownership: Public

CORPORATE MISSION

Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focused on innovative therapeutics for patients suffering from cancer and related conditions. Progenics' pipeline candidates include PSMA ADC, a human monoclonal antibody-drug conjugate in phase 1 testing for treatment of prostate cancer, and preclinical stage novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors for the treatment of cancer. Progenics has exclusively licensed development and commercialization rights for its first commercial product, RELISTOR®, to Salix Pharmaceuticals, Ltd. for markets worldwide other than Japan, where Ono Pharmaceutical Co., Ltd. holds an exclusive license for the subcutaneous formulation. RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection is a first-in-class treatment for opioid-induced constipation approved in more than 50 countries for patients with advanced illness. Regulatory approval is pending for use of RELISTOR® by patients with chronic, non-cancer pain. A phase 3 clinical trial of an oral formulation of methylnaltrexone completed enrollment in mid-2011.

PRODUCTS


Name	Indication	Phase
PSMA ADC	Prostate Cancer	Phase I
RELISTOR	opioid-induced constipation	Cleared for US Marketing
PI3K Inhibitor	novel multiplex phosphoinositide 3-kinase (PI3K) inhibitors	Research

SENIOR MANAGEMENT

Mark R. Baker, Chief Executive Officer

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: PGNX



Market Data

Current Price	6.21
Currency	U.S. Dollar
Net Change	-0.96
Volume	113,066
YTD % Change	0.14
52Wk Range	4.41-8.69
Avg. Daily Volume (thousands)	158,446

First Call Data

Market Cap (MM)	209.3
Short Interest Shares	1,611,639
Short Interest Ratio	13.68
PE (Trailing 12 Months)	-0.05
EPS (Last Fiscal Year)	-0.12
Consensus Estimate (Y)	-0.05
Consensus Recommend	--
Price/Sales	2.75

Shareholders

Institution	Holding %
Federated Investment Management Co.	21.2%
Tudor Investment Corp.	6.9%
BlackRock Fund Advisors	5.7%
Wellington Management Co. LLP	5.1%
The Vanguard Group, Inc.	4.1%

Mutual Fund	Holding %
Federated Investment Management Co.	21.2%
Tudor Investment Corp.	6.9%
BlackRock Fund Advisors	5.7%
Wellington Management Co. LLP	5.1%
The Vanguard Group, Inc.	4.1%

Source: Thomson Reuters

Prognomix Inc.

Clinical Foci: Diagnostics • Cardiovascular Disease • Renal

Normand Balthazard Chief Executive Officer

4010 Molson Suite 201
Montreal, QC H3Y 3L1
Canada

www.prognomix.com
1-514-248-7789

Incorporated: 2005
Employees: 20
Ownership: Private

HIGHLIGHTS

Recent

Validation in multiple cohorts.
Partnership collaboration with Pharma co.

Upcoming

Expect that two tests will be commercialized in 2012, one in 2013 and the fourth one by 1Q14. Clients for the tests are Pharma co's, HMO and Payers organizations.

CORPORATE MISSION

Prognomix Inc. is a privately held Personalized Medicine company incorporated in Montreal in 2005 and focused on discovery and clinical application of genomic signatures predictive of complications from Type 2 Diabetes and individual therapeutic responsiveness to current treatment/drugs.

The company has made exiting progress lately and we expect that two tests will be commercialized in 2012, one in 2013 and the fourth one by 1Q14. Clients for the tests are Pharma co's, HMO and Payers organizations.

The science program is lead by Dr Pavel Hamet, recognized internationally for his contribution to the field of diabetes, hypertension and genetics. He is member of the management of the largest-ever clinical trial in diabetes called ADVANCE. He is a Canada Research Chair in Predictive Genomics.

The chairman of the Company is Dr. Francesco Bellini a successful serial entrepreneur in biotech. He was co-founder and President of Biochem Pharma, (sold to Shire Pharmaceuticals for USD \$5.2 billion in 2000) and Chairman of Virochem, (sold to Vertex in 2009 for \$520 million).

I was Founder and President of BioCapital in 1990, a very successful venture fund in biotech with over 12 IPO's in the portfolio and other corporate M&A transactions.

PROPRIETARY TECHNOLOGY

The company is developing 4 molecular diagnostic tests to:

- 1) Determine the responsiveness of a patient to existing treatments- ie: the right drug to the right patient,
- 2) Screen patients entering clinical trials- ie: to reduce sample size and time of trials,
- 3) Be developed in parallel with new drugs or indications (companion diagnostic) for prevention of cardiovascular and/or renal complications of T2D,
- 4) Assess the long term risk of complications in patients with T2D- ie: to initiate treatment earlier to avoid or postpone future complications.

CORPORATE ALLIANCES

One with Pharma co. (confidential)

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PGX HR 01 HMO/Payers risks evaluation	In-vitro molecular diagnostic tests to determine the responsiveness of a patient to existing treatments- ie: the right drug to the right patient,	Diagnostics	Initiating regulatory procedures for market approval of IVD
PGX GR 01 Screening for Trials	RUO Screening test for patients with complications entering clinical trials- ie: to reduce sample size and time of trials	Diagnostics	Finalizing Signature Validation and ready to partnered by 2Q12.
PGX CD 01 Companion Diagnostic	RUO/IUO in-vitro molecular test to be developed in parallel with new drugs or indications (companion diagnostic) for prevention of cardiovascular and/or renal complications of T2D,	Diagnostics	Ready to be partnered by 2Q12.
PGX IR 01 Predictive of complications	IVD in-vitro molecular Dx to assess the long term risk of complications in patients with T2D- ie: to initiate treatment earlier to avoid or postpone future complications.	Diagnostics	Signature validation

SENIOR MANAGEMENT

Normand Balthazard, Chief Executive Officer • **Dr. Pavel Hamet**, President • **Dr. Johanne Tremblay**, Chief Scientific Officer

BOARD OF DIRECTORS

Dr. Francesco Bellini, Picchio Pharma • **Dr. John Chalmers**, The George Institute, Sydney • **Dr. Mark Woodward**, The George Institute sydney • **Jean Lamarre**, Independent

SCIENTIFIC ADVISORY BOARD

Dr. Mark Woodward, The George Institute • **Dr. John Chalmers**, The George Institute • **Dr. Pavel Hamet**, Prognomix, Inc. • **Dr. Jean-Pierre Kocher**, Mayo Clinic, Minnesota • **Dr. Michel Marre**, Faculté Xavier Bichat, Paris • **Dr. Stephen Harrap**, Melbourne University

FINANCING HISTORY

Round Date (Amount, US\$) 10/04/2006 (5.60 million) • 10/04/2010 (2.20 million)

Investors: Normand Balthazard (10%) • Dr. Pavel Hamet (10%) • Dr. John Chambers / TGI (10%) • Dr. Francesco Bellini, Chairman (20%)

ProNAi Therapeutics, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology, Biopharmaceuticals, Drug Development

Charlie Bisgaier

Chief Executive Officer

2725 S. Industrial Highway, Suite 200
Ann Arbor, MI 48104
USA

www.pronai.com

1-734-369-9953

Incorporated: 2004

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

Clinical Progress: With approved IND by FDA, started Phase 1a trials in the US in 3Q10. To date, safely treated 16 patients with over 100x the starting dose.

Commercial Approach: Assembled an experienced pharma/biotech team, manufactured cost-effectively cGMP drug supply for Phase 1a study, and received newly granted patents from USPTO.

Capital Efficient: Raised USD \$20 million since inception from Apjohn Ventures & Angels (Series A, B, B-1) to bring an novel idea to a product to the clinic.

Upcoming

Clinical Safety: Completion of the Phase Ia study in a few months (4Q11/1Q12) with safety data (for novel drug/delivery), PK data, Biomarker data (bcl2 and immune markers), and Activity data showing signals of efficacy (images)

Clinical Efficacy: Conduct Phase Ib Trial (2012-2013) for safety & tolerability of PNT2258 in combination while exploring efficacy (~50 patients, 2-3 solid & liquid cancers); then Conduct POC Phase II Trial (2013-2014) in ~90 targeted cancer patients

Platform Validation: Work with strategic and non-profit industry partners to bring forward to the clinic the next cancer pipeline leads using novel DNAi oligos and novel liposome delivery

CORPORATE MISSION

ProNAi is a clinical stage cancer company with a novel approach to 'silencing' DNA of cancer causing genes. ProNAi's lead cancer drug can be used multiple cancers including melanoma, CLL, NHL, prostate, breast, and lung cancer. ProNAi is treating patients in a Phase Ia dose-escalating safety and tolerability study of PNT2258. PNT2258 is differentiated as an unmodified, short single-stranded bcl2 targeted DNA encapsulated in a SMARTICLE®, administered IV allowing long half-life and systemic delivery. PNT2258's safety and its ability to turn off oncogenes more upstream than RNAi, antisense, protein or small molecule targets, plus its single and combined agent synergy in four preclinical cancer models opens a potential treatment option for many refractory cancer patients. ProNAi is seeking venture capital and/or strategic partners to further develop PNT2258 and its pipeline.

PROPRIETARY TECHNOLOGY

ProNAi has discovered a new, patent-protected way to attack cancer and prolong survival by targeting sections of DNA of oncogenes (as opposed to antisense or RNAi that target mRNA) to silence cancer causing genes. ProNAi's first product candidate, PNT2258, is delivered IV and consists of the active ingredient PNT100, a 24-base, single-strand, chemically unmodified (natural phosphodiester backbone) oligonucleotide encapsulated in net-negatively charged SMARTICLES®. PNT2258 targets a well known and validated oncogene Bcl-2 involved in the apoptosis pathway. PNT2258 demonstrates potent single agent anti-tumor effects in multiple tumor types that express Bcl-2 and has striking synergistic activity in combination with Rituximab or Docetaxel in these refractory xenograft cancer models.

CORPORATE ALLIANCES

Marina/Novosom - Delivery Licensing Agreement.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
PNT2258	Multiple Cancers (bcl-2 target)	Phase I	Completion of Safety & Tolerability in 4Q11.
PNT200	Multiple Cancers (c-myc target)	Preclinical	In-Vivo Efficacy Studies by 1H12.
PNT300	Multiple Cancers (k-ras target)	Preclinical	In-Vivo Efficacy Studies with Partner

SENIOR MANAGEMENT

Charlie Bisgaier, Chief Executive Officer • **Wendi Rodriguez**, Vice President • **Christopher Whitehead**, Manager

BOARD OF DIRECTORS

Don Parfet, Apjohn Ventures • **Mina Sooch**, Apjohn Ventures • **Charlie Bisgaier**, ProNAi CEO • **Jack Luderer**, Western Michigan University, Upjohn/Pfizer • **Bob Forgey**, Former COO, Monsanto/Pfizer • **John Puisis**, Tolera CEO, Third Wave

FINANCING HISTORY

Investors: Apjohn Ventures (20%) • Angels (50%) • Other/Management (30%)

Prosensa Therapeutics BV

Presenting Company

Clinical Foci: Genetic Disorders • CNS • PGH – Neglected Diseases

Hans Schikan

Chief Executive Officer

J.H. Oortweg 21
2333 CH Leiden
Netherlands

www.prosensa.com

31-71-3322100

Incorporated: 2002

Employees: 80

Ownership: Private

HIGHLIGHTS

Recent

Phase III study with PRO051/GSK968 initiated in Jan. 2011, recruitment Phase IIb study completed in Sept. 2011.

Landmark publication of Phase I/II systemic study with PRO051/GSK2402968 in NEJM. 93 weeks efficacy data from open-label extension with PRO051/GSK968 to be presented at WMS conference mid Oct. 2011.

Accelerated development of three additional compounds in GSK collaboration.

Upcoming

Results from Phase IIb study PRO051/GSK968 to be presented in 2H12.

Two additional DMD compounds directed at two more DMD subpopulations to enter clinical studies in 1H12.

Non-dilutive financing support to accelerate development of additional compounds in DMD and non-DMD areas.

CORPORATE MISSION

Prosensa is an innovative Dutch biopharmaceutical company focused on the discovery, development and commercialization of RNA modulating therapeutics correcting gene expression. The company targets genetic disorders with a large unmet medical need, with a primary focus on neuromuscular and neurodegenerative disorders such as Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy (DM1) and Huntington's Disease (HD). Prosensa focuses on rare diseases and is committed to make a difference for patients and families.

The company has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. The company's primary focus is on developing a treatment for Duchenne Muscular Dystrophy. In 2009 Prosensa entered into a strategic alliance for part of its DMD exon skipping program with GSK. Prosensa's lead compound (GSK2402968/PRO051), being developed by GSK, aims at restoring dystrophin expression and improving muscle condition and function in a relatively large subpopulation of Duchenne patients and entered phase III clinical trials in January 2011.

Prosensa was founded in 2002 and is located in Leiden, The Netherlands. The company works closely together with Leiden University Medical Center (LUMC) and is supported by a consortium of leading biotech investors, including Abingworth, Life Sciences Partners, GIMV, AGF and MedSciences Capital. In October 2009, Prosensa entered into a strategic alliance with GlaxoSmithKline (GSK) to accelerate and broaden the development of its DMD product candidates.

PROPRIETARY TECHNOLOGY

RNA-modulating therapeutics provide a powerful tool for targeted modulation of gene expression. Prosensa's unique proprietary technology platform employs single-stranded RNA-based antisense oligonucleotides (AONs) to correct mutated mRNA causing life threatening disorders.

Prosensa's technological approach applies some of the most advanced techniques known in modern genetics and molecular biology: RNA modulation through exon-skipping, exon inclusion, mutant RNA removal or other proprietary applications.

CORPORATE ALLIANCES

GSK: Prosensa and GSK entered in an exclusive worldwide collaboration for the development and commercialization of RNA based therapeutics for Duchenne Muscular Dystrophy. The scope of the alliance includes four RNA-based products intended to treat specific, but different, subpopulations of patients suffering from DMD. The financial terms include a GBP 16 million (USD 25 million) upfront payment and up to GBP 412 million (USD 655 million) in milestones payments as well as double-digit royalties on product sales. Prosensa will retain commercial participatory rights, and has an option to expand its commercial rights, in certain European countries on products resulting from the collaboration.

SENIOR MANAGEMENT

Hans Schikan, Chief Executive Officer • **Luc Dochez**, Chief Business Officer • **Berndt Modig**, Chief Financial Officer • **Giles Campion**, Chief Medical Officer

Psyadon Pharmaceuticals, Inc.

Clinical Foci: CNS, Neurology, Drug Development

Richard E. Chipkin, PhD President & CEO

20451 Seneca Meadows Parkway
Germantown, MD 20876
USA

www.psyadonrx.com

1-301-919-2020

Incorporated: 2008

Employees: 1

Ownership: Private

HIGHLIGHTS

Recent

Completion of Safety, Tolerability and Pilot Activity Clinical Study of Ecopipam for the Treatment of Self-Injurious Behaviors in Patients with Lesch-Nyhan Disease.

Initiation of Phase 2 Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome.

Initiation of Phase 2 Clinical Trial of Ecopipam for the Treatment of Pathological Gambling.

Upcoming

Initiation of Phase 3 Clinical Trial of Ecopipam for the Treatment of the Self-Injurious Behavior Seen in Patients With Lesch-Nyhan Disease.

Completion of Phase 2 Clinical Trial of Ecopipam for the Treatment of Tourette's Syndrome.

Completion of Phase 2 Clinical Trial of Ecopipam for the Treatment of Pathological Gambling.

CORPORATE MISSION

Psyadon Pharmaceuticals, Inc. is a privately-held pharmaceutical company that develops drugs for the treatment of diseases afflicting the central nervous system. Our strategy is to license mechanism-specific drugs whose primary indication has not been identified, and to do targeted development programs to bring them to market. In particular, we focus on rare and orphan diseases. Psyadon Pharmaceuticals was founded in 2008 and is based in Germantown, Maryland. It receives financial support from New Enterprise Associates (Chevy Chase, MD) whose partner Dr. James Barrett acts as the Chairman of Psyadon's Board of Directors. For more information visit our Web site at www.psyadonrx.com.

PROPRIETARY TECHNOLOGY

Our first licensed compound is ecopipam. This is a novel drug that selectively antagonizes the one of the receptors for dopamine in the brain (the D1-receptor). Ecopipam has a very large clinical safety database and a complete NDA-ready pre-clinical package.

CORPORATE ALLIANCES

We currently have an alliance with the Tourette Syndrome Association who is collaborating with us on the development of ecopipam for the treatment of Tourette Syndrome.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Ecopipam	Treatment of Self-Injurious Behaviors in Patients with Lesch-Nyhan Disease	Phase III	Initiation of Phase 3
Ecopipam	Tourette's Syndrome	Phase II, IIa, IIb	Completion of On-Going Phase 2 Trial
Ecopipam	Pathological Gambling	Phase II, IIa, IIb	Completion of On-Going Phase 2 Trial
Ecopipam	Controlled Release Formulation	Phase I	Completion of On-Going Phase 1 Trial

SENIOR MANAGEMENT

Richard E. Chipkin, PhD, President & CEO • **Rudolf Kwan**, Other • **David Christ**, Other • **Rick Soltero**, Other • **Harold Amkraut**, Other

BOARD OF DIRECTORS

James Barrett, PhD, Partner, New Enterprise Associates • **Jeff Rothstein, MD, PhD**, Professor, Dept. Neurology, Johns Hopkins Medical School

FINANCING HISTORY

Round Date (Amount, US\$) 10/01/2008 (8,000,000.00 million)

Investors: New Enterprise Associates (NEA) (100%)

Rediens, Inc.

Clinical Foci: Musculoskeletal, Immunology, Biopharmaceuticals

Francois Binette

Chief Executive Officer

868 Minnesota St., Suite #513
San Francisco, CA 94107
USA

1-415-404-6417

Incorporated: 2010

Employees: 1

Ownership: Private

HIGHLIGHTS

Recent

API has nearly complete pre-clinical tox package supporting human clinical in different (topical) application.

Data in animal models for pain and degenerative disc disease support both pain/function recovery and disease modification.

Upcoming

IND plan for Phase I/II will provide early proof of concept. The product will be tested in a dose escalation manner on clinical population in first trial.

CORPORATE MISSION

Rediens, Inc. is a San Francisco-based biotech company developing a novel therapeutic approach for the treatment of chronic back pain caused by degenerative disc disease. RED-101 is a first-in-class small molecule drug that antagonizes a master switch controlling inflammation and tissue turnover, the NF-κB transcription factor. The broad activity spectrum of RED-101 is expected to not only modulate pain and function, but also slow or reverse the disease process itself. RED-101 will be delivered by intra-discal injection, which will limit systemic exposure while enhancing local dose in a targeted image-based diagnostic patient population to maximize safety and effectiveness. Rediens is closing a large gap in the continuum of care for the majority of chronic back pain patients with no obvious anatomical deficiencies, addressing by far one of the largest healthcare market opportunity.

PROPRIETARY TECHNOLOGY

RED-101 acts on the NF-κB pathway, which is a master regulator of pain, inflammation, immunity and tissue remodeling. RED-101 is expected to clinically impact both mechanical and inflammatory pain, and suppress/reverse tissue damages resulting from over active inflammatory cytokines and degrading enzymes. Multiple actions on several biological pathways will result in profound effects and a broad therapeutic window of intervention, increasing its likelihood of clinical success.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
RED-101	Chronic Back Pain	Preclinical	IND

SENIOR MANAGEMENT

Francois Binette, Chief Executive Officer • **Lars Boerger**, Business Development

BOARD OF DIRECTORS

Francois Binette, Rediens Inc

SCIENTIFIC ADVISORY BOARD

Prof. Koichi Masuda, MD, University of California San Diego Medical Center • **Prof. Jaro Karppinen, MD, PhD**, University of Oulu, Dept. of Physical Medicine and Rehabilitation, Finland

FINANCING HISTORY

Investors: Francois Binette (100%)

Relypsa, Inc.

BIO Member, Presenting Company

Clinical Foci: Renal, Cardiovascular Disease, Gastroenterology

Gerrit Klaerner, PhD

President

5301 Patrick Henry Drive
Santa Clara, CA 95054
USA

www.relypsa.com

1-408-200-9500

Incorporated: 2007

Employees: 45

Ownership: Private

HIGHLIGHTS

Recent

Positive data from an Phase 2 dose titration study of RLY5016 in patients with heart failure and CKD were presented at two medical conferences. The study showed that normal serum potassium levels could be maintained with few titrations required.

A Phase 2b study of RLY5016 was initiated to treat hyperkalemia in diabetic nephropathy patients with CKD. Up to 300 patients are being enrolled to assess the ability to reduce serum potassium levels in patients treated with RAAS inhibitors.

Upcoming

Complete enrollment of ongoing Phase 2b study in diabetic nephropathy/CKD patients and present data.

Initiate pivotal studies of RLY5016 for the treatment of hyperkalemia.

CORPORATE MISSION

Relypsa is a clinical-stage biopharmaceutical company that is leading the discovery and development of novel, non-absorbed, polymeric drugs for important applications in cardiovascular and renal diseases. Relypsa's lead product candidate is RLY5016, a non-absorbed potassium binder for the treatment of hyperkalemia. Relypsa is pursuing the discovery of additional product candidates through use of its proprietary polymer platform. Privately-held, Relypsa's investors include: OrbiMed Advisors, 5AM Ventures, Delphi Ventures, New Leaf Venture Partners, Sprout Group, Amgen and Mediphase Venture Partners.

PROPRIETARY TECHNOLOGY

Relypsa's current drug candidates are proprietary non-absorbed polymers, where the polymer itself provides the drug function. By binding specific biologic molecules, our polymeric drugs act locally in the gastrointestinal (GI) tract and clear these molecules from the human body through the digestive system. Relypsa's compounds are not systemically absorbed into the bloodstream, which limits side effects, if any, to the GI tract and hence potentially improved safety profiles. Therapeutic candidates are designed for enhanced ease of patient use and compliance.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
RLY5016	Hyperkalemia	Phase II, IIa, IIb	Positive data from Phase 2 trial recently reported. Phase 2b underway. Pivotal studies being planned for 2012.
RLY106	Bile Acid Sequestrant	Preclinical	Advancing toward IND

SENIOR MANAGEMENT

Gerrit Klaerner, PhD, President • **Jerry M. Buysse, PhD**, Chief Scientific Officer • **Ronald Krasnow**, General Counsel • **James A. Johnson**, Chief Financial Officer • **Claire Lockey**, Senior Vice President • **Wilhelm Stahl, PhD**, Senior Vice President • **I-Zu Huang, MD**, Vice President • **Klaus Veitinger, MD**, Consultant • **Mason Freeman, MD**, Consultant

BOARD OF DIRECTORS

Scott M. Rocklage, Ph.D., 5AM Ventures • **Gerrit Klaerner, PhD**, Relypsa • **Vijay Lathi**, New Leaf Venture Partners • **Jonathan T. Silverstein**, OrbiMed Advisors • **Deepa Pakianathan, PhD**, Delphi Ventures • **Thomas J. Schuetz, MD, PhD**, OrbiMed Advisors • **Klaus Veitinger, MD**, OrbiMed Advisors

SCIENTIFIC ADVISORY BOARD

Mason Freeman, MD, Massachusetts General Hospital, Harvard Medical School • **Bertram Pitt, MD**, University Of Michigan School Of Medicine • **George Bakris, MD**, University of Chicago Department of Medicine • **David A. Bushinsky, MD**, University of Rochester School of Medicine • **John Fordtran, MD**, Baylor University Medical Center • **Robert Alpern, MD**, Yale School of Medicine • **Sandra Coufal, MD**, Novartis Research Foundation • **Craig J. Hawker, PhD**, University of California, Santa Barbara

FINANCING HISTORY

Round Date (Amount, US\$) 10/01/2007 (43.00 million) • 09/01/2010 (70.00 million)

ResVerlogix Corporation

BIO Member, Presenting Company

Clinical Foci: Cardiovascular Disease • Drug Development • Biopharmaceuticals

Donald McCaffrey

President & CEO

202 - 279 Midpark Way SE
Calgary, AB T2X 1M2
Canada

www.resverlogix.com

1-403-254-9252

Toronto: RVX

Incorporated: 2001

Employees: 32

Ownership: Public

HIGHLIGHTS

Recent

Commenced ASSURE a Phase 2b intravascular ultrasound (IVUS) clinical trial led by Cleveland Clinic targeting High-Risk Cardiovascular Disease patients.

Commenced SUSTAIN a Phase 2b clinical trial led by Cleveland Clinic targeting High-Risk Cardiovascular Disease patients.

CORPORATE MISSION

ResVerlogix Corp. is a leading biotechnology company engaged in the development of novel therapies for important global medical markets with significant unmet medical needs. The NexVas™ Plaque Regression program is the company's primary focus which is to develop novel small molecules that enhance ApoA-I. These vital therapies address the burden of atherosclerosis and other important diseases such as Acute Coronary Syndrome, Diabetes, Alzheimer's disease, Peripheral Artery Disease and other vascular disorders.

Lead Drug, RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport (RCT). RCT is a pathway by which accumulated cholesterol is transported from the arterial wall to the liver for excretion, thus preventing atherosclerosis. ResVerlogix is currently conducting two Phase 2b clinical trials with the Cleveland Clinic with RVX-208.

PROPRIETARY TECHNOLOGY

The company's primary CVD program is NexVas™ Plaque Regression which targets ApoA-I enhancement via novel small molecules for plaque stabilization and regression. The company's second CVD program, NexVas™ Vascular Inflammation is a research stage technology focused on molecular targets of vascular inflammation. The company's third cardiovascular program ReVas™ is dedicated to the R&D of therapeutic compounds to be used with medical devices and biomaterials for the local non-systemic treatment of CVD. NexVas™ Alzheimer's disease is a

discovery stage technology for the development of drugs that enhance ApoA-I for stabilization and regression of Beta Amyloid Plaque.

PRODUCTS

Name	Indication	Phase
NexVas Plaque Regression	CVD	Phase II, IIa, IIb
NexVas Alzheimer's Disease	Alzheimer's Disease	Phase I
NexVas Auto Immune	RA, MS, Asthma	Preclinical

SENIOR MANAGEMENT


Donald McCaffrey, President & CEO • **Brad A. Cann, CA**, Chief Financial Officer • **Kenneth Lebioda**, Senior Vice President • **Jan Johansson, MD, PhD**, Senior Vice President • **Norman Wong, MD, FRCP**, Chief Scientific Officer • **Gregory Wagner, PhD, DABT**, Senior Vice President • **Allan Gordon, MD, PhD**, Senior Vice President

BOARD OF DIRECTORS

Peter Johann, PhD, Managing General Partner, NGN Capital • **Kenneth Zuerblis**, Former Chief Financial Officer & Senior VP, ImClone Systems • **Arthur Higgins**, Blackstone Group • **Eldon Smith, OC, MD, FRCPC, FCAHS, FAHA, FIACS**, Editor-in-Chief of the Canadian Journal of Cardiology; Former Dean of the Faculty of Medicine, University of Calga • **Donald McCaffrey**, Co-Founder, President, & CEO, Resverlogix Corp. • **Kelly McNeill, BComm (Hons), MAcc, CA**, Exec. Vice President of Finance and Administration & CFO, IMRIS

SCIENTIFIC ADVISORY BOARD

Bo Angelin, MD, PhD, Karolinska Institutet • **Philip Barter, MBBS, PhD, MRACP, FRACP**, The Heart Research Institute, Sydney, Australia • **Steven Nissen, MD**, Cleveland Clinic • **Daniel J. Rader, MD**, Professor of Medicine and Pathology, University of Pennsylvania School of Medicine • **Prediman K. (P.K.) Shah, MD**, Director, Division of Cardiology and the Atherosclerosis Research Center, Cedars-Sinai Medical Center • **Stephen J. Nicholls, MBBS, PhD**, Cleveland Clinic • **Christie M. Ballantyne, MD**, Professor of Medicine & Chief, Section of Atherosclerosis and Vascular Medicine, Baylor College of Medicine • **John J.P. Kastelein, MD, PhD**, Professor of Medicine & Chairman of the Dept. of Vascular Medicine, Academic Medical Centre, University of Amsterdam • **Allen Taylor, MD**, Washington Hospital Center



Market Data

Current Price	1.19
Currency	Canadian Dollar
Net Change	2.59
Volume	67,650
YTD % Change	-0.50
52Wk Range	1.01-6.98
Avg. Daily Volume (thousands)	238,137

First Call Data

Market Cap (MM)	70.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.41
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
S Squared Technology LLC	1.1%
Dimensional Fund Advisors, Inc.	0.3%
BlackRock Fund Advisors	0.1%
Schroder Investment Management Ltd.	0.0%
Bessemer Investment Management LLC	0.0%

<i>Mutual Fund</i>	<i>Holding %</i>
S Squared Technology LLC	1.1%
Dimensional Fund Advisors, Inc.	0.3%
BlackRock Fund Advisors	0.1%
Schroder Investment Management Ltd.	0.0%
Bessemer Investment Management LLC	0.0%

Source: Thomson Reuters

Rib-X Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease

Mark Leuchtenberger

Chief Executive Officer

300 George Street
New Haven, CT 06511
USA

www.rib-x.com

1-203-848-6260

Incorporated: 2001

Employees: 42

Ownership: Private

CORPORATE MISSION

Rib-X Pharmaceuticals is developing broad spectrum antibiotics with superior coverage, safety and convenience to deliver new standards of care for patients with serious infections. The Company's Nobel Prize winning, innovative platform enables a unique understanding of how antibiotics combat infection and has generated an industry leading pipeline spanning all phases of research and clinical development.

PROPRIETARY TECHNOLOGY

The Company's key competitive advantage is its focus on the three-dimensional properties of antibiotics. Rib-X has proprietary understanding of the atomic-level details of the bacterial ribosome – the richest and best validated antibacterial target – and the ability to use those insights in the prospective design of next-generation and completely new antibiotics, two factors central to the discovery process. In addition to designing for greater target potency, Rib-X uses this structural information to design antibiotics with efficacy against highly-resistant Gram-positive and Gram-negative bacteria. Rib-X's unique approach has resulted in the development of a fully integrated, complementary pipeline of next generation compounds and novel classes of antibiotics to combat drug resistance.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Delafloxacin	ABSSSI, CAP/HAP, IAI	Phase II, IIa, IIb	
Radezolid	ABSSSI, Osteomyelitis, CAP	Phase II, IIa, IIb	
RX-04	Gram Negative Infections	Preclinical	Partnered
RX-05	Antibacterial	Research	
RX-06	Fungal Infections	Research	

SENIOR MANAGEMENT

Mark Leuchtenberger, Chief Executive Officer • **Bob Conerly**, Chief Financial Officer • **Jarrod Longcor**, Executive Vice President • **Erin Duffy**, Chief Scientific Officer

Rodman & Renshaw, LLC

Sponsor

Edward Rubin

Chief Executive Officer

1251 Avenue of the Americas
New York, NY 10020-1806
USA

www.rodman.com

1-212-356-0500

NASDAQ: RODM

Incorporated: 2003

Ownership: Public

CORPORATE MISSION

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. Rodman also provides research and sales and trading services to institutional investors. Rodman is the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005.

SENIOR MANAGEMENT


Edward Rubin, Chief Executive Officer • Anthony Sanfilippo, President • David J. Horin, Chief Financial Officer • Michael Vasinkevich, Partner • John J. Borer, III, Director • Ajay Sareen, Chief Operating Officer

BOARD OF DIRECTORS

Wesley K. Clark, Wesley K. Clark & Associates

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: RODM



Market Data

Current Price	0.86
Currency	U.S. Dollar
Net Change	-1.14
Volume	28,535
YTD % Change	-0.68
52Wk Range	0.82-3.33
Avg. Daily Volume (thousands)	113,698

First Call Data

Market Cap (MM)	29.9
Short Interest Shares	591,492
Short Interest Ratio	9.08
PE (Trailing 12 Months)	0.12
EPS (Last Fiscal Year)	-0.31
Consensus Estimate (Y)	0.12
Consensus Recommend	0.12
Price/Sales	0.35

Shareholders

Institution	Holding %
Sandler O'Neill Asset Management LLC	2.2%
CQS (UK) LLP	1.2%
Dimensional Fund Advisors, Inc.	1.1%
BlackRock Fund Advisors	0.6%
Ancora Advisors LLC	0.5%
Mutual Fund	
Sandler O'Neill Asset Management LLC	2.2%
CQS (UK) LLP	1.2%
Dimensional Fund Advisors, Inc.	1.1%
BlackRock Fund Advisors	0.6%
Ancora Advisors LLC	0.5%

Source: Thomson Reuters

Savara Inc.

Presenting Company

Clinical Foci: Pulmonary, Drug Development, Infectious Disease

Rob Neville

President & CEO

5900 Shepherd Mountain Cove #2-205
Austin, TX 78730
USA

www.savarapharma.com

1-512-970-4740

Incorporated: 2007

Employees: 5

Ownership: Private

HIGHLIGHTS

Recent

GMP manufacture complete. Release testing underway of lead product.

Multiple SBIR Grants

Upcoming

Phase 1 and proof-of-concept trial in CF patients this year

CORPORATE MISSION

Savara is an inhalation drug development company targeting niche therapeutic areas with high unmet medical need and high commercial opportunity.

The lead product addresses an unmet clinical need in the treatment of methicillin-resistant *Staphylococcus aureus* (MRSA) infections in patients with cystic fibrosis (CF) and in other high risk patient populations. MRSA is a growing problem, with a six year reduction in life expectancy for infected CF patients and no suitable treatment. Savara's product is a high efficiency inhaled antibiotic powder administered using an easy-to-use capsule inhaler. The product is in preparation for its first human clinical trial.

The second product is a third-generation inhaled corticosteroid intended for the maintenance treatment of pediatric asthma, an underserved segment of the largest respiratory product category. The disease is inadequately controlled in the majority of asthmatic children, attributed largely to inefficient and inconvenient devices, such as nebulizers. The product uses an established corticosteroid drug delivered by a novel pediatric-friendly dry powder inhaler, which is designed to ensure delivery accuracy, patient compliance and convenience. The product is ready for its first human exploratory clinical trial.

PROPRIETARY TECHNOLOGY

Two pulmonary delivery platform technologies as follows:

1. NanoCluster – this technology utilizes nanotechnology to formulate small molecules and peptides into high performance inhalation powder without the need for novel excipients or carrier particles.
2. NanoNucleic – this technology provides a safe, simple, and effective method of delivering genetic material into lung cells. Our formulation consists of cell-penetrating-peptides containing genetic material, complexed with a simple condensing agent. This technology has been validated in vivo with pulmonary delivery with no cyto-toxicity at high levels of concentration.

CORPORATE ALLIANCES

Co-development partnership with top five pharmaceutical companies.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Dry Powder Pediatric Corticosteroid	Asthma	Phase II, IIa, IIb	Ready for Phase 2 Pilot trial
Inhaled Antibiotic	MRSA infections in CF	Phase I	GMP manufacture complete

SENIOR MANAGEMENT

Rob Neville, President & CEO • **Taneli Jouhikainen, MD, PhD, MBA**, Chief Operating Officer • **Chris Marich, MBA**, Chief Business Officer • **Cory Berkland, PhD**, Chief Technology Officer • **John Lord**, Other

BOARD OF DIRECTORS

Rob Neville, President & CEO, Savara Inc. • **Nevan Elam**, Former Head of Nektar Pulmonary • **Richard Benkendorf**, Co-founder and Managing Principal, Technology Impact Partners • **Rick Hawkins**, Founder, Former CEO, PPD

SCIENTIFIC ADVISORY BOARD

Dr. Elliott Dasenbrook • **Dr. Thomas Hofmann** • **Prof. Grant Waterer**

FINANCING HISTORY

Round Date (Amount, US\$) 12/01/2009 (3.30 million) • 05/31/2010 (2.90 million)

Senesco Technologies, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology • Hematology • Gene/Cell Therapy

Leslie J. Browne, PhD

President & CEO

721 Route 202/206
Bridgewater, NJ 08901-2009
USA

www.senesco.com

1-908-864-4444

NYSE Amex: **SNT**

Incorporated: 1999

Employees: 4

Ownership: Public

HIGHLIGHTS

Recent

December 2010: Granted orphan drug status by US FDA.

January 2011: Submitted IND.

4Q-2011: Initiated study in relapsed or refractory multiple myeloma patients at Mayo Clinic.

Upcoming

Initial results of safety and efficacy, 2H11.

Complete study enrollment, 1H12.

Topline results, mid-2012

Start Phase 1b/2a B-cell cancer study, 4Q12.

CORPORATE MISSION

Senesco Technologies is a cancer therapeutics company leveraging its strong proprietary position in eukaryotic translation initiation Factor 5A (eIF5A) technology to regulate programmed cell death, also known as apoptosis. The eIF5A approach has been effective in all human cancer cells tested so far and has been effective against human multiple myeloma tumors in animal models. The company has initiated a clinical study in multiple myeloma patients with its lead therapeutic candidate SNS01-T that incorporates recent developments in siRNA, DNA regulation and nanotechnology. SNS01-T has been granted orphan drug status by the US FDA.

PROPRIETARY TECHNOLOGY

Based on recent discoveries in gene regulation Senesco has developed SNS01-T, which comprises a DNA plasmid that expresses a stable pro-apoptotic form of eIF5A and an siRNA that down regulates the anti-apoptotic form of eIF5A. SNS01-T's two active components are self-assembled into a nanoparticle with polyethylenimine (PEI) to facilitate delivery. PEI is a polycationic carrier that protects the DNA and RNA combination from degradation in the blood stream till it reaches the tumor cells where it is taken up by endocytosis and subsequently releases its active ingredients. In addition to cancer applications eIF5A has been shown to be differentially upregulated in heart failure and has shown potential in animal models of diabetes.

CORPORATE ALLIANCES

Senesco has licensed eIF5A technology to multiple bioag companies including Monsanto and Bayer. Most licenses provide milestones in the short term and royalties to Senesco if the licensee brings a product to market. Human cancer therapeutic applications of eIF5A are being pursued by Senesco. The company is seeking collaborations for the therapeutic applications in cancer but also in inflammation, ischemia and diabetes

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
SNS01-T	Multiple myeloma	Phase I	Study started 4Q11.
SNS01-T	B-cell cancers	Phase I	Study planned for 3Q12.

SENIOR MANAGEMENT


Leslie J Browne, PhD, President & CEO • **Joel Brooks**, Chief Financial Officer • **John Thompson, PhD**, Chief Scientific Officer • **Richard Dondero**, Vice President

BOARD OF DIRECTORS

Harlan Waksal, MD, President, Waksal Consulting LLC • **John N. Braca**, Controller, Iroko Pharmaceuticals • **Christopher Forbes**, Vice Chairman, Forbes, Inc. • **David Rector**, Director, California Gold Corporation • **Thomas C. Quick**, Former President & COO, Quick & Reilly/Fleet Securities, Inc. • **John E. Thompson, PhD**, CSO, Senesco, Fellow Royal Society of Canada • **Jack Van Hulst**, Operating Partner, SK Capital Partners • **Ruedi Stalder**, Former Executive Board Member Credit Suisse • **Warren Isabelle, CFA**, Principal, Ironwood Investment Management LLC • **Leslie J. Browne, PhD**, President & CEO, Senesco Technologies

SCIENTIFIC ADVISORY BOARD

Charles Dinarello, MD, University of Colorado, School of Medicine • **James Mier, MD**, Beth Israel Deaconess Medical Center • **Alan Bennett, PhD**, University of California, Davis



Market Data

Current Price	0.21
Currency	U.S. Dollar
Net Change	7.64
Volume	47,156
YTD % Change	-0.24
52Wk Range	0.18-0.36
Avg. Daily Volume (thousands)	229,790

First Call Data

Market Cap (MM)	16.7
Short Interest Shares	100,484
Short Interest Ratio	1.34
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.14
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	--

Shareholders

<i>Institution</i>	<i>Holding %</i>
LPL Financial LLC	0.3%
Perceptive Advisors LLC	0.3%
Peak6 Advisors LLC	0.2%
BSW Wealth Partners LLC	0.1%
Oberweis Asset Management, Inc.	0.1%

<i>Mutual Fund</i>	<i>Holding %</i>
LPL Financial LLC	0.3%
Perceptive Advisors LLC	0.3%
Peak6 Advisors LLC	0.2%
BSW Wealth Partners LLC	0.1%
Oberweis Asset Management, Inc.	0.1%

Source: Thomson Reuters

Siena Biotech SpA

Clinical Foci: Neurology • Oncology • CNS

Giovanni Gaviraghi Chief Executive Officer

Strada del Petriccio e Belriguardo, 35
53100-Siena
Italy

www.sienabiotech.com
39-0577-381409

Incorporated: 2000
Employees: 130
Ownership: Private

HIGHLIGHTS

Recent

July 2011: Siena Biotech received undisclosed milestone payment from Roche as part of the agreement to develop a disease-modifying treatment for Alzheimer's disease. Siena Biotech is eligible for further success-based milestone payments & royalties.

April 2011: SEN196 (selisistat) entered Phase II trials in Huntington's disease patients. This first in class selective SirT1 inhibitor is being developed as a disease-modifying therapy and has Orphan Drug status in the US, EU and Australia.

February 2011: CHDI Foundation Inc. and Siena Biotech announced a collaboration to validate molecular targets modulating post-translational modification of mutant huntingtin and that could have therapeutic potential in Huntington's disease.

CORPORATE MISSION

Siena Biotech SpA is an innovative, clinical-stage drug discovery company whose R&D efforts are focused on discovering new small molecule drugs for therapeutic intervention against neurodegenerative diseases (in particular Alzheimer's disease and Huntington's disease) and oncology, with a particular focus on neuro-oncology. Emphasis is given to disease-modifying approaches and the construction of successful alliances with other companies with common goals. Siena Biotech has a strong commitment to addressing rare neurodegenerative diseases and rare tumors.

PROPRIETARY TECHNOLOGY

Small molecule drug discovery and development platform for CNS disorders, in particular neurodegenerative diseases and neuro-oncology.

CORPORATE ALLIANCES

Roche; A*STAR; CHDI

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
SEN196	Huntington's disease	Phase II, IIa, IIb
SEN461	Peripheral solid tumors, acting via the Wnt pathway	Preclinical
Wnt pathway antagonist series	Peripheral solid tumors, acting via the Wnt pathway	Lead Series
alpha-7 full agonists	neurodegeneration, neuro-inflammatory conditions, pain	Preclinical
Huntingtin toxicity inhibitors	Huntington's disease	Lead Series
SEN794	CNS and peripheral tumors using a brain-penetrant inhibitor of the hedgehog pathway	Preclinical
SEN826	Peripheral tumors using an inhibitor of the hedgehog pathway	Preclinical

SENIOR MANAGEMENT

Giovanni Gaviraghi, Chief Executive Officer • **Alessandro Padova**, Managing Director • **Russell Thomas**, Director

BOARD OF DIRECTORS

Vittorio Galgani, Monte dei Paschi di Siena Foundation

SCIENTIFIC ADVISORY BOARD

Lee Babiss, Executive Vice-President of Global Lab Services for Pharmaceutical Product Development Inc • **James Neidel**, Founder and Managing Director of New Leaf Venture Partners • **Rolf Bjerkvig**, Professor of Cell Biology at the University of Bergen, Norway and is Co-Director of the NorLux Neuro-Oncology laboratory • **Blair Leavitt**, Associate Professor in the Department of Medical Genetics & the Department of Medicine, University of British Columbia • **Martin van den Bent**, professor of Neuro-Oncology at Erasmus University, Rotterdam • **Xi He**, Professor, Department of Neurology, Harvard Medical School • **Gian Maria Rossolini**, Professor of Microbiology and Clinical Microbiology at the University of Siena Medical School • **Antonio Federico**, Professor of Neurology, University of Siena

FINANCING HISTORY

Investors: Monte dei Paschi di Siena Foundation (100%)

Sirius Genomics, Inc.

BIO Member, Presenting Company

Clinical Foci: Diagnostics, Pharmacogenetics, Genetic Disorders

Chris Wagner

President & CEO

603-1125 Howe Street
Vancouver, BC V6Z 2K8
Canada

www.siriusgenomics.com

1-604-484-7195

Incorporated: 2001

Employees: 9

Ownership: Private

HIGHLIGHTS

Recent

Series A2 financing completed in June 2011.
Validation study (phase III) initiated. n=3500.
(1000 APC treated patients and 2500 Non-APC treated controls).
Expected completion 1Q12.

Upcoming

Commercial launch in 2012.

CORPORATE MISSION

Sirius Genomics, Inc. is a private biotechnology company that develops companion diagnostics (CDx) for critical care medicine. The company's focus is on developing companion diagnostics for therapeutics, leading to better patient outcomes through personalized medicine. Currently, therapeutics follow a one-size-fits-all pattern. However, the inherent genetic differences between individuals can lead to low efficacy or adverse side effects for a drug, which can limit its clinical utility. Sirius addresses this problem by developing companion diagnostics which identify patient populations that will benefit the most from pharmaceutical therapeutics, enabling patients to get the right medication, doctors to more effectively treat the critically ill and, drug companies to fully realize the market potential for their therapeutics. By correlating patient genetics and other markers with clinical outcomes, Sirius' CDx products aim to enable more effective drug treatment.

Sirius Genomics is preparing for a 2012 market launch of a pharmacogenomic CDx for Xigris, a recombinant form of human activated protein C, sold by Eli Lilly for the treatment of severe sepsis, a systemic infection. Although Xigris is currently the only approved therapeutic for severe sepsis, its usage has been limited due to controversy surrounding its safety and efficacy. Sirius' Xigris CDx aims to genetically identify patients with a higher likelihood of survival after Xigris treatment and thus reduce the overall mortality of sepsis patients. The availability of such a predictive test has the potential to significantly increase Xigris utilization and revenues.

Sirius Genomics is seeking funding to commercialize its Xigris CDx, and advance the development of its pipeline, including a companion diagnostic for vasopressors. Vasopressors are used in a variety of critical care diseases.

PROPRIETARY TECHNOLOGY

Sirius Genomics' expertise lies in our ability to correlate genes to physical attributes. Specifically, we look at Single Nucleotide Polymorphisms (SNPs) within genes of interest to determine the phenotypes that are associated with the individual SNPs. In studying these correlations, we look for SNPs that function as biomarkers and are predictive of response to a drug. Linking these genetic correlations to clinical outcomes form the proprietary foundation for the companion diagnostics that Sirius Genomics develops. To date the company has filed 13 patent families and has a commercial assay ready for market launch.

CORPORATE ALLIANCES

Eli Lilly, Luminex, Specialty Pharmaceutical Company, UBC, Golden Helix, Genome BC.

PRODUCTS

<u>Name</u>	<u>Indication</u>	<u>Phase</u>	<u>Milestone</u>
APC (Xigris) Companion Diagnostic	Severe Sepsis	Diagnostics	Validation Study Complete 1Q12; Assay Ready For Launch
Vasopressin Companion Diagnostic	Severe Sepeis	Diagnostics	Replication Study Complete
Anti TNF Companion Diagnostic	Severe Sepsis	Diagnostics	Replication Study Complete

SENIOR MANAGEMENT

Chris Wagner, President & CEO • **Alexandra Mancini**, Senior Vice President • **Celia Courchene**, Vice President • **Jennifer Kaufman-Shaw**, Vice President

BOARD OF DIRECTORS

James A. McEwen • **Patrick Terry** • **Heiner Dreismann** • **Jim Heppell** • **Amos Michelson** • **Bradley Popovich** • **Chris Wagner**

SCIENTIFIC ADVISORY BOARD

James Russell, University of British Columbia, St. Paul's Hospital • **Patrick Heagerty**, University of Washington • **Rob Belshaw**, Syreon Corp • **Nik Schork**, Scripps Genomic Medicine

Sorbent Therapeutics, Inc.

Presenting Company

Clinical Foci: Cardiovascular Disease, Renal, Metabolic Disease

Detlef Albrecht, MD

Chief Business Officer

710 Lakeway Dr. Ste 290
Sunnyvale, CA 94085
USA

www.sorbent.com

1-408-738-8240

Incorporated: 2006

Employees: 4

Ownership: Private

CORPORATE MISSION

Sorbent is a private, venture capital backed company in the Silicon Valley in California. Sorbent is developing polymeric drugs for the treatment of patients with congestive heart failure (CHF), chronic kidney disease (CKD; including dialysis) and hypertension. The company is run by a group of experienced biotechnology executives and drug developers.

The company's lead drug candidate, CLP1001, is a superabsorbent polymer that binds potassium (K), sodium (Na) and fluid and removes them through the gastrointestinal (GI) tract, effectively providing a kidney-independent mechanism for removing ions and fluid from the body. CLP1001 is currently in a 100 patient Phase 2a clinical trial in congestive heart failure CHF patients with concomitant CKD. Specifically, the study is assessing the ability of CLP1001 to prevent hyperkalemia and to improve symptoms caused by Na and fluid imbalances.

Renin-angiotensin-aldosterone system (RAAS) blocker, such as ACE inhibitors, ARBs and aldosterone antagonists (AAs), are prescribed for CHF to reduce mortality and hospitalizations. However, RAAS blockers, especially AAs lead to retention of potassium and increase the risk of hyperkalemia, especially in patients who have CKD, diabetes or are older. This leads many physicians to reduce RAAS blocker doses to sub-optimal levels, or to not prescribe these important life-saving drugs at all. In addition, CHF patients are frequently hospitalized due to dietary sodium related fluid overload, in spite of using high doses of diuretics. Through its effects on potassium, sodium and fluid, CLP1001 is expected to allow the optimization of RAAS blockers and to improve subjective symptoms and exercise capacity in CHF patients with CKD.

PROPRIETARY TECHNOLOGY

CLP is a platform technology based on a superabsorbent polymer that is orally administered, non-absorbed, and removes targeted cations from the GI tract. CLP1001 is a potent K and Na/fluid binder. In Phase 1 studies in dialysis patients, CLP1001 was shown to remove clinically significant amounts of K, Na, fluid and to lower serum potassium, body weight and blood pressure. Tolerability is excellent with no inherent taste or odor.

CORPORATE ALLIANCES

Currently exploring partnering opportunities.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
CLP1001	Ion and fluid balance management in Congestive Heart Failure with concomitant Chronic Kidney Disease	Phase II, IIa, IIb	Phase IIa data at December 2011
CLP1004	Hyperkalemia in Dialysis patients	Phase II, IIa, IIb	Trial not yet started
CLP1001	Hyperkalemia and interdialytic weight management in Dialysis patients	Phase II, IIa, IIb	Trial not yet started

SENIOR MANAGEMENT

Detlef Albrecht, MD, Chief Business Officer • **Linda Ara**, Chief Financial Officer • **Linda De Young, PhD**, Senior Vice President • **Giovanni Ferrara, MBA**, Business Development • **Philip Sager, MD**, Chief Medical Officer

BOARD OF DIRECTORS

Detlef Albrecht, MD, Sorbent Therapeutics • **David Collier, MD**, CMEA Ventures • **Markus Goebel, MD PhD**, Novartis Venture Funds • **Jim Healy, MD PhD**, Sofinnova Ventures • **Donald Joseph**, Founder • **Scott Minick, MBA**, ARCH Venture Partners

SCIENTIFIC ADVISORY BOARD

Maria Rosa Costanza, MD, Midwest Heart Institute • **Lee Henderson, MD**, Founder • **Thomas Heywood, MD**, University of California, San Diego • **Barry Massie, MD**, University of California, San Francisco

FINANCING HISTORY

Round Date (Amount, US\$) 01/03/2006 (14.30 million) • 06/14/2011 (36.00 million)

Spinifex Pharmaceuticals Pty. Ltd.

Presenting Company

Clinical Foci: Neurology, CNS

Tom McCarthy

Chief Executive Officer

South Yarra Corporate Centre, Suite T18,
Level 1, 122 Toorak Rd, South Yarra
Melbourne, VIC 3141
Australia

www.spinifexpharma.com.au

61-3-99381205

Incorporated: 2005

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Close of AUD \$ 18.25 million Series B round, which allows the company to complete our initial three Phase 2 studies on EMA401. Completion of the EMA401 Phase 1 program under an IND with US FDA. Safety database of 118 healthy volunteers.

Upcoming

First patient first dose in the initial EMA401 Phase 2 study in post herpetic neuralgia patients (September 2011).

Initiation of two further Phase 2 clinical trials of EMA401 in (i) patients with pain and hypersensitivity following cancer chemotherapy and (ii) patients with pain and hypersensitivity following peripheral nerve injury (4Q11-1Q12).

Publication of the inventor's and KOL's foundational non-clinical data establishing that blockade of the AT2 receptor is an attractive target for the treatment of chronic pain (2H11-1H12).

CORPORATE MISSION

Spinifex Pharmaceuticals is a pain drug development company focused on taking innovative new pain treatments from discovery through to clinical proof of concept.

PROPRIETARY TECHNOLOGY

EMA401 is an orally bioavailable, first in class potential treatment for neuropathic and inflammatory pain and related disorders.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
EMA401	Neuropathic pain, inflammatory pain and related neurological disorders	Phase II, IIa, IIb	Phase 1 studies completed under a US FDA IND

SENIOR MANAGEMENT

Tom McCarthy, Chief Executive Officer • **Geoff Kitson**, Chief Medical Officer • **Nuket Desem**, Vice President

BOARD OF DIRECTORS

Andrew Baker, GBS Venture Partners • **Tom McCarthy**, Managing Director • **Eliot Forster**, Independent Non-Executive Director • **Josh Funder**, GBS Venture Partners • **Chris Nave**, Brandon Capital Partners • **John Kurek**, Uniseed

SCIENTIFIC ADVISORY BOARD

Chas Bountra, Oxford University • **Praveen Anand**, Hammersmith Hospital and Imperial College London • **Andrew Rice**, Chelsea and Westminster Hospital and Imperial College London • **Alan Naylor**, Drug Discovery/Medicinal Chemistry Consultant

FINANCING HISTORY

Round Date (Amount, US\$) 03/01/2006 (4.00 million) • 08/01/2011 (18.25 million)

Investors: GBS Venture Partners (65%) • Brandon Capital Partners (19%) • Uniseed (8%) • UniQuest (8%)

STATegics, Inc.

Clinical Foci: CNS, Hematology

Juha Punnonen, MD, PhD Chief Executive Officer

1455 Adams Dr.
Menlo Park, CA 94025
USA

www.stategics.com

1-650-804-2051

Incorporated: 2007

Employees: 6

Ownership: Private

HIGHLIGHTS

Recent

STATegics announced on 08/02/11 that the Friedreich's Ataxia Research Alliance (FARA) awarded the Company USD \$152,690 to advance its proprietary small molecule erythropoietin mimetic compounds for the treatment of Friedreich's ataxia (FRDA).

STATegics presented positive preclinical results for its proprietary erythropoietin mimetic, STS-E15, at the American Academy of Neurology (AAN) 63rd Annual Meeting on April 12, 2011.

STATegics announced on 11/16/10 that the Department of Defense awarded the Company USD \$1.7 million to advance its proprietary small molecule mimetics of erythropoietin for the treatment of traumatic brain injury.

CORPORATE MISSION

STATegics, Inc. is focused on the discovery and development of orally available cytokine receptor modulators acting through novel, allosteric sites. STATegics' small molecules, Allomimetics, offer unique competitive advantages when compared to recombinant proteins particularly when bioavailability in the central nervous system (CNS) is required.

STATegics has identified small molecule erythropoietin (EPO) Allomimetics with demonstrated activities in several cellular models of neurological diseases and penetrance into the CNS. Extensive prior literature on recombinant human (rh) EPO in preclinical and clinical settings has validated EPO as a target in several neurological diseases, while STATegics has focused on Friedreich's ataxia and Parkinson's disease. The company has also identified a proprietary thrombopoietin (TPO) Allomimetic that demonstrates best-in-class properties, including improved solubility and potency in vitro when compared to GlaxoSmithKline's (GSK) Promacta®, the first orally available cytokine mimetic on the market.

STATegics' initial focus for clinical development is in Friedreich's ataxia, a debilitating neurodegenerative disease that affects approximately 6,000-10,000 patients in the USA. In Friedreich's ataxia, clinically meaningful results can be obtained in early Phase I trials based on analysis of frataxin levels, reduced expression of which is the underlying cause of the disease. Additional opportunities exist in neurological diseases with significant unmet needs, such as Parkinson's disease, Alzheimer's disease, multiple sclerosis, depression and peripheral neuropathy. TPO Allomimetics have broad applicability in treating thrombocytopenias associated with for example cancer chemotherapy, immune thrombocytopenic purpura or chronic liver diseases. In addition, the direct anti-proliferative effect of the TPO Allomimetic on leukemic cells has opened the opportunity in the treatment of bone marrow malignancies.

PROPRIETARY TECHNOLOGY

STATegics has identified proprietary small molecule product candidates for CNS diseases, acute myeloid leukemia and thrombocytopenia. In addition, the company has demonstrated a proof-of-concept for a platform approach to screen for novel small molecule compounds specific for other cytokine receptors with major clinical and commercial interests.

CORPORATE ALLIANCES

STATegics is collaborating with Friedreich's Ataxia Research Alliance (FARA) and Department of Defense to advance its EPO Allomimetic for the treatment of Friedreich's ataxia and traumatic brain injury, respectively. The programs are supported with approximately USD \$2 million in grant funding. The company is seeking additional investments and partnerships to advance EPO Allomimetic to clinical studies in Friedreich's ataxia, and to facilitate the technology development and partnering efforts for TPO Allomimetic.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
STS-E15	Friedreich's ataxia, Parkinson's disease	Preclinical
STS-E206	Traumatic brain injury, stroke	Preclinical
STS-T4	Thrombocytopenia, hematological malignancies	Preclinical

SENIOR MANAGEMENT

Juha Punnonen, MD, PhD, Chief Executive Officer • **Jeffrey R. Spencer, PhD**, Senior Vice President

BOARD OF DIRECTORS

Juha Punnonen, MD, PhD, STATegics • **Jeffrey R. Spencer, PhD**, STATegics

SuperNova Diagnostics, Inc.

Presenting Company

Clinical Foci: Diagnostics • Pharmacogenetics • Drug Development

Neil Campbell

President & CEO

20271 Goldenrod Lane, Suite 2024
Germantown, MD 20876
USA

www.supernovadiagnostics.com

1-301-768-4230

Incorporated: 2010

Employees: 15

Ownership: Private

CORPORATE MISSION

SuperNova Diagnostics® has developed a powerful proprietary label technology called AmpCrystal® and with it, a solution for providing affordable qualitative and quantitative point-of-care companion diagnostic testing for proteins and nucleic acids.

Using its Solaris(TM) platform, SuperNova can deliver point-of-care companion diagnostic testing, which can be rapidly developed in at the pre-clinical stage and then used through clinical testing and following product launch..

Its AmpCrystal label technology can be backward integrated into current laboratory diagnostic platforms, offering improvements in sensitivity and precision.

PROPRIETARY TECHNOLOGY

AmpCrystals® can be utilized in a wide range of diagnostic formats including lateral flow, self-contained microfluidics cartridges, microtiter, microarrays, closed systems, and research products.

SuperNova can put the lab into the palm of your hand.®

CORPORATE ALLIANCES

Two strategic collaborations in R&D

- 1) oral health & infectious disease (Asia & EU);
- 2) food safety & food/industrial diagnostics (global)

License agreements in place with:

- Concile GmbH, a German assay developer a distributor
- KSB, one of the largest point-of-care diagnostic manufacturers in China

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
AmpCrystals	Diagnostic label	Diagnostics	Available for outlicensing
Q-Test	Urine point-of-care testing	Diagnostics	Available for outlicensing
Solaris (TM)	Point-of-use/ point-of-care diagnostics	Diagnostics	Available for outlicensing
Solaris (TM) Prime	Point-of-use/ point-of-care quantitative diagnostics	Diagnostics	Available for outlicensing

SENIOR MANAGEMENT

Neil Campbell, President & CEO • **Christopher Ball, MD**, Chief Medical Officer • **Dick Sandberg**, Chairman

BOARD OF DIRECTORS

Dick Sandberg, Independent • **Neil Campbell**, President & CEO • **Christopher Ball, MD**, Imprimatur Capital • **George Cautherley**, Nathan International Holdings

SCIENTIFIC ADVISORY BOARD

Dr Hans-Georg Eisenwiener, Independent • **Prof Reinhard Renneberg**, Hong Kong University of Science and Technology

FINANCING HISTORY

Round Date (Amount, US\$) 02/28/2009 (2.20 million)

Investors: Nathan International Holdings Limited (52%) • Imprimatur Capital Limited (25%) • Reinhard Renneberg (10%)

SuppreMol, GmbH

BIO Member, Presenting Company

Clinical Foci: Autoimmune • Hematology • Immunology

Prof. Dr. Peter Buckel

Chief Executive Officer

Am Klopferspitz 19
D-82152 Martinsried/Munich
Germany

www.suppremol.com

49-89-309050680

Incorporated: 2002

Employees: 16

Ownership: Private

HIGHLIGHTS

Recent

Phase I clinical trial with SM101 successfully completed and Phase Ib/IIa (PoC) in ITP ongoing. Phase IIa in SLE started.

Orphan Drug Designation for SM101 granted by the European Commission and the FDA.

EUR €15.5 million series C financing round (2010) and public research funding of more than €10 million secured.

Upcoming

First patient dosing in Phase IIa Clinical Trial in SLE with SM101 (Oct.2011).

Expecting topline results of ongoing Ph IIa study in ITP early 2012.

Further financing of the company in mid 2012.

CORPORATE MISSION

SuppreMol GmbH is focusing on the development of novel therapeutics for the treatment of autoimmune diseases. The company's lead program SM101, a recombinant human therapeutic protein, is based on a soluble form of the Fc gamma receptor IIb, which possesses immunoregulatory properties demonstrated in acute and chronic disease models where the protein proved strong anti-inflammatory and immunosuppressive efficacy. SuppreMol has successfully completed a Phase I study with SM101 and started a proof of concept study in Primary Immune Thrombocytopenia (ITP) early this year. Orphan Drug Designation for SM101 in ITP has been granted by the European Commission and the FDA. The company has also initiated a Phase IIa study in Systemic Lupus Erythematosus (SLE) recently and is currently evaluating Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD). SuppreMol also has a series of early stage programs: Monoclonal antibodies targeting specifically the Fc gamma receptor IIb (autoimmune diseases) and in a bispecific setting also Fc epsilon (asthma, allergy). Another therapeutic antibody is directed against IL3 to treat early onset of RA. Finally a soluble dimeric protein of the Fc gamma receptor IIb with higher affinity is under evaluation.

SuppreMol GmbH is a privately-owned biotechnology company located in Martinsried near Munich, Germany and was founded in 2002 as a spin-off from the Max-Planck-Institute of Biochemistry in Martinsried, out of the laboratories of Prof. Dr. Robert Huber who received the Nobel Prize in chemistry in 1988.

PROPRIETARY TECHNOLOGY

SM 101 is a soluble Fc receptor which has been shown to effectively block autoimmune diseases like ITP, SLE, RA and MS in acute and chronic animal models at a key position of the B-cell activation and inflammatory pathways. In a Phase I study, SM101 was safe and well tolerated in more than 40 healthy individuals. SuppreMol started a proof of concept study in Primary Immune Thrombocytopenia (ITP) with topline results expected in 1Q12. Orphan Drug Designation for SM101 in ITP has been granted by the European Commission and the FDA. The company recently also initiated a Phase II study in Systemic Lupus Erythematosus (SLE) and is currently evaluating Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease (COPD).

CORPORATE ALLIANCES

Various academic collaborations

PRODUCTS

Name	Indication	Phase	Milestone
SM101	Autoimmune Disease	Phase II, IIa, IIb	topline data in ITP expected in 1Q12.

SENIOR MANAGEMENT

Prof. Dr. Peter Buckel, Chief Executive Officer • **Dr. Peter Sondermann**, Chief Scientific Officer • **Sascha Tillmanns**, Director • **Dr. Robert Phelps**, Business Development

BOARD OF DIRECTORS

Dr. Thomas Hecht, Chairman • **Prof. Dr. Dr. Ernst-Günter Afting**, Former President and CEO of the National Research Centre, GSF in Munich, Germany • **Michael Motschmann**, Executive partner of MIG AG • **Dr. Markus Hosang**, General Partner at BioMedPartners • **Ulrich Mahr**, Member of General Management of Max Planck Innovation • **Dr. Thomas Werner**, Former Head of Marketing Europe, GSK

SCIENTIFIC ADVISORY BOARD

Prof. Dr. Robert Huber, chairman • **Dr. Uwe Jacob**, co-founder • **Prof. Dr. Fritz Melchers**, Professor of Immunology at the University Basel • **Dr. Zoltan Nagy**, former Head of Immunology at Hoffmann-La Roche Inc • **Prof. Dr. Falk Nimmerjahn**, Professor for Experimental Immunology and Immune Therapy at the University of Erlangen-Nürnberg, Germany • **Prof. Dr. Jeffrey V. Ravetch**, Professor of Molecular Genetics and Immunology at the Rockefeller University, NY, USA • **Dr. Helmut Lenz**, Expert for immune assays and antibodies (Boehringer Mannheim / Roche) • **Prof. Dr. Christoph Huber**, Director of the III. Medical School, Mainz (Hematology/Immunotherapy), Germany

Susavion Biosciences, Inc.

Clinical Foci: Infectious Disease, Oncology, Immunology

Gregory R. Wolfe, PhD Chief Executive Officer

1615 W. University Drive
Tempe, AZ 85281
USA

www.susavion.com

1-480-921-3795

Incorporated: 2006

Employees: 3

Ownership: Private

HIGHLIGHTS

Recent

Completed funding round in August 2011 for commencement of preclinical studies.

Awarded Qualifying Therapeutic Discovery Project grant, November 2010.

Eggink LL, Salas M, Hanson CV, Hooper JK., 2010, Peptide sugar mimetics prevent HIV type 1 replication in peripheral blood mononuclear cells in the presence of HIV-positive antiserum. AIDS Research and Human Retroviruses 26:149-160.

CORPORATE MISSION

Susavion Biosciences, Inc., has a robust platform to identify novel peptidic drugs that trigger activation of several types of immune effector cells. Susavion's current focus is on infectious diseases. Susavion's lead peptide, SVH1C, is effective at sub-nanomolar concentrations to neutralize HIV-1 in cultures of peripheral blood mononuclear cells in the presence of serum from HIV-positive patients. This peptide is currently moving through the preclinical IND stage. SVL4, another peptide in our pipeline, significantly extends life when administered in conjunction with low doses of radiation in a glioblastoma mouse model system. The peptides have shown no toxicity in rats at 1000-fold greater doses than anticipated for therapeutic use. Additional peptides in our pipeline show potential in diabetic wound healing. These drugs have promise as biological response modifiers and should strongly enhance the immune defense in treatment of viral infections and cancer.

PROPRIETARY TECHNOLOGY

Susavion's platform identifies peptidic drugs that are predicted to engage cell surface receptors. The peptides are designed by computational modeling of binding to receptor analogs and validated by direct binding assays. Ability of the peptides to activate several types of cells provides a valuable approach to enhancing an immune response.

CORPORATE ALLIANCES

Susavion has engaged Russell W. Blacher, Biopharmaceutical Development Consulting to guide the path to the FDA for IND status. Secondly, he has contracted with Jeffrey Miller, JP Miller Associates, a regulatory expert, and Brian Rogers, Pacific BioDevelopment LLC, for toxicology review.

Peptide synthesis is contracted to CBL Biopharma LLC, Patras, Greece.

Viral replication assays are contracted in collaboration with the California Department of Public Health, Viral & Rickettsial Disease Laboratory.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>
SVH1C	Infectious diseases	Preclinical
SVL4	Oncology	Preclinical
SV6C	Infectious diseases	Preclinical
SVC2	Infectious diseases	Preclinical
SV6B	Infectious diseases	Preclinical
SV6D	Wound healing	Research
SVH1B	Wound healing	Research
SVD2	Autoimmune diseases	Research

SENIOR MANAGEMENT

Gregory R. Wolfe, PhD, Chief Executive Officer • **Laura L. Eggink, PhD**, President • **J. Kenneth Hooper, PhD**, Chief Scientific Officer

BOARD OF DIRECTORS

Gregory R. Wolfe, PhD, CEO, Susavion Biosciences, Inc. • **Laura L. Eggink, PhD**, President, Susavion Biosciences, Inc. • **J. Kenneth Hooper, PhD**, Chief Scientific Officer, Susavion Biosciences, Inc.

SCIENTIFIC ADVISORY BOARD

Russell W. Blacher, Biopharmaceutical Development Consulting • **Brian C. Rogers, PhD**, Pacific Biodevelopment LLC, Toxicology • **Jeffrey P. Miller**, JP Miller Associates: Regulatory Affairs and Compliance

FINANCING HISTORY

Round Date (Amount, US\$) 08/01/2011 (1.30 million)

Investors: Richard Rockefeller, MD (4%) • Pamela Omidyar, MS (6%) • J. Kenneth Hooper, PhD (50%) • Laura Eggink, PhD (20%) • Gregory Wolfe, PhD (20%)

Sutro Biopharma, Inc.

William Newell

Chief Executive Officer

310 Utah Avenue South
South San Francisco, CA 94080
USA

www.sutrobio.com

1-650-392-8412

Incorporated: 2003

Employees: 43

Ownership: Private

CORPORATE MISSION

Sutro Biopharma, Inc. discovers and develops a new generation of protein therapeutics with improved properties utilizing a proprietary technology to introduce non-natural amino acids providing either a handle for designer modifications or unique adjustments to active site and binding regions to dial in desired properties. The company's scalable cell-free protein synthesis gives unprecedented access to a broad range of non-natural amino acids in a manner that allows for rapid entrance into a world of proteins of interest followed by virtually guaranteed ability to scale to desired amounts for in-vivo, clinical and commercial applications with a speed that has never been imagined in the biopharmaceutical industry. The Company will have a functional cGMP manufacturing facility for Phase 1 clinical material in 1H12.

PROPRIETARY TECHNOLOGY

The basis of Sutro's technology is its scalable cell free protein synthesis technology which has proven to be versatile in its ability to enable the synthesis of complex eukaryotic proteins rapidly. The technology allows us to go from DNA template to protein in days. The adaptation of the technology to the incorporation of non-natural amino acids is proving to be just as versatile with the ability to incorporate amino acids of almost any type into the protein of interest in a site specific manner.

CORPORATE ALLIANCES

The company has been and is currently collaborating with multiple large pharmaceutical companies. One publicly disclosed relationship is a research and development collaboration with Pfizer that was announced in January.

SENIOR MANAGEMENT

William Newell, Chief Executive Officer • **Lesley Stolz, PhD**, Vice President • **Trevor Hallam, PhD**, Chief Scientific Officer • **Henry Heinsohn**, Vice President • **Christopher J. Murray, PhD**, Vice President

Syndax Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Oncology

Joanna Horobin, MD <i>President & CEO</i> 460 Totten Pond Road Waltham, MA 02451 USA		www.syndax.com 1-781-419-1400	<i>Incorporated:</i> 2005 <i>Employees:</i> 12 <i>Ownership:</i> Private
---	--	--	--

CORPORATE MISSION
 Syndax Pharmaceuticals Inc. is a late-stage epigenetics oncology company focused on mechanisms of drug resistance in solid tumors with worldwide rights to entinostat. Syndax was founded in 2005 by Eckard Weber, MD, Domain Associates, and Ron Evans, PhD, Salk Institute.

PROPRIETARY TECHNOLOGY
 We recently completed a randomized, placebo-controlled phase 2 trial evaluating entinostat with Aromasin® in patients with advanced/metastatic breast cancer, hitting the primary endpoint of an improvement in progression-free survival (PFS) and are moving that program into phase 3 testing. Also, results from a placebo controlled, randomized phase 2 study showed a four-month survival advantage when entinostat was added to erlotinib in patients with lung cancers expressing high levels of E-cadherin. In collaboration with investigators at Johns Hopkins University and the NCI, Phase 2 'double' epigenetic clinical studies are being conducted with entinostat and the DNA methyltransferase inhibitor, Vidaza® in solid tumors, based on the objective clinical responses previously reported in a lung

CORPORATE ALLIANCES
 Syndax is seeking development and marketing partners. The company is also interested in corporate collaborations involving synergistic combinations with approved products with significant commercial potential.

PRODUCTS		
<i>Name</i>	<i>Indication</i>	<i>Phase</i>
Entinostat	Oncology	Phase III

SENIOR MANAGEMENT
Joanna Horobin, MD, President & CEO • **Bob Goodenow, PhD**, Chief Business Officer • **Miranda Rees**, Vice President • **William McCulloch, MB, ChB, FRCP, FFPM**, Chief Medical Officer • **Caryn Peterson**, Vice President

BOARD OF DIRECTORS
Dennis Podlesak, Domain Associates • **Kim Kamdar, PhD**, Domain Associates • **Steven St. Peter, MD**, MPM Capital • **Rosina Maar Pavia**, Pappas Ventures • **Joanna Horobin**, Syndax • **Arlene morris**, Independent

SCIENTIFIC ADVISORY BOARD
Gail Eckhardt, MD, University of Colorado • **Jean-Pierre Issa, MD**, MD Anderson Cancer Center • **Edward Sausville, MD, PhD**, University of Maryland • **George W Sledge, MD**, Indiana University • **Stephen Baylin, MD**, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins

FINANCING HISTORY
Round Date (Amount, US\$) 04/15/2007 (49.00 million) • 07/01/2010 (6.00 million)
Investors: Domain Associates (0%) • MPM Capital (0%) • Pappas Ventures (0%) • Forward Ventures (0%) • Avalon Ventures (0%)

SynTara LLC

Presenting Company

Clinical Foci: Vaccines, Drug Delivery, Oncology

Sterling C. Johnson <i>Chairman</i> 7117 Rockrose Terrace Carlsbad, CA 92011 USA			www.syntara.com 1-760-804-0114	Incorporated: 2010 Ownership: Private
---	--	--	--	--

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
Formation of SynTara LLC by Midatech Ltd. and Immunotope, Inc. in July 2010. Launch of SynTara at BioPharm America 2011 meeting in Boston with announcement of lung cancer progress.	POC Studies to validate the selected lung cancer antigens can be efficiently and effectively delivered with nanoparticle technology.

CORPORATE MISSION
<p>SynTara is a joint venture between Immunotope, Inc. and Midatech Ltd. with the first and possibly only company with a comprehensive CTL (cytotoxic T-lymphocyte) based vaccine. The CTL antigens have been selected and validated for the first project, a lung cancer immunotherapeutic vaccine. These antigens are combined with a delivery system that specifically targets dendritic cells and delivers both antigens and adjuvants for efficient activation of cancer specific CTL. Immunotope is the source of validated antigens and is a clinical stage biotechnology company developing immunotherapy products for the treatment and prevention of cancer and chronic viral infections. Its products activate the patient's own immune system to fight disease and prevent recurrence. This comprehensive approach to cancer therapy focuses on the critical, unmet need to diagnose cancer at the earliest stages and to develop effective treatments that destroy tumors and prevent metastasis. Immunotope's immunoproteomics antigen discovery platform identifies comprehensive antigenic signatures consisting of peptides and parent proteins from tumor pathways that are critical for the development of immunotherapeutic vaccines and antibody therapeutics.</p> <p>Midatech is at the forefront of designing, developing, synthesizing and manufacturing nanomedicines based on its proprietary, self-assembling biocompatible nanoparticle technology. The company has successfully employed its nanotechnology platform and know-how to transition discovery and engineering sciences to practical nanomedicine applications through in-house and partnered drug development programs. Midatech's unique nanoparticles allow rapid targeting of drugs or drug combinations to specific tissues or cells as well as potentially enabling transport across the blood brain barrier. In the field of diabetes Midatech's program to deliver nanoparticle insulin via transbuccal delivery using the technology of MonoSol Rx will enter the clinic later in 2011.</p>

PROPRIETARY TECHNOLOGY
<p>Immunotope's immunoproteomics antigen discovery platform identifies comprehensive antigenic signatures consisting of peptides and parent proteins from tumor pathways that are critical for the development of immunotherapeutic vaccines and antibody therapeutics. Antigen discovery is based on three different strategies:</p> <ol style="list-style-type: none"> 1) MHC class I-processed proteins; 2) Proteins that generate autoantibodies in patients with cancer 3) Glycoproteins with cancer specific aberrant glycosylation. <p>Midatech provides to SynTara the gold-core glyconanoparticles (GNP) for delivery of the selected antigens.</p>

CORPORATE ALLIANCES
<p>SynTara is still at an early stage but has demonstrated preliminary POM and POC in its lung cancer program. Alliances will be forthcoming once POC in man is demonstrated in 2012.</p>

PRODUCTS		
<i>Name</i>	<i>Indication</i>	<i>Phase</i>
No Trade Name	Lung cancer	Optimized Lead
No Trade Name	Pancreatic Cancer	Lead Series

SENIOR MANAGEMENT
<p>Sterling C. Johnson, Chairman • Ramila Philip, PhD, Chief Scientific Officer • Mohan Philip, PhD, MBA, Chief Financial Officer • Professor Thomas Rademacher, Chief Technology Officer</p>

BOARD OF DIRECTORS
<p>Sterling C. Johnson, Midatech • Thomas Rademacher, PhD, Midatech • Ramila Philip, PhD, Immunotope • Mohan Philip, PhD, Immunotope</p>

FINANCING HISTORY
<p><i>Investors:</i> Immunotope, Inc. (50%) • Midatech Ltd. (50%)</p>

Syntaxin Limited

Presenting Company

Clinical Foci: Biopharmaceuticals, Oncology, Drug Development

Dr. Melanie Lee

Chief Executive Officer

Units 4 The Quadrant, Barton Lane
Abingdon
OX14 3YS
United Kingdom

www.syntaxin.com

44-1235-552112

Incorporated: 2006

Employees: 40

Ownership: Private

HIGHLIGHTS

Recent

11 November 2010: Syntaxin Raises £18 million in New Financing.

02 March 2011: Syntaxin announces its partner Allergan enters Phase II trials with Re-Targeted Endopeptidase Drug.

11 May 2011: Syntaxin enters manufacturing agreement with SynCo Bio Partners B.V.

CORPORATE MISSION

The company discovers and develops a new class of biopharmaceuticals, termed Targeted Secretion Inhibitors (TSI), which treat disease through selective inhibition of cell secretory processes. It is backed by a blue chip investor base including: Abingworth, Lundbeckfond Ventures, LSP, Ipsen, JJDC, Quest, Seventure, and SR One. In November 2011, the company raised £18m in a series C financing.

Syntaxin's Targeted Secretion Inhibitor (TSI) platform enables the design and development of therapeutics for treating diseases where inappropriate cell secretion is a primary cause. The TSI molecules selectively bind to targeted cells to prevent secretion, can be administered locally or systemically, and offer the potential of long duration of action from a single dose (from weeks to months). The technology platform has the potential for developing new treatments across multiple disease areas. These include CNS disorders such as neuropathic pain, endocrine disorders such as acromegaly, and certain types of cancers.

Syntaxin's Executive Management brings a wealth of industry experience to the company. Chief Executive Officer, Dr. Melanie Lee, spent a decade in research with GlaxoSmithKline and subsequently held leadership positions at Celltech and UCB. Chief Business Officer, Dr. Nigel Clark, was formerly Vice President Business Development with Vernalis and has a strong track record in building strategic alliances. Dr. John Court, Chief Development Officer, was previously founder and CEO of Fulcrum Pharma, an international contract drug development business, following R&D roles at Roche and Wellcome.

Syntaxin Chairman Dr. Russell Greig has over 30 years experience in the pharmaceutical industry, with knowledge and expertise in research and development, business development and commercial operations. Prior to joining the company, Dr. Greig was President of SR One, GSK's Corporate Venture Group.

PROPRIETARY TECHNOLOGY

Syntaxin's drugs exploit the natural pharmacology of botulinum neurotoxins. The botulinum neurotoxins are potent inhibitors of the vesicular secretion of neurotransmitters from peripheral nerves, particularly acetylcholine at the neuromuscular junction. The result is profound muscle relaxation, which had initial clinical application in the treatment of muscular dystonias. The mechanism of action of the neurotoxins involves three discrete functional domains: targeting, membrane translocation and intracellular inhibition of vesicular secretion via proteolytic cleavage of SNARE proteins (a ubiquitous and essential component of vesicular secretion).

CORPORATE ALLIANCES

Syntaxin has an alliance with Allergan, Inc. a world leader in the commercialisation of botulinum neurotoxin products to discover, develop and commercialise TSI for the treatment of pain in humans. AGN-214868 was discovered under the collaboration with Allergan and is now in Phase II trials in patients with post herpetic neuralgia (PHN) and overactive bladder.

Syntaxin's innovative technology platform offers enormous potential to develop new treatments for a range of diseases. The company plans to maximise the both potential of its unique technology platform and pipeline of products in collaboration with industry partners.

PRODUCTS

Name	Indication	Phase	Milestone
AGN-214868	PHN and OAB	Phase II, IIa, IIb	
SXN101959	Acromegaly	Preclinical	Phase I

SENIOR MANAGEMENT

Dr. Melanie Lee, Chief Executive Officer • **Dr. Nigel Clark**, Chief Business Officer • **Dr. Phil Boyd**, Chief Financial Officer • **Dr. Richard Jones**, Chief Medical Officer • **Dr. Keith Foster**, Chief Technology Officer • **Dr. John Chaddock**, Other • **Dr. Jon Court**, Other

BOARD OF DIRECTORS

Dr. Russel Greig • **Dr. Deborah Harland**, SR One • **Dr. Edward Holdener**, Non-Exec • **Dr. Genghis Lloyd-Harris**, Abingworth Management • **Dr. René Kuijten**, LSP • **Dr. Johan Kördel**, Lundbeckfond Ventures • **Dr. Zeev Zehavi**, JJDC • **Professor Pierre Denys**, Non Executive Director • **Iain Wilcock**, Seventure

SCIENTIFIC ADVISORY BOARD

Professor Julian Jack • **Sir Tom Blundell** • **Professor Peter Goodfellow** • **Barry Furr**

TeraDiscoveries, Inc.

Clinical Foci: Drug Discovery, Drug Development, Diagnostics

Edwin R. Addison Chief Executive Officer

2 Davis Dr.
Research Triangle Park, NC 27709
USA

www.teradiscoveries.com

1-910-398-1200

Incorporated: 2009

Employees: 15

Ownership: Private

HIGHLIGHTS

Recent

TeraDiscoveries Presents its Potential "Best in Class" JAK2 Inhibitor G6 - at the EHA June, 2011 in London.

Patent filed for vitamin, a biomarker for Jak2 mutation.

May 1, 2011: Research Triangle Park, NC. TeraDiscoveries announced the offering of its patented Inverse Design technology for in-silico drug discovery on the Microsoft Azure high performance computing platform.

Upcoming

TeraDiscoveries is at the forefront of a new wave of drug discovery that combines high performance computing with molecular biology, bioinformatics, high throughput screening and sophisticated preclinical development.

Dr. Peter Sayeski to present Jak2 inhibitor G6 as ASH

Protein Symphony™ is an emerging drug discovery search engine and database that will, upon issuing a target protein as a query, will produce immediately the best inhibitors for that protein and their properties, candidate relevant biomarkers,

CORPORATE MISSION

TeraDiscoveries discovers new drugs and develops them by using a leading edge computational chemistry platform. The company is seeking a partner for its "best in class" Jak2 inhibitor, for a Jak2 mutation biomarker, and for its drug discovery platform, as well as an Hdac8 inhibitor. Using breakthrough "chemoinformatics" software developed at and exclusively licensed from Duke University called "Inverse Design," TeraDiscoveries systematically discovers, optimizes and develops early stage drugs from target selection through lead discovery and optimization, synthesis, testing and clinical planning. Using our core competency in bioinformatics and drug discovery, we provide an integrated environment for preclinical drug development that dramatically accelerates drug discovery and development. Our business model is to develop a pipeline of early stage drugs, conduct preclinical research, and take them as far as Phase 1 before partnering.

PROPRIETARY TECHNOLOGY

G6, its derivatives and biomarker for Jak2 inhibition for myeloproliferative disorders;
Inverse design - an in silico drug discovery platform.

CORPORATE ALLIANCES

Duke University; University of Florida; Sid Martin Biotechnology Center; NC Biotechnology Center; Microsoft for Azure Platform

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
G6 and derivatives	myelofibrosis, leukemia, polycythemia vera	Optimized Lead	100% remission in mouse studies
vimentin (Jak2 mutation biomarker)	myelofibrosis, leukemia, polycythemia vera	Diagnostics	patent filed
Inverse Design	drug discovery platform	Other	Patent Issued
Hdac8 inhibitor	T cell lymphoma	Research	

SENIOR MANAGEMENT

Edwin R. Addison, Chief Executive Officer • **Lawrence Husick**, Chief Technology Officer • **Shahar Keinan**, Chief Scientific Officer • **Position Filled, not yet announced**, Business Development • **Leslie Pryce**, Business Development • **Jack Young**, Other • **William Shipman**, Other • **Elizabeth Hobbs**, Other • **Karen Addison**, Administrative Assistant • **Peter Sayeski**, Other

BOARD OF DIRECTORS

Edwin R. Addison, TeraDiscoveries • **Lawrence Husick**, Lipton Weinberger & Husick • **Sandy Wienberg**, (pending)

SCIENTIFIC ADVISORY BOARD

Peter Sayeski, University of Florida • **Sandy Weinberg**, Georgia Tech • **Bruce Dawson**, Infinomics • **Shelby Addison, MD**, Medical University of SC

FINANCING HISTORY

Round Date (Amount, US\$) 01/15/2010 (0.50 million) • 09/15/2011 (1.50 million) • 04/15/2012 (7.00 million)

Investors: Edwin R. Addison (27%) • Lawrence A. Husick (18%) • Shahar Kienan (12%)

Tetraphase Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Infectious Disease • Biopharmaceuticals • Drug Development

Guy Macdonald

President & CEO

480 Arsenal Street
Watertown, MA 02472
USA

www.tphase.com

1-617-715-3551

Incorporated: 2006

Employees: 30

Ownership: Private

HIGHLIGHTS

Recent

Phase 2 trial for TP-434 IV in cIAI underway

Second compound from proprietary chemistry platform - TP-2758 (oral) is in Phase I clinical testing.

Received an award from NIAID for the development of TP-271, a novel antibiotic for respiratory disease caused by bio-threat pathogens and antibiotic-resistant public health pathogens.

Upcoming

Completion of Phase 2 trial for TP-434 IV in cIAI in 1H'12

Completion of Phase 1 trial(s) for TP-2758 (cUTI).

CORPORATE MISSION

Tetraphase Pharmaceuticals is a clinical-stage life science company developing a portfolio of potent, novel and differentiated antibiotics designed to be effective against, drug-resistant bacteria, including multidrug-resistant (MDR) gram-negative pathogens, which pose a major and growing health threat. The company's pipeline consists of product candidates that have broad-spectrum activity and more narrowly focused activity, making for a complementary portfolio of IV and oral step-down drug candidates with the potential to treat a wide range of serious bacterial infections. Tetraphase's lead candidate, TP-434 is ideally suited as a broad-spectrum IV antibiotic with potential for oral step-down for empiric treatment of severe and life-threatening bacterial infections and the potential for once-daily monotherapy capable of treating multidrug-resistant (MDR) gram-negative pathogens. TP-434 also offers potent, broad spectrum coverage of other serious and multidrug-resistant gram-positive, anaerobic and atypical pathogens and is Phase 2 clinical testing in complicated Intra-abdominal infections (cIAI). The company has two additional candidates with potential for both IV and oral activity. TP-2758 is in Phase 1 clinical testing and based on its target product profile is being positioned for complicated urinary tract infections (cUTI). TP-834 targeted for complicated community-acquired bacterial pneumonia (cCABP) is in the process of completing IND-enabling toxicology.

PROPRIETARY TECHNOLOGY

Tetraphase has rapidly built a portfolio of novel, potent and highly-differentiated antibiotics by capitalizing on ground-breaking synthetic chemistry technology that enables for the first time the ability to overcome the technical challenges of traditional approaches (semi-synthesis) to developing pharmaceuticals, such as antibiotics. This proprietary small molecule drug engine has produced >2,500 antibiotic drug candidates, re-invigorating an important and highly successful class of antibiotics (tetracyclines) to create powerful new antibiotics with drug properties capable of treating serious multi-drug resistant infections.

CORPORATE ALLIANCES

No current alliances. Our focus is to develop our portfolio of novel antibiotics while evaluating all opportunities to support the growth of our business.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
TP-434 IV	cIAI; (other potential indications ABSSSI and HAP/VAP)	Phase II, IIa, IIb	Completion - 1H12.
TP-434 Oral	various	Phase I	Ph. I MAD study completed in 2H10.
TP-2758	IV/Oral cUTI	Phase I	completion by 4Q11/1Q12.
TP-834	IV/Oral for CABP	Preclinical	IND-enabling tox. in process.
Pseudomonas Program	TBD	Preclinical	

SENIOR MANAGEMENT

Guy Macdonald, President & CEO • **Patrick Horn, MD**, Chief Medical Officer • **David Lubner**, Chief Financial Officer • **Joyce Sutcliffe**, Senior Vice President • **Leland Webster, PhD**, Vice President • **Magnus Ronn, PhD**, Vice President • **Xiao-Yi Xiao**, Vice President

BOARD OF DIRECTORS

Larry Miller, MD, Mediphase Venture Partners • **Garen Bohlin**, Constellation Pharma • **Doug Cole, MD**, Flagship Ventures • **Eric Gordon, PhD**, Skyline Ventures • **Steve Gullans, PhD**, Excel Ventures • **Karl Handelsman**, CMEA Ventures • **Robert Weisskoff, PhD**, Fidelity Biosciences • **Guy Macdonald**, Tetraphase Pharmaceuticals, Inc.

SCIENTIFIC ADVISORY BOARD

Helen W. Boucher, MD, New England Medical Center • **Thomas M. File, Jr., MD, MSc**, Summa Health System • **David Livermore, PhD**, UK Government Health Protection Agency • **Robert C. Moellering, Jr., MD**, Harvard Medical School • **Andrew G. Myers, PhD**, Harvard University • **David P. Nicolau, PharmD, FCCP, FIDS**, Hartford Hospital • **Louis B. Rice, MD**, Case Western Reserve University • **David Shlaes, MD, PhD**, Anti-infectives Consulting LLC • **Joseph S. Solomkin, MD**, University of Cincinnati

FINANCING HISTORY

Round Date (Amount, US\$) 09/01/2006 (25.00 million) • 09/11/2009 (10.00 million) • 05/14/2010 (45.00 million)

Investors: CMEA Ventres (0%) • Excel Ventures (0%) • Fidelity Biosciences (0%) • Flagship Ventures (0%) • Mediphase Venture Partners (0%)

The Salter Group

Sam Renwick

Managing Director

7000 Sunne Lane #210
Walnut Creek, CA 94597
USA

www.saltergroup.com

1-925-942-0373

Incorporated: 2003

Employees: 20

Ownership: Private

CORPORATE MISSION

Salter Group is a leading financial and strategic advisory firm specializing in providing independent forecasting services, valuations, financial opinions, financial and strategic advisory services and transaction support. Since our formation in 2003, Salter Group has completed over 500 life sciences and health care engagements representing over USD \$10 billion in asset and transaction values.

We offer a unique perspective for the development of forecasts, valuations and advisory services by combining the analytical and modeling rigor of a capital markets constituent with a robust data-intensive primary and secondary research capability that spans 100,000's of thought leaders, care providers, payors and other experts through our partners. We do this in a flexible and cost-efficient manner. Rather than relying on a significant up-front fee regardless of whether a transaction closes (the model for many consulting firms), we have the flexibility to earn our fees in a different fashion, charging less up front but earning a fee if a transaction is successfully completed. The end result is a cost-effective integrated research and model solution that can help your company be better prepared in your discussions with licensing partners, investors, lenders or acquirers.

SENIOR MANAGEMENT

Sam Renwick, Managing Director

Theraclone Sciences, Inc.

BIO Member

Clinical Foci: Infectious Disease, Drug Discovery, Oncology

Steve Gillis, PhD

President

1124 Columbia Street, Suite 300
Seattle, WA 98104
USA

www.theraclone-sciences.com

1-206-805-1600

Incorporated: 2005

Employees: 20

Ownership: Private

HIGHLIGHTS

Recent

Initiation of P1 clinical trials of TCN-032 for influenza A. TCN-032 was described in a July 2010 publication of PNAS. It is a novel human antibody against a highly conserved epitope on influenza A viruses.

USD \$10.6 million in Series B Extension Financing September, 2011.

In January 2011, Theraclone announced collaboration with Pfizer for the discovery of therapeutic antibodies in oncology and infectious disease indications.

Upcoming

IND filing H1, 2012 for TCN-202, the lead anti-HCMV therapeutic antibody drug candidate.

Additional corporate partnerships in influenza, HCMV, or other indications and for technology platform in 2011-2012

Safety & PK data from P1 clinical trials for TCN-032 1H12.

CORPORATE MISSION

Theraclone Sciences is a discovery and development biotechnology company developing novel therapeutic antibodies for the treatment of indications in infectious disease and cancer. Our proprietary discovery platform allows us to comprehensively screen and identify the rare antibodies that select individuals produce to successfully ward off disease. Central to our discovery approach, we identify antibodies produced naturally by human memory B cells in response to disease. This allows us to identify monoclonal antibodies that are likely to be highly effective in combating disease in a broad patient population. The antibodies identified through our discovery process can be further studied as tools for vaccine development. Our most advanced development programs are focused on infectious disease including novel antibodies to fight pandemic and severe seasonal influenza and cytomegalovirus infections. We have also partnered with the International AIDS Vaccine Initiative (IAVI) to identify the most potent and broadly neutralizing anti-HIV antibodies yet discovered, despite more than 10 years of intensive research by investigators worldwide. Theraclone is a venture-funded company founded in 2005. Our investors include ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM, and AREE. We are actively seeking development partners in the US, Europe, and Japan to help us create and commercialize antibody therapeutic products.

PROPRIETARY TECHNOLOGY

I-STAR™ Technology. The human immune system responds to pathogens, like viruses and bacteria, by evolving in real time highly protective proteins called antibodies. The immunological history of these protective responses is archived in human memory B cells, a specialized type of blood cell. The I-STAR platform allows comprehensive interrogation of this memory B cell archive. Theraclone's technology is unique because it enables us to rapidly test the function of tens of thousands of natural human antibodies to find those with exceptional biological activities. The antibodies identified through our discovery process are appropriate for further study as novel therapies to help patients fight existing disease.

CORPORATE ALLIANCES

Funded collaboration agreement with Zenyaku Kogyo for the discovery and development of antibodies for the treatment of pandemic and severe seasonal influenza. Funded collaboration agreement with Pfizer for the discovery of therapeutic antibody candidates for indications in oncology and infectious disease. Funded collaboration agreement with IAVI for the discovery of anti-HIV antibodies.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
TCN-032	Severe seasonal and pandemic influenza	Phase I	Phase I clinical data 1H12.
TCN-202	HCMV infection	Preclinical	IND Filing 1H12.
TCN-350	Asthma, RA	Optimized Lead	

SENIOR MANAGEMENT

Steve Gillis, PhD, President • **Russ Hawkinson**, Chief Financial Officer • **Kristine Swiderek, PhD**, Vice President • **Eleanor Ramos**, Chief Medical Officer

BOARD OF DIRECTORS

Steve Gillis, PhD, President, Theraclone Sciences; Managing Director, ARCH Venture Partners • **Wende Hutton**, Canaan Partners • **Chris Mirabelli, PhD**, HealthCare Ventures • **Bill Greene**, MPM Capital

SCIENTIFIC ADVISORY BOARD

K. Frank Austen, MD, Harvard Medical School • **Laurie Glimcher, MD**, Harvard Medical School • **Robert Schooley, MD**, UCSD • **Robert Lamb, PhD**, Northwestern University

FINANCING HISTORY

Investors: ARCH Venture Partners • Canaan Partners • HealthCare Ventures • MPM Capital • Amgen Ventures (0%)

Transcept Pharmaceuticals, Inc.

BIO Member, Presenting Company

Clinical Foci: Specialty Pharmaceutical • Neurology • Other

Glenn Oclassen <i>President & CEO</i> 1003 West Cutting Boulevard Point Richmond, CA 94804 USA		www.transcept.com 1-510-215-3500	NASDAQ: TSPT <i>Incorporated:</i> 2001 <i>Employees:</i> 19 <i>Ownership:</i> Public
---	--	--	--

HIGHLIGHTS	
<i>Recent</i>	<i>Upcoming</i>
September 2011: Intermezzo NDA Class 1 resubmission.	Nov. 27, 2011: Intermezzo PDUFA date. Late 2012: Data from Phase 2 study of TO-2061 as adjunctive therapy in treatment resistant OCD.


CORPORATE MISSION
 Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Transcept is developing Intermezzo® (zolpidem tartrate sublingual tablet) as a prescription sleep aid for use as needed when a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Purdue Pharmaceutical Products L.P. have entered into a collaboration agreement for the development and commercialization of Intermezzo® in the United States. Transcept is also developing TO-2061, a low dose ondansetron augmentation therapy for patients with obsessive compulsive disorder (OCD) who have not adequately responded to treatment with approved first-line pharmacotherapy.

CORPORATE ALLIANCES
 Purdue Pharma - U.S. primary care sales and marketing agreement for Intermezzo.

PRODUCTS			
<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Intermezzo(R)	Use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep	NDA/BLA filed, or in process	Nov. 27, 2011 PDUFA date.
TO-2061	Adjunctive therapy in patients with obsessive compulsive disorder (OCD) who have not adequately responded to SSRI treatment	Phase II, IIa, IIb	late 2012.

SENIOR MANAGEMENT
Glenn Oclassen, President & CEO • **Thomas Soloway**, Chief Financial Officer • **Nikhilesh Singh, PhD**, Chief Scientific Officer • **Joseph Kennedy**, General Counsel • **Dennie Dyer**, Vice President • **Marilyn Wortzman**, Vice President • **Sharon Sakai**, Vice President • **Greg Mann**, Investor Relations

BOARD OF DIRECTORS
Kirk Raab, Abbott, Genentech (ret'd) • **Chris Ehrlich**, InterWest • **Thomas D. Kiley**, Independent Consultant and Investor • **Kathy LaPorte**, New Leaf Venture Partners • **Jake Nunn**, NEA • **Glenn Oclassen**, Transcept Pharmaceuticals • **Frederick Ruegsegger**, Sterigenics International



Market Data

Current Price	8.85
Currency	U.S. Dollar
Net Change	9.53
Volume	1,649,780
YTD % Change	0.20
52Wk Range	2.58-11.88
Avg. Daily Volume (thousands)	160,617

First Call Data

Market Cap (MM)	119.7
Short Interest Shares	679,326
Short Interest Ratio	0.70
PE (Trailing 12 Months)	-1.47
EPS (Last Fiscal Year)	-0.72
Consensus Estimate (Y)	-1.47
Consensus Recommend	--
Price/Sales	9.57

Shareholders

<i>Institution</i>	<i>Holding %</i>
Franklin Advisers, Inc.	3.5%
Dimensional Fund Advisors, Inc.	3.2%
BlackRock Fund Advisors	1.3%
Ingalls & Snyder Asset Management	0.8%
Bass Enterprises	0.7%
<i>Mutual Fund</i>	<i>Holding %</i>
Franklin Advisers, Inc.	3.5%
Dimensional Fund Advisors, Inc.	3.2%
BlackRock Fund Advisors	1.3%
Ingalls & Snyder Asset Management	0.8%
Bass Enterprises	0.7%

Source: Thomson Reuters

Tranzyme, Inc.

BIO Member, Presenting Company

Clinical Foci: Gastroenterology, Metabolic Disease, Drug Discovery

Vipin Garg, PhD Chief Executive Officer

4819 Emperor Boulevard
Durham, NC 27703
USA

www.tranzyme.com

1-919-313-4760

Euronext Paris: TZYM

Incorporated: 1998

Employees: 40

Ownership: Public

CORPORATE MISSION

Tranzyme is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel, first-in-class small molecule therapeutics for the treatment of acute (hospital-based) and chronic gastrointestinal motility disorders. Our two most advanced product candidates, ulimorelin (in Phase 3) and TZP-102 (in Phase 2), are being evaluated for the treatment of predominantly upper GI motility disorders. We believe approximately 20% of adults worldwide are affected by conditions these product candidates are designed to tract. While upper GI motility disorders are a highly prevalent group of persistent and recurring conditions, there are currently a limited number of treatment options for patients suffering from these conditions. Ulimorelin and TZP-102 target the ghrelin receptor, a novel mechanism of action, with a highly potent and direct role in the stimulation of GI motility. Current and formerly available drugs targeted the GI function primarily through either the serotonin or dopamine receptors and have had significant safety issues, resulting in product recalls. We believe our product candidates have the potential to offer a safe and effective treatment for GI motility disorders, an area of significant unmet medical need.

PROPRIETARY TECHNOLOGY

Tranzyme's product candidates have been discovered using our proprietary chemistry technology platform, MATCH™ (Macrocyclic Template Chemistry), which enables us to construct synthetic libraries of drug-like, macrocyclic compounds in a predictable and efficient manner. MATCH™ compounds mimic the favorable binding characteristics of proteins and peptides such as tight receptor binding for high potency and selectivity, while eliminating the drawbacks associated with these biomolecules — poor metabolic stability, low oral bioavailability, lack of membrane permeability, high manufacturing costs and antigenicity. As part of our business strategy, we continue to leverage our technology platform to discover, develop and commercialize first-in-class products in collaboration with discovery partners.

CORPORATE ALLIANCES

In December, 2009, Tranzyme entered into a strategic collaboration with BMS to discover, develop and commercialize novel compounds discovered using our proprietary chemistry technology platform, against a limited number of targets of interest to BMS. BMS is funding our early lead discovery efforts on these targets and is also responsible for optimizing the identified lead compounds.

In June 2010, Tranzyme entered into a license agreement with Norgine B.V., a leading, GI-focused European specialty pharmaceutical company that provides Norgine with exclusive rights to develop and commercialize ulimorelin in Europe and other select territories. Tranzyme retained rights to ulimorelin in North & South America and Asia. Norgine will share the cost of our development.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Ulimorelin (TZP-101)	Management of postoperative ileus	Phase III	Complete Phase III program
TZP-102	Diabetic gastroparesis	Phase II, IIa, IIb	Initiate Phase IIb
TZP-201	Chemo-induced diarrhea	Preclinical	
TZP-301	Metabolic disease	Lead Series	
Chemistry	Available for collaboration	Research	

SENIOR MANAGEMENT

Vipin Garg, PhD, Chief Executive Officer • **Richard Eisenstadt**, Chief Financial Officer • **Helmut Thomas, PhD**, Senior Vice President • **Gordana Kosutic, MD**, Vice President • **Jennifer Filbey**, Vice President • **Mark Peterson**, Vice President • **David Moore**, Vice President • **Brent Bankoskcy**, Vice President

BOARD OF DIRECTORS

John H. Johnson, Savient Pharmaceuticals, Inc. • **Jean-Paul Castaigne**, Angiochem, Inc. • **Aaron Davidson**, H.I.G. BioVentures • **Brenda D. Gavin**, Quaker BioVentures • **Anne M. VanLent**, AMV Advisors • **Alex Zisson**, Thomas, McInerney & Partners



Market Data

Current Price	1.09
Currency	Euro
Net Change	-0.91
Volume.....	17,345
YTD % Change	-0.15
52Wk Range	1.01-2.04
Avg. Daily Volume (thousands)	73,666

First Call Data

Market Cap (MM)	14.9
Short Interest Shares.....	--
Short Interest Ratio.....	--
PE (Trailing 12 Months)	-0.27
EPS (Last Fiscal Year).....	-0.37
Consensus Estimate (Y)	-0.27
Consensus Recommend.....	--
Price/Sales	3.32

Shareholders

<i>Institution</i>	<i>Holding %</i>
HSBC Global Asset Management (France) SA	0.4%
La Mondiale Groupe	0.0%
<i>Mutual Fund</i>	<i>Holding %</i>
HSBC Global Asset Management (France) SA	0.4%
La Mondiale Groupe	0.0%

Source: Thomson Reuters

Trevena, Inc.

BIO Member, , BIO Board Member, Presenting Company

Clinical Foci: Drug Development, Cardiovascular Disease, CNS

Maxine Gowen

President & CEO

1018 West 8th Avenue
King of Prussia, PA 19406
USA

www.trevenainc.com

1-610-354-8840

Incorporated: 2007

Employees: 33

Ownership: Private

HIGHLIGHTS

Recent

Phase 2a trial for TRV027 was initiated in early 2011 for the development of TRV027 to treat acute heart failure.
IND enabling studies for a novel opioid analgesic, TRV130, were initiated in 3Q11.
Trevena was awarded an NIH grant under the Blueprint Neurotherapeutics Network Program to develop novel agents to treat Major Depressive Disorders.

Upcoming

Phase 2b trial for TRV027 is expected to start in 2H12.
IND for the novel opioid analgesic, TRV130, is expected to be filed in 2Q12.

CORPORATE MISSION

Trevena is a clinical stage drug discovery & development company with a new approach to drugs targeting G-protein coupled receptors (GPCRs) by selective signaling. These are called biased ligands as they activate either G-protein or beta-arrestin signaling through specific GPCRs. Our novel technology has allowed us to develop differentiated drug candidates for both acute heart failure and acute and chronic pain. TRV027 is currently in Phase 2a proof of concept clinical trials for acute heart failure and is a novel iv drug that safely improves the symptoms of heart failure while improving renal function and increasing cardiac contractility. Our second candidate is a novel analgesic with opioid like efficacy but with significantly reduced effects on GI motility and respiratory suppression. This is expected to enter clinical trials in 1H12.

PROPRIETARY TECHNOLOGY

Trevena's proprietary platform enable it to identify pharmacologically distinct biased GPCR ligands which drive beneficial biology without activating responses associated with adverse events. There are at least two major intracellular signaling pathways from nearly all GPCRs which are linked to distinct biologies. When a 'biased ligand' binds to the receptor, it activates one of these pathways while deactivating the other (as opposed to the current industry approach of activating or deactivating all signaling pathways). This enhanced functional specificity enables Trevena to create and characterize agents with increased efficacy and/or decreased adverse effects. Trevena's approach represents the latest development in targeted therapies and will provide the next generation of GPCR drugs.

PRODUCTS

<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
TRV027	Acute Heart Failure	Phase II, IIa, IIb	Phase 2 data in 1H12.
TRV130	Post surgical pain	Preclinical	IND file, 2Q12.
Kappa opioid biased ligand	Neuropathic pain	Lead Series	
Delta opioid biased ligand	Depression, pain, Parkinson's Disease	Lead Series	

SENIOR MANAGEMENT

Maxine Gowen, President & CEO • **Art Fratamico**, Chief Business Officer • **Michael Lark**, Chief Scientific Officer • **David Soergel**, Vice President

BOARD OF DIRECTORS

Maxine Gowen, Trevena Inc. • **Terrance G. McGuire**, Polaris Ventures • **Robert Garland**, NEA • **Farah Champs**, Alta Partners • **Christopher K. Mirabelli**, HealthCare Ventures • **Robert R. Ruffolo**, Former President R&D, Wyeth Pharmaceuticals • **Ralph Snyderman**, Duke University

SCIENTIFIC ADVISORY BOARD

Robert J. Lefkowitz, MD, Duke University Medical Center • **Howard A. Rockman, MD**, Duke University Medical Center • **John L. LaMattina, PhD**, Former President, Global Research and Development at Pfizer • **Robert R. Ruffolo, Jr., PhD**, Former President of R&D at Wyeth Pharmaceuticals

FINANCING HISTORY

Round Date (Amount, US\$) 01/01/2008 (25.00 million) • 07/17/2010 (35.00 million)

Investors: Alta Partners (1%) • HealthCare Ventures (1%) • NEA (1%) • Polaris Ventures (1%) • Yasuda (1%)

Trius Therapeutics, Inc.

Presenting Company

Clinical Foci: Infectious Disease, Skin/Dermatological, Pulmonary

Jeff Stein, PhD

Chief Executive Officer

6310 Nancy Ridge Dr, Suite 105
San Diego, CA 92121
USA

www.triusrx.com

1-858-452-0370

NASDAQ: TSRX

Incorporated: 2007

Employees: 68

Ownership: Public

HIGHLIGHTS

Recent

August 5, 2011: Trius Therapeutics Obtains Special Protocol Assessment With FDA for Second Phase 3 Study of Torezolid Phosphate.

July 27, 2011: Trius Therapeutics and Bayer Form Strategic Collaboration to Develop and Commercialize Torezolid Phosphate in Asia-Pacific and Emerging Markets.

May 25, 2011: Trius Therapeutics Announces Pricing of USD \$30 million Financing.

Upcoming

Trius complete enrollment of Phase 3 trial of oral dosage form of tedizolid phosphate

Trius initiates enrollment of Phase 3 trial testing IV to oral dosing of tedizolid phosphate

CORPORATE MISSION

Trius Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections.

We are conducting Phase 3 clinical trials for our lead compound tedizolid (TR-701), an IV and orally administered next generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant *Staphylococcus aureus* (MRSA). With significantly improved potency, safety and compliance, TR-701 is effective against severe skin, lung, blood and bone infections caused by a wide spectrum of bacteria including those resistant to all commonly used drugs. TR-701 is currently the being tested in Phase 3 clinical trials under a Special Protocol Assessment (SPA).

In addition to TR-701, Trius has two ongoing preclinical programs that have emerged from our proprietary discovery platform. Both the GyrB/ParE program and our Marine Natural Products Program are focused on identifying and develop antibiotics to treat infections caused by gram-negative and gram-positive bacteria. These programs are currently funded with USD \$57 million by the U. S. government. Trius is headquartered in San Diego, California. We have built a strong management team with significant development and regulatory experience. Our senior management team collectively has over 90 years of experience in the development and approval of antibiotics.

PROPRIETARY TECHNOLOGY

Trius has developed a proprietary platform called focused antisense screening technology (FAST) which uses antisense technology to identify suitable bacterial drug targets. We have also built state-of-the-art capabilities in structure based drug design (SBDD). These proprietary capabilities enable us to rapidly identify optimal bacterial targets and subsequently design highly potent and selective small molecule inhibitors, which enables us to develop new differentiated antibiotics.

The FAST platform consists of a set of engineered bacterial strains containing antisense DNA fragments whose synthesis can be regulated to inhibit the production of a targeted protein. We have demonstrated that compounds that act on the protein down regulated in the FAST antisense strain require a significantly

CORPORATE ALLIANCES

Trius recently announced a collaboration with Bayer HealthCare to develop and commercialize TR-701 in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East. Under the collaboration agreement Trius retains full development and commercialization rights outside the licensed territory including the United States, Canada and the European Union.

PRODUCTS

Name	Indication	Phase	Milestone
GyrB/ParE	Gram-negative nosocomial infections: cUTI, Intra-abdominal infections, pneumonia	Preclinical	
Marine Natural Products	Gram-negative and gram-positive infections	Preclinical	
TR-701	P3 for acute bacterial skin and skin structure infections (ABSSI). Future: CAP/HAP, osteomyelitis, bacteremia	Phase III	Complete enrollment of oral trial; start enrollment of IV/oral trial

SENIOR MANAGEMENT


Jeff Stein, PhD, Chief Executive Officer • **John Schmid**, Chief Financial Officer • **John Finn**, Chief Scientific Officer • **Craig Thompson**, Marketing • **Karen Shaw**, Senior Vice President • **Karen Potts**, Vice President • **Philippe Prokocimer**, Chief Medical Officer • **Ken Bartizal**, Other • **Neil Abdollahian**, Vice President

BOARD OF DIRECTORS

David Kabakoff, Sofinnova Ventures • **Brian Atwood**, Versant Ventures • **Karin Eastham**, Independent • **Nina Kjellson**, InterWest Partners • **Brendan O'Leary**, Prism Ventures • **Michael Powell**, Sofinnova Ventures • **Theodore Schroeder**, CEO, Cadence Pharmaceuticals • **Risa Stack**, Kleiner Perkins Caufield & Byers • **Paul Truex**, CEO, Anthera Pharmaceuticals • **Jeffrey Stein**, CEO, Trius Therapeutics

TRADING STATUS AS OF OCTOBER 5, 2011

NASDAQ: TSRX



Market Data

Current Price	6.31
Currency	US Dollar
Net Change	4.30
Volume	44,867
YTD % Change	0.70
52Wk Range	2.93–9.00
Avg. Daily Volume (thousands).....	52,729

First Call Data

Market Cap (MM)	180.2
Short Interest Shares	341,512
Short Interest Ratio	9.41
PE (Trailing 12 Months)	-1.30
EPS (Last Fiscal Year)	-2.53
Consensus Estimate (Y)	-1.30
Consensus Recommend	-1.29
Price/Sales	17.94

Shareholders

<i>Institution</i>	<i>Holding %</i>
Wellington Management Co. LLP	4.6%
Sectoral Asset Management, Inc.	3.6%
Redmile Group LLC	2.8%
Great Point Partners LLC	2.6%
Manatuck Hill Partners LLC	2.0%
<i>Mutual Fund</i>	
Wellington Management Co. LLP	4.6%
Sectoral Asset Management, Inc.	3.6%
Redmile Group LLC	2.8%
Great Point Partners LLC	2.6%
Manatuck Hill Partners LLC	2.0%

Source: Thomson Reuters

Unigene Laboratories, Inc.

Presenting Company

Clinical Foci: Drug Delivery • Drug Development • Biopharmaceuticals

Ashleigh Palmer Chief Executive Officer

81 Fulton St.
Boonton, NJ 07005
USA

www.unigene.com

1-973-882-0860

OTC BB: UGNE

Incorporated: 1980

Employees: 70

Ownership: Public

HIGHLIGHTS

Recent

Unigene and Nordic Bioscience Combine Industry Leading Capabilities to Advance Unigene's Proprietary Peptides through Phase 2 Proof-of-Concept for the Treatment of Type 2 Diabetes, Osteoarthritis and Osteoporosis.

Unigene's Leading Peptide Development Expertise Endorsed with Strategic Equity Investment of up to USD \$6 million by Industry Legend Dr. Claus Christiansen.

Unigene's Industry Leading, Proprietary Oral Delivery and Recombinant Manufacturing Technology Platforms are Further Validated with Positive Phase 3 Safety and Efficacy Data for OSTORA(TM); Data Presented by Licensee, Tarsa at ASBMR 2011.

CORPORATE MISSION

Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligence™ platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.

PROPRIETARY TECHNOLOGY

Unigene's patented oral delivery technology has been shown to effectively deliver therapeutically important peptides. Oral Peptide Delivery: Peptides and proteins possess several inherent properties that limit oral bioavailability. Unigene's technology has overcome these physiological barriers by several mechanisms resulting in excellent bioavailability: Enteric coating permits passage of the tablet or capsule through the stomach into the small intestine; Novel excipients prevent proteolytic cleavage and enhance transport of drug into the blood stream; and Absolute bioavailability from 1% to greater than 20% compared to IV infusion.

CORPORATE ALLIANCES

Alliances Unigene's technologies have extensive clinical and partner validation. The company's first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, who announced positive and statistically significant Phase 3 results for the treatment of osteoporosis. Other validating relationships include an oral parathyroid hormone in Phase 2 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
Fortical	Osteoporosis	On Market	
OSTORA(TM)	Osteoporosis	NDA/BLA filed, or in process	Preparation for NDA filing underway; exit transaction anticipated
Oral PTH	Osteoporosis	Phase II, IIa, IIb	Phase 2 results expected before year end
UGP-281	Obesity	Preclinical	Filing of IND and initiation of Phase 1 in 1H12.
Metabolic peptides	Type 2 diabetes	Preclinical	JDV with Nordic Bioscience; development plan to be announced 1H12.

SENIOR MANAGEMENT

Ashleigh Palmer, Chief Executive Officer • **Gregory T. Mayes**, Business Development • **Nozer Mehta**, Vice President • **Roxanne Tavakkol**, Vice President • **Paul Shields**, Vice President • **William Steinhauer**, Vice President • **Jenene Thomas**, Investor Relations

BOARD OF DIRECTORS

Richard Levy, Victory Park Capital Advisors • **Joel Tune**, President, JTune Consulting LLC • **Theron (Ted) Odlaug, PhD**, Executive Chairman & CEO, Planet Biopharmaceuticals • **Zvi Eiref**, Former Chief Financial Officer, Church & Dwight Co. • **Allen Bloom, PhD**, Patent Attorney & Independent Consultant • **Marvin Miller**, Independent Consultant



Market Data

Current Price	1.07
Currency	U.S. Dollar
Net Change	21.02
Volume	--
YTD % Change	0.57
52Wk Range	0.40-1.42
Avg. Daily Volume (thousands)	74,751

First Call Data

Market Cap (MM)	99.0
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	-0.22
EPS (Last Fiscal Year)	-0.25
Consensus Estimate (Y)	-0.22
Consensus Recommend	--
Price/Sales	9.51

Shareholders

<i>Institution</i>	<i>Holding %</i>
Victory Park Capital Advisors LLC	9.8%
Wynnefield Capital Management LLC	6.2%
Goldman Capital Management, Inc.	0.6%
People's United Wealth Management & Trust	0.0%
Manulife Asset Management Ltd.	0.0%
<i>Mutual Fund</i>	<i>Holding %</i>
Victory Park Capital Advisors LLC	9.8%
Wynnefield Capital Management LLC	6.2%
Goldman Capital Management, Inc.	0.6%
People's United Wealth Management & Trust	0.0%
Manulife Asset Management Ltd.	0.0%

Source: Thomson Reuters

Xcenda LLC

Amy L. Grogg, PharmD
President

4114 Woodlands Parkway
Palm Harbor, FL 34685
USA

www.xcenda.com
1-800-320-6497

NYSE: ABC
Incorporated: 2002
Ownership: Public

CORPORATE MISSION


Xcenda is a premier full-service consultancy and leading managed markets agency whose experienced consulting team helps manufacturers identify, demonstrate, and deliver their brand's value proposition to all healthcare stakeholders. For 15 years, Xcenda has been an essential partner, offering both strategic guidance and field support, to global pharmaceutical, device, and diagnostic companies, as well as emerging pre-commercialization phase firms.

SENIOR MANAGEMENT

Amy L. Grogg, PharmD, President • **Loreen M. Brown, MSW**, Vice President • **Susan Maue, PhD**, Vice President • **Tom Mullin**, Vice President • **Brian S. Nightengale, RPh, PhD**, Vice President • **Thomas J. Bramley RPh, PhD**, Vice President • **Peyton Howell, MHA**, Other • **Doug Neely, CMPE, MHA**, Director

TRADING STATUS AS OF OCTOBER 5, 2011

NYSE: ABC



Market Data

Current Price	36.38
Currency	U.S. Dollar
Net Change	1.28
Volume.....	4,208,919
YTD % Change	0.07
52Wk Range	30.51–43.47
Avg. Daily Volume (thousands)	2,815,192

First Call Data

Market Cap (MM)	9,795.6
Short Interest Shares.....	6,454,988
Short Interest Ratio.....	2.23
PE (Trailing 12 Months).....	2.71
EPS (Last Fiscal Year).....	2.50
Consensus Estimate (Y)	2.71
Consensus Recommend	2.72
Price/Sales	0.12

Shareholders

<i>Institution</i>	<i>Holding %</i>
The Vanguard Group, Inc.....	5.8%
BlackRock Advisors LLC.....	4.9%
BlackRock Fund Advisors	4.0%
State Street Global Advisors.....	3.9%
Wellington Management Co. LLP	3.5%
<i>Mutual Fund</i>	<i>Holding %</i>
The Vanguard Group, Inc.....	5.8%
BlackRock Advisors LLC.....	4.9%
BlackRock Fund Advisors	4.0%
State Street Global Advisors.....	3.9%
Wellington Management Co. LLP	3.5%

Source: Thomson Reuters

XOMA Ltd.

BIO Member, BIO Board Member, Presenting Company

Clinical Foci: Ophthalmic • Autoimmune • Oncology

John Varian

Chief Executive Officer

2910 Seventh Street
Berkeley, CA 94710
USA

www.xoma.com

1-510-204-7200

NASDAQ: XOMA

Incorporated: 1981

Employees: 240

Ownership: Public

HIGHLIGHTS

Recent

Announced discovery of new classes of insulin receptor-regulating antibodies for potential treatment of diabetes, available for licensing discussions.

Entered XOMA 3AB triple antibody product for treatment of botulism poisoning into Phase 1 testing.

Completed Phase 2 trials of XOMA 052 in Type 2 diabetes, demonstrating reductions in C-reactive protein, a cardiovascular risk and inflammatory biomarker.

Upcoming

Initiation of Phase 3 development of XOMA 052 in Behcet's uveitis. Initiation of Phase 2 development of XOMA 052 in a cardiovascular disease indication.

Additional licensing and collaboration agreements for XOMA technologies and preclinical pipeline products.

CORPORATE MISSION

XOMA is a leader in the discovery and development of novel antibody therapeutics. The company's product pipeline includes:

- XOMA 052, a potentially best-in-class antibody that binds to the inflammatory cytokine interleukin-1 beta, or IL-1 beta. Les Laboratoires Servier is XOMA's development and commercialization partner for XOMA 052. XOMA and Servier plan to enter XOMA 052 into Phase 3 clinical development for Behcet's uveitis, an orphan indication, and Phase 2 development for cardiovascular disease.
- XOMA 3AB, a novel combination of three antibodies in one product under development to prevent and treat botulism poisoning caused by exposure to botulinum neurotoxin Type A, among the most deadly bioterror threats. XOMA 3AB is in a Phase 1 clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). XOMA receives funding for development of XOMA 3AB under NIAID Contract # HHSN266200600008C.
- A preclinical pipeline with candidates in development for autoimmune, cardio-metabolic, inflammatory and oncologic diseases.

XOMA has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary optimization and expression and manufacturing technologies that it uses for its own pipeline and in collaborations with pharmaceutical and biotechnology companies. XOMA technologies have contributed to the success of marketed antibody products including LUCENTIS® for wet age-related macular degeneration and CIMZIA® for rheumatoid arthritis and Crohn's disease. XOMA's fully integrated product development infrastructure extends from preclinical science to approval and is located in Berkeley, California.

PROPRIETARY TECHNOLOGY

XOMA has a premier antibody discovery and development platform that incorporates an expertise in creating novel, very large antibody phage display libraries for its own pipeline and for licensing, access to an unmatched collection of commercial antibody phage display libraries, and proprietary Human Engineering(tm), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.

CORPORATE ALLIANCES

Servier: XOMA 052, worldwide rights to cardiovascular and diabetes indications, ex-U.S. and Japan rights to Behcet's uveitis, inflammatory, oncology and other indications. XOMA may acquire all U.S. and Japan rights.

Arana (Cephalon), Kaketsuken, Takeda: antibody discovery technology collaboration agreements.

Novartis: antibody development for HCD 122 and LFA 102.

PRODUCTS


<i>Name</i>	<i>Indication</i>	<i>Phase</i>	<i>Milestone</i>
XOMA 052	Behcet's uveitis	Phase III	Initiation of Phase 3 program
XOMA 052	Cardiovascular disease	Phase II, IIa, IIb	Initiation of Phase 2 program
XOMA 3AB	Botulism poisoning	Phase I	Trial completion
XMetA insulin receptor activating antibodies	Diabetes	Preclinical	Completion of additional studies
XMetS insulin receptor sensitizing antibodies	Diabetes	Preclinical	Completion of additional studies

SENIOR MANAGEMENT

John Varian, Chief Executive Officer • **Fred Kurland**, Chief Financial Officer • **Jim Neal**, Business Development • **Svetlana Lucas**, Business Development

BOARD OF DIRECTORS

W. Denman Van Ness, Hidden Hill Partners • **William K. Bowes, Jr.**, US Venture Partners • **Peter Barton Hutt**, Covington & Burling • **Patrick J. Scannon, MD, PhD**, XOMA Ltd. • **John Varian**, XOMA Ltd. • **Timothy P. Walbert**, Horizon Pharma • **Jack L. Wyszomierski**

TRADING STATUS AS OF OCTOBER 5, 2011**NASDAQ: XOMA****Market Data**

Current Price	1.83
Currency	U.S. Dollar
Net Change	14.38
Volume	409,806
YTD % Change	-0.64
52Wk Range	1.38-7.71
Avg. Daily Volume (thousands)	1,501,271

First Call Data

Market Cap (MM)	59.6
Short Interest Shares	1,631,293
Short Interest Ratio	8.79
PE (Trailing 12 Months)	-1.00
EPS (Last Fiscal Year)	-2.17
Consensus Estimate (Y)	-1.00
Consensus Recommend	--
Price/Sales	1.12

Shareholders**Institution****Holding %**

Eastern Capital Ltd.	7.9%
The Vanguard Group, Inc.	2.4%
BlackRock Fund Advisors	2.2%
Baker Bros. Advisors LLC	1.2%
Banque BPP SA	0.4%

Mutual Fund**Holding %**

Eastern Capital Ltd.	7.9%
The Vanguard Group, Inc.	2.4%
BlackRock Fund Advisors	2.2%
Baker Bros. Advisors LLC	1.2%
Banque BPP SA	0.4%

Source: Thomson Reuters

Zalicus Inc.

BIO Member, Presenting Company

Clinical Foci: Biopharmaceuticals • Immunology • Neurology

Mark H.N. Corrigan Chief Executive Officer

245 First Street
Cambridge, MA 02142
USA

www.zalicus.com
1-617-301-7000

ASX: ZLCS
Incorporated: 2000
Employees: 68
Ownership: Public

CORPORATE MISSION

Zalicus Inc. utilizes its unique drug discovery and development capabilities to develop a pipeline of innovative therapies for the treatment of pain and inflammation. Our unique mix of powerful discovery technologies, novel clinical programs and experienced drug development professionals provide a solid foundation for success.

PROPRIETARY TECHNOLOGY

Zalicus has two unique drug discovery platforms that fuel its future pipeline and enable additional revenue generating collaborations. Our industry leading Ion Channel platform allows us to identify candidates that harness the potential of the electrophysiology of calcium channel blockers for acute and chronic pain. Our proprietary cell-based combination High Throughput Screening (cHTS) technology evaluates the therapeutic potential of various drug combinations while elucidating new mechanisms to treat diseases.

CORPORATE ALLIANCES

Collaboration is an important component of Zalicus' business strategy. We form collaborations with pharmaceutical and biotechnology companies, as well as US government agencies, to support the development of select product candidates generated by our discovery technologies. Zalicus has multiple revenue-generating collaborations and continues to leverage its proprietary discovery technologies with ongoing research collaborations. Our drug discovery technology has identified Prednisporin, one of our most advanced clinical product candidates, on behalf of our partners at Fovea Pharmaceuticals (a division of Sanofi Aventis), and has also been seen as an important technology by our collaborators at Novartis in support of their oncology research efforts.

PRODUCTS


Name	Indication	Phase	Milestone
Synavive	Rheumatoid arthritis	Phase II, IIa, IIb	Complete enrollment 1H12, Data 2H12.
Z160	Neuropathic Pain	Preclinical	Initiate Phase 1
Z944	Pain	Preclinical	Initiate Phase 1
Sodium Channel Blockers	Pain	Preclinical	Initiate Phase 1

SENIOR MANAGEMENT

Mark H.N. Corrigan, Chief Executive Officer • **Justin Renz**, Chief Financial Officer

TRADING STATUS AS OF OCTOBER 5, 2011

ASX: ZLCS



Market Data

Current Price	0.05
Currency	Australian Dollar
Net Change	0.00
Volume	150,000
YTD % Change	-0.66
52Wk Range	0.05–0.22
Avg. Daily Volume (thousands)	376,571

First Call Data

Market Cap (MM)	15.5
Short Interest Shares	--
Short Interest Ratio	--
PE (Trailing 12 Months)	--
EPS (Last Fiscal Year)	-0.02
Consensus Estimate (Y)	--
Consensus Recommend	--
Price/Sales	86.62

Shareholders

<i>Institution</i>	<i>Holding %</i>
Persistency Capital LLC	7.6%
<i>Mutual Fund</i>	<i>Holding %</i>
Persistency Capital LLC	7.6%

Source: Thomson Reuters

Zymeworks Inc.

Presenting Company

Clinical Foci: Drug Development

Ali Tehrani

Chief Executive Officer

#540-1385 West 8th Ave
Vancouver, BC V6H 3V9
Canada

www.zymeworks.com

1-604-678-1388

Incorporated: 2004

Employees: 37

Ownership: Private

HIGHLIGHTS

Recent

Zymeworks Inc signed a collaborative research and license agreement with US pharmaceutical giant Merck Sharpe and Dohme Research for up to USD \$1.85 million plus royalties. This will validate Zymeworks asymmetric antibody platform.

CORPORATE MISSION

Zymeworks is focused on developing a pipeline of biobetter candidates through applying its proprietary protein engineering platform to monoclonal antibodies and other classes of protein therapeutics. Zymeworks is also seeking to establish strategic collaborations with leading pharmaceutical and biotechnology companies in the design of novel cross-reactive antibodies and improving antibody dependent cell cytotoxicity (ADCC) response and other effector functions. Zymeworks is a computational biotechnology company with structure-guided technologies for the predictive engineering and optimization of antibodies and protein therapeutics.

PROPRIETARY TECHNOLOGY

Zymeworks has developed a proprietary molecular simulation platform that relates a protein's function and biophysical characteristics to its structure. This insight allows Zymeworks to make knowledge-based modifications to the protein that result in new or improved functional properties leading to more efficacious drugs. In the design of a novel heterodimeric scaffold, novel cross-reactive antibodies and the improvement of ADCC, Zymeworks' platform has the distinctive advantage in the optimization of multiple biophysical properties (affinity, selectivity, stability, effector function) on one protein framework. Zymeworks can design complex mutations (multiple simultaneous changes) and compensating mutations that take into account cooperativity and distal effects using the full-length mAb.

CORPORATE ALLIANCES

Zymeworks has a collaboration with Merck to develop bi-specific antibody therapeutics using Zymeworks' Azymetric™ platform. Under the terms of the agreement Zymeworks has granted Merck, through a subsidiary, a worldwide license to develop and commercialize bi-specific antibodies generated through use of the Azymetric™ platform toward certain exclusive therapeutic targets. Both companies will collaborate to advance the technology platform, with Merck working to progress the bi-specific therapeutic antibody candidates through clinical development and commercialization.

SENIOR MANAGEMENT

Ali Tehrani, Chief Executive Officer • **Surjit Dixit**, Chief Technology Officer • **Neil Klompas**, Chief Financial Officer • **David Tucker**, Chief Operating Officer

BOARD OF DIRECTORS

Nick Bedford, Former Head of German Equities, UBS Warburg • **Haig Farris**, President, Fractal Capital Corp. • **Kenneth Galbraith**, General Partner, Ventures West Management • **Noel Hall**, Former Co-founder & President of Aspreva Pharmaceuticals • **Patrick McCroskey**, Principal, TPG Biotech • **Ali Tehrani**, President & CEO, Zymeworks Inc. • **Shermaine Tilley**, Partner, CTI Life Sciences Fund • **Don Drakeman**, Venture Partner at Advent Venture Partners

SCIENTIFIC ADVISORY BOARD

Michael J. Gresser, CSO, Oxford BioTherapeutics • **C. Geoffrey Davis**, President & CEO of Angelica Therapeutics • **Richard Lavery**, Head, Department of Molecular Biostructures - Institute de Biologie et Chimie des Proteines • **Mihaly Mezei**, Associate Professor and Director of Molecular Modelling Core, Mt. Sinai School of Medicine • **Bruce Tidor**, Professor, Biological Engineering and Computer Science, MIT